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Abstract 
Pulmonary arterial hypertension (PAH) is a progressive disease of the small pulmonary 
arteries, characterised by pulmonary vascular remodelling due to excessive proliferation 
and resistance to apoptosis of pulmonary artery endothelial cells (PAECs) and pulmonary 
artery smooth muscle cells (PASMCs). The increased pulmonary vascular resistance and 
elevated pulmonary artery pressures result in right heart failure and premature death. 
Germline mutations of the bone morphogenetic protein receptor-2 (bmpr2) gene, a receptor 
of the transforming growth factor beta (TGF-β) superfamily, account for approximately 
75%-80% of the cases of heritable form of PAH (HPAH) and 20% of sporadic cases or id-
iopathic PAH (IPAH). IPAH patients without known bmpr2 mutations show reduced ex-
pression of BMPR2. However only ~ 20% of bmpr2-mutation carriers will develop the 
disease, due to an incomplete penetrance, thus the need for a ‘second hit’ including other 
genetic and/or environmental factors is accepted. Diagnosis of PAH occurs most frequently 
when patients have reached an advanced stage of disease. Although modern PAH therapies 
can markedly improve a patient’s symptoms and slow the rate of clinical deterioration, the 
mortality rate from PAH remains unacceptably high. Therefore, the development of novel 
therapeutic approaches is required for the treatment of this multifaceted disease.  
 
Noncoding RNAs (ncRNAs) include microRNAs (miRNAs) and long noncoding RNAs 
(lncRNAs). MiRNAs are ~ 22 nucleotide long and act as negative regulators of gene ex-
pression via degradation or translational inhibition of their target mRNAs. Previous studies 
showed extensive evidence for the role of miRNAs in the development of PAH. LncRNAs 
are transcribed RNA molecules greater than 200 nucleotides in length. Similar to classical 
mRNA, lncRNAs are translated by RNA polymerase II and are generally alternatively 
spliced and polyadenylated. LncRNAs are highly versatile and function to regulate gene 
expression by diverse mechanisms. Unlike miRNAs, which exhibit well-defined actions in 
negatively regulating gene expression via the 3’-UTR of mRNAs, lncRNAs play more di-
verse and unpredictable regulatory roles. Although a number of lncRNAs have been inten-
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sively investigated in the cancer field, studies of the role of lncRNAs in vascular diseases 
such as PAH are still at a very early stage. The aim of this study was to investigate the in-
volvement of specific ncRNAs in the development of PAH using experimental animal 
models and cell culture.  
 
The first ncRNA we focused on was miR-143, which is up-regulated in the lung and right 
ventricle tissues of various animal models of PH, as well as in the lungs and PASMCs of 
PAH patients. We show that genetic ablation of miR-143 is protective against the devel-
opment of chronic hypoxia induced PH in mice, assessed via measurement of right ven-
tricular systolic pressure (RVSP), right ventricular hypertrophy (RVH) and pulmonary 
vascular remodelling. We further report that knockdown of miR-143-3p in WT mice via 
antimiR-143-3p administration prior to exposure of mice to chronic hypoxia significantly 
decreases certain indices of PH (RVSP) although no significant changes in RVH and pul-
monary vascular remodelling were observed. However, a reversal study using anti-
miR-143-3p treatment to modulate miR-143-3p demonstrated a protective effect on RVSP, 
RVH, and muscularisation of pulmonary arteries in the mouse chronic hypoxia induced PH 
model.  
 
In vitro experiments showed that miR-143-3p overexpression promotes PASMC migration 
and inhibits PASMC apoptosis, while knockdown miR-143-3p elicits the opposite effect, 
with no effects observed on cellular proliferation. Interestingly, miR-143-3p-enriched ex-
osomes derived from PASMCs mediated cell-to-cell communication between PASMCs 
and PAECs, contributing to the pro-migratory and pro-angiogenic phenotype of PAECs 
that underlies the pathogenesis of PAH.  
 
Previous work has shown that miR-145-5p expression is upregulated in the chronic hy-
poxia induced mouse model of PH, as well as in PAH patients. Genetic ablation and phar-
macological inhibition (subcutaneous injection) of miR-145-5p exert a protective against 
the development of PAH. In order to explore the potential for alternative, more 
lung-targeted delivery strategies, miR-145-5p expression was inhibited in WT mice using 
	 xxii	
intranasal-delivered antimiR-145-5p both prior to and post exposure to chronic hypoxia. 
The decreased expression of miR-145-5p in lung showed no beneficial effect on the de-
velopment of PH compared with control antimiRNA treated mice exposed to chronic hy-
poxia. Thus, miR-143-3p modulated both cellular and exosome-mediated responses in 
pulmonary vascular cells, while the inhibition of miR-143-3p prevented the development 
of experimental pulmonary hypertension.  
 
We focused on two lncRNAs in this project: Myocardin-induced Smooth Muscle Long 
noncoding RNA, Inducer of Differentiation (MYOSLID) and non-annotated Myolnc16, 
which were identified from RNA sequencing studies in human coronary artery smooth 
muscle cells (HCASMCs) that overexpress myocardin. MYOSLID was significantly in-
creased in PASMCs from patients with IPAH compared to healthy controls and increased 
in circulating endothelial progenitor cells (EPCs) from bmpr2 mutant PAH patients. Ex-
posure of PASMCs to hypoxia in vitro led to a significant upregulation in MYOSLID ex-
pression. MYOSLID expression was also induced by treatment of PASMC with BMP4, 
TGF-β and PDGF, which are known to be triggers of PAH in vitro. Small interfering RNA 
(siRNA)-mediated knockdown MYOSLID inhibited migration and induced cell apoptosis 
without affecting cell proliferation and upregulated several genes in the BMP pathway in-
cluding bmpr1α, bmpr2, id1, and id3. Modulation of MYOSLID also affected expression of 
BMPR2 at the protein level. In addition, MYOSLID knockdown affected the BMP-Smad 
and BMP-non-Smad signalling pathways in PASMCs assessed by phosphorylation of 
Smad1/5/9 and ERK1/2, respectively. In PAECs, MYOSLID expression was also induced 
by hypoxia exposure, VEGF and FGF2 treatment. In addition, MYOSLID knockdown sig-
nificantly decreased the proliferation of PAECs. Thus, MYOSLID may be a novel modula-
tor in pulmonary vascular cell functions, likely through the BMP-Smad and –non-Smad 
pathways.  
 
Treatment of PASMCs with inflammatory cytokines (IL-1 and TNF-α) significantly in-
duced the expression of Myolnc16 at a very early time point. Knockdown of Myolnc16 in 
vitro decreased the expression of il-6, and upregulated the expression of il-1 and il-8 in 
	 xxiii	
PASMCs. Moreover, the expression levels of chemokines (cxcl1, cxcl6 and cxcl8) were 
significantly decreased with Myolnc16 knockdown. In addition, Myolnc16 knockdown de-
creased the MAP kinase signalling pathway assessed by phosphorylation of ERK1/2 and 
p38 MAPK and inhibited cell migration and proliferation in PASMCs. Thus, Myolnc16 
may a novel modulator of PASMCs functions through anti-inflammatory signalling path-
ways.  
 
In summary, in this thesis we have demonstrated how miR-143-3p plays a protective role 
in the development of PH both in vivo animal models and patients, as well as in vitro cell 
culture. Moreover, we have showed the role of two novel lncRNAs in pulmonary vascular 
cells. These ncRNAs represent potential novel therapeutic targets for the treatment of PAH 
with further work addressing to investigate the target genes, and the pathways modulated 
by these ncRNAs during the development of PAH.  
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1.1	Pulmonary	Circulation	 	
1.1.1 Structure of the Pulmonary Circulation 
The pulmonary circulation carries oxygen-depleted blood away from the heart, to the lungs, 
and returns oxygenated blood back to the heart. The pulmonary vasculature consists of 
thin-walled, low-pressure arteries, unlike the thick-walled high-pressure arteries of the 
systemic vasculature. Under physiological conditions, the pulmonary circulation facilitates 
the oxygenation of blood in the lungs, where gaseous exchange occurs between the pul-
monary capillaries and the air-filled alveolar sacs. The right ventricle of the pulmonary 
circulation receives mixed venous blood (deoxygenated blood) draining into the right 
atrium from the systemic circulation via the superior and inferior vena cava. After the de-
oxygenated blood enters the right ventricle through the tricuspid valve, contraction of the 
right ventricle forces blood against the tricuspid valve through the pulmonary semilunar 
valve to enter the pulmonary trunk and its branches, the pulmonary arteries. Upon relaxa-
tion of the right ventricle, the pulmonary semilunar valve closes, preventing blood from 
re-entering the right ventricle. The pulmonary artery originates at the anterior base of the 
right ventricle, from which it bifurcates to become the left and right pulmonary artery, 
which both enter into the lung hilum. The human lungs are divided into five independent 
lobes, with a lobar fissure separating the lung lobes. The anatomy of the left lung is divid-
ed into the left upper (superior) and the left lower (inferior) lobes, separated by the oblique 
fissure and each received an arterial branch form the left pulmonary artery. In contrast, the 
right lung is partitioned into the right upper lobe (superior), middle lobe (middle), and the 
lower lobe (inferior), separated by the oblique and horizontal fissures and each supplied 
with a branch from the bifurcation of the right pulmonary artery (Ding et al., 2009). Each 
of these five lobes can be further subdivided into distinct anatomical compartments, which 
are bronchopulmonary segments. Each of these segments contains segmental bronchi and 
corresponding pulmonary arterial branch. In addition, each segment is anatomically and 
functionally distinct. The pulmonary arteries continue branching irregularly but in parallel 
series with the bronchial tree until the terminal alveoli reach at the periphery of the lung 
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pleural. Then the oxygenated blood is carried from the lungs to the left atrium via the pul-
monary veins. Contraction of the left atrium forces the blood pass through the bicuspid 
valve into the left ventricle. Further contraction of the left ventricle forces the blood 
through the aortic semilunar valve into the aorta, and the oxygenated blood is distributed 
throughout the body via the systemic circulation (Figure 1.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic of the pulmonary circulation 
Deoxygenate blood in the right heart pump into the pulmonary artery and bifurcates into the right and left 
lung where gaseous exchange takes place. Oxygenated blood is then returned to the left heart via pulmonary 
vein. With the left ventricle contraction, oxygenated blood is pumped into the aorta and distributed through-
out the body. Adapted from (http://www.freelearningchannel.com/). 
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1.1.2 Structure of the Pulmonary Vessels 
The pulmonary vasculature comprises three anatomic compartments connected in series: 
the arterial tree, and extensive capillary bed, and the venular tree (Townsley, 2012). A total 
of 15 orders of arteries were found between the main pulmonary artery and the capillaries 
in the left lung and a total of 15 orders of veins between the capillaries and the left atrium 
in the right lung. In convergence, the most peripheral pulmonary arteries (the smallest 
noncapillary vessels) are termed order 1vessel. This numbering continues with each prox-
imal branch-point until the large proximal pulmonary vessel, which is defined as order 15. 
These orders are categorised using the Strahler ordering system, which shows the order 1 
arteries have an average diameter of 20 µm, whereas the diameter of order 15 pulmonary 
arteries is 14.8 mm (Huang et al., 1996). The large proximal elastic arteries of order 15-13 
have an internal diameter general > 1000 µm and are highly compliant with increased elas-
tic laminae in the tunica media to facilitate compliance. The more distal muscular arteries 
(order 12-4) have a reduction of diameter between 100 to 1000 µm and progressively lose 
their compliance with continual branching due to the increased smooth muscle and de-
creased elastic laminae in the tunica media. These pulmonary arteries are important in the 
blood pressure regulation as these vessels characterised with increased presence of medial 
smooth muscle. The most distal pulmonary arteries (order 3-1) are less than 100 µm in 
diameter and characterised with non-muscular pre-capillary arteries that medial smooth 
muscle is completely diminished. These pulmonary vessels are extremely thin-walled 
composed of endothelial cells and pericytes (undifferentiated smooth muscle cells) to facil-
itate the blood-gas exchange.  
 
The adult human lung contains approximately 300 million alveoli, each of which made up 
of approximately 1000 capillary segments with the entire network connecting to 300 mil-
lion arterioles and venules. That it approximately 85-95% of alveolar surface is interwined 
with pulmonary capillaries, with 280 billion capillaries supplying 300 million alveoli. Each 
capillary has an internal diameter less that 10 µm and supplies blood to several alveoli. 
Thus, the pulmonary capillary bed is a huge reservoir with a large surface area about 125 
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m2 and the gas exchange surface is very thin (0.2 - 0.5 µm), which efficiently facilitates the 
blood oxygenation. The exchange of oxygen from the alveolus into the pulmonary capil-
lary blood occurs rapidly with the pressures equalizing in the two areas in 0.25 second. 
And the blood requires 0.75 second to move through the pulmonary capillary bed under 
resting conditions. 	
1.1.3 Function of the Pulmonary Circulation 
In the pulmonary circulation, the left and right sides of the heart operate in series, that is, 
blood flows sequentially from the left heart to the right heart and back to the left heart. 
Thus, in the steady state, the cardiac output of the right ventricle (pulmonary blood flow) 
equals the cardiac output of the left ventricle. The cardiac output increases from the resting 
value of approximately 5 litres per minute and can reach 25 litres per minute (or even 35 
litres per minute in elite athletes). The primary function of the pulmonary circulation is to 
facilitate the oxygenation of the deoxygenated blood arriving from the systemic circulation 
by close contact with the alveoli to all gas exchange (Comroe, 1966). After the deoxygen-
ated blood arriving from the systemic circulation, which is oxygenated by the rapid un-
loading of excess CO2 and subsequent binding of O2 molecules to haemoglobin that resides 
within the red blood cells. The protein haemoglobin is molecule that is responsible for 
carrying almost all the oxygen in the blood. It is composed of four subunits, each with a 
heme group plus a globin chain (Pittman, 2011). This CO2/O2 exchange within the lung 
produces the re-oxygenation blood, which is vital to maintain the metabolic throughout the 
body.  
 
Apart from the gas exchange function, the pulmonary circulation also participates other 
important non-respiratory functions. The pulmonary circulation is proposed to function as 
a blood reservoir. The pulmonary vessels normally contain about 600ml of blood and most 
of this is in readily distensible vessels. This blood and the blood in the left atrium together 
serve as a reservoir that supplies blood to fill the left ventricle and maintain the cardiac 
output (Comroe, 1966). Another function is served as blood filter and physical barrier, 
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which can filter and prevent the passage of inhaled foreign bodies form the respiratory 
system to the cardiovascular system and dissipation of small emboli by pulmonary endo-
thelium, fibrinolysis, and absorption of air emboli. In addition, the pulmonary circulation 
also can mediate the  metabolic activity, which can activation/inactivation of vasoactive 
substances such as prostacyclin and nitric oxide synthesised and released from pulmonary 
arterial endothelial cells.  
1.1.4 Control of the Pulmonary Circulation 
As mentioned above, the pulmonary circulation is a low pressure, low resistance, highly 
compliant circulation and pulmonary vessels are thinner walled and have less smooth mus-
cle and elastic components compared with the systemic counterparts. Especially for the 
pulmonary capillaries, which are exceptionally thin walled (Kilner, 2004). As a conse-
quence, the pulmonary arterial pressure (PAP) is typically 24/9 mmHg (systolic/diastolic), 
which is significantly lower than the systemic arterial pressure (SAP) that is typically 
120/80 mmHg) Thus, the mean pulmonary arterial pressure (mPAP) for a healthy adult is 
10-20 mmHg, whereas mean systemic arterial pressure is 70-105 mmHg. Similarly, the 
cardiac output is pumped through the pulmonary circulation at a much lower pressure that 
through the systemic circulation. The 10 mmHg pressure gradient across the pulmonary 
circulation drives the same blood flow as the pressure gradient almost 100mmHg in the 
systemic circulation.  
1.1.5 Pulmonary Vascular Resistance 
Pulmonary vascular resistance (PVR) is defined as the total peripheral resistance which 
much be overcome to maintain continuous blood flow through the pulmonary arteries. The 
PVR is mainly related to the geometry of small distal resistive pulmonary arterioles. Ac-
cording to the Poiseuille’s law, PVR is inversely related to the fourth power of arterial ra-
dius, which indicates that even small changes in lumen diameter are likely to significantly 
resulting in large changes in PVR. Thus, PVR is considered to mainly reflected the func-
tional status of pulmonary vascular /smooth muscle cell coupled system. PVR is also posi-
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tively related to blood viscosity and may be influenced by changes in perivascular alveolar 
and pleural pressure (Chemla et al., 2002). Intimal thickening due to the vascular remodel-
ling of the pulmonary vascular wall results in an irreversible reduction of lumen diameter 
and consequently results in sustained increases in PAP. 																																	
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1.2	Pulmonary	arterial	hypertension	 	
1.2.1 Classification 
Primary pulmonary hypertension (PPH) was first described by Dresdale et al. in 1951, 
when a clinical description together with cardiac catheterization data was published 
(Dresdale et al., 1951). The first classification of pulmonary hypertension (PH) was pro-
posed in 1973 at an international conference on PPH endorsed by the World Health Organ-
isation. At that time, PH was classified into two categories: primary pulmonary hyperten-
sion (PPH) or secondary pulmonary hypertension, depending on the presence or absence of 
identifiable causes or risk factors (1973). The 2nd World Symposium on Pulmonary Arterial 
Hypertension (PAH) was held in Evian, France in 1998. The aim of the “Evian classifica-
tion” was to individualise different categories of PH sharing similarities in pathophysio-
logical mechanisms, clinical features, and therapeutic options and management (Galie et 
al., 2015, Galie et al., 2009b). Five groups of disorders that cause PH were identified: 
pulmonary arterial hypertension (Group 1); pulmonary hypertension due to left heart dis-
ease (Group 2); pulmonary hypertension due to chronic lung disease and/or hypoxia 
(Group 3); chronic thromboembolic pulmonary hypertension (Group 4); and pulmonary 
hypertension due to unclear multifactorial mechanisms (Group 5). Such a clinical classifi-
cation allowed investigators to conduct clinical trials in a well-defined group of patients 
with a shared underlying pathogenesis.  
 
The 3rd World Symposium on PAH was held in Venice, Italy in 2003. At this conference, 
the most notable change was to abandon the term PPH in favour of idiopathic pulmonary 
arterial hypertension (IPAH), familial PAH if there is a family history of PAH; or associat-
ed PAH if another cause (Simonneau et al., 2004). The 4th World Symposium on PAH was 
held in Dana Point, California in 2008. The modifications adopted in this meeting mainly 
concerned Group 1 PAH, which included patients with PAH and a family history of disease, 
or patients with idiopathic PAH possessing germline mutations (e.g., mutations in the 
genes encoding bone morphogenetic protein receptor-2 (bmpr2), activin receptor-like ki-
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nase type 1 (alk1) and/or endoglin (eng)) (Simonneau et al., 2009). The 5th World Sympo-
sium was held in 2013 in Nice, France. The consensus of this meeting was to maintain the 
general disposition of previous clinical classification, albeit with some modifications and 
updates especially for Group 1 PAH. It was also decided in agreement with the Task Force 
on Paediatric PH to add some specific items relating to paediatric PH, in order to have a 
comprehensive classification common for adults and children. The most up-to-date classi-
fication of pulmonary hypertension is listed in (Table 1-1) (Galie and Simonneau, 2013).  
 
Despite well-defined groups of PAH; functional classification (FC) is widely used as 
marker of disease severity in pulmonary hypertension and is strongly predictive of mortal-
ity (Bennett et al., 2002). The published treatment guidelines include functional classifica-
tion in their recommendations for the evaluation and treatment of patients with PAH (Galie 
et al., 2009b, Rubin and American College of Chest, 2004), based on the severity of the 
symptoms and the patient’s ability performing physical tasks. PAH patients can be further 
categorised into groups according to severity using the New York Heart Association/World 
Health Organisation (NYHA/WHO) functional classification system (Table 1-3). This 
classification is based on the physical limitations imposed on the patients, with four dif-
ferent stages from early stage Class 1 and the late stage Class 4 (patients with right heart 
failure). The NYHA/WHO classification is a very powerful predictor of survival in PH pa-
tients (Benza et al., 2010). For example, in untreated patients with IPAH or HPAH, median 
survival was six months for patients with NYHA/WHO FC IV, two and a half years for 
NYHA/WHO FC 3 and six years for NYHA/WHO FC1 and FC 2. In addition, FC is also 
an important endpoint in clinical trials of PAH therapy as the therapeutic changes can be 
easily measured and assessed within three months of therapy and are predictive of mortal-
ity (D'Alonzo et al., 1991).  	
The focus of this project is Group 1 PAH, which is divided into disease subgroups that in-
clude idiopathic PAH (IPAH), heritable PAH (HPAH, formerly familial PAH) and PAH as-
sociated with a variety of other systemic diseases or drug/toxin exposures (Austin and 
Loyd, 2014). IPAH describes a sporadic disease with neither a family history of PAH nor 
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an identified risk factor. HPAH is diagnosed in those patients with two or more family 
members presenting with disease, as well as in those patients without family history found 
to have genetic mutations in genes known to be associated with PAH (McLaughlin and 
McGoon, 2006). Germline mutations in the bone morphogenetic protein receptor type 2 
(bmpr2) gene, as well as genes encoding a number of transforming growth factor-β (TGF-β) 
signalling pathway members can be identified in ~80% of families with multiple cases of 
PAH. In addition, about 5% patients with PAH have rare mutations in other genes belong-
ing to the TGF-β super family including activin-like receptor 1 (alk1), endoglin (eng), and 
mothers against decapentaplegic homolog 9 (Smad9) (Simonneau et al., 2013).  Recently, 
two new PAH-associated genes have been identified; caveolin-1 (cav-1), a membrane pro-
tein present in caveolae that is abundant in the endothelial cells of the lung, and kcnk3, a 
gene encoding potassium channel super family K member-3. However, there are still ap-
proximately 20% of patients with no detectable mutations genes are currently known to be 
associated with PAH (Austin and Loyd, 2014). In addition, a number of drugs and toxins 
have been demonstrated as risk factors for the development of PAH, which were catego-
rised in (Table 1-3).  																				
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Table 1-1 WHO Classification of Pulmonary Hypertension 
Reproduced from (Simonneau et al., 2013). 
			
1 Pulmonary arterial hypertension    
1.1 Idiopathic PAH 
1.2 Heritable PAH 
1.2.1 BMPR2 
1.2.2 ALK1, ENG, SMAD9, CAV1, KCNK3 
1.2.3 Unknown 
1.3 Drug and toxin induced 
1.4 Associated with: 
1.4.1 Connective tissue disease 
1.4.2 Portal hypertension 
1.4.3 HIV infection 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1’’Persistent pulmonary hypertension of the newborn (PPHN) 
2 Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital 
Cardiomyopathies 
3 Pulmonary hypertension due to lung diseases and /or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude  
3.7 Developmental lung diseases 
4 Chronic thromboembolic pulmonary hypertension  
5 Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, sple-
nectomy 
5.2 Systemic disorders: sarcoilosis, pulmonary histiocytosis, lymphangioleiomyomatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental 
PH  
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Table 1-2 New York Heart Association/World Health Organization (NYHA/WHO) 
functional classification of pulmonary hypertension  	
Class Description 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
Patients with pulmonary hypertension but without resulting limitation of phys-
ical activity. Ordinary physical activity does not cause undue dyspnea or fa-
tigue, chest pain or near syncope. 
 
Patients with pulmonary hypertension with slight limitation of physical activi-
ty. They are comfortable at rest. Ordinary physical activity causes undue dysp-
nea or fatigue, chest pain or near syncope. 
 
Patients with pulmonary hypertension with marked limitation of physical ac-
tivity. They are comfortable at rest. Less than ordinary physical activity causes 
undue dyspnea of fatigue, chest pain or near syncope 
 
Patients with pulmonary hypertension with inability to carry out any physical 
activity without symptoms. These patients manifest signs of right heart failure. 
Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by 
any physical activity. 	
Table 1-3 Classification for Drug-and Toxin-Induced PAH 
Reproduced from (Simonneau et al., 2013) 																			
       Definite                                 Possible 
Aminorex                             Cocaine 
Fenfluramine                          Phenylpropanolamine 
Dexfenfluramine                       St. John’s wort 
Toxic rapeseed oil                      Chemotherapeutic agents 
Benfluorex                            Interferon α and β 
SSRIs                                Amphetamine-like drugs 
      Likely                                   Unlikely 
Amphetamines                         Oral contraceptives 
L-Trytophan                            Estrogen 
Methamphetamines                      Cigarette smoking 
Dasatinib 
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1.2.2 Clinical Definition and Diagnosis  
PH is a rare, progressive disease characterised by vasoconstriction and remodelling of the 
pulmonary vasculature and a rise in right ventricular pressure, resulting in right heart fail-
ure and eventual death. PH is currently defined by a mean pulmonary artery pressure 
(mPAP) of > 25 mmHg at rest measured by right heart catheterisation (RHC). Due to the 
insufficient evidence of exercise conditions, an exercise criterion to the PH definition is 
excluded. PH is also characterised hemodynamically by the presence of pre-capillary PH, 
including an end-expiratory pulmonary artery wedge pressure (PAWP) < 15 mmHg and a 
pulmonary vascular resistance > 3 Wood units (Hoeper et al., 2013). 
 
In the early phases of the disease, PH may be asymptomatic. Patients usually present with 
dyspnea exacerbated by exertion, fatigue, chest pain, and palpitations. These symptoms are 
ambiguous and not specific, which often lead to delays in the diagnosis of PH. The differ-
ential diagnosis includes congestive heart failure, coronary artery disease, pulmonary em-
bolism, and chronic obstructive pulmonary disease. PH patients in advanced stages of the 
disease may exhibit clinically evident right-sided heart failure, dizziness, syncope, edema, 
or cyanosis (Stringham and Shah, 2010). Due to the classifications of PH, the diagnosis of 
disease needs a series of investigations to confirm the diagnosis and establish the cause of 
PH and determine the severity. A detailed patient history, thorough physical examination, 
and a high index of suspicion are essential to diagnosing PH. Other investigations include 
laboratory tests (blood tests), chest radiography, electrocardiography (ECG), echocardiog-
raphy, pulmonary function tests, lung scintigraphy, computed tomography scans, cardiac 
magnetic resonance imaging (MRI), positron emission tomography scanning, vasodilator 
testing, assessment of ventriculoarterial coupling, and right heart catheterisation (RHC) 
(Rich and Rich, 2014).  			
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1.2.3 Epidemiology of Pulmonary Arterial Hypertension 
PAH is a rare disease, with an estimated worldwide prevalence ranging from 10 to 52 cases 
per million of population (Peacock et al., 2007). In the United Kingdom (UK.) and Ireland 
registry, the incidence is between 2001 and 2009 was shown to be 1.1 per million per an-
num (Ling et al., 2012). A US National Institutes of Health (NIH) registry study conducted 
in the 1980s showed that IPAH patients were typically diagnosed in young adults with a 
mean age of 36±15 years (Rich et al., 1987). Data from the PH registry of the UK and Ire-
land in 2001-2009 found that 26% of patients were aged 51-65 years and 23% were aged > 
65 years (Ling et al., 2012). A recent audit of PAH patient in the UK from 2013, similar to 
previous audits in 2010-2012 reported that 21% of PAH patients were in the 60-69 years’ 
age bracket. In general, registry data show a greater incidence of PAH in female patients, 
with approximately 70-80% female PAH patients in most registries. This strong gender bi-
as has increased since the 1980s, when the NIH registry in the US showed that 63% of 
PAH patients were female (Rich et al., 1987). The recent five-year outcomes of patients 
enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management 
(REVEAL Registry) showed that female patients account for 79.4% of the registry mem-
bership (the female: male ratio is 3.9:1.0). The female: male ratio is variable when evalu-
ated by functional classes (FCs) including FC 1 (2.9:1.0), FC 2 (3.4:1.0), FC 3 (4.6:1.0), 
and FC 4 (4.2:1.0) (Farber et al., 2015). The underlying reasons for this variance in fe-
male/male ratio across functional class include several factors such as geography, age and 
aetiology.  
 
Analysis study characterises the 5-year survival in the United States of a cohort included 
2039 previously diagnosed and 710 newly diagnosed patients stratified by baseline func-
tional class (FC). Observes survival rates in the PAH patients at 1, 3, and 5 years were 
90.4%, 76.2%, and 65.4% respectively; in newly diagnosed patients, survival rate were 
86.3%, 69.3, and 61.2% respectively. In according to the function classification (FC), pre-
vious diagnosed patients in FC 1, 2, 3, and 4 had an estimated 5-year survival rate of 
88.0%, 75.7%, 57.0%, and 27.2%, respectively, compared with 72.2%, 71.7%, 60%, and 
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43.8% for newly diagnosed patients in FC 1, 2, 3, and 4, respectively (14). In addition, the 
UK and Ireland registry described a 1-, 3-, and 5-year survival of 92.7%, 73.3%, and 61.1% 
respectively (Ling et al., 2012).  
1.2.4 BMPR2 Mutations in PAH 
PAH is a disease with an underlying genetic susceptibility. Cases of HPAH occur due to 
mutations in PAH predisposing genes, most frequently with autosomal dominant modes of 
inheritance. This accounts for the familial distribution of HPAH, as each child of an af-
fected individual is at a 50% risk of inheriting the mutant allele (Thompson and McRae, 
1970). The first report of linkage in HPAH showed the disease locus was mapped to a 
27-cM region on chromosome 2q31-q32, and was termed primary pulmonary hypertension 
1 (pph1) (Morse et al., 1997). Subsequent studies identified that HPAH can be caused by 
mutations in the bone morphogenetic protein type II receptor gene (bmpr2), a ser-
ine/threonine kinase which binds a specific subset of the TGF-β superfamily of ligands 
(International et al., 2000). We now know that bmpr2 mutations are responsible for the 
majority of HPAH cases (80%) and for a significantly subset of sporadic PAH patients 
(Austin et al., 2013, Fessel et al., 2011, Morrell, 2010). There are over 300 different bmpr2 
mutations have been identified (Evans et al., 2016). The bmpr2 gene is located on chro-
mosome 2q33 and contains 13 exons. Exons 1-3 encode an extracellular domain, exon 4 
encodes the transmembrane domain, exons 5-11 encode a serine/threonine kinase domain, 
and exons 12 and 13 encode a very large intracellular C-terminus (Newman et al., 2004) 
(Figure 1.2). In normal lung vasculature, bmpr2 is predominantly localised to the vascular 
endothelium, with much lower levels of expression in vascular smooth muscle and fibro-
blasts (Atkinson et al., 2002). The expression of bmpr2 is decreased in the pulmonary vas-
culature of bmpr2 mutant HPAH patients as well as in IPAH patients without bmpr2 muta-
tion, suggesting the important role of bmpr2 in the pathogenesis of PAH (Morrell, 2010, 
Evans et al., 2016). The average penetrance of bmpr2 pathogenic variants is very low, with 
approximately 20% overall penetrance, and is sex dependent. For example, the lifetime 
risk of developing HPAH with a bmpr2 pathogenic variation in males is 14%, whereas in a 
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female is 42% (Austin and Loyd, 2013). Therefore, it is suggested that additional genetic 
or environmental factors are involved in the pathogenesis of HPAH. 
  
 
 
 
Figure 1.2 Schematic representation of bmpr2 functional domains 
Genetic characteristics of patients with PAH demonstrated the range of bmpr-2 mutations and indicated the 
nature of amino acid substitution or nonsense mutations (X). Adapted from (Dewachter et al., 2009) 
1.2.5 Pathobiology of Pulmonary Arterial Hypertension 
PAH has a multifactorial pathobiology. Vasoconstriction, remodelling of the pulmonary 
vessel wall, and thrombosis contribute to increased pulmonary vascular resistance in PAH 
(Rubin, 1995). The pulmonary vascular remodelling process involves all layers (adventitia, 
media, and intima) of the pulmonary vessel wall and is complicated by cellular heteroge-
neity within each cellular compartment of the vessel wall (Jeffery and Morrell, 2002).  
 
All pulmonary vascular cell types (endothelial cell (ECs), smooth muscle cells (SMCs), 
fibroblasts), as well as inflammatory cells and platelets contribute to the pathogenesis of 
PAH (Hassoun et al., 2009, Morrell et al., 2009, Humbert et al., 2004b). Pulmonary vaso-
constrictions, initiated by hypoxia, elevations in cytoplasmic Ca2+ or decreased volt-
age-gated K+ channel depolarisation, are believed to be an early initiation factor of the 
pulmonary hypertensive process (Mandegar et al., 2004). Excessive and sustained eleva-
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tion of vasoconstriction is related to endothelial dysfunction, which further leads to medial 
hypertrophy, a central aspect of pulmonary vascular remodelling. Indeed, it is widely rec-
ognised that the hallmarks of PAH are sustained vasoconstriction and vascular remodelling, 
leading to a progressive increase in pulmonary artery pressure (Shimoda and Laurie, 2013). 
PAH often leads to right heart failure, the primary cause of mortality in patients with PAH, 
although in the early stages of the disease there is a compensatory increase in right ven-
tricular hypertrophy (Zangiabadi et al., 2014). There are several specific signalling path-
ways known to regulate pulmonary vasoconstriction and remodelling in PAH including 
bone morphogenetic proteins (BMPs)/transforming growth factor-β (TGF-β) pathways 
(Long et al., 2009, Zaiman et al., 2008), endothelin-1 (ET-1), nitric oxide (NO), and pros-
tacyclin (PGI2) pathways (Humbert et al., 2004c). The identification and pharmacological 
targeting of these signalling pathways are considered as the therapeutic strategies for dis-
eased treatment of PAH. 
1.2.5.1	Vasoconstriction	 	
Vasoconstriction of the small pulmonary arteries is an essential initiating factor in the 
pathogenesis of PAH. Vasoconstriction represents an early and potentially reversible stage 
in the development of PAH when it occurs without complications such as microthrombosis 
and pulmonary vascular remodelling (Mandegar et al., 2004). Hypoxic pulmonary vaso-
constriction, or HPV, is a physiological response to alveolar hypoxia that distributes pul-
monary capillary blood flow to alveolar areas of high oxygen partial pressure. HPV is 
caused by hypoxia-driven decreases in the expression of potassium channel proteins, 
which result in PASMC membrane depolarisation and subsequent induction of calcium in-
flux and calcium release from intracellular stores, leading to smooth muscle cell contrac-
tion (Sommer et al., 2008, Arrigo and Huber, 2013). The sustained vasoconstriction in-
duced in the early stages of PAH leads to endothelial cell dysfunction alongside impaired 
production of vasodilators including prostacyclin, and nitric oxide (NO), and increased 
synthesis of vasoconstrictors such as endothelin-1 (ET-1) (Lai et al., 2014), all of these 
three pathways are involved in the development and progression of PAH (Humbert et al., 
	 18	
2004c). These three mediators act to regulate the diameter of the pulmonary vessel by fur-
ther reducing vasodilatation (NO and prostacyclin) or by exacerbating hypoxia-induced 
vasoconstriction (ET-1) (Chester and Yacoub, 2014). Under physiological conditions, all 
these mediators maintain pulmonary vascular tone at an optimal level. In PAH disease, the 
profile of endothelium-released vasoactive factors is dysregulated, with reduced produc-
tion of vasodilator agents NO and prostacyclin (Ghofrani et al., 2002, McLaughlin and 
McGoon, 2006, Mitchell et al., 2008). In addition, NO and prostacyclin also exert an in-
hibitory effect on the regulation of smooth muscle cell proliferation and platelet activation 
(Mitchell et al., 2008).  
1.2.5.1	Pulmonary	Vascular	Remodelling	
PAH is associated with structural and mechanical changes in the pulmonary vascular bed 
that increase the right ventricular afterload, leading to narrowing and stiffening of both 
proximal and distal pulmonary arteries. PAEC apoptosis occurs in the early stages of the 
vascular remodelling process results in the selection of an apoptosis-resistant, proliferation 
and phenotypically altered EC phenotype and the damage of EC may stimulate PASMCs 
phenotype change due to the exposure to the circulating mitogenic factors (Sakao et al., 
2009, Sakao et al., 2005). It is widely recognised that the hallmarks of PAH are sustained 
vasoconstriction and pulmonary vascular remodelling (Stacher et al., 2012). PAH is char-
acterised primarily by increase in proliferation, migration, resistance to apoptosis, and 
glycolytic metabolism in pulmonary artery smooth muscle, fibroblasts, and endothelial 
cells (Archer et al., 2010). Remodelling might involve both arterial and venous compo-
nents of the pulmonary vascular bed: especially in small distal pulmonary arteries 
(Dorfmuller et al., 2010). Typically, a transverse section of a remodelled pulmonary artery 
reveals neointimal thickening and fibrosis, smooth muscle hypertrophy arising from 
PASMC hyperplasia and adventitial thickening and/or fibrosis (Figure 1.3). 	
There are several histopathological subtypes observed in the pulmonary vascular remodel-
ling in human patients with PAH (Cool et al., 2005). Hyperplasia and thickening of smooth 
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muscle, adventitial fibrosis, and increased medial thickness occur in most form of 
mild/moderate-stage PAH, which leads to occlusion and eventual loss of small pulmonary 
arteries and results in reduced perfusion of the lung (Moledina et al., 2011, Humbert et al., 
2004b). In addition to affect the distal pulmonary arteries, pulmonary vascular remodelling 
also affects the large proximal pulmonary artery. Medial and adventitial hypertrophy oc-
curs in the large proximal leads to the loss of pulmonary vascular compliance and proximal 
pulmonary artery stiffening, which can predict mortality in patients with PAH (Tian and 
Chesler, 2012). In severe/end-stage PAH, plexiform lesions are usually observed in the 
most severe subtype of pulmonary vascular remodelling. The plexiform lesion is a focal 
proliferation of endothelial channels lined by myofibroblasts, SMCs, and connective tissue 
matrix, which represent an extreme example of pulmonary vascular remodelling usually 
observed in severe patients with PAH (Pietra et al., 2004). These lesions are most com-
monly formed just distal to the bifurcation site of small pulmonary arteries (approximately 
50 to 300 µm) (Tuder et al., 1994). Fibrin thrombi and platelets are frequently present in 
the plexiform lesions (Pietra et al., 2004). The endothelial cells within the plexiform le-
sions express high levels of vascular endothelium growth factor (VEGF) and VEGF re-
ceptor (Cool et al., 1999), key regulators of endothelial angiogenesis, as well as the cell 
adhesion molecule CD44. The cell adhesion molecule CD44 have been demonstrated in-
volved in angiogenesis, endothelial cell proliferation and migration (Ohta-Ogo et al., 2012). 
Thus, the disordered angiogenesis, proliferation and migration of endothelial cells are be-
lieved to contribute to the plexiform lesions formation.  	
The presence of inflammatory cells in the surrounding area of plexiform lesions composed 
of T cells, B cells and macrophages also are thought to be involved in the development of 
the plexiform lesion (Tuder et al., 1994). The consequence of plexiform lesion formation is 
the complete obliteration of the distal small pulmonary arteries, resulting in the severe im-
pairment and cessation of the blood flow and leading to increased pulmonary vascular re-
sistance. Targeting the disordered angiogenesis, proliferation, apoptosis, and inflammatory 
is believed to resulting in inhibition of the pulmonary vascular remodelling process and 
considered the effective therapeutic strategies in treatment of PAH. For example, 
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pexoxisome proliferator-activated receptor-gamma (ppar-γ) has anti-proliferative, 
pro-apoptotic and anti-inflammatory functions as well as inhibiting angiogenesis (Humbert 
et al., 2004b, Hassoun et al., 2009, Pullamsetti et al., 2011). The decreased expression of 
ppar-γ is observed in plexiform lesions of patients with PAH (Ameshima et al., 2003)  
and PPAR-γ agonist has shown to mediate a protective role in the experimental PH model 
(Hansmann et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Histopathologically changes observed in pulmonary vascular remodelling in human patients 
with PAH 
The comparison of the Histopathologically subtypes of PAH. Top left, A: plexiform lesion characterised by 
exuberant proliferation of cells and lumen obliteration. Top right, B: Smooth muscle hypertrophy/hyperplasia 
typically observed in mild/moderate human PAH. Bottom left, C: Adventitial fibrosis observed in moderate 
PAH patients. Bottom right, D: a normal pulmonary artery. Adapted from (Cool et al., 2005).  
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1.2.6 Cellular Components of PAH 
As illustrated in the previous section, pulmonary endothelial cell (ECs), smooth muscle 
cells (SMCs), and fibroblasts of the pulmonary vessel wall, as well as platelets and in-
flammatory cells play an important role in PAH pathogenesis. The interactions including 
ECs, SMCs, fibroblasts, circulating platelets and inflammatory cells are regulated by sev-
eral autocrine and paracrine mediators, contributing to the pathophysiologic features of 
PAH (Hung et al., 2011). Vascular stressors, such as endothelial injury, inflammation, 
flow/shear stress, and hypoxia can result in constrictive remodelling of the pulmonary 
vessels, which in PAH primarily affects the small distal pulmonary arteries (Cabili et al., 
2011, Pugliese et al., 2015) (Figure 1.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Schematic showing the different cells types involved in pulmonary vascular remodelling 
In PAH, the pulmonary artery undergoes changes to all three layers of the vessel, including adventitial thick-
ening with fibroblast proliferation and inflammatory cells recruitment (macrophages, dendritic cells, mast 
cells, B cells, and T cells), proliferation, resistance to apoptosis and hypertrophy of pulmonary artery smooth 
muscle and endothelial cells result in medial and intimal thickening of the pulmonary vessel wall.  
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1.2.6.1	Endothelial	Cells	
Endothelial cells (ECs) are located in the inner layer of the pulmonary artery wall. Endo-
thelial damage and dysfunction play a key role in the initial event in PAH. The mecha-
nisms underlying these observations are largely unknown, however the insults may include 
hypoxia, inflammation, viral infection, mechanical stretch or shear stress, and/or aberrant 
responses to drugs or toxins on a background of genetic susceptibility (Pullamsetti et al., 
2011). In severe and end-stage PAH, the formation of ‘plexiform’ vascular lesions is 
caused by dramatically increased EC proliferation and resistance to apoptosis in response 
to the initial EC attrition that occurs in the early stages of the disease (Sakao et al., 2009). 
The bone morphogenetic proteins have showed anti-apoptosis effect in PAECs (Hirose et 
al., 2000). The impaired BMP signalling due to the loss of function mutations in bmpr2 
leads to increased PAEC apoptosis could explain the loss of PAECs in the early stages of 
PAH (Teichert-Kuliszewska et al., 2006). In IPAH patients, the apoptosis-resistant ECs ex-
ert robust proliferation and migration than the ECs from healthy donors (Masri et al., 2007). 
Endothelial cells also regulate the vasoconstriction and thrombosis processes through the 
production and release of several vasodilatory and vasoconstrictory mediators. The imbal-
ance between these vasoactive mediators can lead to dysregulation of vascular tone (Wil-
kins, 2012). In addition, growth factors released by endothelial cells can modulate SMC 
proliferation and migration, contributing to the abnormal vascular remodelling process that 
is the hallmark of PAH. For example, over-production of fibroblast growth factor 2 (FGF2), 
serotonin, and endothelin-1 (ET-1) by PAECs leads to increased PASMC proliferation, 
which is a critical component of the abnormal crosstalk between these two cell types con-
tributing to pulmonary vascular remodelling during the progression of PAH (Izikki et al., 
2009). The excessive autocrine release of endothelial-derived FGF2 in PAH also contrib-
utes to the acquisition and maintenance of an abnormal endothelial phenotype, enhancing 
proliferation through constitutive activation of ERK1/2 and decreasing apoptosis by in-
creasing B-cell lymphoma 2 (bcl2) and B-cell lymphoma extra-long (bcl-xl) (Tu et al., 
2011). Fluid shear stress decreases the expression of the tumour suppressor gene peroxi-
some proliferator-activated receptor-γ (ppar-γ) in endothelial cells and that loss of ppar-γ 
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expression characterises an abnormal, proliferating, apoptosis-resistant endothelial cell 
phenotype (Ameshima et al., 2003). This is of particular relevance to PAH, as complex 
vascular lesions within the lungs of patients with severe PAH show decreased or absent 
ppar-γ expression (Ameshima et al., 2003).  
1.2.6.2	Smooth	Muscle	Cells	 	
Smooth muscle cells (SMCs) located in the medial layer of the vessel wall can present 
various phenotypes including cell morphology, proliferation and migration rates and the 
expression of protein markers, which are depending on their functions (Nogueira-Ferreira 
et al., 2014). For example, elongated cells with slow proliferative and migratory rates typ-
ify the contractile SMC phenotype. On the contrary, a rhomboid morphology and higher 
proliferative and migratory features typify the synthetic phenotype (Hao et al., 2003). The 
mechanisms involved in the SMC phenotype modulation include pathways/mediators such 
as the transforming growth factor beta (TGF-β) superfamily, tumour necrosis factor-α 
(TNF-α), PDGF platelet-derived growth factor (PDGF), and angiotensin II (Rensen et al., 
2007). PASMC derived from PAH patients exhibit a significant resistance to apoptosis in-
ducers such as bone morphogenetic protein 2 (BMP2) and bone morphogenetic protein 7 
(BMP7) (Voelkel and Tuder, 1997) and show more proliferative and increased migration 
phenotypes, which suggest that increased PASMC proliferation, migration and decreased 
PASMC apoptosis can concurrently mediate thickening of the pulmonary vasculature, 
subsequently narrowing the inner-lumen diameter of pulmonary arteries leading to pulmo-
nary vascular resistance increasing (Savai et al., 2014, Voelkel and Tuder, 1997). The distal 
extension of smooth muscle into non-muscular small peripheral pulmonary arteries result-
ing in muscularisation of the terminal portion of the pulmonary artery due to the differenti-
ation and hypertrophy of SMC precursor cells and pericytes already present in the vessel 
wall (Stenmark et al., 2002, Aggarwal et al., 2013). In addition, the medial SMC layer ex-
hibits a variety of changes during PAH pathogenesis, including SMC hypertrophy, SMC 
hyperplasia and extensive extracellular matrix protein deposition (collagen and elastin). 
SMC hypertrophy is a predominant feature of larger proximal pulmonary vessels, whereas 
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the small distal pulmonary vessels undergo hyperplasia (Aggarwal et al., 2013, Stenmark 
et al., 2006b). Recently study found that bone morphogenic protein-4 (BMP4), TGF-β, 
Serotonin or 5-hydroxytryptamine (5-HT), and ET-1 can induce the PASMC hypertrophy, 
which showed increased cell size, protein synthesis, and contractile protein expression 
(Deng et al., 2010). Moreover, PAEC can also directly influence the behaviour of PASMC 
during PAH pathogenesis, for example by secreting growth factors that stimulate the pro-
liferation of PASMC such as platelet-derived growth factor (PDGF) and FGF2 or by re-
ducing and/or failing to produce factors that suppress PASMC proliferation, such as apelin 
(Crosswhite and Sun, 2014).  
1.2.6.3	Fibroblasts	
The adventitia of the vessel wall is predominantly composed of fibroblasts, and undergoes 
a variety of changes during the development of PAH. The fibroblast populations are heter-
ogeneous within specific tissues including the lung and with significantly diversity popula-
tions comprising the pulmonary artery adventitia. This can explain only certain subsets of 
fibroblasts are in responding to injury and stress (Das et al., 2002). Fibroblasts response to 
injury and other pathophysiological stimuli through activation of vascular NADPH oxi-
dases, inducing the production of reactive oxygen species (ROS) (Meier et al., 1989). The 
hypoxia induced ROS generated by pulmonary artery adventitial fibroblasts drives hypoxia 
induced fibroblast proliferation and can act as paracrine effect on neighbouring SMCs to 
increase their contraction (Li et al., 2008, Touyz and Schiffrin, 2004). In addition, adventi-
tial fibroblasts in response to ROS or other stimuli are capable of releasing a number of 
mediators such as ET-1, PDGF, FGF2, and Heat shock protein 90 (HSP-90), which could 
affect vascular tone. Activated resident fibroblasts are also affecting SMC proliferation and 
extracellular matrix (ECM) production by releasing cytokines and growth factors 
(Herrmann et al., 2002, Stenmark et al., 2011). The mechanisms of hypoxia induced ad-
ventitial fibroblast proliferation include the activation of Gαi and Gq family members and 
subsequent stimulation of protein kinase C and mitogen-activated protein kinase (MAPK) 
family members (Das et al., 2001, Das et al., 2000). The activation of phosphatidylinosi-
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tol-3-kinase (PI3K), synergistic interactions with Akt mammalian target of rapamycin 
(mTOR), and p70 ribosomal protein S6 kinase has also been implicated (Gerasimovskaya 
et al., 2005, Krick et al., 2005). 
 
From the activated adventitial fibroblasts, a subset population of activated fibroblasts can 
differentiate into a myofibroblast phenotype (Stenmark et al., 2002). Myofibroblasts ex-
press α-Smooth muscle actin (α-SMA), which is the most common marker for myofibro-
blast identification (Desmouliere et al., 2005, Phan, 2002). The differentiation of fibro-
blasts into myofibroblasts is regulated by a variety of factors including growth factors, cy-
tokines, adhesion molecules, and ECM. All these factors including TGF-β, thrombin, ET-1, 
Angiotensin II (Ang-II), and Interleukin-6 (IL-6) can induce the differentiation of fibro-
blasts into a myofibroblast phenotype and are upregulation by hypoxia stimulation and ob-
served in the pulmonary artery adventitia of chronic hypoxic animals (Stenmark et al., 
2002, Gao et al., 2003, Gallucci et al., 2006, Shi-Wen et al., 2004). In addition, hypoxia 
can stimulate the transition of fibroblast to myofibroblast along with the induction of pro-
liferation of pulmonary artery adventitial fibroblasts (Short et al., 2004). There is early and 
dramatic increase in the appearance of α-SMA expressed myofibroblasts in the adventitia 
in the chronic hypoxia induced PH (Sobin et al., 1983). Myofibroblasts are also the main 
producers of collagen and other ECM proteins such as fibronectin, tenascina and elastin 
(Stenmark et al., 2006a). An excessive deposition of ECM proteins was observed in the 
adventitia in PAH (Durmowicz et al., 1994). 
 
The composition of the adventitial ECM is largely regulated by fibroblasts. The production 
of ECM is dependent on the stresses or injuries on the fibroblast, which accumulation can 
have a profound effect on vascular structure and function (Stenmark et al., 2011). In addi-
tion to secreting ECM proteins, fibroblasts produce matrix metalloproteinases (MMPs), 
which allow fibroblasts to move through the adventitial matrix into the media or intima by 
promoting ECM remodelling (Shi et al., 1999). Taken together, the changes of adventitial 
fibroblasts in response to vascular stimuli and injuries facilitate fibroblast proliferation, 
migration, and differentiation, which can affect the vascular function, structure and the 
	 26	
vascular remodelling.  
1.2.6.4	Inflammatory	Cells	
Inflammatory cells have been demonstrated as major pathogenic components of the pul-
monary vascular remodelling (Hassoun et al., 2009). Pulmonary vascular lesions occurring 
in PAH patients and animal models of PH are characterised by varying degrees of peri-
vascular inflammatory infiltrates, comprising T- and B-lymphocytes, macrophages, den-
dritic cells and mast cells (Rabinovitch et al., 2014). T cells are increased in pulmonary 
vasculature in lungs of PAH patients. Cytotoxic CD8+ T cells constitute the major part of 
the inflammatory component in plexiform lesions (Savai et al., 2012) and deficiency of 
cytotoxic CD8+ T cell in patients is associated with an increased risk of death in PAH pa-
tients (Edwards et al., 2013). In addition, decreased regulatory T cell (Treg) function, 
which can control T-cells and regulate monocytes, macrophages, dendritic cells, natural 
killer cells, and B cells, may predispose individuals to PAH as well as in animals (Rab-
inovitch et al., 2014). For example, the failure of Treg control endothelial injury may lead 
to PAH, which suggest that Treg normally function to limit vascular injury and may protect 
against the development of PAH (Tamosiuniene et al., 2011).  
 
Increased numbers of macrophages are observed in the plexiform lesions of patient with 
severe PAH (Gerasimovskaya et al., 2012). Activation of macrophages induced the release 
of inflammatory cytokines such as Interleukin-1(IL-1), Interleukin-6 (IL-6), TNF-α, and 
Interleukin-10 (IL-10) which are involved in the pathogenesis of PAH (Stow et al., 2009). 
Macrophages activation is also linked to epigenetic changes that stimulate and induce pro-
liferation of vascular fibroblasts in patients and in experimental models of PH (Li et al., 
2011). Macrophages can secret MMPs, which inappropriate expression is contribute to the 
pathogenesis of PAH (Brauer, 2006). In addition, mast cell population was shown to be 
abundantly present in patients with PAH (Dahal et al., 2011). And the activation of mast 
cell contribute to the vascular remodelling and dysfunction in PAH (Farha et al., 2012). 
Peripheral blood lymphocyte analysis showed B cells are activated in IPAH patients, which 
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have a distinct RNA expression profile of the peripheral blood B-lymphocytes compared to 
healthy controls (Ulrich et al., 2008). 
1.2.7 Current Approved Therapeutic Strategies in PAH 
PAH is a complex disease that requires an integrated therapeutic approach involving mul-
tiple clinical disciplines. As discussed above there are many cell types and signalling 
pathways involved in the pathobiology of PAH, and the incomplete understanding of the 
molecular pathways resulting to the lack of sufficient treatment strategies. Over the past 
decade, recent advances in the understanding of the mechanisms underlying the develop-
ment of PAH have led to major progress in treatment options for PAH patients. Unfortu-
nately, while modern PAH therapies can markedly improve patient symptoms and slow the 
rate of clinical deterioration, there is currently no cure for PAH (Galie et al., 2009b, Hum-
bert et al., 2010a). Although the life expectancy for PAH patients is now significantly im-
proved compared to the 1980’s, with 5-year mortality rates increasing from 60% in the 
1987 NIH registry to 40% in the recent U.K. and Ireland registry (Rich et al., 1987, Ling et 
al., 2012), the mortality rates remain unacceptably high. Thus there is great rationale to 
development new therapeutic routes or drugs to reduce pulmonary arterial pressure and 
decrease the pressure in the right ventricular in order to prevent right ventricular failure, 
which are the fundamental aims of PA treatment. The current three therapeutically exploit-
ed signalling pathways involved in the pathology of PAH are the prostacyclin (also called 
prostaglandin I2 (PGI2)), endothelin and nitric oxide pathways (Humbert et al., 2004c, 
Mubarak, 2010, Norel, 2007, Hata and Breyer, 2004, Whittle et al., 2012, Abramovitz et al., 
2000, Kuwano et al., 2008, Aronoff et al., 2007, Chen et al., 2013, Ghofrani and Humbert, 
2014, Shao et al., 2011, Stitham et al., 2011, Wilson and Giles, 2005, Woodward et al., 
2011) (Figure 1.5). Treatments that target these three signalling pathways in PAH have 
now been approved for clinical use (Galie et al., 2016, Galie et al., 2013), and other novel 
targets for drug treatment are currently under investigation including guanylate cyclase ac-
tivators and tyrosine kinase inhibitors (Hu et al., 2015). Currently approved treatments for 
PAH include prostacyclin analogues and the IP receptor agonist selexipag, which target the 
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prostacyclin pathway; endothelin receptor antagonists (ERAs), which target the endothelin 
pathway; and the phosphodiesterase type 5 inhibitors (PDE-5I) and soluble guanylate 
cyclase stimulators, which target the nitric oxide pathway. The current PAH treatment al-
gorithm, updated following the 5th World Symposium on Pulmonary Hypertension, rec-
ommends targeting at least one of the three main disease pathways (Galie et al., 2009b, 
Farber et al., 2013). The evidence provided by longer term randomised controlled trials 
(RCTs) indicates that specific combination therapies for PAH may provide an effective 
therapeutic approach for patients (Ghofrani and Humbert, 2014) Thus, combination thera-
py is now considered an important part of the treatment algorithm for PAH (Ghofrani and 
Humbert, 2014).  
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Figure 1.5 Major pathways approved for current therapies for PAH patients 
Three pathways were targeted for PAH treatment including a) endothelin (ET) (ET receptor antagonists), b) 
nitric oxide (NO) (phosphodiesterase type-5 inhibitors (PDE-5 inhibitors)), and c) prostacyclin (PGI2) (pros-
tacyclin analogues) pathways. Adapted from (Sitbon and Morrell, 2012). 
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1.2.7.1	Prostacyclin	Analogues	
Prostacyclin is produced primarily by pulmonary artery endothelial cells and is a natural 
ligand for the prostacyclin IP receptor, which is widely expressed in the vasculature, in-
cluding in the aorta, coronary arteries, pulmonary arteries, the cerebral arteries, where its 
expression was confined to smooth muscle cells (Oida et al., 1995, Norel, 2007, Narumiya, 
2007). Prostacyclin is synthesised from arachidonic acid (AA) by the concerted actions of 
the enzymes cyclo-oxygenase (COX) and prostacyclin synthase. AA is liberated by from 
plasma phospholipids by phospholipase enzymes, and after which it is metabolised to 
prostaglandin (PGH2) by COX. PGH2 is then further metabolised by prostacyclin synthase 
to PGI2, and by PEG2 synthases/isomerases to PGE2 or thromboxane synthase to throm-
boxane (TXA2) (Mitchell et al., 2014). Studies have demonstrated that the PGI2 pathway 
has an important role in increasing vasodilation and inhibiting vascular smooth muscle cell 
proliferation and migration (Sitbon and Morrell, 2012). The activation of the IP receptor by 
prostacyclin or its analogues also inhibits platelet aggregation (Mubarak, 2010). Converse-
ly, TXA2 elicits the opposite effect, acting as a potent pulmonary vasoconstrictor and acti-
vator of platelet aggregation. An imbalance between these vasoactive prostanoids (prosta-
cyclin and TXA2) has been demonstrated in PAH patients (Christman et al., 1992). PAH is 
associated with reduced urinary markers of prostacyclin and increased marker of throm-
boxane. Similarly, there is reduced prostacyclin synthase in the pulmonary arteries of pa-
tients with idiopathic PAH (Christman et al., 1992, Tuder et al., 1999). The observation of 
reduced levels of prostacyclin in PAH provides a rationale for therapies targeting the pros-
tacyclin pathway. In pre-clinical animal models, PGI2 receptor (PGI-R) knockout mice de-
veloped more severe pulmonary hypertension and vascular remodelling following chronic 
hypoxic exposure compared with the WT mice (Hoshikawa et al., 2001). The transgenic 
mice overexpressing prostacyclin synthase selectively in the pulmonary vasculature are 
protected against chronic hypoxia induced PH and rats with gene transfer of human pros-
tacyclin synthase ameliorated the MCT-induced PH (Gubrij et al., 2014, Nagaya et al., 
2000, Geraci et al., 1999). Further, engineered endothelial-like progenitor cells producing 
prostacyclin and mesenchymal stem cell-based prostacyclin synthase gene therapies pro-
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tected against the development of experimental pulmonary hypertension (Zhou et al., 2013, 
Takemiya et al., 2010). The currently available drugs that target the prostacyclin pathway 
are epoprostenol, iloprost, treprostinil and beraprost. These drugs are recommended for the 
treatment of patients at FC III–IV, according to the WHO/NYHA functional classification 
(Galie et al., 2016, Galie et al., 2013).  
 
Epoprostenol was the first prostacyclin analogue to be approved by the FDA, and is the 
first exogenous prostanoid to be used in the treatment of PAH (Mubarak, 2010). Epo-
prostenol is a chemically unstable compound with a short half-life (of about 6 min) which 
must be administered continuously via intravenous infusion (Badesch et al., 2007). As Ep-
oprostenol showed rapidly effective therapy in PAH, it has been recommended as an initial 
treatment for patients in FC III and IV stages. Epoprostanol treatment has improved the 
prognosis of patients with PAH, and has also been shown to improve hemodynamic 
measures (Rubin et al., 1990) (McLaughlin et al., 2002) and exercise capacity (Barst et al., 
1996, Badesch et al., 2000, McLaughlin et al., 2002). Apart from monotherapy, short-term 
studies have shown the efficacy of combining epoprostenol with PDE-5i and/or ERAs 
(Humbert et al., 2004a). Despite substantial evidence to support the use of epoprostenol in 
PAH, its short half-life, inconvenient route of administration and side effects (attributed to 
the vasodilatory effects of epoprostenol including flushing, jaw pain, arthralgias, myalgias, 
and headache (Myers et al., 2004, Delcroix and Howard, 2015)) mean that it is underused 
as a treatment for PAH. Fortunately, thermostable formulation of epoprostenol is now in 
development, while a variety of prostacyclin analogues are now available for clinical use.  
1.2.7.2	Endothelin	Receptor	Antagonists	
Endothelin-1 (ET-1), originally isolated from endothelial cells, is a potent vasoconstrictor 
and has a proliferative effect on pulmonary artery smooth muscle cells (Davie et al., 2002). 
Plasma levels of ET-1 are increased in PAH patients and correlate with PAH severity and 
prognosis (Rubens et al., 2001). There are two types of ET receptors: endothelin receptor A 
(ETAR) and B (ETBR), which are both upregulated in PAH patients (Davie et al., 2002). 
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ETAR is mainly expressed in PASMCs, and is thought to mediate ET-1-induced contraction 
and proliferation of PASMCs during PAH pathogenesis (Rubin, 2012, Frumkin, 2012); 
ETBR promotes vasodilation and clearance of ET-1 in endothelial cells (where it is highly 
expressed) and has vasoconstrictive and proliferative actions in PASMCs (Seo et al., 1994, 
Raja and Dreyfus, 2008, Raja, 2010, Eguchi et al., 1993). Currently, both selective and 
nonselective ET receptor antagonists (ERA) are approved and used for treatment of PAH 
patients. The dual ERAs bosentan and macitentan, and the selective ETAR antagonist am-
brisentan target the actions of ET-1 in the pulmonary vasculature by binding and blocking 
activation of the ET receptors, preventing ET-1-mediated responses (Humbert and Ghofra-
ni, 2016). 
 
Bosentan is a nonselective orally active dual endothelin receptor antagonist used for the 
treatment of FC III and IV stages patients (Humbert et al., 2007), as well as for FC II pa-
tients (Task Force for et al., 2009). The first randomised placebo-controlled 12-week clini-
cal study showed that bosentan could increase exercise capacity and improved hemody-
namics in patients with PAH (Channick et al., 2001). Another larger multicenter study as-
sessing 213 PAH patients for 16 weeks showed orally administered bosentan significantly 
improved exercise capacity and increased the time to clinical worsening in patients with 
severe PAH either primary or associated with connective-tissue disease (Rubin et al., 2002). 
The side effects of bosentan are associated with hepatic toxicity, headaches, flushing and 
syncope, which are probably due to the effects of bosentan on the systemic vasculature and 
associated systemic vasodilatation (Gabbay et al., 2007).  
1.2.7.3	Phosphodiesterase	Type	5	Inhibitors	
Nitric oxide (NO) released from endothelial cells induces relaxation and inhibition of 
PASMC proliferation by binding to soluble guanylyl cyclase (sGC) to increase intracellular 
cyclic guanosine monophosphate (cGMP) levels (Vakrilova, 2014). The key enzyme 
phosphodiesterase type-5 (PDE-5) is abundantly and predominantly expressed in PASMCs 
and shows increased activity in animal models of PH Which can degrade cGMP levels in 
	 33	
smooth muscle cells to terminate the action of cGMP (Corbin et al., 2005, Li and Chen, 
2013). Inhibition of PDE-5 activity by sildenafil and tadalafil has shown both acute and 
long-term beneficial effects in patients with PAH (Galie et al., 2005, Galie et al., 2009a).  
 
Sildenafil is a highly potent and selective PDE-5 inhibitor, which can inhibit the hydrolysis 
of cGMP to GMP to allowing accumulation of NO-mediated cGMP and subsequently in-
duce vasodilation and inhibit proliferation (Ghofrani et al., 2006, Michelakis et al., 2002). 
In vivo studies have shown that oral sildenafil treatment can attenuate chronic hypoxia- and 
MCT-induced pulmonary hypertension (Zhao et al., 2001, Schermuly et al., 2004). The 
SUPER-1 trial with sildenafil treatment showed improvements in 6MWD, NYHA FC and 
pulmonary haemodynamics, but with adverse events including headache, flushing and 
dyspepsia (Galie et al., 2005). The follow-up SUPER-2 trial showed sustained improve-
ments in 6 MWD and NYHA FC with an estimated 3-year survival rate of 79% (Rubin et 
al., 2011). Currently, sildenafil is approved for the treatment of patients with FC II–III in 
Europe and FC II–IV in the USA.  
1.2.8 Combination Therapy 
In most cases, monotherapy does not adequately control disease progression in PAH pa-
tients due to the involvement and interaction of several signalling pathways contributing to 
PAH pathogenesis. Using more than one class of drug to target multiple disease pathways 
may potentially increase the overall impact on each or all of the mechanisms involved in 
PAH to improve the treatment efficiency (Humbert et al., 2004c, McGoon, 2014). In se-
quential combination therapy studies, there was no significant improvement in 6MWD ob-
served in the 16-week FREEDOM-C1 and FREEDOM-C2 trials, both investigating oral 
trepostinil on a background of bosentan and/or sildenafil (Tapson et al., 2012, Tapson et al., 
2013). In the upfront combination therapy study, the efficacy and safety of first-line com-
bined bosentan plus epoprostenol versus epoprostenol alone was investigated in patients 
with severe PAH. This double blind, placebo-controlled prospective study showed a greater 
improvement in hemodynamic measurements, exercise capacity and function capacity in 
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the combined treatment group compared with monotherapy (Humbert et al., 2004a). In ad-
dition, triple upfront combination therapy has been trialled in patients with severe PAH. 
The observational analysis in PAH patients showed significant improvements in haemo-
dynamics, WHO functional class status and 6MWD using combination therapy with i.v. 
epoprostenol, bosentan, and sildenafil compared with baseline (Sitbon et al., 2014). Taken 
together, these clinical studies indicate that specific combination therapies for PAH might 
provide an effective therapeutic approach for patients. Further studies are required to in-
vestigate the optimal combination treatment algorithm for PAH in order to provide the pa-
tients with the treatment plan that will result in the best possible outcome. 	
1.2.9 Traditional Animal Models of Pulmonary Hypertension 
In order to investigate the molecular mechanisms involved in the pathophysiology of PAH 
and to perform preclinical studies for drug development, appropriate animal models of 
PAH are required. Indeed, animal models are an essential platform for investigating and 
understanding the pathophysiological processes that underlie PAH progression. The most 
commonly used animal models of PH are the chronic hypoxic model and the monocrotal-
ine (MCT) injury model, which are single-pathological-insult models.  
1.2.9.1	Chronic	Hypoxia	
The right heart catheterisation studies carried out several decades ago in people born and 
living at high altitudes compared with people born and living at sea level showed mild 
pulmonary hypertension and moderate increases in pulmonary vascular resistance and right 
ventricular load in persons living at high altitude compared to those living at sea level 
(Arias-Stella and Saldana, 1963). Moreover, a much greater increase in pulmonary artery 
pressure in response to exercise is observed in people living at high altitude compared with 
sea-level dwellers (Arias-Stella and Saldana, 1963, Sime et al., 1963). Based on these 
findings, researchers maintained various animals (mouse, rat, calf, and pig) at high altitude, 
or simulated high altitudes using tools such as hypobaric chambers. These treatments re-
sulted in the development of a pulmonary hypertension disease phenotype (Hislop and 
	 35	
Reid, 1976, Stenmark et al., 1987, James and Thomas, 1968, Hassoun et al., 1989), show-
ing that chronic hypoxia makes a significant contribution to PH. The most popular hypoxic 
animal models are using mice and rats, with PH induction achieved in the lab using hypo-
baric hypoxic chambers with exposure to 10% O2 for 2-4 weeks. This model is widely 
used, as it is very predictable and reproducible within a selected animal strain (Stenmark et 
al., 2009).  Exposure of mice and rats to chronic hypoxia exposure results in a reliable 
increase in right ventricular systolic pressure (RVSP) of about 10 mmHg in mice and high-
er in rats, together with right ventricular hypertrophy and remodelling of the pulmonary 
vasculature (Das et al., 2012). 	
There are a number of features observed in the pulmonary arteries (PAs) (all the three lay-
ers of the vessel) in mammals following chronic exposure to chronic hypoxia. These 
structural changes include muscularisation of small, normally nonmuscular arteries in the 
alveolar and increases in the appearance of cells expressing α-smooth muscle actin in the 
previously nonmuscularised vessels, as well as medial and adventitial thickening of the 
muscular and elastic vessels (Stenmark et al., 2006b). The contributors to these changes are 
including smooth muscle cell hypotrophy, proliferation, and migration, differentiation of 
pericytes, recruitment and differentiation of local fibroblasts, mononuclear cell/progenitor 
cell recruitment, transdifferentiation of endothelial cells into mesenchymal-like cells, and 
the increased deposition of extracellular matrix proteins (Meyrick and Perkett, 1989, 
Stenmark et al., 2006b, Stenmark et al., 2006a). Furthermore, chronic hypoxia also induces 
an early and persistent pulmonary artery specific vascular inflammatory response, which 
suggests inflammation playing a significant role in the hypoxia induced remodelling pro-
cess (Burke et al., 2009). Although significant stiffening of the conduit vessels, severe in-
flammatory and fibrotic lesions have been noted, unlike human PAH disease, chronic hy-
poxia induced PH in animals can be reversed following a return to normoxic conditions 
(Lammers et al., 2008, Stenmark et al., 2009).  
 
The phenotype of chronic hypoxia induced PH models differs between strains of animal 
and indeed species. For example, exposure of mice to chronic hypoxia induces minimal 
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vascular remodelling compared to rats (Dempsey et al., 2009, Frank et al., 2008, 
Nozik-Grayck et al., 2008). In hamsters, chronic hypoxia induced PH also causes less 
muscularisation of the precapillary arteries than in rats (Walker et al., 1984). In contrast, 
neonatal calves exposed to chronic hypoxia develop very severe PH with exceeded sys-
temic pressures and vascular remodelling in both distal and proximal pulmonary arteries, 
which is far more striking compared with mouse and rat model (Orton et al., 1988, Sten-
mark et al., 1987, Stenmark et al., 2006b). In addition, intimal morphology changes are 
usually minimal in the hypoxic rat and mouse models but with very pronounced intimal 
thickening in the hypoxic neonatal calves (Meyrick and Reid, 1980, Stenmark et al., 
2006b). Microarray analysis demonstrates that chronic hypoxia induced lung gene expres-
sion profiles show distinct differences between species. For example, rats exposed to hy-
poxic conditions show increased expression of genes involved in endothelial cell prolifera-
tion and decreased expression of those associated with apoptosis; while the gene expres-
sion pattern in hypoxic mouse lung shows decreased expression of genes that regulate 
vascular smooth muscle proliferation (Bull et al., 2007, Hoshikawa et al., 2003).  
 
The main advantage to chronic hypoxia is its simplicity and reliability, and widely used as 
PH model in the literature. The shortcomings of the chronic hypoxia induced PH model 
include the absence of significant pulmonary vascular remodelling, especially within the 
mouse model, and the absence of plexiform lesions even following longer exposure times, 
which cannot fully recapitulate the pulmonary vascular damage observed in human pa-
tients (Voelkel and Tuder, 2000, Herget et al., 1978, Campian et al., 2006). Moreover, 
while chronic hypoxia can induce right ventricular hypertrophy (RVH) in animals there is 
little evidence of right ventricular failure, which is the main cause of death in patients with 
PAH (Drexler et al., 2008, Stenmark et al., 2009). 	
1.2.9.2	Monocrotaline	(MCT)	Injury	Model	
Monocrotaline (MCT) is a toxic pyrrolizidine alkaloid present in the plant Crotalaria 
spectabilis and it is known for its ability to cause hepatotoxicity and PH (Heath et al., 1975, 
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Kay, 1994). Feeding rats with the seeds of Crotalaria spectabilis or by injecting nonhuman 
primates with a suspension of MCT results in a pulmonary hypertensive phenotype char-
acterised by RVH and pulmonary vascular remodelling due to the medial hypertrophy in 
the distal pulmonary vessels (Kay et al., 1967, Chesney and Allen, 1973b, Chesney and 
Allen, 1973a, Kolettis et al., 2007). Following administration of MCT, it is metabolised 
into pyrrolic derivatives in the liver by the enzyme cytochrome-P450, which initiates en-
dothelial injury in the pulmonary vessel wall (Shah et al., 2005). Due to differences in he-
patic metabolism by cytochrome P-450, the response to MCT is variable among species, 
strains, and even animals. The ideal species for the MCT-induced PH model is the rat. Alt-
hough injection or oral administration of MCT in mice causes liver damage (Miranda et al., 
1983), modest pulmonary fibrosis (Yasuhara et al., 1997, Molteni et al., 1989, Hayashi et 
al., 1995), and immunotoxicity (Deyo and Kerkvliet, 1990, Deyo and Kerkvliet, 1991), 
they do not develop a PH.  
 
The histological features of the pulmonary vasculature of MCT-induced PH include intimal 
hyperplasia, medial hypertrophy, and adventitial thickening. This model is also character-
ised by increased apoptosis of endothelial cells, proliferation and resistance to apoptosis of 
PASMCs (Kolettis et al., 2007, Gomez-Arroyo et al., 2012, Stenmark et al., 2009, Ryan et 
al., 2011). Although the exact mechanism of MCT-induced PH has not yet been fully char-
acterised, it is widely accepted that MCT metabolism causes endothelial cell damage and 
then triggers pulmonary vasculitis and obstructive pulmonary vascular remodelling (Jas-
min et al., 2001). This is consistent with the observations showing that rats exposed to 
MCT only develop increased pulmonary arterial pressures and vascular remodelling 1-2 
weeks after the initial MCT dose (Meyrick et al., 1980). In the MCT model, inflammatory 
cells (macrophages, dendritic cells, and mast cells) and cytokines (IL-1, and IL-6) play a 
pivotal role in the early stages of pulmonary vascular remodelling (Savai et al., 2012, Da-
hal et al., 2011, Henriques-Coelho et al., 2008b). Macrophage and dendritic cell accumula-
tion are believed to facilitate the inflammatory response in PH, thereby contributing to 
pulmonary vascular remodelling. In addition, mast cells are thought to have direct vasoac-
tive effects and to stimulate remodelling by increasing the production of matrix metallo-
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proteinases (Dorfmuller et al., 2003, Price et al., 2012, Thienemann et al., 2004). It has also 
been demonstrated that right heart failure in the MCT-induced rat PH model is associated 
with up-regulated expression and infiltration of both neutrophils and mono-
cytes/macrophages (Campian et al., 2010).  
 
The MCT-induced PH model is widely used by researchers. The procedure is relatively 
simple and does not require meticulous technical skills, and is also reproducible and inex-
pensive (Gomez-Arroyo et al., 2012). One of the advantages of this model is that it is a 
good model to investigate the pulmonary vascular remodelling process and its role in PAH 
pathophysiology. However, there are several shortcomings of the MCT model. The side 
effects of MCT treatment include significant liver and kidney damage, and also consisting 
of pulmonary interstitial edema, myocarditis, and hepatic veno-oclusive disease that is un-
characteristic of severe human PAH disease (Gomez-Arroyo et al., 2012). The myocarditis 
caused by MCT affects both the right and left ventricle, which complicates the study of the 
right ventricular hypertrophy/failure associated with the severe PH (Miyauchi et al., 1993). 
The disease progression toward death in MCT model might be too short for compensatory 
mechanisms to develop (Buermans et al., 2005), and most experimental treatment studies 
seem to improve, reverse, and prevent pulmonary vascular damage and PH, which has re-
sulted in criticisms that this model does not accurately recapitulate the progression of PH 
observed in humans (Stenmark et al., 2009, Ryan et al., 2011). In addition, the use of MCT 
is restricted to rats due to the differences in cytochrome P-450- mediated hepatic metabo-
lism between species (Dumitrascu et al., 2008).  
1.2.10 Alternative Animal Models of PAH 
As mentioned above, traditional models of PH provided a vast amount of knowledge in the 
understanding of the disease pathophysiology of PH. However, the chronic hypoxia and 
MCT models do not recapitulate certain aspects of PAH, such as neointimal and plex-
ogenic arteriopathy. As a result, new experimental strategies based on the two principal 
models of PAH have been developed, aimed at including progressive pulmonary vascular 
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disease with neointimal changes observed in human PAH disease. These models include 
the multiple-pathological-insult (MPI) models, which appear to correlate better with PAH 
disease in humans. In addition, several genetic modified mice models have been used for 
PH studies, which provide a tool to study specific genes and pathways in the pathobiology 
of PAH.   
1.2.10.1	Sugen	5416	(SU5416)	and	Hypoxia	 	
In the lungs of PAH patients, affected pulmonary arteries exhibit deregulated angiogenesis, 
caused by abnormal proliferation of endothelial cells into the lumen. VEGF and its recep-
tor (VEGFR-2) are required for normal endothelial cell maintenance, function and signal-
ling, and blockade of VEGF induces endothelial cell dysfunction and death, while promot-
ing apoptosis-resistant endothelial cell proliferation (Stenmark et al., 2009). In order to 
develop a better PH model to recreate the plexiform neointimal lesions observed in patients 
with PAH, a combination of VEGFR-2 blockade (using the tyrosine kinase inhibitor 
SU5416) and chronic hypoxia showed a severe, irreversible PH associated with precapil-
lary arterial occlusion by proliferating endothelial cells in rats (Taraseviciene-Stewart et al., 
2001). These severe and irreversible phenotypes were confirmed by a single subcutaneous 
with SU5416 with chronic hypoxia and then return to normoxic condition develop a severe, 
sustained PH in the last stage accompanied by severe right ventricular pressure overload 
and the formation of lesions that are indistinguishable from the pulmonary arteriopathy of 
human PAH. This PH model provides a new and rigorous approach for investigation the 
genesis, hemodynamic effects and reversibility of plexiform and other occlusive lesions in 
PAH (Abe et al., 2010). Under normoxic conditions, treatment with SU5416 also resulted 
in mild PH and pulmonary vascular remodelling in normoxic exposure rats (Tarase-
viciene-Stewart et al., 2001, Fong et al., 1999). In addition, the SU5416-injected rats ex-
hibited increase vascular smooth muscle cell proliferation due to the Vascular endothelial 
growth factor (VEGF) receptor blockade caused endothelial cell apoptosis, indicating that 
the endothelial cell VEGF receptor can regulate pulmonary vascular SMC growth (Sten-
mark et al., 2009, Taraseviciene-Stewart et al., 2001). Furthermore, the VEGF receptor 
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blockade by SU5416 only affects the lung rather than other organs and does not find peri-
vascular infiltration of monocytes/macrophages in this model (Burke et al., 2009).  
 
Contrary to rats, which require a single injection of SU5416, mice require weekly injec-
tions of SU5416 during a 3-week hypoxic exposure for induction of severe PH. Compared 
with chronic hypoxia alone, mice which receive multiple SU5416 injections show exacer-
bations in all measures of PAH pathology such as RVSP and RVH and pulmonary vascular 
remodelling. In addition, hypoxia/SU5416 treatment steadily decreases cardiac output, in-
dicating incipient heart failure. Molecular analysis showed a dysregulated 
TGF-β/BMP/Smad axis as well as augmented induction of IL-6 and Hypoxia-inducible 
factor 1 α (HIF-1α) in SU5416-and/or hypoxia-treated mice (Ciuclan et al., 2011). In con-
trast to the rat model, mice injected with SU5416 weekly during three-week chronic hy-
poxia and then with 10-week recovery in normoxia. Following ten weeks after hypoxic 
exposure, several indices of PH are reduced including RVSP, angioobliterative lesions and 
the PH and RV dysfunction does not show even worse (Vitali et al., 2014), which suggest 
this PH model is reversible. Although this mouse model of PH is less severe than the rat 
model, it is still a useful adjunct to other PH models, particularly when genetic modifica-
tion or long-term intervention is desired.  
 
The SU5416/hypoxia model has proved to be a particularly robust model of PH, which re-
semble human PAH disease more closely than the single insult models. This is in accord-
ance with ‘multiple hit’ hypothesis for the development of PH including the genetic and 
environment insults (Geraci et al., 2010). This indicates that MPI models developed form 
SPI models of PH are more correlated with human PAH disease. In addition, the 
SU5416/hypoxia model is unresponsive to treatments such as calcium-entry blocker, ACE 
inhibitors, and bosentan, and displays increased RVSP and RVH. This model appeared 
progressive and refractory to treatment and the unresponsiveness to treatment and irre-
versibility of PH features are more relevant to human PAH (Nicolls et al., 2012). Thus, the 
data generated from this new model may add greater clinical relevance.  
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1.2.10.2	Overexpression	of	S100A4/Mts	in	Mice	
The S100A4/Mts-1 gene was identified as a differentially expressed gene in highly meta-
static mouse mammary adenocarcinoma cells (Ebralidze et al., 1989). S100A4/Mts-1 is a 
metastasis-promoting protein belonging to the S100 family of calcium-binding proteins. 
The S100 family members are involved in numerous physiological functions include cell 
proliferation, differentiation, cytoskeleton dynamics, and apoptosis (Schafer and Heizmann, 
1996). The first S100A4/Mts-1transgenic mouse was created in 1998 (Ambartsumian et al., 
1998), and about 5% of transgenic mice overexpression S100A4/Mts-1 developed pulmo-
nary arterial changes resembling human plexogenic arteriopathy with intimal hyperplasia 
leading to occlusion of the arterial lumen (Greenway et al., 2004). SMC-like and endothe-
lial-like cells are found in the plexogenic lesions of S100A4/Mts-1 overexpressing mice; 
while a marked periarterial inflammatory response in plexogenic arteriophy, suggesting 
that inflammatory insult may trigger the development of plexogenic arteriophy in these 
mice (Greenway et al., 2004). The expression of S100A4/Mts-1 was absent in human lungs 
with no PH or early-stage disease, but the expression was markedly increased in the 
late-stage plexogenic arteriopathy. This suggests that S100A4/Mts-1 is not involved in the 
initial responses but may be functionally significant in the development of the more severe 
arterial lesions seen in the end-stage disease. In addition, lung biopsies from children with 
PH associated with congenital heart defects showed increased expression of 
S100A4/Mts-1in PASMCs of lesions associated with neointimal formation and plexiform 
lesions (Greenway et al., 2004). 
 
One of the principal reasons for using this model to study PAH is that most animal PH 
models lack neointimal thickening and plexiform lesions. In addition, these mice show 
gender differences. Female mice overexpression S100A4/Mts-1 developed plexiform le-
sions and increased RVSP but not observed in male mice (Greenway et al., 2004). Fur-
thermore, S100A4/Mts-1 overexpressing mice showed greater pulmonary arterial pressure 
increases and more RVH in the chronic hypoxia condition, and will sustain the disease 
phenotype even after 3 months normoxia exposure. The S100A4/Mts-1 mice develop sim-
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ilar peripheral vascular disease as control mice in response to hypoxia. Interestingly, those 
changes did not regress after normoxic exposure in S100A4/Mts-1 mice. The protein fibu-
lin-5 might contribute to these findings, which is a matrix component necessary for elastin 
fibrin assembly (Merklinger et al., 2005).  
1.2.10.3	IL-6	Overexpression	in	Mice	
Interleukin 6 (IL-6) is a cytokine produced mainly by T cells and macrophages. IL-6 is not 
only involved in inflammation and infection responses but also plays a role in the regula-
tion of metabolic, regenerative, and neural processes (Scheller et al., 2011). Both human 
PAH patients and animal PH models showed elevated levels of IL-6 and IL-6 seems to 
correlate well with disease severity and mortality (Dorfmuller et al., 2003, Price et al., 
2012, Humbert et al., 1995). In order to investigate the role of IL-6 in the development of 
PH, transgenic mice overexpression lung-specific IL-6 were created. The transgenic mice 
exhibited elevated RVSP and RVH with corresponding pulmonary vasculopathic changes, 
all of which were exacerbated by chronic hypoxia exposure. In addition, the mice had 
muscularisation of the proximal arterial tree, and chronic hypoxia enhanced this effect. 
Similar to what is observed in PAH patients, muscularisation and proliferative arteriopathy 
was seen in the distal arteriolar vessels. In the later stages of disease, animals developed 
occlusive neointimal angioproliferative lesions composed of endothelial cells and 
T-lymphocytes. This is thought to be due to the IL-6-induced activation of a proangiogenic 
factor, vascular endothelial growth factor (VEGF), the proproliferative kinase extracellular 
signal-regulated kinase, proproliferative transcription factors c-MYC and MAX, and the 
anti-apoptotic proteins survivin and Bcl-2 and downregulation of the growth inhibitor 
TGF-β and proapoptotic kinases JNK and p38 (Steiner et al., 2009). Thus, this IL-6 trans-
genic mouse model recapitulated similar features seen in patients with severe PAH includ-
ing concentric intimal wall thickening, arteriolar wall muscularization, plexogenic lesions 
and recruitment of inflammatory cells (Steiner et al., 2009). In order to further confirm the 
important role for IL-6 in the development of PH, IL-6 knockout mice exposed to chronic 
hypoxia displayed reduced RVSP, RVH, and both the number and medial thickness of 
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muscular pulmonary vessels. These knockout mice also showed less inflammatory cell re-
cruitment in the lungs compared with wild-type mice as analysed by protein levels and 
immunostaining for the specific macrophage marker F4/80 (Savale et al., 2009).  
1.2.10.4	BMPR2	Mutant	Mice	 	
As mentioned in Section 1.2.4, the genetic basis of HPAH and IPAH is related to mutations 
in bmpr2. A total of 298 different bmpr2 mutations have been identified in PAH patients 
(Machado et al., 2006). Due to the high proportion of PAH patients possessing mutations 
in bmpr2, genetic models of bmpr2 have been used to investigate the role of bmpr2 in the 
pathogenesis of PAH.  
 
Initial studies attempted to generate homozygous bmpr2 genetic ablation mice, however 
these failed to develop due to an absence of organised mesoderm (Beppu et al., 2000). 
Therefore, mice heterozygous for a bmpr2 mutant allele (bmpr-2+/-) were developed for 
PAH studies. These mice showed normal survival rates and reproduced normally, despite a 
50% reduction in bmpr2 mRNA expression in isolated PASMCs. This is consistent with 
the human observations that heterozygous bmpr2 mutations themselves are insufficient to 
account for the clinical manifestation of PAH and multiple environmental or genetic hits 
are required to trigger the disease (Morrell, 2006). In basal conditions, one study reported 
that bmpr-2+/- mice (a mutant bmpr2 allele lacking exons 4 and 5) exhibit mild PH with 
muscularisation and thickening of the pulmonary arteries, and a mild increase in pulmo-
nary arterial pressure (Beppu et al., 2004). However, the mice carrying a heterozygous par-
tially inactivation (hypomorphic) mutation at the bmpr2 locus (bmpr2δex2/+) does not de-
velop mild spontaneous PH (Frank et al., 2008) and silence bmpr2 expression by RNA in-
terference in mice does not increase pulmonary arterial resistance (Liu et al., 2007). This 
phenotype variation may due to the different bmpr2 gene mutations have different effects 
on BMPR2 protein production, which are likely to cause differences in phenotype (Austin 
et al., 2009). Importantly, these bmpr-2+/- mice exposed with a secondary insult (e.g. hy-
poxia, serotonin, or inflammation) result in development of PH such as increased pulmo-
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nary artery pressure and pulmonary vascular remodelling (Long et al., 2006, Song et al., 
2005, Frank et al., 2008, Beppu et al., 2004). These observations are similar to human pa-
tients, which the penetrance of the bmpr2 mutations is remarkably low, with only 20-30% 
of carriers actually developing HPAH (Newman	et	al.,	2001,	Newman	et	al.,	2004). 
 
The smooth muscle cell-specific transgenic mice expressing a dominant-negative bmpr2 
under control of a tetracycline gene switch (SM22-tet-BMPR2 (delx4+) mice) developed 
increased RVSP, RVH, and pulmonary arterial muscularisation (West et al., 2004). Another 
smooth muscle-specific doxycycline-inducible bmpr2 mutation with an arginine to termi-
nation mutation at amino acid 899 (SM22-rtTAx TetO (7)-BMPR2 (R899X)) mice devel-
oped elevated RVSP, associated with extensive vascular pruning, muscularisation of small 
pulmonary vessels, and development of large structural pulmonary vascular changes 9 
weeks after transgene induction. Pulmonary vascular lesions were filled with smooth mus-
cle cells and endothelial cells, and were surrounded by a large numbers of macrophages 
and T cells (West et al., 2008b). These features were confirmed with the later study using 
SM22-tet-BMPR2 (R899X) mice showed elevated RVSP, RVH, muscularisation of small 
pulmonary arteries, and associated disturbed blood flow in their lungs (Yasuda et al., 
2011).  
 
In normal lungs, bmpr2 expression is prominent on the vascular endothelium. In pulmo-
nary hypertension cases, however, the expression of bmpr2 is markedly reduced in the pe-
ripheral lung of HPAH patients, especially with heterozygous bmpr2 mutations (Atkinson 
et al., 2002). The mice with bmpr2 conditional knockout in endothelial cells revealed, but 
not all mice, elevated RVSP, developed RVH, and increased the number and wall thickness 
of muscularised (αSMA-positive) distal pulmonary arteries. In addition, there are elevated 
proteins involved in the pathogenesis of PAH include serotonin transporter and tenascin-C 
in the distal arteries and with a high incidence of perivascular leukocyte infiltration and in 
situ thrombosis (Hong et al., 2008).  
 
The conditional knockout bmpr2 in SMCs and ECs is sufficient to induce PH within a 
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subsection of mice, which demonstrated that conditional heterozygous or homozygous 
bmpr2 deletion predisposes mice to develop PH (Hong et al., 2008). This is in accordance 
with human that bmpr2 mutations predispose patients to develop PAH. Thus, the genetic 
models of bmpr2 mutations provide useful genetic resources to further investigate the 
pathogenesis regarding gene mutations in PAH. Furthermore, these models also present 
opportunities to further identify environmental and genetic factors that involved in the de-
velopment.  
 
Taken together, various animal models of PH provide valuable knowledge to understand-
ing the pathophysiology of PH. Although there is no perfect animal model can mimic hu-
man PAH disease, a number of MPI animal models developed from SPI animal models are 
more closely correlate with human disease. The MPI models tend to correlate better with 
severe PAH in human than do SPI models. However, the SPI models provide the early 
stages of PAH disease in humans, which can be reversed with proper treatment. Unfortu-
nately, PAH patients in their early stages are often missed diagnosis. Therefore, different 
animal models can be used to assess various stages of the disease progression. There is still 
a long way to cure PAH disease, and more animal models of PH need to be developed to 
provide better preclinical studies. 	
1.3	Non-coding	RNA(ncRNA)	
High-throughput transcriptomic analyses have revealed that eukaryotic genomes transcribe 
up to 90% of the genomic DNA. Only 1-2% of these transcripts encode for proteins, 
whereas the vast majority are transcribed as non-coding RNAs (ncRNAs) (Consortium, 
2004). These non-protein-coding sequences increasingly dominate the genomes of multi-
cellular organisms as their complexity in contrast to protein-coding genes. NcRNAs are 
expressed in a cell/tissue-specific manner or in a developmental stage-specific manner (van 
Rooij, 2011, Ward et al., 2015). There are mounting evidences that ncRNAs are involved 
in the pathogenesis of human diseases such as cancer, cardiovascular, neurological, devel-
opmental, and other diseases (Esteller, 2011).  
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NcRNAs can be divided into infrastructural ncRNAs and regulatory ncRNAs. Constitu-
tively-expressed infrastructural ncRNAs include ribosomal, transfer, small nuclear, and 
small nucleolar RNAs. Regulatory ncRNAs can be classified into microRNAs (miRNAs), 
Piwi-interacting RNAs (piRNAs), small interfering RNAs (siRNAs), long non-coding 
RNAs (lncRNAs), promoter-associated RNAs (PARs), enhancer RNAs (eRNAs), and cir-
cular RNAs (Cech and Steitz, 2014). This project is focused on miRNAs and lncRNAs.  
1.3.1 MicroRNAs  
1.3.1.1	MicroRNA	Genomics	and	Biogenesis	
MiRNAs are a novel class of endogenous, small/short noncoding transcripts of 16 to 29 
nucleotide RNAs that negatively regulate gene expression via degradation or translational 
inhibition of their target mRNAs (Bartel, 2004, van Rooij and Olson, 2007). The first 
miRNA identified in 1993, when researchers discovered that the lin-4 gene in C.elegans 
encoded a pair of short RNA transcripts rather a protein (Lee et al., 1993).These RNA 
transcripts were able to regulate larval development through translational repression of 
LIN-14 protein (Le Contel et al., 1995). They found that lin-4 transcripts in C.elegans con-
tain sequences complementary to a repeated sequence element in 3’UTR of lin-14 mRNA. 
lin-4 regulates lin-14 through RNA-RNA interactions with the 3’ untranslated region (Le 
Contel et al., 1995, Parant et al., 1995). In 2000, a second miRNA, let-7, was discovered, 
and since then thousands more miRNAs have been identified (Reinhart et al., 2000). In it’s 
most recent version, miRBase reports ~ 2000 human miRNAs (version 20: 
www.mirbase.org 2014) and current estimates suggest that over 30% of human genes are 
regulated by miRNAs (Filipowicz et al., 2008), leading to diverse effects on multiple cel-
lular processes. MiRNA genes can be classified into four groups according to their ge-
nomic location: intronic miRNA encoded in noncoding transcriptional units; exonic miR-
NA encoded in noncoding transcriptional units; intronic miRNA encoded in protein-coding 
transcript units, and exonic miRNAs encoded in protein-coding transcripts (Rodriguez et 
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al., 2004). Nearly half of the known human miRNAs are found in clusters, which are tran-
scribed as polycistronic primary transcripts (Lagos-Quintana et al., 2001, Lau et al., 2001). 
Each cluster usually contains two or three miRNA genes and the largest cluster, at 13q31, 
is composed of seven genes (Calin et al., 2004, He et al., 2005). About 37% of mammalian 
miRNAs appear to be located within the introns of protein-coding genes, linking their ex-
pression to the promoter-driven regulation of the host gene (Lutter et al., 2010, Baskerville 
and Bartel, 2005). Human miRNAs are located on all chromosomes except the Y chromo-
some, and are nonrandomly distributed in the human genome.  
 
MiRNA transcripts are synthesised and processed through a series of cleavage steps (Fig-
ure 1.6). The biogenesis of miRNA begins with transcription of a primary miRNAs 
(pri-miRNA) from a miRNA gene by RNA polymerase Ⅱ in the nucleus (Pedron et al., 
1993). Pri-miRNAs are structurally analogous to mRNA as they are 5’-capped and spliced 
and bear a 3’ poly-A tail, and often can produce more than one functional miRNA (Cai et 
al., 2004, Lee et al., 2004). Following association with the Drosha-DGCR8 complex, 
pri-miRNAs are processed into approximately 70 nucleotides (nt) long precursor hairpin 
structures (Pre-miRNA) in the nucleus (Gregory et al., 2004, Han et al., 2004). The 
pre-miRNA is characterised by a two nucleotide single stranded overhang on the 3’ end, 
which is recognised by Exportin-5 (XPO5) and Dicer for further processing (Du and Za-
more, 2005). Exportin-5 is a member of the karyopherin family of nucleocytoplasmic 
transport factors that can bind pre-miRNAs in the presence of a Ran-GTP cofactor, ex-
porting precursor miRNAs into the cytoplasm. Once in the cytoplasm, hydrolysis occurs 
converting RanGTP into RanGDP and releasing the pre-miRNA from the Ex-
portin-5/RanGTP complex (Yi et al., 2003). Following export of the pre-miRNAs from the 
nucleus, pre-miRNAs are further processed by a cytoplasmic RNase III endonuclease 
(Dicer) in complex with the double-stranded RNA-banding protein TRBP, which digests 
the pre-miRNAs resulting in an imperfect miRNA-miRNA duplex. This mature miRNA 
duplex is about 22 nucleotides in length, and containing the mature miRNA guide or lead 
strand and the passenger strand (Lee et al., 2002). After separation of the two miRNA 
strands by the helicase enzyme, the passenger strand is degraded, and the guide strand of 
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the mature miRNA is loaded with Argonaute (Ago2) proteins and incorporated into the 
RNA-induced silencing complex (RISC). Depending on the complementarity of the “seed 
region” of mRNA targets, the guide stand recognises and binds the 3’ untranslated regions 
(UTRs) of target mRNAs via Watson-Crick base pairing. This interaction leads to either 
translational repression/activation or degradation of its target mRNAs, and repression of 
protein translation (Winter et al., 2009).  
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Figure 1.6 MiRNA biogenesis 
Transcription by RNA polymerase II gives rise to the pri-miRNA, which can produce multiple mature 
miRNAs. Processing by the RNase III enzyme Drosha along with cofactor DGCR8 produces the stem-loop 
pre-miRNA that is exported out of the nucleus by Exportin-5. In the cytoplasm, cleavage by Dicer results in a 
miRNA duplex, ~22 nucleotides long. The mature miRNA is incorporated into the RNA-induced silencing 
complex (RISC) and targets the 3′-UTR of mRNA. Gene silencing is achieved by either mRNA degradation 
or translational repression (adapted from (Grant et al., 2013)) 
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1.3.1.2	The	Function	of	MiRNAs	 	
The regulatory functions of miRNAs are accomplished through the RNA-induced silencing 
complex (RISC). MiRNAs assembled into RISC function as guides, directing the silencing 
of target mRNA. Ago2 is the only argonaute protein that possesses endonuclease activity 
and is required for mediating mRNA cleavage. However, all four Ago proteins are associ-
ated with miRNAs as well as RISC activity in human cell lines (Meister et al., 2004). 
Structural analyses have shown that the Ago2 PIWI domain is similar to ribonuclease H, 
which cleaves mRNA to form 5’ phosphate and 3’ hydroxyl groups products, and muta-
tions within a cryptic ribonuclease H domain with Ago2 inactivate RISC(Song et al., 2004, 
Liu et al., 2004). The activated RISC binds target mRNA by complementary base pairing 
the guide stand and the 3’UTR of the target mRNA. The target recognition relies heavily 
on base pairing between the highly evolutionary conserved ‘seed sequence’ nucleotides 2-8 
at the 5’end and the corresponding 3’ region of its target mRNA (Lewis et al., 2003, Grim-
son et al., 2007). The degree and nature of complementarity between the guide miRNA and 
the target mRNA appear to determine the gene silencing mechanism (either mRNA degra-
dation or repression; (Zeng et al., 2003). Full complementarity of miRNA with the ‘seed 
region’ in the target mRNA 3’ UTR can lead to target mRNA cleavage, a process that is 
much more common in plants compared to animal cells (Rhoades et al., 2002, Davis et al., 
2005). Conversely, incomplete complementation between MiRNA and mRNA target 
3’UTR triggers the repression of mRNA translation rather than mRNA cleavage and deg-
radation (Zeng et al., 2003). This incomplete binding can prevent the initiation of mRNA 
translation, and can also inhibit mRNA translation that has already been initiated (Petersen 
et al., 2006, Nottrott et al., 2006). Incomplete complementation of miRNAs: mRNAs have 
showed to regulate target expression via initiating degradation pathways. This has been 
found act through accelerating deadenylation and decapping of the their target mRNAs 
(Rehwinkel et al., 2005, Wu et al., 2006). In addition, in addition to binding to the 3’UTR 
of target mRNA, some miRNAs have demonstrated to binding to the 5’-UTR and coding 
sequences of the mRNA (Tay et al., 2008). For example, in human Hela cells, which ex-
press endogenous let-7a miRNA. Let-7a can bind both 3’-UTR and 5’-UTR to mediate 
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translation repression of target mRNAs (Lytle et al., 2007). Thus, a variety of regulation 
mechanisms are involved in the regulation of mRNA by miRNA-RISC complex, which 
mainly depend on the miRNA: mRNA complementarity.  
 
It is generally accepted that the passenger strand of the miRNAs duplex is degraded during 
miRNA biogenesis and only the guide stand is incorporated into RISC as a functional ma-
ture miRNA. However, some miRNA passenger strands are not degraded and can also tar-
get mRNAs (Yang et al., 2013, Eulalio et al., 2012, Kos et al., 2012). For example, over-
expression of miR-590-3p or miR-199a-3p in vitro promoted cell cycle re-entry of adult 
cardiomyocytes and induced cardiomyocytes proliferation in both neonatal and adult ani-
mals. In a mouse model of myocardial infarction, overexpression of these miRNAs stimu-
lated marked cardiac regeneration and almost completely recovery of cardiac functional 
parameters (Eulalio et al., 2012). Another passenger miRNA, miR-21-3p, is enriched in 
fibroblast - derived exosomes, which cause hypertrophy when taken up by cardiomyocytes 
(Bang et al., 2014). Transfection of pre-miR-21-3p or inhibitor of miR-21-3p in cardiomy-
ocytes was showed an increase or opposite effect on the cardiomyocytes cell size. In addi-
tion, miR-21-3p was shown to inhibit the expression of target genes sorbin and SH3 do-
main-containing protein 2 (sorbs2) and PDZ and LIM domain 5 (pdlim5), which have been 
reported involved in the cardiac pathologies and cardiomyopathy (Cheng et al., 2010, Ka-
kimoto et al., 2013). Furthermore, miR-21-3p expression was elevated in pericardial fluid 
of mice with transverse aortic constriction-induced cardiac hypertrophy and administration 
of miR-21-3p antagomiR to mice with angiotensin II–induced cardiac hypertrophy resulted 
in reduced heart/body weight ratio and decreased cardiomyocytes diameter (Bang et al., 
2014). In addition, some miRNAs showed both stands were functionally inhibited target 
expression. Both miR-126-5p and miR-126-3p were shown to directly inhibit stromal 
cell-derived factor-1 alpha (sdf-1α) to inhibit lung metastasis by breast tumour cells in a 
mouse xenograft model (Zhang et al., 2013c). 
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1.3.1.3	MicroRNAs	Involved	in	PAH	
1.3.1.3.1	MiR-204	
MiR-204 were among the first studies to show a mechanistic link between miRNA dysreg-
ulation and signalling pathways involved in the pathogenesis of PAH (Courboulin et al., 
2011). The miR-204 gene is located intronic region of the transient receptor potential me-
lastatin 3 (trpm3) (Wang et al., 2010a). The decreased expression levels of miR-204 were 
found in total lung and plexiform lesions from patients with PAH, as well as animal PH 
models (chronic hypoxia mouse model and MCT rat model) (Courboulin et al., 2011) 
(Brock et al., 2014). The expression level of miR-204 also found correlated with PAH se-
verity (Courboulin et al., 2011). In addition, in vivo study showed that intratracheal nebu-
lization of miR-204 by administration with miR-204 mimics decreased the pulmonary ar-
tery pressure, right ventricular wall thickness and reduced medial hypertrophy of pulmo-
nary arteries in the MCT-induced rat PH model (Courboulin et al., 2011). These findings 
suggest miR-204 is important in the pathogenesis of PAH and can be served as a potential 
clinical biomarker of PAH disease.  
 
Mechanically, previous studies showed that in retinal epithelial cells and several cancer 
cells, miR-204 down-regulation has been demonstrated associated with enhanced prolifer-
ation and membrane potential depolarization (Lee et al., 2010, Wang et al., 2010a). The 
pro-proliferative phenotype was associated in part with the activation of the Scr-STAT3 
(accounting for bmpr2 down-regulation) (Wong et al., 2005) and NFAT pathways in sever-
al cancer cells (Bonnet et al., 2007). In PAH setting, miR-204 is primarily expressed in 
PASMCs, and the expression of miR-204 is decreased in PASMCs isolated from distal 
pulmonary arteries from IPAH patients compared with controls (Courboulin et al., 2011).  
In vitro study showed miR-204 inhibition increased proliferation and resistance to apopto-
sis in control PASMCs, which were similar to those seen in the PASMCs isolated from pa-
tients with PAH. And increasing miR-204 expression level in PAH-PASMCs reversed the 
pro-proliferation and anti-apoptotic phenotype (Courboulin et al., 2011). These beneficial 
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effects of miR-204 exert on PASMC proliferation and apoptosis activation of 
Src-STAT3-NFAT pathway in PASMCs. The PAH-induced growth factors PDGF, endo-
thelin-1 and angiotensin Ⅱ can stimulate the activation of STAT3 to mediate the downreg-
ulation of miR-204. Knockdown of STAT3 abolished the down-regulation of miR-204 in 
PAH-PASMCs, which suggest STAT3 is responsible for the decreased of miR-204 in 
PAH-PASMCs (Courboulin et al., 2011). The STAT3 activation suppresses the miR-204 
and leads to the up-regulation of shp2, which is the direct target of miR-204. The increased 
shp2 expression further activates the Src kinase and NFAT. STAT3 also directly induces 
NFATc2 expression. The activations of STAT3 and NFATc2 were observed in PAH lungs 
(Bonnet et al., 2007). Both nfat and shp2 were needed to sustain PAH-PASMCs prolifera-
tion and resistance to apoptosis (Courboulin et al., 2011). 
 
The activation of miR-204-Scr-STAT3-NFAT pathway in the development of PAH also 
confirmed in the experimental rat model. In the MCT-induced rat model of PH, the activa-
tion of STAT3 in the pulmonary arteries is earlier than the decrease of miR-204. This fur-
ther confirms the activation of STAT3 drives the down-regulation of miR-204. The 
down-regulation of miR-204 leads to the increase of SHP2, which further pushed up the 
activation of STAT3. This positive feedback between STAT-3 and miR-204 may contribute 
to the development and progression of PAH. Once the STAT3 activation becomes maximal, 
and then NFAT gets activated and results in NFAT-dependent PASMC proliferation and 
resistance to apoptosis and increasing pulmonary artery remodelling and pressures (Cour-
boulin et al., 2011). The activation of STAT3 signalling in PAH is also found in the chronic 
hypoxia induced mouse PH model. Administration of mesenchymal stromal cell-derived 
exosomes inhibited the vascular remodelling and chronic hypoxia induced PH. The mech-
anism of the protective effect is mesenchymal stromal cell-derived exosomes suppresses 
the activation of STAT3 and increases the lung levels of miR-204 (Lee et al., 2012a). 
 
In systemic vascular diseases, reduced expression of miR-204 promotes vascular bio-
mineralization by augmenting the expression of the transcription factor RUNX2 (Huang et 
al., 2010). In the PAH disease, runx2 expression was up-regulated in lungs, distal PAs and 
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primary cultured human PASMCs isolated form patients with PAH. MiR-204 inhibition 
induced runx2 up-regulation and the sustained runx2 expression activated hif-1α activation, 
leading to aberrant proliferation, resistance to apoptosis and subsequent 
trans-differentiation of PAH-PASMCs into osteoblast-like cells. In vivo model showed that 
inhibition of rnux2 reversed the SU5416/hypoxia induced PH rat model (Ruffenach et al., 
2016). 
 
MiR-204 also involved in the DNA damage in PAH. Distal PASMCs from patients with 
PAH exhibit increased DNA damage and overexpression of parp-1. parp-1 activation ac-
counts for miR-204 downregulation and subsequent activation of the transcription factors 
nuclear factor of activated T cells (NFAT) and hypoxia-inducible factor 1-α (HIF-1α) in 
PAH-PASMCs. In vitro PARP-1 inhibitor using the chemical inhibitor ABT-888 in 
PAH-PASMCs increases miR-204 expression and thereby decreases NFAT and HIF-1α ac-
tivation. Inhibition of PARP-1 in vivo improves PAH prognoses in MCT-and 
SU5416/hypoxia-induced PAH rat models (Meloche et al., 2014b), which is consistent 
with overexpression of miR-204 exerts protective role in the development of MCT-induced 
PH rat model (Courboulin et al., 2011). 
1.3.1.3.2	MiR-21	
MiR-21 is a very extensive studied miRNA in human diseases and miR-21 has been found 
to be upregulated in many pathological conditions including cancer and cardiovascular 
diseases (Jazbutyte and Thum, 2010). There are considerable studies have been carried out 
to investigate the role of miR-21 in the development of PAH using both in vitro cell culture 
and in vivo animal PH models. MiR-21 significantly upregulated in human PASMCs after 
6 h of hypoxia and remained high till 24 h of hypoxia (Sarkar et al., 2010). Both mature 
miR-21 and pri-miR-21 are increased in human PAECs after hypoxia (Parikh et al., 2012). 
In situ hybridization showed miR-21 expression increased in the distal diseased pulmonary 
vessels (< 200 µm) and the plexiform lesions in patients with PAH (Bockmeyer et al., 2012, 
Parikh et al., 2012). In the PH animal models include chronic hypoxia induced PH model 
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(Yang et al., 2012), SU5415/hypoxia mice PH model, and MCT-induced rat PH model 
(Parikh et al., 2012) revealed increased expression of miR-21. However, another study 
showed that miR-21 expression significantly reduced in MCT-induced rat PH model (Ca-
ruso et al., 2010).  
 
Due to the dysregulation of miR-21 expressions in PAH patients and various animal PH 
models, the effect of manipulation of miR-21 on PH progression and development was in-
vestigated. Yang and colleagues performed sequestration of miR-21 by LNA-modified an-
timiR-21 treatment, either before or after chronic hypoxia exposure, diminished chronic 
hypoxia induced pulmonary hypertension and attenuated the pulmonary vascular remodel-
ling in the chronic hypoxia included mouse model. The potential mechanism of this pro-
tective role is the upregulation of the putative targets of miR-21 including bmpr2, SATB 
homeobox 1 (satb1), and YOD1 deubiquitinase (yod1) (Yang et al., 2012). As the increased 
expression of BMPR2 is beneficial to the development PAH (Morrell et al., 2001, Nakaoka 
et al., 1997). Consistent results obtained with another study use antimiR-21 treatment in 
chronic hypoxia induced mice PH model, which showed reduced RVSP, and decreased 
pulmonary arterial muscularization but no effect on RVH (Pullamsetti et al., 2012). Con-
trary to these findings, Parikh and colleagues use miR-21 knockout mice exposed to the 
SU5416/hypoxia conditions showed exaggerated manifestations in PH phenotype such as 
increased RVSP, RVH and pulmonary vascular remodelling. The potential mechanism is 
the increased expression of ras homolog family member B (RhoB) in the vascular intima 
and media of small pulmonary vessels. These vessels display increased Rho ki-
nasee-dependent levels of phosphorylated myoslin phosphatase in miR-21knockout mice. 
In addition, these treated mice exhibits a substantial increase in the transcriptional expres-
sion of at least one Rho-dependent vasoconstrictive effector of PH, such as endothelin-1 
(Parikh et al., 2012). In the pulmonary vasculature RhoB enhances vasoconstriction and 
remodelling pulmonary arteries and genetic deletion of RhoB prevents the development of 
hypoxia induced PH (Wojciak-Stothard et al., 2012). This exaggerated phenotype further 
confirmed by using both miR-21 knockout mice and miR-21 overexpression transgenic 
mice in the SU5416/hypoxia induced PH model. The potential mechanism for is the loss of 
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miR-21 leads to the direct activation of PDCD4/caspase-3 axis and as a consequence re-
sults in the onset of progressive PH and vice versa (White et al., 2014).  
 
In vitro, miR-21 has been showed to modulate the cellular behaviours of PASMSs such as 
proliferation, migration, and contractility, which are key components contribute to the de-
velopment of PAH. MiR-21 knockdown significantly reduced chronic hypoxia induced 
proliferation, and migration in PASMCs and overexpression of miR-21 reverses these be-
haviours by targeting phosphatase and tensin homologue (pten), programmed cell death 
protein 4 (pdcd4), sprout homolog 2 (spry2) and peroxisome proliferator-activated receptor 
receptor alpha (ppra-α) (Sarkar et al., 2010) (Green et al., 2015). MiR-21 also demonstrat-
ed involved in cell cycle, cell proliferation and apoptosis by affecting the expression of 
proliferating cell nuclear antigen (pcna), cyclin d1, and bcl-xl in PASMCs (Yang et al., 
2012). In addition, miR-21 expression is modulated by BMP signalling pathway. BMP4 
stimulated miR-21 expression and further directly target members of the dedicator of cyto-
kinesis (DOCK) 180-related protein superfamily including DOCK4, -5, and -7 to modulate 
cell migration and contractility (Kang et al., 2012). In PAECs, miR-21 has plentiful target 
genes including the proteins integral to BMP, BMPR2, and RhoB/Rho-kinase signalling, 
which connect miR-21 to hypoxia, inflammation and angiogenesis signalling pathways 
associated with the pathogenesis of PAH (Parikh et al., 2012).  
 
From the studies discussed above, while conflicting, highlights the complex role of miR-21 
in the PAH disease. The variation among different studies may due to the different experi-
mental conditions such as animal strain and species difference, gender difference, age, and 
different PH models. The different pharmological manipulation strategies of miR-21 in vi-
vo also should be considered. However, based on the findings of miR-21 in PAH, it is 
clearly deserving further research attention designed to investigate the true potential in the 
development of PAH.  
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1.3.1.3.3	MiR-17/92	
The miR-17-92 cluster is one of the best-characterised miRNA families located on human 
chromosome 13 consists of six distinct mature miRNAs: miR-17, miR-18a, miR-19a, 
miR-20a, miR-19b-1, and miR-92-1, each of which have a specific set of target genes that 
exert their functions (Tanzer and Stadler, 2004). With regard to the hypoxia and PAH, it 
has been reported that miR-17-92 cluster expression is regulated positively by the c-myc 
transcription factor (O'Donnell et al., 2005) and the IL-6/STAT3 pathway (Steiner et al., 
2009, Brock et al., 2009). C-myc gene expression levels are increased in the lungs and 
PASMCs of the chronic hypoxia induced rat PH model (Cai et al., 1996, Luo et al., 1996), 
which can active the expression of miR-17-92 cluster (specifically miR-17-5p and 
miR-20a) directly target transcription factor E2F1, which can promote cell cycle progres-
sion (O'Donnell et al., 2005, Woods et al., 2007). The IL-6 expression levels were elevated 
in the PAH patients and animal models of PH. And miR-17-92 cluster is modulated by IL-6. 
IL-6 induced arteriopathic changes were accompanied with pro-proliferative transcription 
factor C-myc, which is a potential mechanism to induce the expression of miR-17-92 clus-
ter in the PAH setting (Steiner et al., 2009). In addition, IL-6 also activates STAT3 in hu-
man PAECs, which bind directly to a highly conserved STAT3 binding site in the promoter 
region of miR-17-92 gene to regulate miR-17-92 expression (Brock et al., 2009).  
 
A reduction or mutation of bmpr2 is found in majority of HPAH and isolated cases of 
IPAH. In silico analysis revealed the bmpr2 was a putative target of the miR-17-92 cluster. 
Experimental overexpression of miR-17-92 results in a strong reduction of the BMPR2 
protein, and reporter gene assay showed that bmpr2 is directed targeted by miR-17-5p and 
miR-20a in PAECs. Interestingly, the persistent activation of STAT3 also leads to repressed 
protein expression of BMPR2 (Brock et al., 2009). These studies describe novel 
IL-6-STAT3-miR-17-92-BMPR2 pathways involved in the development of PAH and pro-
vide a possible mechanism to explain the loss of bmpr2 during PAH development.  
 
Individual miRNAs from this cluster have been investigated in PAH. AntagomiR of 
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miR-17 treatment reversed the PH phenotype in both the chronic hypoxia induced mouse 
model and MCT rat model. The potential mechanism is that miR-17 targets cy-
clin-dependent kinase inhibitor 1A (p21) to regulate PASMCs proliferation, which overex-
pression of miR-17 reduces the expression of p21 and increases the proliferation of 
PASMCs (Pullamsetti et al., 2012). In addition, MiR-17 expression levels are significantly 
elevated with the chronic hypoxia exposure and associated with an increase in arginase Ⅱ 
in PASMCs, and their expression levels are positively related (Jin et al., 2014). Further-
more, Chen and colleagues found decreased expression levels of miR-17-92 cluster in 
PASMCs from patients with PAH as well as the decrease of TGF-β and SMC markers. 
Overexpression of miR-17-92 restored the expression of TGF-β, Smad3, and SMC markers 
in patients with IPAH. SMC-specific knockout of miR-17-92 attenuated chronic hypoxia 
induced PH in mice, and reconstitution of miR-17-92 restored chronic hypoxia induced PH 
in these mice. The mechanism is that miR-17-92 direct target PDZ and LIM domain 5 
(pdlim5), which expression levels are elevated in hypertensive human and mouse PASMCs. 
Suppression pdlim5 increased expression of SMC marker and enhanced TGF-β/Smad2/3 
activity in vitro and enhanced chronic hypoxia induced PH in vivo, whereas overexpression 
of pdlim5 attenuated chronic hypoxia induced PH (Chen et al., 2015). This study demon-
strates that miR-17-92 induced TGF-β/Smad3 pathway via inhibiting pdlim5 expression 
contributing to the pathogenesis of PAH. 
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1.3.2 Long non-coding RNAs (lncRNAs) 
Long noncoding RNAs (lncRNAs) are currently defined as RNA transcripts longer than 
200 nucleotides with no potential to encode for functional proteins of more than 30 amino 
acids, which separate them from miRNAs and from protein-coding genes (Rinn and Chang, 
2012). Due to the development of next generation sequencing techniques, many new 
lncRNAs are discovered and annotated each year. Thus far, more than 100,000 lncRNA 
genes have been defined in human genome. In comparison, there are currently 20,345 an-
notated protein-coding genes in the human genome. This suggests a dominant role of 
lncRNA genes in mammalian genome (O'Donnell et al., 2005). The biological functions of 
most lncRNAs are currently still unknown, as only a handful of lncRNAs have been stud-
ied in detail. LncRNAs can be classified into different subtypes based on their genomic 
location: sense lncRNAs (when they overlap one or more exons of another transcript on 
the same strand); antisense lncRNAs (when they overlap one or more exons of another 
transcript on the opposite stand); bidirectional lncRNAs (when their expression and that of 
a neighbouring coding transcript on the opposite strand are initiated in close genomic 
proximity); intronic lncRNAs (when they are derived from an intron of a second transcript); 
and intergenic lncRNAs (when found as an independent unit within the genomic interval 
between two genes) (Figure 1.7) (Thum and Condorelli, 2015).  
1.3.2.1	Biogenesis	and	Function	of	LncRNAs	
LncRNAs can be transcribed from intergenic regions, promoter regions or be interleaved, 
overlapping or antisense to annotated protein-coding genes and display remarkable simi-
larity to classical mRNA in that they are generally translated by RNA polymerase II. Fol-
lowing RNA polymerase production, the individual lncRNA is subjected to 5’-capped 
(m7G), alternative splicing, RNA editing, and 3’-polyadenylated (Sun and Kraus, 2015). 
Final lncRNA developments essentially involve the formation of a stable secondary (and 
tertiary) structure, which confer the individual lncRNA with its unique function roles (Li 
and Chen, 2013). In most cases, they lack any biochemical distinction from mRNAs be-
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sides the absence of translated open reading frame (ORF). There are other more general 
features of lncRNAs that distinguish them from mRNAs, including their shorter length, 
having fewer but longer exons, and being expressed at relatively low levels with poor pri-
mary sequence conservation (Derrien et al., 2012, Cabili et al., 2011). Based on their mo-
lecular mechanisms of action, lncRNAs can be classified into four archetypes (Fig 1-6) 
(Wang and Chang, 2011). An individual lncRNA may fulfil several archetypes and these 
archetypes are not meant to be mutually exclusive.   
 
Archetype I: Signals.  
LncRNAs are expressed in cell type-, tissue-, developmental stage or disease state-specific 
manner (Flynn and Chang, 2014, Batista and Chang, 2013) and respond to diverse stimuli, 
suggesting that lncRNA expression is under considerable transcriptional control. Thus, 
lncRNA can serve as molecular signals due to the temporal and spatial restriction of their 
transcription to integrate developmental cues and interpret cellular context or as a response 
to specific stimuli. For example, lincRNA-RoR is required in the process of somatic cell 
reprogramming of induced-pluripotent stem cells (iPSCs). LincRNA-RoR was showed to 
be directly targeted by the key pluripotency factors octamer-binding transcription factor 4 
(OCT4), SYR box-containing factor 2 (SOX2), and homeobox protein NANOG (NANOG) 
through colocalisation of the three factors in close proximity to lincRNA-ROR promoters 
(Loewer et al., 2010).  
 
Archetype Ⅱ：Decoys.  
The central role of lncRNAs is regulating transcription both positively and negatively 
(Guenther et al., 2007). This indicates that lncRNAs regulate transcription via diverse 
mechanisms, a major one of which is to act molecular decoys. This archetype of lncRNA is 
transcribed and then binds and titrates away a target protein but doses not exert any addi-
tional functions functions (Wang and Chang, 2011). Thus lncRNAs within this archetype 
can function as a “molecular sink” for RNA-binding proteins (RBPs), transcription factors, 
chromatin modifiers, or other regulatory factors. For example, the lncRNA p21-associated 
ncRNA DNA damage-activated (PANDA) is induced in a p53-dependent manner in human 
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fetal lung fibroblasts FL3. The PANDA is located approximately 5 kilobases upstream of 
the cdkn1a transcriptional start site (TSS) together with 5’-capped and polyadenylated 
non-spliced lncRNA that is transcribed antisense to cdkn1a. The induction of PANDA dur-
ing DNA damage is p53-dependent. Depletion of PANDA or cdkn1a has no effect on each 
other’s response to DNA damage. Importantly, PANDA acts as a decoy binding to tran-
scription factor NF-YA to prevent NF-YA binding to occupy target gene promoter to repress 
expression of pro-apoptotic genes (Hung et al., 2011).  
 
Archetype III：Guides.  
The guide lncRNAs act as molecular chaperones and localise the ribonucleoprotein com-
plex to specific genomic targets. These lncRNAs can also guide changes in gene expres-
sion either in cis (on neighbouring genes) or in trans (distantly located genes) in a manner 
that is difficult to predicted based on the lncRNA sequence. For example, the lateral mes-
oderm-specific lncRNA fetal-lethal non-coding development regulatory RNA (Fendrr) can 
bind to both the polycomb repressive complex 2 (PRC2) and Trithorax group/Mixed line-
age leukemia (TrxG/MLL) complexes, which play pivotal roles in determining the activa-
tion state of gene controlling pluripotency, lineage commitment, and cell differentiation 
(Grote et al., 2013). Fendrr can guide PRC2 to target genes to increase PRC2 occupancy 
and H3K27 trimethylation or decrease H3K4 trimethylation (Grote et al., 2013). Similarly, 
LincRNA-p21, which is regulated by p53, can guide hnRNP-K to the promoter of the p21 
gene and act as a co-activator for p53-dependent p21 transcription to mediate gene repres-
sion and apoptosis in the p53 pathway (Huarte et al., 2010). This study proposes a model 
whereby transcription factors activate lncRNAs that serve as key repressors by physically 
associating with repressive complexes and modulates their localization to set of previously 
active genes (Huarte et al., 2010). 
 
Archetype IV：Scaffolds.  
Scaffold lncRNAs have multiple domains, enabling them to form complexes with proteins 
such as transcription factors or components of chromatin modifying complexes that allows 
them to function as transcriptional activators or repressors. For example, the lncRNA 
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HOTAIR serves as a scaffold for at least two distinct histone modification complexes. The 
5’ domain of HOTAIR binds Polycomb repressive complex-2 (PRC2), whereas its 3’ do-
main binds to the LSD1/CoREST/REST complex (Tsai et al., 2010). This ability to tether 
two distinct complexes enables RNA-mediated assembly of PRC2 and LSD1 and coordi-
nates targeting of PRC2 and LSD1 to chromatin for coupled histone H3 lysine 27 methyla-
tion and lysine 4 demethylation (Tsai et al., 2010). Taken together, these studies demon-
strate that lncRNAs can serve as scaffolds by providing surfaces to assemble select histone 
modification enzymes to specify the pattern of histone modifications on target genes (Fig-
ure 1.7). 	
1.3.2.2	Long	non-coding	RNA	in	PAH	 	
Accumulating evidence suggests that lncRNAs play a significant role in a wide variety of 
important biological processes including regulating gene transcription, splicing, translation, 
cell cycle and apoptosis, cell differentiation, stem cell pluripotency and reprogramming, 
and heat shock response (Loewer et al., 2010). In addition, lncRNAs have been demon-
strated play important roles in many diseases including cancer (Sahu et al., 2015, Huarte, 
2015) and cardiovascular disease (Uchida and Dimmeler, 2015, Lorenzen and Thum, 2016, 
Schonrock et al., 2012). However, to date there have been very few studies investigating 
the role of lncRNA in PAH. The only study on lncRNA in PAH to date assessed the ex-
pression of lncRNAs in lung tissue from rats following hypoxia-mediated induction of PH 
(Wang et al., 2016). Microarray analysis and qRT-PCR target validation revealed 362 
lncRNAs that were differentially expressed in hypoxic animals compared to normoxic 
controls (Wang et al., 2016). A related study performed microarray analysis on endothelial 
tissues from the pulmonary arteries of chronic thromboembolic pulmonary hypertension 
(CETPH) patients and healthy controls, identifying 185 differentially-expressed lncRNAs 
observed in the CTEPH tissues compared with healthy controls. Gene ontology and path-
way analysis suggested that these lncRNAs might play a role in the regulation of the in-
flammatory response, responses to endogenous stimuli and antigen processing and presen-
tation (Gu et al., 2015). In addition, RNA-seq analysed the expression of lncRNAs in hu-
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man heart failure, which is the primary cause of death in patients with PAH. There are 105 
differentially expressed lncRNAs in heart failure heart compared with donor hearts (Di 
Salvo et al., 2015). The expression profiles of lncRNAs in animal models and human tis-
sues show that lncRNAs may participate into the pathogenesis of PAH.  	
			
Figure 1.7 Overview of the genome location and functions of lncRNAs 
(A) Based on their genomic locations, lncRNA transcripts can be classified as sense (transcribed from the 
sense strand of a protein-coding gene) antisense (transcribed from the antisense strand of a protein-coding 
gene) intronic (transcribed entirely from an intron of a protein-coding gene); intergenic (transcribed se-
quences is not located near any other protein-coding loci) or bidirectional (transcribed sequences are located 
on the opposite strand from a protein-coding gene whose transcription is initiated less than 1000 base pairs 
away). (B) The main functions of lncRNA include SIGNALLING: lncRNA can function as molecular signal 
or indicator of transcriptional activity; DECOY: lncRNAs can preclude the access of regulatory proteins to 
DNA; GUIDES: lncRNA can be required for the localisation of specific protein complexes either in cis (on 
neighbouring genes) or in trans (on distantly located genes); SCAFFOLDS: lncRNAs can serve as adaptors 
to bring two or more proteins into discrete complexes (adapted from (Deng et al., 2016)).  	
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1.4	Exosomes	 	
Extracellular vehicles (EVs) consist of a lipid bilayer membrane, containing diverse car-
goes including proteins, RNA species (mRNA, miRNA, lncRNA, and other RNA species), 
DNAs (mtDNA, ssDNA, and dsDNA), and lipids than can be transported and exchanged 
between cells as a means of intercellular communication at both paracrine and systemic 
levels. EVs are released from virtually all cell types (Simpson et al., 2009, Colombo et al., 
2014, Rajendran et al., 2014). A number of different EV subpopulations have been de-
scribed, classified based on their size and mode of biogenesis. The most extensively stud-
ied of these are exosomes, which range from 30 to 130 nm in diameter and are generated 
by reverse budding of multivesicular bodies within cells before their secretion (Raposo and 
Stoorvogel, 2013). Other notable EVs include microvesicles (100 nm to 1 µm in diameter), 
which are directly shed from the plasma membrane of cells, and apoptotic bodies (ranging 
from 1 µm to > 2 µm in diameter), which arise from cells undergoing apoptosis.  
1.4.1 Exosome Biogenesis  
The generation of exosomes through budding from the limiting membrane of intracellular 
vesicles was first reported in sheep during reticulocyte maturation (Pan	et	al.,	1985). Ex-
osome biogenesis is initiated when small amounts of intracellular fluid are engulfed, 
forming a small intracellular body call an endosome (Thery et al., 2002, Keller et al., 2006). 
These early endosomes are subjected to a maturation process that includes an interaction 
with the Golgi complex to develop into the late endosome, which is characterised by the 
formation of intraluminal vesicles (ILV) inside the lumen of the endosome. Endosome 
maturation can also be detected by observing a change in their shape and location: while 
early endosomes are tube-like in shape and are usually located in the outer portion of the 
cytoplasm, the late endosome is spherical and found closer to the nucleus (Keller et al., 
2006). ILVs are formed by inward budding of the endosomal membrane, randomly en-
gulfing portions of the cytosol and incorporating transmembrane and peripheral proteins 
into the invaginating membrane. Late endosomes that contain ILVs are called multivesicu-
lar bodies (MVBs) (van Niel et al., 2006, Thery et al., 1999). MVBs undergo fusion with 
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lysosomes, following which the MVB contents are degraded through hydrolysis. Subse-
quent lysosome fusion with the plasma membrane leads to the release and exocytosis of 
ILVs, also known as exosomes (Figure 1.8) (Waldenstrom and Ronquist, 2014, Beach et al., 
2014).  
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Figure 1.8 Biogenesis of exosomes 
Exosomes are generated in the late endosomal compartment and carry recycled proteins from coated 
pits/lipid rafts in the cellular membrane, proteins directly sorted to the MVBs from rough endoplasmic retic-
ulum (RER) and Golgi complex (GC), mRNA, microRNA, and DNA. Note that the generation of exosomes 
by inward budding of the limiting membrane of MVB ensures that the membrane-bound proteins preserve 
the same orientation and folding on the exosomal membrane as those on the plasma membrane. The exo-
some-filled MVBs are either fused with the plasma membrane to release exosomes or sent to lysosomes for 
degradation. Adapted from (Waldenstrom and Ronquist, 2014) 					
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1.4.2 Exosome Composition 
Exosomes contain various types of biomolecules including protein, carbohydrates, lipids 
and nucleic acids. In addition to most cell lines, exosomes have been isolated from most 
body fluids including saliva, urine, and plasma (Mathivanan et al., 2010, Dragovic et al., 
2011, Caby et al., 2005, Lasser et al., 2011). Exosome composition is dynamic and varies 
depending on the cellular origin and release site, as well as the body’s physiological or 
pathological state (Sreekumar et al., 2010). The lipid composition of exosomes includes 
cholesterol, sphingomyelin, hexosylceramides, phosphatidylserine, and saturated fatty ac-
ids, all of which are components of the synthesising cell plasma membrane (Colombo et al., 
2014). The proteome of exosomes includes endosomal, plasma, cytosolic, and nuclear pro-
teins. Exosomes also contain tetraspanins (CD9, CD63, CD81, and CD82), as well as 
co-stimulatory molecules (CD86) and adhesion molecules (CD11b and CD54). Other 
common exosomal proteins include heat shock proteins (HSP70 and HSP90), integrins, 
MHC class Ⅱ proteins, epithelial cell adhesion molecules (EpCAM), and members of the 
human epidermal growth factor receptor (HER) family (Beach et al., 2014, Kalluri, 2016). 
Many exosomal proteins are required for exosome biogenesis, while other proteins that are 
enriched in exosomes reflect the composition of the cell or tissue of origin. Exosome pro-
tein composition proteins present on the surface of the exosomes can engage cell surface 
receptors on recipient cells to induce intracellular signalling (Raposo and Stoorvogel, 2013, 
Colombo et al., 2014, Zhang et al., 2015). For example, exosomes produced by human 
cancer cells (A431 human squamous cell carcinoma cell line) containing activated endo-
thelial growth factor receptors (EGFR) can be taken up be cultured endothelial cells, in 
which they elicit EGFR-dependent responses, including activation of mitogen-activated 
protein kinases (MAPK) and Akt pathways (Al-Nedawi et al., 2009). Moreover, a number 
of proteomic and transcriptomic profiling analyses have been performed on exosomes 
showed that exosomes contain cell-type specific proteins that define their functional activ-
ity (Simpson et al., 2008, Thery et al., 2001). Thus, the composition of the exosome mem-
brane, and by extension the state of the cell from which the exosomes are released, is a 
critical determining factor in their biological function. 
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In addition to their protein and lipid cargoes, exosomes also contain diverse nucleic acid 
species, including mRNA and miRNA. Pioneering work carried out by two independent 
groups demonstrated that exosomes could –mediate the transfer of mRNA and miRNAs 
from host to recipient cells (Ratajczak et al., 2006, Valadi et al., 2007). Subsequently, other 
RNA species were also founded in exosomes including transfer RNAs (tRNAs), lncRNAs, 
and viral RNA (Gusachenko et al., 2013, Yang et al., 2016). Importantly, different types of 
RNAs such as miRNAs and lncRNAs present within exosomes are biologically active, in-
dicating that they can function to modulate the protein profile, transcriptome, and cellular 
state of the recipient cells (Lee et al., 2012c, Melo et al., 2014, Chen et al., 2014b). In ad-
dition, exosomal RNA content can also vary depending on the cellular origin, the physio-
logical or pathological state of the originating cell, indicating that the incorporation of 
RNA into exosomes is a regulated and selective event (Schorey and Harding, 2016).  
1.4.3 The Function of Exosomes  
As shown in the previous sections, there are a large variety of constitutive elements in ex-
osomes including > 4563 proteins, 193 lipids, 1639 mRNA, 764 miRNA and other com-
ponents, underlining the complexity and potential functional diversity of exosomes 
(Mathivanan et al., 2012, Mathivanan and Simpson, 2009). Exosomes are emerging as 
important mediators of cell-to-cell communication in both the physiological and patholog-
ical context such as cancer (Zhang et al., 2015), and cardiovascular diseases (Zhao et al., 
2015c). Exosomes can be transported between different cells and can activate or inactivate 
different pathways on surrounding or remotely-located cells depending on their molecular 
composition, which is influenced by the activation state of the secreting cell and cell type 
of origin. Exosomes can also interact with recipient target cells by fusion with the plasma 
membrane or adhesion to corresponding receptors on the plasma membrane (Lakkaraju 
and Rodriguez-Boulan, 2008). When the recipient cells uptake the exosomes, which will 
mediate functional and phenotypic changes in recipient cells such as proliferation and mi-
gration (Pfeifer et al., 2015). Furthermore, exosomes also observed in the blood, body flu-
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ids and tissues, which suggest that exosomes can be served as novel biomarkers for clinical 
diagnosis (Lin et al., 2015).  
1.4.4 The Role of Exosomes in PAH  
There are several studies showing the emerging role of exosomes in PAH. Aslam and col-
leagues administered bone marrow stromal cell-conditioned media (BMSC-CM) via the 
superficial temporal vein to neonatal mice on postnatal day 4 of a 14-day period of hypoxia. 
BMSC-CM injection reduced alveolar loss and lung inflammation, attenuating both pul-
monary vessel remodelling and alveolar injury, and preventing the development of pulmo-
nary hypertension (Aslam et al., 2009). A related study used mesenchymal stem cell condi-
tioned media (MSC-CM) from hypoxic cells to treat pulmonary artery rings, which signif-
icantly reduced acute hypoxia induced pulmonary vasoconstriction (Patel et al., 2007). 
These studies suggested that BMSCs and MSCs could have a protective role in PAH by 
acting through a paracrine mechanism. Subsequent studies showed that both BMSCs and 
MSCs could release exosomes into conditioned media (Wang et al., 2014, Yu et al., 2014), 
indicating that this protective role may be due to the biological functions of the secreted 
exosomes. The first demonstration of the therapeutic potential of MSC-derived exosomes 
for pulmonary hypertension was achieved by Lee and colleagues by using fractionated 
mouse and human umbilical cord MSC-CM and showed that the biologically active com-
ponent included exosomes (Lee et al., 2012a). In the chronic hypoxia induced mouse mod-
el of PH, intravenous delivery of MSC-derived exosomes suppressed the influx of macro-
phages to the lungs of hypoxic animals, as well as the induction of proinflammatory and 
proproliferative mediators, inhibiting vascular remodelling. In addition, MSC-derived ex-
osomes suppressed the hypoxic activation of STAT3 and upregulation of the miR-17 su-
perfamily, increasing the expression of miR-204 (Lee et al., 2012a). Intravenous injection 
of MSC-derived microvesicles in the MCT-induced rat PH model also ameliorated the 
mean pulmonary artery pressure (mPAP), mean right ventricular pressure (mRVP), RVH, 
and pulmonary arteriole area index and thickness index (Chen et al., 2014a). These studies 
show administration of MSC-derived microvesicles/exosomes produce similar beneficial 
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effects in different animal models of PH, which provide a potential therapeutic application 
of cell-free approach in stem cell therapy in PAH. The potential mechanisms underlie the 
protective effect of MSC-derived exosomes are dependent on their cargoes, such as miR-
NAs. For example, the injection of exosomes derived from the plasma and lung from 
MCT-induced mice PH model increased the RVH and the pulmonary vascular remodelling 
in healthy mice. MSC-derived exosomes prevented any increase in RVH and pulmonary 
vascular remodelling when given at the time of MCT injection and reversed the increase in 
these indices when given after MCT administration. The microarray analyses of the exo-
somes from MCT-induced mice PH and human IPAH patients showed increased expres-
sion of miRNA-19b, 20a, 20b, and -145, whereas miRNAs isolated from MSC-derived 
exosomes had increased levels of anti-inflammatory, anti-proliferative miRNAs including 
miRNA-34a, -122, -124, and -127 (Aliotta et al., 2016, Aliotta et al., 2013).  
1.5	Aims	 	
Building evidence indicates that ncRNAs (particularly miRNAs and lncRNAs) may be 
central mediators of PAH pathogenesis. However, despite intensive studies of miRNAs in 
PAH, the mechanisms of miRNA regulating the disease onset and pathogenesis are still 
largely unknown. In particular, there is a paucity of data on how exosome RNA cargoes 
influence the dysfunctional vascular cell behaviour that characterises PAH. Moreover, 
there have been very few studies investigating the role of lncRNAs in PAH. Therefore, the 
principal research aim of this thesis was to investigate the role of miR-143 in the pulmo-
nary vasculature using clinical samples from PAH patients, in vivo models and in vitro ex-
periments. The specific aims of this project were: 
     
l To identify the role of miR-143 in the development of PAH using both in vivo and in 
vitro techniques 
l To investigate the role of exosomal miR-143 in cell-to-cell communication between 
pulmonary vascular cells during PAH pathogenesis 
l To determine the role of the lncRNAs MYOSLID and Myolnc16 in human pulmonary 
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2 Materials & Methods 
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2.1	Chemicals	
All chemicals and reagents unless otherwise indicated were supplied from Sigma-Aldrich 
(Dorset, UK). All tissue culture reagents unless otherwise stated were obtained from Gibco 
(Paisley, UK). All transfection reagents were purchased from Life Technologies (Paisley, 
UK) unless otherwise stated. 
2.2	Ethical	Information	
All experimental procedures conform to the United Kingdom Animal Procedures Act 
(1986) and to the ‘Guide for the Care and Use of Laboratory Animals’ published by the US 
National Institutes of Health (NIH publication No. 85-23, revised 1996). All transgenic 
mice were bred under the Home Office project licence 60/4429 held by Professor A. H. 
Baker (University of Glasgow, UK). In vivo procedures using the hypoxic mice model of 
PH were conducted under Home Office project licence 60/3773 held by Professor M. R. 
MacLean (University of Glasgow, UK) and Lin Deng personal licence 60/13805 (Univer-
stiy of Glasgow, UK). Experimental procedures using human pulmonary artery smooth 
muscle cells conform to the principles outlined in the declaration of Helsinki. 
2.3	Animals	
All animals were housed either at the Central Research Facility (CRF) or the licensed fa-
cility located in the West Medical Building, University of Glasgow. All animals were 
maintained in a continuous 12 h light/dark cycle with access to water and food ad libitum. 
Cages were cleaned and replaced twice a week. The genetically modified animals were ear 
clipped by CRF staff and genetic background confirmed by genotyping.  
 
2.3.1 Wild-type Mice 
Inbred wild-type (WT) mice (C57 BL6/J) at 7 weeks old were obtained from Charles River 
(United Kingdom). The mice were housed at the CRF for a one-week acclimatization and 
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monitoring period before any experimental procedures were performed.  
2.3.2 MiR-143 Knockout Mice 
MiR-143 knockout (KO) mice were kindly supplied by Eric Olson (University of Texas 
SouthWestern, USA). The KO mice were generated at the University of Texas SouthWest-
ern and have previously been described (Xin et al., 2009). Briefly, the targeting strategy 
deleted the 70-bp pre-miRNA stem-loop sequence of miR-143 and replaced it with a neo-
mycin resistance cassette flanked by loxP sites. Chimeric mice obtained by blastocyst in-
jection of targeted embryonic stem (EC) cells transmitted the mutant allele through the 
germline, yielding mice heterozygous for miR-143 allele. The neomycin resistance cassette 
was removed by breeding these mice with mice expressing a ubiquitously expressed 
CAG-Cre transgene. Breeding of these heterozygous mice produced global knockout of the 
miR-143.  
2.3.3 Chronic Hypoxia Model of PH 
Pulmonary hypertension (PH) was induced in mice by exposure to chronic hypoxia using a 
hypobaric hypoxia chamber. The hypoxic chamber was depressurised over the course of 
two days to 550 mbar (equivalent to 10% O2) to allow for acclimatization of animals.  
The development of chronic hypoxic PH in mice was achieved through a continuous 
14-day exposure to chronic hypoxia resulting in pulmonary vasoconstriction (Hoeper and 
Welte, 2006). Normoxic mice were exposed to atmospheric pressure. The temperature and 
relative humidity were constantly monitored and cages were changed and cleaned every 
three days, with food and water accessible ad libitum.  
2.4	AntimiR-143/145	Administration	
An antimiRNA targeting mature miR-143/145 (antimiR-143/145) was used to silence 
miR-143-3p and miR-145-5p in vivo. AntimiR-143/145 (in collaboration with miRagen 
Therapeutics Ltd, Boulder, Colorado) are 16 nt in length with phosphorothioate backbones 
and consisted of a mixture of LNA and DNA bases complementary to the 5’ end of mature 
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miR-143-3p (antimiR-143-3p) or miR-145-5p (antimiR-145-5p). The antimiRNA was 
suspended in PBS at 5 mg/kg or 25 mg/kg and stored at -80 °C. Scramble/control anti-
miRNA (similar molecular composition to the antimiR-143/145 but directed against a 
miRNA in C.elegans) was used as control.  
2.4.1 PAH Prevention Study 
Adult female C57BL/6J mice (aged 8 weeks) were administered antimiR-143-3p, control 
antimiRNA or PBS subcutaneously at a dose of 25 mg/kg at day 0 and day 7 in a blinded 
study. Mice were maintained in hypoxic or normoxic conditions for 14 days. On day 14, 
hemodynamic pressures were taken and right ventricle hypertrophy (RVH) measured prior 
to tissue harvest. The design of the antimiR-143-3p prevention study is shown in Figure 
3-11 (Chapter 3).   
2.4.2 PAH Reversal of Study  
Adult female C57BL/6J mice (8 weeks old) were maintained in a hypoxic chamber (10% 
O2) for 14 days to develop the PH phenotype. Then, subcutaneous administration of anti-
miR-143-3p, control antimiRNA or PBS was performed at a dose of 25 mg/kg on day 14 
and day 17 in a blinded study with another 7 days chronic hypoxia exposure. On day 21, 
hemodynamic pressures were taken and right ventricle hypertrophy (RVH) measured prior 
to tissue harvest. The antimiR-143-3p reversal in vivo study design is shown in Figure 3-15 
(Chapter 3).  
2.4.3 Intranasal Delivery of antimiR-145-5p 
Adult female C57BL/6J mice (aged 8 weeks) were treated with antimiR-145-5p by in-
tranasal delivery. All intranasal instillations were performed using 200 µl sterile pipette 
tips, with fresh tips used for each mouse. Prior to intranasal instillation, the mice were 
anaesthetised via exposure to 3% (v/v) isoflurane in O2. Once the animals were under 
shallow anaesthesia, mice were held with the body tilted at a 45º angle. Using a 200 µl pi-
pette, 25 µl were administered dropwise to each nare, waiting between drips to ensure the 
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mouse has inhaled the liquid. The total administration volume did not exceed 50 µl (25 
/nare). Animals were then returned to their cages.  	
Normoxic animals received intranasal instillation of antimiR-145-5p at day 1, 7, 14, and 21, 
with mice culled at day 28 for tissue harvest. Animals maintained in hypoxic conditions 
received antimiR-145-5p by intranasal instillation at days 1 and 7 (under normoxic condi-
tions), and were then maintained in a hypoxic chamber for two weeks from day 14 of the 
procedure, with a further two doses of antimiRNA at days 14 and 21. Hemodynamic 
measurements, RVH assessment and tissues harvests were performed on day 28. The anti-
miR-145-5p intranasal delivery study design is shown in Figure 3.19 and Figure 3.22 
(Chapter 3).  
2.4.4 Hypoxia/SU5416 rat model of PH 
Adult male Wistar Kyoto rats (150-200 g body weight) were maintained in normoxic (~21% 
O2) or in a normobaric hypoxic chamber (10% O2) for 14 days with subcutaneous admin-
istration of SU5416 or vehicle at a dose of 20 mg/kg on day 0. This was then immediately 
followed by varying lengths of time in normoxia (Figure 2.1). At each time point a group 
of animals (n = 5) were tested for hemodynamic pressures and tissues were harvested.  
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Figure 2.1 Rat 14 week hypoxia/SU5416 in vivo study design 
Male Wistar Kyoto rats were maintained in normoxic or hypoxic conditions for 14 days with SU5416 or ve-
hicle administered subcutaneously at 20 mg/kg on day 0. This was then followed by varying lengths of time 
in normoxic conditions. At each time point, hemodynamic measurements were taken along with right ven-
tricular hypertrophy assessment and tissues harvested.  
2.4.5 Neonatal calf model 
The neonatal calf model of severe hypoxia-induced pulmonary hypertension includes the 
development of pulmonary artery (PA) pressure equal to, or exceeding, systemic pressure, 
accompanied by remarkable PA remodelling with medial and adventitial thickening, as 
well as perivascular inflammation. Briefly, one-day-old male Holstein calves were exposed 
to hypobaric hypoxia (PB = 445 mmHg) for 2 weeks, while age-matched controls were 
kept at ambient Denver altitude (PB = 640 mmHg). Standard veterinary care was used fol-
lowing Institutional guidelines, and procedures were approved by Colorado State Univer-
sity IACUC and performed at Department of Physiology, School of Veterinary Medicine, 
Colorado State University (Fort Collins, CO). Animals were euthanized by overdose of 
sodium pentobarbital (160 mg/kg body weight). 
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2.5	Assessment	of	PH	 	
2.5.1 Anaesthetic Induction 
Anaesthesia was induced in an induction chamber containing 3% (v/v) isoflurane (Abbot 
Laboratories, Berkshire, United Kingdom) supplemented with O2 (flow rate, 0.5 L/min). 
Post-induction, mice were immediately weighed before being enclosed in a facemask sup-
plied with 1.5% (v/v) isoflurane supplemented with O2 (flow rate, 0.5 L/min). The appro-
priate level of anaesthesia was confirmed by the absence of hind limb reflex before and 
throughout the surgery.  
2.5.2 Right Ventricular Systolic Pressure measurements 
Right ventricular systolic pressure (RVSP) was measured by a transdiaphragmatic ap-
proach by catheterization of the right ventricle of the heart to allow measurement of right 
ventricular pressure (RVP). The continuous measurement of RVSP was achieved by using 
a calibrated 25 mm gauge heparinized saline filled needle attached to an Elcomatic E751A 
pressure transducer connected a MP100 data acquisition system (BIOPAC Systems Inc, 
Santa Barbar, USA). Specifically, mean RVSP, systolic and diastolic RVSP were measured 
at three independent areas of the steady trace.  
 
Briefly, the anterior sternum was exposed by removing a small portion of skin from the 
ventral chest. A 25 mm gauge heparinised needle was centrally aligned and then advanced 
into the mid-portion of the abdomen using a micromanipulator (Warner Instruments, Con-
necticut, U.S.A). Needle entry into the diaphragm has a negative effect on pressure and 
RVSP was monitored to ensure correct positioning and puncture of the right ventricle free 
wall by looking for a characteristic waveform (such as in Figure 2.1). Following a 
five-to-eight min trace, the measurement of RVSP was used as a surrogate of PH. For 
analysis, the RVSP and heart rate was obtained from the pressure readings. A noticeable 
puncture wound could be found in the right ventricle free wall to confirm the needle punc-
turing into the right ventricle wall.  
	 78	
														
Figure 2.2 Representative recording of right ventricular systolic pressure 
Three-second representative measurement of right ventricular systolic pressure in normoxia mice. Y-axis 
expressed in mmHg. 	
2.5.3 Systemic Arterial Pressure 
The systemic arterial pressure (SAP) was measured by cannulation of the left common ca-
rotid artery. An incision was made in the ventral neck and we carefully blunt dissected the 
smooth muscle layers until the trachea was reached. The left common carotid artery is typ-
ically positioned ~ 2 mm lateral (left) and less than ~ 1mm posterior to the trachea and can 
be identified by its pulsation and the presence of the vagus nerve (white in appearance) 
running alongside. Then the carotid artery was isolated by precision dissection from the 
vagus nerve without severing the nerve and cleaned of any connecting tissues. The carotid 
artery was ligated at the proximal (head) end with a surgical silk monofilament suture (size 
5.0, Harvard Apparatus, Massachusetts, U.S.A). A microsurgical artery clip (Fine Science 
Tools, Heidelberg, Germany, FST18055-04) was placed on the distal end of the carotid ar-
tery to temporarily occlude blood flow through the lumen proximal to the heart. A small 
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incision was made in the carotid artery above the suture tie and inserted a heparinised sa-
line-filled micro-cannula (Harvard Apparatus, Massachusetts, U.S.A) with curved forceps 
to open the incision. A micro-cannula was then advanced gently into the lumen of the ca-
rotid artery and ligated in place with a 5.0 silk suture before removal of the artery clip. 
Continuous measurement of SAP was obtained using the same technique as for RVSP us-
ing an Elcomatic E751A pressure transducer and an MP100 data acquisition system.  
 
After the measurement of RVSP and SAP, mice were killed by cervical dislocation. The 
heart and lungs were gently flushed with ice-cold PBS by injection through the right ven-
tricle and dissected out immediately and placed in ice cold PBS. Liver, spleen, kidneys 
were also dissected out and then snap frozen in liquid nitrogen and further put into -80 °C 
freezer until further use. A typical SAP waveform is shown in Figure 2.2.  
 
 
 
 
 
Figure 2.3 Representative recording of systemic arterial pressure 
Three-second representative measurement of systemic arterial pressure in normoxia mice. Y-axis expressed 
in mmHg.	
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2.5.4 Right Ventricular Hypertrophy 
The excised whole hearts were cleared of adjoining fatty tissue and blood vessels. After 
removing the right and left atria, the right ventricle (RV) was dissected from the left ven-
tricle plus septum (LV + S) and both were dry blotted and weighed. Measurement of right 
ventricular hypertrophy (RVH) was determined by the ratio of RV over LV + S, and the 
ratio (RV/LV + S) was used in the PAH assessment methodology.  
2.5.5 Pulmonary Vascular Remodelling 
In order to assess the extent of pulmonary vascular remodelling in PH, 3 µm frontal plane 
lung sections were prepared and stained immunohistochemically for α-smooth muscle ac-
tin (α-SMA) and microscopically examined for non-remodelled and remodelled pulmonary 
arteries < 80 µm external diameter in a blinded fashion. The arteries were considered 
muscularised by the presence of a visible distinct thick vascular wall. In α-SMA stained 
pulmonary arteries, a ratio of vascular wall thickness: vascular diameter was determined 
and used as a surrogate value to define the extent of pulmonary vascular thickness and re-
modelling. Lung sections from 6-8 mice for each experimental group were assessed. Five 
small pulmonary arteries were quantitatively analysed in each animal to generate a mean 
vasculopathy score per animal.  
2.6	Histology	 	
2.6.1 Fixation, Paraffin Embedding and Sectioning of Lung Tissue 
Following Schedule I cull of animals, the inferior and middle lobes of the right lung and 
right ventricle (RV) were dissected free and fixed in 10% (v/v) neutral buffered formalin 
(NBF) overnight at room temperature with gentle agitation. Tissues were processed 
through a series of dehydration steps and to xylene and finally to 62 °C paraffin wax using 
the Shandon Excelsior tissue processor (Thermo Scientific, United Kingdom). An over-
view of the process is shown in Table 2-1.  	
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Table 2-1 Tissue processing for paraffin embedding 	
Solution                    Incubation Period 
70% Ethanol                    30 min 
95% Ethanol                    30 min 
100% Ethanol                   30 min 
100% Ethanol                   30 min 
100% Ethanol                   45 min 
100% Ethanol                   45 min 
100% Ethanol                   60 min 
Xylene                         30 min 
Xylene                         30 min 
Xylene                         30 min 
Paraffin wax                     30 min 
Paraffin wax                     45 min 
Paraffin wax                     45 min 	
Following the tissue processing sequence, lungs and right ventricle (RV) were placed in the 
right position in biopsy cassettes and embedded in paraffin wax using the Shandon Histo-
center 3 (Thermo Scientific, United Kingdom). Paraffin embedded lung blocks were stored 
at room temperature. Lung blocks were placed in 4 °C overnight or -20 °C for 1 h prior to 
sectioning to aid with the cutting process. 3-5 µm frontal plane lung sections were cut us-
ing a Leica microtome and transferred to a 45 °C water bath from where they were 
mounted onto silanised glass microscopic slides and then baked overnight at 60 °C in a 
histology oven.  
2.6.2 Immunohistochemistry  
Tissue sections were de-paraffinised then rehydrated by placing in two changes of His-
to-Clear (Fisher Scientific Ltd, Leicestershire, UK) and followed by 100%, 95%, 70%, 50% 
ethanol and distilled water each for 5 min. Rehydrated sections were then immersed in 10 
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mM citric acid buffer at pH 6 and boiled in a microwave for 4 x 5min to perform antigen 
retrieval. Lung sections then were then cooled to room temperature for 20 min in the citric 
acid buffer, followed by washing in running tap water for 10 min. Sections were then in-
cubated with 20% normal goat serum/PBS for 60 min to reduce non-specific background 
staining in a humidified chamber at room temperature. The sections were then incubated 
with primary antibodies at appropriate dilutions in 2% goat serum in PBS and incubated at 
4 °C overnight in a humidified chamber. An immunoglobulin G (IgG) negative control was 
used on duplicate tissue sections at the same concentration to observe any non-specific 
binding. After primary antibody incubation, lung sections were washed three times in 
tris-buffered saline (TBS) for 10 min and then incubate with HRP-conjugated secondary 
antibodies (Vector Labs BA-1000) diluted 1/200 in PBS with 1% BSA for 60 min in a hu-
midified chamber at room temperature. After incubation, sections were then washed three 
times in TBS for 10 min. Sections were then incubated with Extravidin-Peroxidase LSAB 
reagent (Sigma E2886) diluted 1/200 in PBS with 1% BSA for 30 min at room temperature. 
Following three TBS 10 min washes. Protein immunolocalisation was visualised by incu-
bation with DAB solution (Vector Labs SK-4100) for 3 or 5 min. Dark brown staining was 
indicative of positive immunolocalisation. To quench the reaction, sections were immersed 
in running tap water for 10 min. Lung sections were then counterstained with haematoxy-
lin (Cell Pathology Ltd, Newtown Powys, UK) for 1 min and washed in running tap water 
for 10 min. Lung sections were dehydrated by a water/alcohol gradient consisting of 70% 
ethanol for 1 min, 90% ethanol for 1 min, 100% ethanol for 1 min and finally twice in 
Histo-clear for 5 min. The lung sections were mounted with glass coverslips using DPX 
non-aqueous mounting medium (Merck Millipore, Darmstadt, Germany).  
2.6.3 Immunofluorescence 
For mouse lung immunofluorescence, all the steps before the lung sections blocking were 
the same as immunohistochemistry in section 2.6.2. Lung sections were then incubated in 
20% goat serum for 60 min in a humidified chamber at room temperature, and then incu-
bated with primary antibodies in PBS-1% BSA overnight at 4 °C. Lung sections were 
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washed three times for 10 min in TBS prior to incubation with secondary antibodies 
(Alexa Fluor®488/590, dilution 1:500) (ThermoScientific, United Kingdom) for 1 h at 
room temperature protected from light. After three times wash with TBS for 10 min in the 
dark and then sections were mounted with glass coverslides using ProLong® Gold antifade 
reagent with Dapi (Molecular Probes).  
 2.6.4 Immunocytochemistry (ICC) 
PASMCs were plated on sterile coverslips in 24-well plates and further treated with in-
flammatory cytokines to induce DNA damage. When the cells reached the desired density, 
culture media were removed from each well and cells washed twice with PBS. The cells 
then were fixed with 4% PFA at room temperature for 10 min, the PFA discarded and 
washed twice with PBS. After washing, cells were permeabilised with PBS-Triton (0.05%) 
at room temperature for 10 min and followed by three washes with PBS. Cells were 
blocked using 10% goat serum diluted in PBST for 30 min at room temperature to avoid 
non-specific staining. Cells were washed with PBST once and incubated with primary an-
tibodies diluted in 1% goat serum PBST (1:200) overnight at 4 °C. The next day, cells 
were washed three times with PBS and incubated with secondary antibodies diluted 1:500 
in PBS at room temperature for 1 h in the dark. Then cells were washed with PBS three 
times in the dark and coverslips were carefully removed from the wells and blotted to re-
move any excess PBS. Cells were mounted on microscope slides using ProLong® Gold 
antifade reagent with DAPI (Molecular Pobes). The mounted slides were stored on the 
bench at room temperature in the dark overnight to allow the mounting medium to harden. 	
2.6.5 Haematoxylin and Eosin Staining 
Haematoxylin and eosin (H&E) staining was performed on the right ventricle (RV) of 
mouse. 5 µm RV sections were deparaffinised and rehydrated by placing in two changes of 
Histo-Clear (Fisher Scientific Ltd, Leicestershire, UK) and followed by 100%, 95%, 70%, 
50% ethanol and distilled water each for 5 min. Nuclei were stained with Harris’ modified 
haematoxylin (Cell Pathology Ltd, Newtown Powys, UK) for 5 min and then rinsed in 
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running tap water for 5 min and transferred to 70% ethanol for 1 min. RV sections were 
further counterstained in eosin Y solution (Sigma-Aldrich) for 2 min to stain cytoplasmic 
structures before being dehydrated in two changes of each of the following: 95% ethanol, 
100% ethanol and Histo-Clear each for 5 min. The RV sections were mounted with glass 
coverslips using DPX non-aqueous mounting medium (Merck Millipore, Damstadt, Ger-
many).  
 2.6.6 In Situ Hybridisation 
In situ hybridisation was performed to detect miR-143-3p in tissues from experimental 
mice, hypoxia-exposed neonatal calves, Brisket disease cattle and human PAH patients. 5 
µm sections were deparaffinised and rehydrated with Histo-Clear and graded concentra-
tions of ethanol same as described in previous sections. Antigen retrieval was performed 
by boiling slides for 10 min in DEPC treated 10 mM sodium citrate buffer (pH 6.0). After 
being cooled to room temperature on the bench, slides were immersed s in 0.2 M HCL for 
20 min. After three washes in DEPC-PBS, 0.3% Triton-X-100/PBS was added on the 
slides for 10 min, then incubated with 10 µg proteinase K at 37 °C for 15 min and finally 
fixed with 4% PFA for 10 min. Following incubation with hybridization buffer (50% (v/v) 
formamide, 4 X SSC, 2.5 X Denhardt’s solution, 2.5 mg/ml salmon DNA, 0.6 mg/ml yeast 
tRNA, 0.025% (v/v) SDS and 0.1% (w/v) blocking reagent) at 60 °C for 1 h followed by 
overnight incubation with 40 nM miR-143-3p or scramble miRCURY LNATM Detection 
probe, 5’-DIG labelled (Exiqon, Denmark) in the same buffer at 60 °C. After stringency 
washing with different concentrations of SSC buffer and DEPC-PBS, sections were 
blocked in 1% (w/v) blocking reagent in PBS and 10% FCS for 1 h at room temperature. 
Immunodetection was performed by 4 °C incubation with an anti-DIG antibody (Roche 
Applied Science, Indianapolis, IN, USA) diluted 1:500 overnight. After washing in 
DEPC-PBS with agitation, slides were then incubated with 0.1M Tris pH 9.0 twice for 5 
min. In order to visualise hybridised miR-143-3p probes, BM purple solution or 
NBT/BCIP solution (Roche Applied Science, Mannheim, Germany) was added to each 
section, respectively and left at room temperature overnight. Slides were checked the next 
	 85	
day and excessive development of the purple colouration was stopped by washing with 
PBS. Finally, slides were mounted using glass coverslips and Vectamount AQ (Vector 
Labs).  	
2.7	Cell	Culture	 	
All cell culture procedures were carried out under sterile conditions using class Ⅱ Biolog-
ical Safety vertical laminar flow cabinet. Cells were maintained in a humidified incubator 
with a constant supply of 5% CO2 and 95% air. All the PASMCs and PAECs used in this 
study are derived from females.  
2.7.1 Human Pulmonary Artery Smooth Muscle Cells (PASMCs) 
Distal human female pulmonary artery smooth muscle cells (PASMCs) were generated and 
provided by Prof N.W Morrell, University of Cambridge, UK. Distal PASMCs were iso-
lated from distal pulmonary arteries (~1-3 mm external diameter) from female patients 
with PAH and non-PAH patients (Table 2-2). Proximal female human PASMCs were pur-
chased from Lonza (Slough, UK). PASMCS were maintained in T150 culture flasks cul-
tured in smooth muscle cell medium 2 (Promocell, Heidelberg, Germany) containing 15% 
FCS, 0.5 ng/ml epidermal growth factor, 2 ng/ml basic fibroblast growth factor, 5 µg/ml 
insulin, 2 mM L-glutamine, and 100 U/mL penicillin/streptomycin.  
 
PASMCs were routinely passaged when monolayer cell growth reached 85%-95% conflu-
ence, avoiding cell growth arrest via contact inhibition. For passaging, cells were washed 
twice with sterile Dulbecco’s calcium and magnesium free phosphate buffered saline (PBS) 
and incubated with trypsin EDTA (0.05% trypsin, 0.02% EDTA) at 37 °C and 5% CO2 in-
cubator until cells had detached from the flasks. Following detachment of cells, 5ml of full 
growth medium was added to the flasks to neutralise the trypsin. Cells were pelleted by 
centrifugation at 1,500 g for 5 min and resuspended in fresh full growth medium. Where 
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necessary for sub-culturing purposes, cells density was assessed via cell counts using a 
haemocytometer.  
 
Table 2-2 Patient information for human pulmonary arterial smooth muscle cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.7.2 Human Pulmonary Endothelial Cells (PAECs) 
Female pulmonary arterial endothelial cells (PAECs) were purchased from Lonza (Lonza, 
Slough, UK) and cultured in EBM-2 Endothelial Growth Basal Medium supplemented 
with BulletKitTM (Lonza, Slough, UK, CC-3162), 15% FBS, 2 mM L-glutamine, and 100 
U/mL penicillin/streptomycin. PAECs cell culture was carried out as described in section 
2.7.1 except the culture media was EBM-2 Endothelial Growth Basal Medium.  
Name Gender Age Type Disease Status 
MP27 F   CTL  N/A 
MP32 F  58 CTL  Mild Emphysema 
MP77 F  64 CTL  Mild Emphysema 
MP79      F N/A CTL  
82MP F N/A CTL  
83MP F N/A CTL  
MP84 F  59 CTL 
 Squamous cell car-
cinoma 
MP85 F   CTL  N/A 
9MP M  72 CTL  N/A 
34MP M  62 CTL  Emphysema 
78MP M  68 CTL  Lung Carcinoma 
73MP F  30 hPAH(R899X)  
MP35 F   hPAH(N903S)  
67MP M  17 hPAH(W9X)  
56MP     F N/A     hPAH(C347R)  
MP37 F 24 IPAH   
MP23 M 43 APAH Eisenmengers 
36MP     F 33 IPAH  
38MP      F N/A PAH  
98MP     F N/A IPAH  
113MP F N/A IPAH  
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2.7.3 Human Embryonic Kidney (HEK) 293T cell 
HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate and 100 U/mL penicil-
lin/streptomycin. HEK293T cells were grown in T150 flasks and routinely passaged when 
monolayer cell growth reached 85%-95% confluence. For passaging, cells were washed 
twice with sterile Dulbecco’s calcium and magnesium free phosphate buffered saline (PBS) 
and incubated with 5 ml 1 X citric saline at 37 °C and 5% CO2 incubator until cells had 
detached from the flasks. The full growth medium was added to the flasks to pipet the cells 
up and down to disperse them. Cells were pelleted by centrifugation at 1,500 g for 5 min 
and resuspended in fresh full growth medium in fresh flasks.  
2.8	Cell	Transfection	and	Transduction	
2.8.1 MiRNA Transfection  
Reverse transfection of human PASMCs and PAECs with pre-miR-143-3p or anti-
miR-143-3p was performed using siPORT NeoFX Transfection Agent according to manu-
facturer’s instructions. Briefly, Siport NeoFX Transfection Agent was diluted 1:20 into 
100ul of Opti-MEM® reduced serum medium and incubated in the hood for 10 min at 
room temperature. Pre-miR-143-3p and antimiR-143-3p were diluted in a total volume of 
100 µl Opti-MEM® reduced serum medium to various final concentrations including 10 
nM, 50nM, and 100nM. siPORT NeoFX/Opti-MEM® and diluted 
pre-/anti-miRNA-143-3p/ Opti-MEM® were combined and mixed gently and incubated for 
a further 10 min at room temperature to allow transfection complexes to form. During the 
time for transfection complex preparation, cells were trypsinised with 1 X TE as described 
in section 2.7.1. Transfection complexes were then added to 6 well plates (200 µl per well) 
and then the cell suspension overlayed on to the transfection mix complex (1800 µl cell 
suspension with 2 x 105 cells). The final volumes were 2000 µl for 6 well plates. Cells 
were incubated with transfection complexes/culture media overnight at 37 °C and 5% CO2 
incubator. The following day media was removed and cells were used for further experi-
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ments.    
 
PASMC cells (2.5 x 105) were transfected with 100 nm of Cy3 labelled pre-miR miRNA 
precursor using siPORT NeoFX Transfection Agent and cultured in full SMC media for 24 
h described above. The day after transfection, cells were washed with PBS, and the medi-
um was switched to fresh exosome-free SMC media. After incubation for 36 h, the culture 
media was collected and used for exosome preparation according to section 2.15. 
2.8.2 SiRNA Transfection 
PASMCs and PAECs were transfected with siRNAs using Lipofectamine® 2000. Briefly, 
PASMCs and PAECs were seeded in 6-well plates overnight. The following day 5 µl (10 
nM) siRNA oligomer was diluted into 250 µl Opti-MEM® per well and mixed gently. At 
the same time, 5 µl Lipofectamine® 2000 were diluted into 250 µl Opti-MEM® and mixed 
gently and incubated for 5 min at room temperature. After the incubation, Lipofectamine® 
2000/ Opti-MEM® and siRNA/ Opti-MEM® were combined and mixed gently and incu-
bated for a further 20 min at room temperature to allow transfection complexes to form. 
During the incubation time, cells were washed with PBS twice and 500 µl of 5% FCS 
added to the culture medium without penicillin/streptomycin. Then, 500 µl transfection 
complexes were added to each well containing 500 µl media and incubated at 37 ℃and 5% 
CO2 for 6-8 h and changed with fresh full culture media after. The cells were ready for the 
further experiments. The siRNA sequences were described in table 2-3 	
Table 2-3 The siRNA sequences of lncRNA 	
Name of siRNA Sequence 
siMYOSLID-1-Sense 5’ rGrGrArGrArArUrGrArArCrUrUrCrUrUrArArArGrCrUrGAA 3’ 
siMYOSLID-1-Antisense 5’ rUrUrCrArGrCrUrUrUrArArGrAr ArGrUrUrCrArUrUrCrUrCrArC 3’ 
siMYOSLID-2-Sense 5’ rGrArGrCrCrArCrCrUrUrGrCrUrCrUrArGrGrArUrGrUrGCC 3’  
siMYOSLID-2-Antisense 5’ rGrGrCrArCrArUrCrCrUrArGrArGrCrArArGrGrUrGrGrCrUrCrUrU 3’ 
siMyolnc16-1-Sense 5’ rGrCrArArCrArUrGrCrArGrCrCrArGrCrCrArUrUrUrCrCAG 3’ 
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siMyolnc16-1-Antisense 5’rCrUrGrGrArArArUrGrGrCrUrGrGrCrUrGrCrArUrGrUrUrGrCrUrU 3’ 
siMyolnc16-2-Sense 5’ rUrGrCrCrArCrCrCrUrGrUrArArGrArUrArUrGrArCrUrUGC 3’ 
siMyolnc16-2-Antisense 5’rGrCrArArGrUrCrArUrArUrCrUrUrArCrArGrGrGrUrGrGrCrArGrG 3’ 	
2.8.3 Cell Transduction  
Lentiviral transduction of PASMCs was performed in 6 well plates. PASMCs were seeded 
into 6 well plates at a density of 1.5 x 105 per well. The following day, media was replaced 
with fresh full media containing appropriate amount of virus. Cells were incubated at 37 ℃	
and 5% CO2 for 48 h. After the experimental period, cells were lysed for RNA extraction 
and following gene expression analysis. 
2.9	Cellular	Function	Assays	
2.9.1 Proliferation Assay 
2.9.1.1	BrdU	Cell	Proliferation	Assay	 	
Cell proliferation was measured by BrdU incorporation using Proliferation Assay Kits 
(Millipore BrdU Cell Proliferation Assay Kit) according to the manufacturer’s instructions. 
PASMCs and PAECs were seeded into a 96-well culture plates at densities of 1 x 104 and 5 
x 103, respectively. Where required, cells were transfected the next day. The day following 
transfection, cells were serum-starved for 24 h (PAECs) and 48 h (PASMCs) in serum 
starvation media (0.2% FCS media). Cells were then treated with PDGF (20 ng/µl) 
(PASMCs) and VEGF (50 ng/µl) (PAECs) for 72 h (PASMCs) and 48 h (PAECs). A work-
ing stock of BrdU was prepared by diluting the BrdU stock 1:2000 into fresh cell culture 
media and pipetting 20 µl of this working stock to each well after 5 h stimulation with 
PDGF and VEGF. Two types of controls were set up to ensure validity of the experiments, 
including a blank control: a no cells control, and a background control: cells without BrdU 
added. The BrdU incorporation was stopped by removing the contents of wells by invert-
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ing over sink and blotting gently on paper towels and then adding 200 µl of the Fixa-
tive/Denaturing Solution to each well and allowing to incubate at room temperature for 30 
min. Antibody solution was prepared by diluting the 100 X Anti-BrdU antibody 1:100 into 
the Antibody Dilution Buffer and then added to the wells and incubated at room tempera-
ture for 1 h after removed the Fixative/Denaturing Solution. The wells were washed three 
times with 1 X Wash Buffer making sure each well was filled completely and blotted the 
plate gently on paper towels. Conjugate solution were prepared by diluting the reconstitut-
ed (in 1 X PBS) Peroxidase Goat Anti-Mouse IgG HRP Conjugate into the Conjugate Dil-
uent and then added 100 µl into each well and incubated for 30 min at room temperature. 
The entire plate was flooded with dH2O and then washed by 1 X Wash Buffer three times. 
We then added 100 µl of Substrate Solution to each well and incubated in the dark at room 
temperature for 15 min and followed by adding 100 µl Stop Solution to each well to stop 
the reaction. The absorbance was measured in each well using a spectrophotometric plate 
reader, Victor (Perkin EImer, Waltham, USA) at dual wavelengths of 450-540 nm in 30 
min after adding the Stop Solution.  
2.9.1.2	EdU	Proliferation	Assay	
Cell proliferation also quantified using EdU proliferation assay (Click-iT® Plus EdU 
Alexa Fluor® 488 Flow Cytometry Assay Kit, C10633) according to the manufacturer’s 
instructions. Briefly, PASMCs seeded in 6-well plates were stimulated with full culture 
medium and EdU (20 µg/ml in 2 ml culture media) was added at the point of stimulation 
for the remaining time to allow cell proliferation to occur for 48 h. The cells were tryp-
sinised and harvested after 48 h stimulation and placed in 15 ml falcon tubes and centri-
fuged at 600 g for 6 min. Following centrifugation, the supernatants were discarded and 
cells resuspended in 0.5 ml PBS and fixed by adding 4.5 ml 70% ethanol overnight. Fixed 
cells were then centrifuged at 600 g for 6 min and 5 ml 0.2% Triton X-100 added follow-
ing removal of supernatants. Samples were mixed and incubated for 30 min at room tem-
perature. 0.5 ml PBS + 1% BSA was then added to cells, which were mixed for 60 sec and 
then centrifuged at 600 g for 6 min allowing removal of the supernatant. The Click-it Alexa 
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reagent stock was prepared as described in Table 2-4. 0.5 ml Click-it reagent was added 
per tube, mixed well and incubated at room temperature for 60-90 min in the dark. Fol-
lowing incubation, 5 ml PBS + 1% BSA was added to cells which were then centrifuged at 
600 g for 5 min and removed the supernatant. Finally, 500 µl PBS to each sample of pel-
leted cells and resuspended cells were transferred to Fluorescence Activated Cell Sorting 
(FACS) tubes for FACS analysis.   	
Table 2-4 The Click-it reagent components 	
Reaction Component Number of reactions (500µL volumes) 
1 2 3 4 6 9 10 
PBS 438 µl 875 µl 1.3 ml 1.75 ml 2.6 ml 3.95 ml 4.38 ml 
CuSO4 (2 mM final concentration) 
Component F (Room temp) 
10 µl 20 µl 30 µl 40 µl 60 µl 90 µl 100 µl 
Alexa Fluor azide - 7.14 µg/µl 
Component B – 18 µg/reaction 
(18ng/µl; 23 µM final concentration)  
(-20ºC)  
2.5 µl 5 µl 7.5 µl 10 µl 15 µl 22.5 µl 25 µl 
1X Reaction buffer additive 
(-20ºC)  
50 µl 100 µl 150 µl 200 µl 300 µl 450 µl 500 µl 	
2.9.2 Apoptosis Assay 
PASMC and PAEC apoptosis was analysed by by measuring Caspase3/7 activity using 
Caspase-Glo® 3/7 Assay (Promega, G8091) according to the manufacturer’s protocol. 
PASMCs and PAECs were seeded in 96-well plates and followed by different treatments. 
To induce apoptosis, PASMCs were treated with H2O2 (50 µm) for 12 h and PAECs were 
treated with Cycloheximide (CHX, 25 ng/ml) and TNF-α (4 ng/ml) for 7 h. Briefly, the 
Caspase-Glo® 3/7 Buffer and lyophilised Caspase-Glo® 3/7 Substrate were equilibrated to 
room temperature and mixed the Substrate and buffer. The 96-well plates were removed 
from the incubator and allowed to equilibrate to room temperature, after which 100 µl of 
Caspase-Glo® 3/7 Reagent was added to each well of the 96-well plate containing 100 µl 
of blank, negative control cells or treated cells in culture medium. The well contents were 
gently mixed using a plate shaker and incubated at room temperature for 2 h. The solution 
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was transferred to a white-walled 96-well plate and luminescence measured in a plate lu-
minometer (VICTOR X3 Multimode Plate Reader, PerkiElmer) in the wavelength range of 
510-570 nm.  
2.9.3 Wound Healing Migration Assay 
Migration of PASMCs and PAECs was analysed using the scratch wound-healing assay in 
6-well plates. All cells were serum-starved for 24 h after various treatments (transfections, 
conditioned medium, and exosomes treatment), and vertical scratches were drawn through 
the confluent monolayer of cells using a P200 pipette tip. Cells were washed with PBS to 
remove any cell debris caused by induction of the wound and fresh full cell culture media 
(10% FBS) was added to the cells. For migration assay, it is recommended to use a lower 
percentage of serum in the growth medium to minimize the cell proliferation, however suf-
ficient serum is required to prevent apoptosis and/or cell detachment, which is a particular 
concern for transfection experiments. Scratches were imaged at 0, 10, or 12 h post scratch 
using the Nikon Eclipse TS100 microscope and imaged on QICAM Fast 1394 camera 
(QImaging, Burnaby, Canada), with three images captured for each well. Migration dis-
tance analysis was performed using Image J software where a grid composed of 10 hori-
zontal lines was placed over the photo. The distance between the edges of the scratch 
wound was measured along the grid lines and a relative migrated distance was expressed 
as a proportion of the migrated distance based on 0 h time point. Independent experiments 
were performed three times, with three independent wells per condition.  
2.9.4 Multiple Scratches Assay 
The multiple scratches are to apply a high density field of scratches to maximize the area 
of wound edges, while leaving sufficient undamaged cells to migrate into the gap. This 
form of high density wounding creates a high proportion of migrating cells to quiescent 
monolayer cells, which permits sensitive detection of the biochemical events occurring, 
specifically in the migrating cell population. Briefly, each well of the 6-well plate was 
scratched 10-12 scratches horizontally and vertically using P200 pipette tip. Then the wells 
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were washed with PBS and supplemented with full medium. After the desired time, media 
is removed and gently washed with PBS. Cells were harvested for RNA extraction and 
further analysed by Taqman PCR. The PASMCs closure after multiple scratches at differ-
ent time points were shown in Figure.   
 
 
	
Figure 2.4 PASMCs migration with multiple scratches 
PASMCs were scratched with P200 pipette tip in 6 well plate. Pictures were shown the cell migration at dif-
ferent time points.  
2.9.5 In Vitro Tube Formation Assay  
PAEC tube formation assays were performed in 96-well plates containing 50 µl Matrigel 
(in vitro angiogenesis assay ECM625, Millipore, USA) according to the manufacturer’s 
protocol. Briefly, Matrigel solution was added to the wells of a 96-well plate and allowed 
to solidify and polymerize in a 5% CO2 incubator at 37 °C for 1 h. PAECs were then disso-
ciated, centrifuged at 1200 rpm for 5 min and resuspended in full endothelial cell media at 
a density of 1 x 104/100 µl. 100 µl of cell suspension was layered on top of the Matrigel. 
After 6-12 h incubation at 37 °C and 5% CO2, tube formation was inspected using a light 
microscope. Tube-like formations were evaluated in 15 pictures per condition (magnifica-
tion 10x) and the number of cells, number of branches, average length of the capillary 
branches, number of branches to the length of capillaries ratio and the pattern of branching 
were assessed using the angiogenesis analyser module for Image J. 
2.10	DNA	Damage	Assay	
PASMCs were seeded in 6-well plates and treated with TNF-α (100 ng/ml), IL-6 (100 nm) 
and PDGF (30 ng/ml) for 48 h in cell incubator at 37 °C and 5% CO2. Immunocytochemis-
0h	 	 3h	 	 8h	 	 16h	 	 24h	 	
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try for γ-H2AX was performed as section 2.6.4 using a monoclonal antibody directed 
against γ-H2AX (ab11174, Abcam) at 1: 200 dilutions. The DNA damage in vitro was im-
aged with a Zeiss LSM510 confocal microscope. Cells were classified based on the num-
ber of foci in the nucleus: cells with greater than 10 foci were counted as positive DNA 
damage. 	
2.11	Western	Blotting	
2.11.1 Protein Extraction and Preparation 
Protein lysis buffer was prepared on ice including the following reagents: 20mM Tris pH 
7.5, 1 mM EDTA, 150 mM NaCl, 1 mM Ethylene glycol tetra-acetic acid (EGTA), 1 mM 
β-glycerophosphate, 2.5 mM Na pyrophosphate, 1 mM Na3VO4, 0.5% (w/v) sodium de-
oxycholate, 1 mM phenylmethylsulfonylfluoride (PMSF), 2 mM NaF, 1µg/ml leupeptin. 
Protease inhibitor cocktail (1 tablet diluted in 10 ml lysis buffer) (Roche Applied Sciences), 
and phosphatase inhibitor cocktail 2 (1:100 in dilution in lysis buffer) were added freshly 
before protein extraction.  	
PASMCs and PAECs were seeded in 6-well plates and grown to 80% confluence. Follow-
ing various stimulations for the required time, experiments were stopped by 6-well plate 
incubation on ice. Immediately, the cell culture media was aspirated and washed with 
ice-cold PBS twice. Ice-cold protein lysis buffer (120 µl) was then added to each well for 
15 min. Keeping the 6-well plate on ice, the cells were scraped using a sterile plastic 
scraper and cell lysates collected in a pre-chilled 1.5 ml Eppendorf tube. These samples 
were further incubated on ice for 30 min and then centrifuged at 14,000 g for 10 min at 
4 °C. The protein supernatant was collected and store at -80 °C for western blot analysis.  	
To prepare protein lysates of tissues, 200 µl ice-cold protein lysis buffer was added to 2 ml 
Eppendorf tubes containing about 25 mg frozen tissues and one 5mm stainless steel bead 
(Qiagen, United Kingdom), which was placed in a Tissue Lyser Ⅱ (Qiagen, United King-
dom) for homogenisation. High-speed shaking was performed for 4 X 30 sec intervals. Af-
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ter homogenisation, samples were incubated at 4 °C for 1h with shaking, then centrifuged 
at 14,000 g for 30 min at 4 °C. Supernatants were collected and stored at -80℃ for western 
blot analysis.  
2.11.2 Protein Quantification 
Quantification of total protein was performed using the Pierce Bicinchonic Acid (BCA) 
protein Assay Kit (ThermoScientific, United Kingdom, catalog number: 23225) according 
to the manufacturer’s instructions. Bovine serum albumin was diluted at different concen-
trations ranging from 25 µg/ml to 2000 µg/ml to prepare diluted BSA standards. These 
standard samples were used to generate a standard curve. Working reagent was prepared by 
mixing 50 parts of BCA reagent A with 1 part of BCA reagent B. Protein samples and 
standards (10 µl each well) were added to the 96-well plate with 200 µl of working reagent, 
mixed thoroughly, protected from light and incubated at 37 ℃ for 30 min. Absorbance was 
measured at 560 nm using the Wallac 1420 Victor 2TM plate reader (Wallac). Sample pro-
tein concentrations were calculated using the standard curve generated by the protein 
standards.   
 2.11.3 SDS-PAGE 
Protein was separated by molecular weight using SDS-PAGE on a XCell4 SureLockTM 
Midi-Cell Electrophoresis System (ThermoFisher Scientific, UK) according to the manu-
facturer’s instructions. Briefly, 20 µg protein samples were mixed with NUPAGE® 4 X 
LDS Sample Buffer and denatured by heating at 95 °C for 10 min. Samples were loaded 
into the precast NuPAGE Novex 4-12% Bis-Tris Midi Gels along with a rainbow marker 
(Amersham). Electrophoresis was performed at 80-160 V in NuPAGE MOPS SDS running 
buffer until adequate migration and separation of protein samples was achieved.  
 
Proteins were transferred onto Amersham Hybond P nitrocellulose membranes (0.2 µm 
pore) (GE Life Sciences) at 100 V for 1.5 h in transfer buffer (25 mM Tris, 0.2 M glycine, 
20% (v/v) methanol) at 4 °C. The membranes were soaked into distilled H2O for 5 min and 
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balanced in the transfer buffer for 10 min before transfer. 	
2.11.4 Immunoblotting 
Immunoblotting was performed to quantitatively evaluate protein expression. Following 
transfer, nitrocellulose membranes were washed with PBS for 5 min. For specific protein 
analysis, the membranes were blocked at room temperature for 1h on a shaker in blocking 
buffer containing 50% Odyssey® Blocking Buffer in Tris buffered saline plus tween 
(TBST) (150 mM NaCl, 2mM KCl, 25 mM Tris and 1% (v/v) Tween-20). Membranes 
were incubated with specific primary antibodies (see Table 2-5 for a complete list) at 4 °C 
overnight. The following day membranes were washed in TBST for 3 X 10 min and then 
incubated with fluorescently-labelled secondary antibodies (1:10000) in Odyssey® block-
ing buffer diluted 1:1 in TBST for 1 h at room temperature with gentle shaking. The mem-
brane was then washed in TBST for 3 X 10 min and another wash with PBS for 10 min 
with gently shaking and protected from light. Membranes were then imaged on a Li-COR 
Odyssey imager.  
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Table 2-5 Antibodies used for western blotting 	
	
2.12	RNA	Extraction,	Purification	and	Quantification	 	
2.12.1 Cells  
Total RNA from PASMCs and PAECs was extracted using the QIAGEN miRNeasy mini 
kit (including on-column DNase treatment) following manufacturer’s instructions. Briefly, 
cells were lysed directly with 700 µl QIAzol lysis reagent and homogenised by repeated 
pipetting. The cell homogenate was added to 140 µl chloroform and mixed by shaking the 
tube vigorously for 10-15 sec. After incubation for 3 min at room temperature, samples 
were centrifuged at 12,000 g for 15 min at 4 ºC to separate the sample into aqueous and 
organic phases. The upper aqueous phase was transferred to a new collection tube 1.5 
volumes of 100% ethanol was added and mixed thoroughly by pipetting. Samples were 
transferred into an RNeasy Mini spin column and centrifuged at 8,000 g for 1 min at room 
temperature. Total RNA was bound to the silica membrane while contaminants, such as 
Antibody Dilution Supplier 
PCNA (rabbit) (100 µg/ml) 1:1000 Abcam-18197 
CD63 (rabbit) (200 µg/ml) 1:1000 Santa Cruz Biotech (sc-15363) 
CD9 (rabbit) (200 µg/ml) 1:1000 Santa Cruz Biotech (sc-9148) 
GAPDH (rabbit) (100 µg/ml) 1:1000 Cell Signalling (2118) 
β-Tubulin (rabbit) (100 µg/ml) 1:1000 Cell Signalling (2146) 
MAPK Family Antibody Kit (rabbit) 1:1000 Cell Signalling (9926) 
Smad 1/5/9 Antibody Kit (rabbit) 1:1000 Cell Signalling (12656) 
BMPR2 (mouse) (250 µg/ml) 1:500 BD Biosciences (612292) 
IRDye® 800CW Goat  
anti-Mouse IgG (goat) (100 µg/ml) 
1:10000 
 
LI-COR (P/N 925-32210) 
 
IRDye® 800CW Goat 
anti-Rabbit IgG (goat) (100 µg/ml) 
1:10000 
 
LI-COR (P/N 925-33211)  
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phenol, were washed away in the subsequent wash steps. Columns were washed with 350 
µl buffer RWT at 8,000 g for 1 min at room temperature. At this stage, on-column DNase 
digestion was performed to remove contaminating genomic DNA from the samples, which 
couldt interfere with downstream applications. DNase stock solution was diluted 1:8 (v/v) 
in buffer RDD (10 µl to 70 µl). The DNase/RDD mixture (80 µl) was added directly onto 
the column membrane and incubated at room temperature for 15 min.  
 
The columns were washed once with 350 µl buffer RWT and twice with 500 µl buffer RPE 
with centrifugation at 8,000 g for 1 min at room temperature between each wash. The 
columns were placed into a fresh collection tubes and centrifuged at 14,000 g for 2 min at 
room temperature to remove any buffer contaminants. Spin columns were then transferred 
to new RNase-free tubes and RNA was eluted by adding 30 µl RNase-free H2O to the 
columns and centrifuging at 8,000 g for 1 min at room temperature. In order to increase 
RNA yield, the RNA eluates were collected and re-eluted through the column. 	
2.12.2 Tissues 
Total tissue RNA was extracted using the QIAGEN miRNeasy mini kit including 
on-column DNase treatment following manufacturer’s instructions. Snap frozen tissues 
were stored at -80 °C until processing. Tissues were lysed using 700 µl QIAzol lysis rea-
gent and disrupted and homogenised using 5 mm stainless steel beads in the TissuLyser 
(QIAGEN) at 25 Hz FOR 1-2 min until full tissue disruption. Following homogenisation, 
140 µl chloroform was added to each sample and followed the next steps described in sec-
tion 2.12.1. 	
2.12.3 Nano-Drop 
Total RNA was quantified using the NanoDrop 1000 Spectrophotometer (Thermo Scien-
tific). The spectrophotometer measured the absorbance of each sample at 260 nm (absorb-
ance of RNA) and 280 nm (absorbance of protein) and 230 nm (absorbance of contamina-
tions). The ratio of absorbance at 260 nm and 280 nm is used to assess the purity of DNA 
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and RNA. A 260 nm/280 nm ratio of ~2.0 is generally accepted as “pure” for RNA. If the 
ratio is appreciably lower in either case, it may indicate the presence of protein, phenol or 
other contaminants, which absorb strongly at or near 280 nm. The 260 nm/ 230 nm ratio is 
used as a secondary measure of nucleic acid purity. The 260/230 values for “pure” nucleic 
acid often higher than the respective 260/230 values. Expected 260/230 value are com-
monly in range of 2.0-2.2. If the ratio is appreciably lower than expected, it may indicate 
the presence of contaminants which absorb at 230 nm.  
 2.12.4 Agilent Testing of RNA Quality 
The RNA extracted from PASMCs and PAECs for microarray assays were further analysed 
by a Small RNA Assay performed on the Agilent Bioanalyzer 2100 system (Agilent Tech-
nologies, Berkshire, UK) at the Sir Henry Wellcome Functional Genomics Facility, Micro-
array Unit at the University of Glasgow. The negatively charged RNA molecules were 
eletrophoretically separated by size to produce gel images and electropherograms, allowing 
assessment of RNA quality. The percentage of miRNA (relative to small RNA) in the sam-
ple was also calculated using the Agilent 2100 software. 	
2.13	Reverse	Transcription	Polymerase	Chain	Reaction	(RT-PCR)	
2.13.1 MiRNA Reverse Transcription  
For the detection of miRNA expression, cDNA was synthesised using stem-loop reverse 
transcription primers as per the Taqman microRNA assay protocol (Applied Biosystems, 
Paisley, UK) according to the manufacturer’s instructions. Each reaction contained 2.5 µl 
of 2 ng/µl sample RNA, 0.25 mM of each deoxyribonuclecotide triphophate (dNTP), 3.33 
U/µl multiscribe reverse transcriptase, 0.25 U/µl RNase inhibitor, 1 X Reverse Transcrip-
tase buffer, 2.08 µl RNase-free water, and Taqman® miRNA Reverse Transcription 
Primers for the mature sequence of the miRNA of interest. Both human and mouse endog-
enous controls RNU48 and U6 were also performed for each sample to normalise changes 
in the miRNA expression. The mature sequence of miRNA of interest and endogenous 
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control sequences shown in table 2-6. cDNA synthesis reactions were incubated at 16 ºC 
for 30 min, 42 ºC for 30 min, and 85 ºC for 5 min and then held at 4 ºC. Samples were 
stored at -20 ºC before quantitative PCR was performed.  
 
Table 2-6 MiRNA reverse transcription primers 	
MiRNA/Control Sequence Species 
Has-miR-143-3p 5’UGAGAUGAAGCACUGUAGCUC 3’ Human/mouse 
Has-miR-143-5p 5’ GGUGCAGUGCUGCAUCUCUGGU 3’ Human/mouse 
Has-miR-145-5p 5’ GUCCAGUUUUCCCAGGAAUCCCU 3’ Human/mouse 
Has-miR-145-3p 5’ GGAUUCCUGGAAAUACUGUUCU 3’ Human/mouse 
RNU48 5’GATGACCCCAGGTAACTCTGAGTGTGT 
CGCTGATGCCATCACCGCAGCGCTCTGAC 
C 3’ 
Human 
U6 5’GTGCTCGCTTCGGCAGCACATATACTAA 
AATTGGAACGATACAGAGAAGATTAGCAT 
GGCCCCTGCGCAAGGATGACACGCAAA 
TTCGTGAAGCGTTCCATATTTT 3’ 
Mouse 
 
2.13.2 mRNA Reverse Transcription 
For gene expression analysis, cDNA was synthesised using the SuperScript™ II Reverse 
Transcriptase (RT) system. Each reaction contained 4 µl 5 X First strand buffer, 1µl 10 mM 
dNTP, 1 µl Random Primers (9 units), 1 µl 0.1 M DTT, 0.5 µl RNasin® Ribonuclease In-
hibitor (2500 units) (Promega), 1 µl SuperScript™ II Reverse Transcriptase, 1.5 µl 
RNase-free H2O and 100-1000 ng RNA (diluted into 10 µl) to a total volume of 20 µl 
(same concentration of RNA used per experiment). Samples were incubated at 70 ºC for 10 
min, 4 ºC for 10 min (mastermix added to each reaction), 25 ºC 10 min, 42 ºC 1 h, 72 ºC 
15 min and held at 4 ºC. Samples were stored at -20 ºC when not being used immediately.  
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2.14	Taqman	Quantitative	Real-Time	PCR	 	
Quantitative PCR is the second step in the real-time PCR assay. MiRNA qRT-PCR was 
performed using Taqman® miRNA Assay RT-PCR Probes and Taqman® Universal Mas-
termix II (containing AmpliTaq Gold® DNA polymerase, dNTP mixture and optimal salt 
conditions, no UNG; Invitrogen) in accordance with the manufacturer’s instructions. Each 
reaction mastermix contained 250 nM Taqman probe, 1 X Taqman Universal PCR Mas-
terMix II (Invitrogen) and nuclease-free H2O to a total volume of 9.33 µl per sample. 
cDNA was pipetted in technical triplicate into a 384 well plate 0.67 µl per well and the 
mastermix added to each well to give a total reaction volume of 10 µl. Human RNU48, or 
mouse U6 were used as an endogenous control in separate wells.  
 
Quantitative qRT-PCR for mRNA expression samples was performed using Taqman® 
Gene Expression Assays and Taqman® Universal Mastermix II in accordance with the 
manufacturer’s instructions. Each reaction mastermix contained 1 X Taqman® gene probe, 
1 X Taqman® Mastermix and H2O to a total volume of 10 µl. cDNA samples were diluted 
with RNase-free H2O dependent on how much RNA was added to the RT reaction. For 
example, where 1000 ng RNA added per sample in RT reactions then cDNA was diluted to 
200 µl with nuclease-free H2O. qRT-PCR reactions were performed using 2.5 µl diluted 
cDNA in technical triplicate into a 384 well plate and added with mastermix to give a total 
reaction volume of 12.5 µl.  
 
MiRNA and mRNA expression was measured using the ABI Prism 7900HT sequence de-
tection system (Applied Biosystems). Thermal cycling conditions began with 10 min in-
cubation at 95 ºC，then followed by 40 cycles of 15 sec at 95 ºC and then 60 sec at 60 ºC.  
 
Results were shown relative to the control sample using the -2ΔΔCt method and expressed as 
relative fold change. For miRNA expression, results were normalised to U6 and RNU48 
for mouse and human samples, respectively. For mRNA and long non-coding RNA expres-
sion, results were normalised to 18S rRNA or UBC for experiments that involved hypoxia, 
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as this gene remains unchanged in hypoxic conditions. Experiments performed in normox-
ic conditions were normalised to GAPDH, as study showed that GAPDH expression was 
upregulated in hypoxic conditions (Yamaji et al., 2003).	
2.15	Exosome	Extraction,	Purification	and	Quantification	 	
PASMCs were seeded in 6-well plates with cell number at 2 x105/well with or without 
transfection. In the following day, cells were washed twice with PBS and replaced with 10% 
exosome free-FCS (exosome remove by 18 h ultracentrifugation) SMC medium and cells 
were incubated at 37 °C and 5% CO2 for 36 - 48 h.  
 
Cell culture medium was collected for each sample and centrifuged at 2,000 g for 30 min 
to remove cell debris at room temperature. Supernatants containing cell free cell media 
were transferred to a clean tube and held on ice until use. Supernatants were then com-
bined with total exosome isolation reagent (Invitrogen) and mixed well by vortexing until a 
homogenous solution was formed. The samples were incubated at 4 °C overnight and then 
centrifuged at 4 °C at 10,000 g for 1 h. The supernatant was aspirated and discarded, and 
the exosome pellet was resuspended in PBS buffer, then stored at 4 °C for short term (1-7 
day) and -20 °C for long term until use. 
 
Exosomes were also extracted by ultracentrifugation for western blot analysis. Superna-
tants from PASMC cultures were collected and pre-cleared by centrifugation at 4,000 g for 
10 min at 4 °C to remove cell debris. To pellet the exosomes, the supernatant was centri-
fuged at 23,000 g for 70 min at 4 °C. Supernatants were removed and discarded, and the 
pelleted exosomes were washed with ice-cold PBS and pelleted again by ultracentrifuga-
tion at 23,000 g for 70 min at 4 °C. Finally, the supernatant was removed and discarded 
and the pelleted exosomes were resuspended in 150 µl protein lysis buffer. After incuba-
tion on ice for 30 min, the lysed exosomes were centrifuged at 14,000 g for 10 min at 4 °C 
to harvest the supernatant (exosome protein) and store at -80 °C. Protein analysis by west-
ern blot for CD63 (H-193: sc-15363) and CD9 (H-110: sc-9148) were carried out to assess 
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the purity of the exosome isolation. RNA was extracted from exosomes by following the 
protocol for RNA extraction from cells described in section 2.12.1.  
2.16	Nanoparticle	Tracking	Analysis	(NTA)	 	
Exosomes isolated from cell culture media and the exosome size and numbers were meas-
ured using a NonoSight LM system. The instrument, which is based on a conventional op-
tical microscope, uses a laser light source to illuminate nano-scale particles within a 0.3 ml 
sample introduced to the viewing unit with a 1ml disposable syringe. Enhance by a near 
perfect black background, particles appear individually as point scatters moving under 
Brownian motion. The NanoSight instrument tracks the Brownian motion of nanoparticles 
in liquid suspension (exosomes diluted in PBS) on a particle-by-particle basis. Subsequent 
application of the Stokes-Einstein equation allows the derivation of particle (exosomes) 
size and concentration. The size of exosome particles is from 30nm to 130 nm.  	
2.17	Microarray	Analysis	
Microarray analysis was performed on PASMC and PAECs transfected with scramble or 
pre-miR-143-3p. RNA quantity and quality were assessed by NanoDrop® Spectrophotom-
eter (Thermo Scientific, Wilmington, DE, USA). RNA integrity was assessed with the Ag-
ilent 2100 bioanalyser using the RNA 6000 Nano Kit (Santa Clara, CA). The Illumina To-
talPrep RNA amplification kit (Ambion) was used to generate biotinylated, amplified RNA, 
from 500 ng input RNA, for hybridization with the Illumina arrays (Applied Biosystems 
Carlsbad, California). The Illumina humanHumanHT-12 v4.0 Expression BeadChips were 
hybridised following the manufacturer’s protocol, scanned with the Illumina BeadArray 
Reader and read into Illumina GenomeStudio® software (version 1.1.1).  
For microarray data analysis and validation, quantile normalised and background subtract-
ed intensity values were exported from GenomeStudio® software for data processing and 
analysis in R (http://www.R-project.org) in which limma statistical analysis was carried 
out(Ritchie et al., 2015), including pairwise comparisons between the 3 groups. The mi-
croarray data and experimental design was submitted online to the ArrayExpress database 
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(www.ebi.ac.uk/arrayexpress) following MIAME guidelines. The accessions 
E-MTAB-3566 and E-MTAB-3567 were allocated to the PAEC and PASMC arrays respec-
tively. To gain further biological insights into the gene expression profiling experiments, 
pathway analysis was performed using Ingenuity Pathway Analysis software (Ingenuity 
Systems, www.ingenuity.com). To account for potentially subtle changes in levels of gene 
expression caused by the action of miRNAs and to ensure these changes were included in 
the pathway analysis we used a fold change threshold of ± 1.25. 
2.18	Lentivirus	Production	and	Titering	
Lentiviral vectors were produced by triple transient transfection of HEK293T cells with a 
packaging plasmid (pCMV∆8.74), a plasmid encoding the envelope of vesicular stomatitis 
virus (VSVg) (pMDG) (Plasmid Factory, Bielefeld, Germany) and lentiviral vector 
(pFUGW) plasmid employing polyethylenimine. The lentiviral plasmid (pFUGW) carrying 
the MYOSLID transcript and vector control were generated as previous described (Zhao et 
al., 2016) and kindly gifted by Dr. Xiaochun Long (Albany Medical College, NY). 
 
Briefly, HEK239T cells grown to 80% confluency in 3 T150 flasks and transfected using 
polyethylenimine (3 µl (1 mg/ml) diluted in 5 ml OptiMEM) precomplexed with 50 µg of 
the lentiviral vector along with 17.5 µg pMDG envelope plasmid and 32.5 µg packaging 
plasmid (pCMV∆8.74) dilute in 5 ml OptiMEM. The combination mixture was incubated 
for 20 min at room temperature to allow the DNA/PEI complexes formation. HEK293T 
cells were washed with 5 ml OptiMEM and 10 ml DNA/PEI complexes were added to 
each flask, with cells incubated at 37 °C and 5% CO2 for 4 h. Transfection media were re-
placed after the 4h transfection period with 20 ml fresh complete MEM. Cell media were 
harvested at 48 h and 72 h, filtered through a 0.22 µm Millipore™ Stericup™ Vacuum Fil-
ter Unit (Millipore) and lentiviruses were pelleted by centrifugation at 23,000 rpm for 1 h 
at 4 °C. The viral pellet was resuspended in 50 ul OptiMEM per flask and left for 20 min 
on ice before aliquoting and storage at -80 °C.  
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The viral titer was determined using Lenti-X qRT-PCR titration kit (Clontech) according to 
the manufacturer’s instructions. Briefly, viral RNA was isolated from the resuspended len-
tivirus. Viruses were first lysed by add 600 µl Buffer RAV1containing Carrier RNA to 150 
µl lentivirus and mixed well and incubated for 5 min at 70 °C. 600 µl 100% ethanol was 
added to lysed lentiviruses and mixed by vortexing (10-15 s). Lysed samples were then 
loaded onto the NucleoSpin® Virus Columns and centrifuged for 1 min at 8,000 g at room 
temperature. Three washes were then performed: once 500 µl Buffer RAW, once 600 µl 
Buffer RAV3, and once 200 µl Buffer RAV3. The last spin was at 11,000 g to remove eth-
anolic Buffer RVA3 completely. The NucleoSpin® Virus Columns were placed into new, 
sterile 1.5 ml microcentrifuge tubes and added 50 µl nuclease-free H2O (preheated to 70 °C) 
and incubated for 2 min and centrifuged for 1 min at 11,000 g at room temperature.  
 
QRT-PCR for the viral RNA samples was performed using Lenti-X primers and Quant-X 
Buffer in accordance with the manufacturer’s instructions. Briefly, Master Reaction Mix 
were set up to contain 12.5 µl Quant-X Buffer (2 X), 0.5 µl Lenti-X Forward/Reverse Pri-
mer (10 µm), ROX Reference Dye LSR or LMP (50 X), 0.5 µl Quant-X Enzyme, 0.5 µl 
RT-enzyme Mix, and 8 µl H2O to a total volume of 23 µl per well. Viral RNA and the di-
luted Lenti-X RNA control Template were pipetted in duplex into a 384 well plate with 2 
µl per well and the Master Reaction Mix added to each well to give a total reaction volume 
of 25 µl. The plate was centrifuge at 2000 rpm for 2 min to remove any bubbles and in-
stalled the plate in the Applied Biosystems 7900T sequence detection system. Cycling 
condition were: RT Reaction step: 42 °C 5 min and 95 °C 10 sec; qRT-PCR step: 95 °C 5 
sec and 60 °C 30 sec with 40 cycles; Dissociation Curve step: 95 °C 15 sec, 60 °C 30 sec 
and all (60 °C - 95 °C).   
 
A standard curve was generated using the average Ct values from each of the Lenti-X RNA 
Control Template duplicate sample dilutions plotted against copy number (log scale) for 
the calculation of the quantity of viral RNA. Once an average Ct value for each sample 
was determined and then a corresponding value got from the standard curve, the copy 
number of sample viral RNA per ml was calculated using the equation below: 
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 𝐶𝑜𝑝𝑖𝑒𝑠/𝑚𝑙 = (𝑐𝑜𝑝𝑦	𝑛𝑢𝑚𝑏𝑒𝑟𝑓𝑟𝑜𝑚	𝐶𝑡𝑆)(1000	𝜇𝑙/𝑚𝑙)(50	𝜇𝑙	𝑅𝑁𝐴	𝑒𝑙𝜇𝑡𝑖𝑜𝑛)(150	𝜇𝑙	𝑠𝑎𝑚𝑝𝑙𝑒)(2	𝜇𝑙	𝑎𝑑𝑑𝑒𝑑	𝑡𝑜	𝑒𝑎𝑐ℎ𝑤𝑒𝑙𝑙) 			
2.19	Co-culture	Model	
The co-culture model was showed in Figure 2.3. 6-well transwell inserts with 0.4 µm pores 
were purchased from Greiner and used following the manufacturer’s instructions. Briefly, 
PASMCs (1.5 x 105) were seeded in the well inserts and/or transfected with pre-miR143 
(100 nM) using siPORT NeoFX Transfection Agent and cultured in full SMC medium for 
24 h detailed in section 2.8.1. PAECs (2 x 105) were seeded into the 6-well plate with full 
EBM media. On the following day before starting the co-culture experiments, both 
PASMCs and PAECs were washed with PBS then the well insert seeded with transfected 
PASMC putted into the 6-well plate seeded with PAECs. All co-culture experiments were 
done in full EBM-2 media.  
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Figure 2.5 Co-culture model of cell-to-cell communication 
A co-culture model was used for cell-to-cell communication between PASMCs and PAECs. PASMCs were 
seeded in the top well, and PAECs were seeded in the bottom well, and a 0.4 µm porous membrane between 
the 2 wells inhibiting cell-cell contract. 	
2.20	Labelling	Pre-miR-143-3p	Precursor	with	Cy3	In	Vitro	 	
Pre-miR miRNA precursor (has-miR-143-3p) was labelled with Label Cy3 using IT siRNA 
Tracker Cy3 Kit, according to the manufacturer’s instructions (Mirus, Madison, WI, USA). 
Briefly, Label IT® siRNA Tracker Reagent was added 50 µl Label IT® Reconstitution So-
lution to complete reconstitute the pellet, mix well by gentle pipetting. The labelling reac-
tion samples were prepared as follows: molecular biology-grade H2O 60 µl, 10 X Labeling 
Buffer A 10 µl, pre-miR-143-3p precursor 20 µl of a 40 µm stock, and the reconstituted 
Label IT® siRNA Tracker Reagent 10 µl. The reaction samples were incubated at 37 °C 
for 1 h and protected from light. After incubation, 0.1 volumes of 5 M sodium chloride and 
2.5 volumes of ice cold 100% ethanol were added to reaction samples which were placed 
in -20 °C freezer for at least 30 min. This step was to remove the unreacted Label IT® 
siRNA Tracker Reagent from the labelled pre-miR precursor by ethanol precipitation. The 
reaction samples were further centrifuged at 14,000 g for 15 min at 4 °C to pellet the la-
belled pre-miR precursor, with supernatants carefully removed using a pipette. The la-
belled pellet was washed with 500 µl room temperature 70% ethanol and centrifuged at 
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14,000 g at 4 °C for 15 min and removed all traces of ethanol with a micropipette. The 
pellet was resuspended in 20 µl Dilution Buffer to bring the concentration to approximate-
ly 40 µM. Labelled pre-miRNAs were aliquoted and stored at -20 °C, protected from light. 	
2.21	Statistical	Analysis	 	 	
All Taqman qRT-PCR results are expressed as mean and standard error of the mean (SEM). 
Statistical analysis was performed using Graphpad Prism 5 Software (California, USA) by 
unpaired student’s t-test when comparing two experimental groups. When more than two 
groups were compared, a one-way ANOVA was performed followed by a Tukey’s post hoc 
test. All statistics for individual experiments are showed in figure legends. Significance 
was determined as a P value of P < 0.05.  	
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3 Evaluation of miR-143/145 in pulmonary 
arterial hypertension patient samples and 
in experimental animal models of PAH 
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3.1	Introduction	
The first study to identify the expression of miR-143 and miR-145 showed that their ex-
pression levels were reduced in precancerous and neoplastic colorectal tissue, indicating 
that these miRNAs may affect the early processes of tumorigenesis in the colon (Michael 
et al., 2003). MiR-143 and miR-145 have been deemed as “tumor suppressors” after exten-
sive studies in human cancer (Akao et al., 2006, Zhang et al., 2012, Takagi et al., 2009, 
Kent et al., 2014). Later studies showed that miRNA expression broadly contributes to the 
tissue specificity of mRNA expression in many human tissues (Sood et al., 2006), under-
lining the importance of evaluating the pattern of miR-143/145 expression in different cell 
types in order to increase our understanding of the role of these miRNAs in the patho-
physiological processes that drive human diseases.  
 
The miR-143 encoding gene is highly conserved and lies with 1.4 kilobases (kb) of another 
conserved miRNA, miR-145, on mouse chromosome 18 and human chromosome 5. 
RT-PCR using primers from the stem-loop sequences of the miR-143/145 showed that they 
are derived from a common bicistronic precursor, indicating that they are co-transcribed 
from the same gene. Although miR-143 and miR-145 exist in a cluster, their mature forms 
exhibit no sequence homology (Cordes et al., 2009, Elia et al., 2009, Xin et al., 2009). The 
restricted expression of miR-143/145 was initially in early cardiomyocytes (E8.5 onward) 
but disappeared from cardiomyocytes at later stages (E16.5) and then express exclusively 
in SMCs. Interestingly, microarray experiments performed on various mouse tissues at 
different developmental stages revealed that the expression of miR-143 and miR-145 
strongly correlated with the number of SMCs present in the organ analysed. For example, 
expression of these miRNAs was particularly high in aorta and bladder (Boettger et al., 
2009). This observation was further confirmed by another study by evaluating the expres-
sion of miR-143/145 in various mouse tissues by northern blotting, which found that 
miR-143 and miR-145 is present in lung, skeletal muscle, heart, skin, and was most abun-
dant in aorta and fat (Elia et al., 2009). Thus, miR-143/145 cluster is known as smooth 
muscle cell (SMCs)-enriched miRNAs.  
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There are several studies that have reported a role for miR-143/145 in vascular diseases in 
which SMCs play fundamental role in disease pathogenesis such as acute vascular injury 
(carotid artery balloon injury, wire injury, ligation injury), atherosclerosis, and cardiac dis-
ease (transverse aortic constriction (TAC) mouse model). In the carotid balloon injury 
model in male Sprague-Dawley rats, miR-143/145 expression was significantly downreg-
ulated at day 7, 14 and 28 days after balloon injury (Ji et al., 2007). Adenovirus-mediated 
restoration of miR-145 (Ad-miR-145) in balloon-injured arteries inhibited neointimal 
growth (Cheng et al., 2009), in line with similar studies performed by Elia et al using 
Ad-miR-145 and Ad-miR-143 (Elia et al, 2009). Using the carotid artery ligation model, 
which results in narrowing of the vascular lumen as a result of phenotypic modulation and 
proliferation of VSMCs, a significant downregulation of miR-143 and miR-145 expression 
was observed when injured vessels were compared to sham contralateral vessels (Cordes et 
al, 2009). Consistent with this results, miR-143/145 knockout (KO) aged mice (18 month) 
develop neointimal lesions in the femoral arteries (Boettger et al., 2009). However, another 
study use different miR-143/145 mutant mice following carotid artery ligation showed that 
miR-143 KO, miR-145 KO and miR-143/145 double KO mice dramatically reduced the 
neointimal formation (Xin et al., 2009). These data suggest that miR-143/145 cluster is key 
regulator in the response of vascular SMCs to vessel injury.  
 
In atherosclerosis disease, apolipoprotein E (ApoE) knockout mice is a classic model to 
study atherosclerosis, which can induce vascular stress and damage by a hypercholesterol-
aemic diet (Breslow, 1996). The qRT-PCR results showed miR-143/145 expression level 
was significantly reduced in the aorta of ApoE KO mice, and the expression was further 
reduced with high fat diet (HFD) feeding (Elia et al., 2009). The downregulation of 
miR-145 in atherosclerosis was further confirm with ApoE KO mice maintained with 
Western diet for 12 weeks compared with WT control and before diet initiation. In human 
carotid artery segments with plaque containing also have reduced level of miR-145 com-
pared with normal controls. Vascular smooth muscle cell (VSMC)-specific miR-145 lenti-
virus treated ApoE-/- mice markedly reduced atherosclerosis in vivo (Lovren et al., 2012). 
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In addition, the transcripts of miR-145 were downregulated to nearly undetectable levels in 
atherosclerotic lesions with significant neointimal formation (Cordes et al., 2009). In addi-
tion, the Dimmeler group demonstrated that shear stress could induce KLF2 and 
miR-143/145 expression and KLF2 also induced miR-143/145 increase in endothelial cells 
(ECs). These miRNAs packaged in EC secreted extracellular vesicles, which can transfer 
miR-143/145 to target VSMCs. In the atherosclerosis mouse model, the injection of extra-
cellular vesicles from KLF2 transduced mouse ECs that contained enriched miR-143/145 
resulted in marked reduction of atherosclerosis in ApoE-/- mice (Hergenreider et al., 2012). 
All these studies suggested at miR-143/145 cluster have an anti-atherogenic role in athero-
sclerosis. In contrast with these observations, the genetic ablation of miR-143/145 attenu-
ated the progression of atherosclerosis in Ldlr-/- mice duo to the changes in VSMC func-
tions and lipid metabolism (Sala et al., 2014). These discrepancies may be due to the dis-
parities between the transient overexpression and genetic ablation of miR-143/145 in vivo.  
 
In addition to the interventional animal studies described above, several studies have 
shown dysregulation of the miR-143/145 cluster in samples from patients suffering from 
cardiovascular disease and related conditions. In patients, miR-143/145 significantly de-
creased in aortic aneurysm compared with normal aortic biopsies (Elia et al., 2009). 
MiR-145 was also reported significantly reduced in the blood of patients with coronary 
artery disease (CAD) compared with healthy individuals (Fichtlscherer et al., 2010). In 
Type 2 diabetes derived saphenous vein SMCs, both miR-143 and miR-145 were signifi-
cantly elevated compared with non-diabetic patients (Riches et al., 2014). In vitro, Elia et 
al also showed that miR-143/145 KO derived VSMCs showed increased migration towards 
PDGF (Elia et al., 2009). A follow-up study demonstrated that loss of miR-143/145 in vitro 
and in vivo results in the formation of podosomes, which are actin-rich membrane protru-
sions involved in the migration of several cell types, including SMCs (Quintavalle et al., 
2010). 
 
In PAH, previous studies have demonstrated the dysregulation of the miR-143/145 cluster 
in PAH. Taqman low density arrays (TLDAs) performed in pulmonary artery smooth mus-
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cle cells (PASMCs) derived from distal pulmonary arteries (PAs) of patients with idio-
pathic PAH and controls was the first to demonstrate that miR-145 was up-regulated in 
PASMCs from IPAH patients (Courboulin et al., 2011). This observation was further con-
firmed by Bockmeyer and colleagues and our group, who found that miR-143/145 expres-
sion levels were significantly higher in concentric lesions (CLs) than plexiform lesions in 
PAH patients (Bockmeyer et al., 2012) and that miR-145-5p was up-regulated in distal 
PASMCs and in lung tissues from IPAH and HPAH patients. In the mouse chronic hypoxia 
induced PH model, miR-145-5p expression was significantly increased in the total lungs 
and the right ventricle. To further study the role of miR-145 in the pathogenesis of PAH, 
Caruso et al. found that genetic ablation of miR-145 in female mice prevented the devel-
opment of chronic hypoxia induced PH, showing a significant reduction of right ventricu-
lar systolic pressure, right ventricular hypertrophy and pulmonary vascular remodelling 
compared with hypoxic control WT mice (Caruso et al., 2012).  
 
Gain of function and loss of function studies of specific miRNAs in animal disease models 
show that miRNAs are viable targets for therapeutics (van Rooij and Olson, 2012, Mont-
gomery et al., 2011). In general, therapeutic approaches targeting ncRNAs involve inhibit-
ing or overexpressing the ncRNAs. Currently, two major approaches are applied to modu-
late miRNA activity. First, restoring the function of specific miRNAs using either synthet-
ic double-stranded miRNAs (e.g miRNA mimics, which imitate the mature miRNAs) or 
viral vector-based overepression (Lentivirus or adenovirus vectors). Second, inhibiting the 
function of a miRNA using chemically modified single-stranded antimiRNA oligonucleo-
tides, which can bind irreversibly to the endogenous miRNAs and inactive their function 
(van Rooij and Kauppinen, 2014, Samanta et al., 2016). Manipulation of miR-143/145 in 
vivo has been reported in several studies, showing efficacy in modulation of disease path-
ogenesis (Cheng et al., 2009, Elia et al., 2009, Cordes et al., 2009, Caruso et al., 2012, 
McLendon et al., 2015). In the context of PAH, therapeutic miRNA delivery to the lung in 
animal PAH models has been achieved via several routes: (a) subcutaneous injection (Ca-
ruso et al., 2012, Deng et al., 2015), (b) intravenous delivery (Bonci, 2010), (c) intranasal 
delivery (Kim et al., 2013), (d) Intratracheal delivery (Courboulin et al., 2011) and (e) in-
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traperitoneal injection (Caruso et al., 2010).  
 
An antimR-145-5p approach was used to investigate whether pharmacological inhibition 
of miR-145-5p produced similar results to genetic knockout in chronic hypoxia induced 
PH, showing that antimiR-14-5p treatment could significantly reduce the right ventricular 
systolic pressure and vascular remodelling, without inducing changes in right ventricular 
hypertrophy (Caruso et al., 2012). Another study used antimiR-145-5p formulated with 
Star: Star-mPEG lipid nanoparticles and delivered by intravenous in rat with 
SU5416/hypoxia induced PAH model. They showed Star:Star-mPEG delivery of anti-
miR-145-5p elicited therapeutic effect in the PAH rat model through reduced pulmonary 
arteriopathy and cardiac dysfunction (McLendon et al., 2015). These studies demonstrate 
the important role that miR-145-5p plays in PAH, showing that manipulation of 
miR-145-5p is a potential therapeutic strategy in the treatment of PAH.  
 
In general terms, in vitro studies have demonstrated the essential role for miR-143/145 in 
regulating SMC functions. Meanwhile, in vivo studies illustrate that specific knock down of 
miR-145 expression ameliorated the chronic hypoxia induced PH in mice. Further investiga-
tion the role of miR-143 in the development of pulmonary arterial hypertension would in-
crease our depth of understanding the miR-143/145 cluster in PAH.  
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3.2	Aims	
The miR-143/145 cluster has a pivotal role in VSMC differentiation and disease. Previous 
studies have demonstrated miR-145-5p expression upregulated in PASMCs from patients 
with PAH and miR-145-5p knocking down protected against the development of PH.  
However, it is not yet known about the role of miR-143 in PAH. The aims investigated in 
this chapter were:  
l To evaluate the miR-143 expression profile in cells and tissues from pulmonary hy-
pertension animal models and human patients with PAH.  
l To assess whether miR-143 knockout can prevent the development of chronic hypoxia 
induced PH in a mouse model. 
l To determine the effect of silencing miR-143-3p both in a prevention and rescue 
therapy study on the development of PH in the chronic hypoxia mouse model. 
l To evaluate the therapeutic effect of intranasal delivery of antimiR-145-5p in the 
chronic hypoxia induced PH mouse model. 				
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3.3	Results	 	
3.3.1 MiR-143 is Highly Expressed in PASMCs Compared to PAECs 
To investigate miR-143 expression in female pulmonary artery smooth muscle cells 
(PASMCs) and pulmonary artery endothelial cells (PAECs), Taqman qRT-PCR assays for 
miR-143-3p (lead strand) and miR-143-5p (passenger strand) were performed in PASMCs 
and PAECs isolated from healthy female donors. We found that both miR-143 lead strand 
and passenger strand (miR-143-3p/5p) were expressed in PASMCs. However, only 
miR-143 lead strand (miR-143-3p) was expressed in PAECs (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Analysis of miR-143 expression levels in pulmonary vascular cells 
Pulmonary artery smooth muscle cells (PASMCs) and pulmonary artery endothelial cells (PAECs) from fe-
male healthy donors were cultured, RNA extracted and expression of miR-143-3p/5p was assessed using 
TaqMan qRT-PCR. n = 3 per group in triplicate.  
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3.3.2 MiR-143-3p is Upregulated in PAH Patients 
Having shown that miR-143 is expressed mostly in the SMC compartment, we wished to 
examine the relative expression levels of miR-143 in PASMCs from PAH patients (both 
idiopathic and familial PAH (IPAH/FPAH)) and healthy controls. Here, we showed that 
miR-143-3p expression was significantly increased in PASMC from PAH patients com-
pared with healthy donors (Figure 3.2 A) (P < 0.05). However, there was no significant 
change in miR-143-5p (Figure 3.2 B). These results indicate miR-143-3p dysregulation 
may be involved in the pathogenesis of PAH. In order to further evaluate miR-143-3p ex-
pression in PAH patients, we use in situ hybridization to analyse miR-143-3p expression in 
the lung tissues from patients with PAH and healthy controls. The results showed that 
miR-143-3p appears to have a higher expression level in the smooth muscle cell layer 
(co-localised by staining with a-SMC) in the constrictive lesions and complex lesions in 
patients (Figure 3.2 C). The constrictive lesions include medial hypertrophy, and intimal 
and adventitial thickening. And plexiform lesions, dilation lesions, and arteritis are classi-
fied as complex lesions.  
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Figure 3.2 Analysis of miR-143 expression in PAH patients and healthy controls 
Taqman qRT-PCR analyses were performed on distal PASMCs isolated from PAH patients and healthy con-
trols to analyse the expression of miR-143. (A) MiR-143-3p was significantly upregulated in the patient cells 
compared with controls. (B) MiR-143-5p did not show any significant change. Data are expressed as mean ± 
SEM and analysed by Student t-test; *P < 0.05. n =3 independent patients and performed in triplicate. (C) In 
situ hybridization of miR-143-3p in the lung tissues from PAH patients and healthy controls. In the patient 
group, miR-143-3p staining is much higher in the constrictive lesions and complex lesions. Localization of 
alpha smooth muscle action (α-SMA) staining in lung was shown the smooth muscle cell layer in the pul-
monary arteries. n = 3 patient samples. Magnification X 10. Scale bar = 100 µm. IgG = isotype control. This 
work was done by Dr. Ruifang Lu.	
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3.3.3 MiR-143-3p is Upregulated in Animal Models of Pulmonary Hy-
pertension 
In order to further investigate the dysregulation of miR-143 in PAH, we assessed the ex-
pression of miR-143 in different in vivo PAH models, including the chronic hypoxia in-
duced PH mouse model, rat SU5416/hypoxia PH model, hypoxia neonatal calf model of 
PH, and Brisket Disease. There are no perfect animal models that completely recapitulate 
human PAH disease. However, different models provided valuable insight into various 
signalling pathways involved in the pathogenesis of PAH. First, we analysed miR-143 ex-
pression in the total lung and right ventricle (RV) from mice exposed to chronic hypoxia 
(the chronic hypoxia induced mouse pulmonary hypertension (PH) model). We found that 
miR-143-3p was significantly upregulated in both lung and right ventricle tissue from the 
chronic hypoxia group (Figure 3.3 A and B) (P < 0.01, and P < 0.001), however, there was 
no difference in miR-143-5p levels between chronic hypoxia treated mice and normoxic 
controls (Figure 3.3 A and B). In situ staining in the mouse right ventricle showed highly 
expression of miR-143-3p in the chronic hypoxia group (Figure 3.4). To confirm this ob-
servation, we further analysed miR-143 expression in cardiomyocytes and fibroblasts from 
mouse heart, Taqman qRT-PCR results showed that miR-143-3p/5p were expressed in both 
cell types (Figure 3.5). Second, we analysed the miR-143-3p expression in the rat SU5416 
model of PH. There were three groups in this analysis including normoxia/vehicle group, 
normoxia/SU5416, and hypoxia/SU5416. SU5416 is inhibitor of the vascular endothelial 
growth factor receptor-2 (VEGFR2), which is mainly expressed in endothelial cells and 
plays a vital role in the cell maintenance and functions (Lee et al., 2007). The hypox-
ia/SU5416 model of PH is characterised by endothelial dysfunction (Ciuclan et al., 2011). 
TaqMan qRT-PCR found that miR-143-3p significantly increased in hypoxia + SU5416 
group compared with normoxic groups at different time-points (2 weeks, 3 weeks, 8 weeks, 
and 14 weeks) (Figure 3.6) (P < 0.01 and P < 0.001). Third, we analysed the expression of 
miR-143-3p in the new-born calves that develop severe pulmonary hypertension after ex-
posure to hypoxia, which associated with many of the same functional and structural ab-
normalities observed in human infants with pulmonary hypertension (Stenmark et al., 
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1987). In situ hybridization results revealed increased miR-143-3p level in the vascular 
wall of the small pulmonary arterioles. In addition, we further assessed the miR-143-3p 
level in the lung tissue of calves suffering from Brisket disease, which is a naturally occur-
ring animal model of hypoxia induced pulmonary hypertension (Rhodes, 2005). In situ hy-
bridization showed highly express of miR-143-3p in the vascular wall of distal pulmonary 
arterioles. Smooth muscle cell identity was confirmed by immunostaining for smooth 
muscle myosin (Figure 3.7). Taken together, miR-143-3p expression was significantly up-
regulated in different animal models of pulmonary hypertension, which indicates that 
miR-143-3p may be involved in the pathogenesis of PAH. 
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Figure 3.3 Analysis of miR-143 in chronic hypoxia induced PH mouse model 
Mature miR-143 expression was detected by Taqman qRT-PCR in whole lung and right ventricle from female 
mice after 2 weeks exposure to normoxic and hypoxic conditions. (A) Taqman qRT-PCR showed that 
miR-143-3p was significantly upregulated in the lung in the chronic hypoxia group compared with normoxia 
group. There was no difference for miR-143-5p (n = 6). (B) Taqman qRT-PCR showed that miR-143-3p sig-
nificantly upregulated in the RV in the chronic hypoxia group compared with normoxia group. There was no 
difference for miR-143-5p (n = 3). Data are expression as mean ± SEM and analysed by Student t-test. **P < 
0.01, ***P < 0.001. 
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Figure 3.4 In situ hybridization analysis of miR-143-3p in right ventricle 
Paraffin sections of RV with 5 µm were rehydrated and incubated with miR-143-3p probe and scramble 
probe. In situ hybridization analysed the miR-143-3p expression in right ventricle of the hypoxic and 
normoxic mice. Right ventricular morphological changes were observed by Hematoxylin and eosin (H&E) 
staining. Images X 40 magnification. Scale bar = 50 µm. n = 3 animals per group. This work was done by Dr. 
Hannah Stevens.   
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Figure 3.5 Analysis of miR-143 expression in mouse cardiomyocytes and fibroblasts 
Taqman qRT-PCR was performed on isolated adult mouse cardiomyocytes and fibroblasts to analyse the ex-
pression of miR-143-3p and-5p. Results showed that miR-143-3p/5p were expressed in cardiomyocytes and 
fibroblasts. n = 3 individual mice and performed in triplicate. This work was done by Dr. Hannah Stevens.  	
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Figure 3.6 Analysis of miR-143-3p expression in SU5416/hypoxia rat PH model 
MiR-143-3p detected by qRT-PCR in lung from male rats exposed to normoxic or hypoxic conditions for 2 
weeks coupled with subcutaneous administration of 20 mg/kg SU5416 on day 0, followed by varying lengths 
of time in normoxic conditions. Total study time indicated on x-axis. Arbitrary value of 1 assigned to 14 wk 
normoxia + vehicle. Data represented as fold change ± SEM and analysed by a one-way ANOVA followed 
by Tukey’s post hoc test, n = 5 animals per group. *P < 0.05, **P < 0.01, ***P < 0.001 vs 14 week normoxia 
+ vehicle, ##P < 0.01 vs time matched normoxia + SU5416. n = 5 animals per group. RQ = Relative Quanti-
fication. This work was done by Dr. Jenny Grant.  
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Figure 3.7 In situ hybridization analysis of miR-143-3p expression in hypoxia neonatal calf PH model 
and brisket disease 
In situ hybridization and immunohistochemistry (IHC) were performed on fixed lung tissues of one-day-old 
Holstein calves were exposed to hypoxia for 2 weeks, and age-matched controls were kept at ambient alti-
tude, and cattle naturally susceptible to pulmonary hypertension at high altitude (Brisket Disease, BD). In 
situ hybridization of miR-143-3p in lung tissue of hypoxic neonatal calf showed miR-143-3p level increased 
in the distal pulmonary arterioles compared with normoxic controls. In the brisket disease, miR-143-3p 
showed high expression level in the distal pulmonary arterioles. IHC for SM-myosin located the smooth 
muscle cell layer. n = 5 for hypoxia neonatal calves and control calves. n = 3 for brisket disease. This work 
was done by Prof. Kurt Stenmark lab.  	
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3.3.4 Genetic Deletion of miR-143 in Mice Prevents Chronic Hypoxia 
Induced PH   
Our previous data showed that miR-143-3p expression increased in animal models of PH 
and in PAH patients, suggesting that a reduction of miR-143-3p in vivo may attenuate the 
development of chronic hypoxia induced PH. We therefore used miR-143 knockout mice 
to study the effect of miR-143 genetic ablation in the chronic hypoxia induced PH model. 
The miR-143 mutant mice were generated by deletion of miR-143 stem loop (both 
miR-143-3p and -5p) (Xin et al., 2009). The targeting strategy was designed to replace the 
pre-miR-143 sequences with the neomycin resistance cassette flanked by loxP sites, which 
deleted both miR-143 stem loop and did not affect miR-145 level. MiR-143 KO mice and 
age-matched wild type control mice were exposure to hypoxic and normoxic conditions for 
14 days, after which hemodynamic measurements, right ventricular hypertrophy and pul-
monary vascular remodelling measurements were taken to assess the development of PH. 
 
Systemic arterial pressure (SAP) was significantly increased after hypoxic exposure com-
pared to basal conditions (normoxic). However, we did not observe any difference in SAP 
between the miR-143 KO and WT mice in both normoxic and chronic hypoxia (Figure 3.8 
A). There was also no difference in heart rate between the two groups (Figure 3.8 B) and 
no difference in basal right ventricular systolic pressure (RVSP) between miR-143 KO and 
WT mice (normoxic condition) (Figure 3.9). In the hypoxia condition, both WT and 
miR-143 KO showed significantly increase in RVSP with hypoxia exposure (P < 0.05 and 
P < 0.001). In addition, compared with two groups in the chronic hypoxia condition, the 
RVSP of miR-143 KO mice significantly decreased compared with WT mice (P < 0.001) 
(Figure 3.9). After 14 days chronic hypoxia exposure, right ventricular hypertrophy (RVH) 
significantly increased in the WT mice. However, there was no significant increase in RVH 
in miR-143 KO mice after hypoxic exposure and miR-143 KO mice showed significantly 
reduced RVH compared with WT mice in the chronic hypoxia (Figure 3.10 A) (P < 0.001). 
In line with these results, miR-143 KO animals exhibited decreased pulmonary vascular 
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remodelling compared with WT mice in chronic hypoxia (Figure 3.10 B) (P < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Effect of miR-143 knockout on systemic arterial pressure and heart rate 
Mir-143 KO and WT control mice exposed to chronic hypoxia for 14 days together with normoxia controls. 
Quantification of (A) systemic arterial pressure (SAP) in female miR-143 KO and WT mice showed that 
SAP significantly increased in chronic hypoxia exposure compared with normoxia. However, no differences 
were observed between miR-143 KO and WT in both conditions. (B) Heart rate in female miR-143 KO and 
WT controls exposure to normoxic or hypoxic conditions for showed no changes. Data are expression as 
mean ± SEM and analysed by Student t-test. ***P < 0.001, n = 6-10 animals per group. 
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Figure 3.9 Effect of miR-143 knockout on right ventricular systolic pressure 
Mir-143 KO and WT control mice were exposed to chronic hypoxia for 14 days together with normoxia con-
ditions. (A) Representative recording of right ventricular pressure and (B) quantification of RVSP in female 
miR-143 KO and WT controls exposure to normoxic or hypoxic conditions. Both miR-143 KO and WT mice 
showed significantly increased RVSP in chronic hypoxia exposure compared with normoxia. And the eleva-
tion of RVSP in WT mice revealed significantly higher than miR-143 KO mice in the chronic hypoxia. Data 
are expression as mean ± SEM and analysed by Student t-test *P < 0.5, ***P < 0.001. n = 6-9 animals per 
group. 
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Figure 3.10 Effect of miR-143 knockout on right ventricular hypertrophy and pulmonary vascular re-
modelling 
Mir-143 KO and WT control mice exposed to chronic hypoxia for 14 days together with normoxic controls. 
(A), quantification of right ventricular hypertrophy (RVH, n = 6-12 mice per group) in WT and miR-143 KO 
mice showed that miR-143 KO mice had less RVH compared with WT mice in chronic hypoxia. And chronic 
hypoxia exposure significantly induced RVH in WT mice rather than miR-143 KO mice. (B) Distal pulmo-
nary artery vessel wall thickness and remodelling were analysed by α-smooth muscle actin (α-SMA) (Red), 
CD31 (Green) and DAPI (Blue) staining in miR-143 KO mice compared with their WT littermate controls in 
both normoxic and chronic hypoxia (n = 4 mice per group). MiR-143 KO mice showed decreased pulmonary 
vascular remodelling compared with WT control in chronic hypoxia. Data are expression as mean ± SEM 
and analysed by Student t-test. Scale bar = 20 µm. *P < 0.05, **P < 0.01, ***P < 0.001. 
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3.3.5 Pharmacological Inhibition of miR-143-3p in Mice Alleviates the 
Development of PH 
Genetic ablation of miR-143 proved to beneficial in the chronic hypoxia induced PH 
mouse model. In order to assess the therapeutic role of miR-143-3p in PAH, silencing of 
miR-143-3p was applied in vivo in the mouse chronic hypoxia model of PH using an anti-
miRNA oligonucleotides inhibiting the mature miR-143-3p in competition with cellular 
target mRNAs leading to function inhibition of the miR-143-3p and derepression of their 
direct targets mRNA. Locked nucleic acid anti-miR probes bind to and form heterodu-
plexes with target miRNA, thereby sequestering and preventing the miRNA from binding 
to the 3’ UTR of it target mRNAs (Giaid et al., 1993). AntimiR-143-3p is 16-mer oligonu-
cleotides comprising at least 9 LNAs with an LNA at both 5' and 3' ends and with full 
phosphorothioate linkages (In collaboration with MiRagen Therapeutics, Boulder, Colora-
do, USA). Administration of antimiR-143-3p was subcutaneously injected at day 0 and day 
7 during the period of 14 days in both normoxia and chronic hypoxia at a 25 mg/kg con-
centration (Figure 3.11). To verify the knockdown of miR-143-3p by antimiR-143-3p 
treatment, lung, pulmonary artery (PA) and right ventricle (RV) were harvested and 
miR-143-3p expression was analysed by Taqman qRT-PCR. MiR-143-3p levels were sig-
nificantly reduced in the antimiR-143-3p treated group compared with both control anti-
miRNA (Scramble) and PBS treatment groups (Figure 3.12) (P < 0.01 and P < 0.001).  
 
The effect of knockdown miR-143-3p on the development of chronic hypoxia induced PH 
in female mice was quantified by analysis of key indicators of PH including systemic arte-
rial pressure (SAP), right ventricular systolic pressure (RVSP), right ventricular hypertro-
phy (RVH) and pulmonary vascular remodelling. There was no significant change in SAP 
between normoxia and chronic hypoxia groups. However, we observed that the basal 
(normoxic) SAP in the control (Scramble) group was significantly higher than basal SAP 
in animals treated with vehicle control (Figure 3.13 A) (P < 0.05). This may result from 
off-target effects of the scramble control antimiRNA. Mice exposure to chronic hypoxia by 
14 days displayed a significantly increase in RVSP and RVH compared with normoxic 
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groups (Figure 3.13 B and C) (P < 0.001). Notably, the RVSP in antimiR-143-3p treated 
group significantly reduced compared with control groups in chronic hypoxia condition, 
but no significant difference observed in normoxic condition (Figure 3.13 B) (P < 0.01). In 
addition, pulmonary vascular remodelling did not have any changes between groups (Fig-
ure 3.14). Taken together, antimiR-143-3p treatment reduced the right ventricular systolic 
pressure in the chronic hypoxia induced PH mice model.  
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Figure 3.11 Prevention study of antimiR-143-3p in vivo study design 
Female mice were administrated with antimiR-143-3p, control antimiRNA (Scramble) or PBS subcutane-
ously at 25 mg/kg every 7 days following 14 days normoxic or chronic hypoxia. On day 14, hemodynamic 
measurements were taken and tissues harvested.  
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Figure 3.12 Analysis of MiR-143-3p expression in lung, PA and RV of antimiR-143-3p prevention study 
Expression of miR-143-3p in female mice lung tissue, pulmonary artery (PA) and right ventricle (RV) from 
antimiR-143-3p prevention study were detected by qRT-PCR. (A) In the normoxia condition, miR-143-3p 
expression in lung (n = 10) and PA (n = 7) significantly reduced in the antimiR-143-3p treated group com-
pared with control groups. (B) In The hypoxia condition, miR-143-3p expression in lung (n = 5), PA (n = 6) 
and RV (n = 4) significantly reduced in the antimiR-143-3p treated group compared with control groups.  
All data analysed by a one-way ANOVA followed by Tukey’s post hoc tests. **P < 0.01, ***P < 0.001 
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Figure 3.13 Quantification of PH indices antimiR-143-3p prevention study 
Quantification of (A) SAP, (B) RVSP and (C) RVH were performed in female mice from antimiR-143-3p 
study at day 14. In normoxic condition, both RVSP and RVH showed no difference among three groups. 
However, SAP in the control antimiRNA (Scramble) significantly increased compared with vehicle control. 
In the chronic hypoxia, there were no significant changes in SAP and RVH. However, RVSP in anti-
miR-143-3p treated group significantly reduced compared with control groups. All data analysed by a 
one-way ANOVA followed by Tukey’s post hoc tests. n = 7-16 mice per group. **P < 0.01, ***P < 0.001. 
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Figure 3.14 Effect of antimiR-143-3p treatment on the pulmonary vascular remodelling 
Distal pulmonary artery vessel wall thickness and remodelling were analysed by α-smooth muscle actin 
(α-SMC) and CD31 staining in prevention PH model by anti-miR-143-3p injection compared with control 
groups. There was no difference among groups. All data analysed by a one-way ANOVA followed by Tuk-
ey’s post hoc tests. n =5 mice per group. Scale bar = 20 µm. α-SMC (red), CD31 (green), and DAPI (blue). 
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3.3.6 AntimiR-143-3p Treatment Shows Therapeutic Effect in Chronic 
Hypoxia Induced PH Mice  
As the prevention study using antimiR-143-3p treatment protected mice from the devel-
opment of chronic hypoxia induced PH, we aimed to assess the therapeutic role of anti-
miR-143-3p in established PH by performing a reversal study in female mice in established 
chronic hypoxia induced PH. In this reversal study, administration of antimiR-143-3p or a 
scramble control antimiRNA was performed at day 14 and day 21 during the period of 21 
days exposure to chronic hypoxia (Figure 3.15). As in the prevention study, miR-143-3p 
knocking down in the total lung, pulmonary artery (PA) and right ventricle (RV) were ana-
lysed using Taqman qRT-PCR. Expressions of miR-143 were significantly down-regulated 
in the antimiR-143-3p treated group compared to control antimiRNA (Scramble) and vehi-
cle treated group (Figure 3.16) (P < 0.05, and P < 0.001). 
 
The effect of knocking down miR-143-3p levels in mice with established PH was quanti-
fied by measuring the key indices of PH as for the prevention study. SAP did not differ 
between the three groups. However, we observed the SAP of two mice in the control anti-
miRNA (Scramble) group was much higher than other mice. This may also result from 
off-target effects of the scramble antimiRNA, as per the prevention study (Figure 3.17 A). 
Again, similar to the prevention study, the RVSP in the antimiR-143-3p treated group was 
significantly decreased compared with the control groups (Figure 3.17 B) (P < 0.01). Im-
portantly, we observed a significantly reduction of RVH in the antimiR-143-3p treated 
group compared with control groups (Figure 3.17 C) (P < 0.01 and P < 0.001), while the 
prevention study did not have significant differences. In addition, there was a significant 
reduction in the pulmonary vascular remodelling in the antimiR-143-3p treated mice com-
pared to control groups (Figure 3.18) (P < 0.05 and P < 0.01). Taken together, anti-
miR-143-3p treatment reversed the established PH in female mice, showing a therapeutic 
effect in the treatment of chronic hypoxia induced PH.  
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Figure 3.15 Reverse study of antimiR-143-3p in vivo study design 
Female mice were administrated with antimiR-143-3p, control antimiRNA (Scramble) or PBS subcutane-
ously at 25 mg/kg on day 14 and 17 following 21 days chronic hypoxia. On day 21, hemodynamic measure-
ments were taken and tissues harvested.  
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Figure 3.16 Analysis of miR-143-3p expression in lung, PA and RV from antimiR-143-3p prevention 
study 
Expression of miR-143-3p in female mice lung tissue, pulmonary artery (PA) and right ventricle (RV) from 
antimiR-143-3p reversal study were detected by qRT-PCR. MiR-143-3p expression in lung (A), PA (B) and 
RV (C) significantly reduced in the antimiR-143-3p treated group compared with control groups. All data 
were analysed by a one-way ANOVA followed by Tukey’s post hoc tests. n = 5 mice per group. *P < 0.05, 
***P < 0.001 
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Figure 3.17 Quantification of PH indices antimiR-143-3p reversal study 
Quantification of SAP, RVSP and RVH in female mice from antimiR-143-3p reversal study was performed at 
day 21. In the therapeutic study, there are no changes in SAP. However, RVSP and RVH in antimiR-143-3p 
treated group significantly reduced compared with control groups. All data analysed by a one-way ANOVA 
followed by Tukey’s post hoc tests. n = 6-10 mice per group. **P < 0.01, ***P < 0.001 
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Figure 3.18 Effect of antimiR-143-3p reversal study on the pulmonary vascular remodelling. 
Distal pulmonary artery vessel wall thickness and remodelling were analysed by α-smooth muscle actin 
(α-SMC) and CD31 staining in reversal PH model by anti-miR-143-3p injection compared with control 
groups. The vascular remodelling in antimiR-143-3p treated group was significantly reduced compared with 
control groups. All data analysed by a one-way ANOVA followed by Tukey’s post hoc tests. n = 5 mice per 
group. Scae bar = 20 µm. *P < 0.05, **P < 0.01  
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3.3.7 Intranasal Delivery of antimiR-145-5p Significantly Reduced the 
miR-145-5p Level in Pulmonary System 
Previously our group found that increased expression of miR-145-5p in lung smooth mus-
cle in wild-type mice exposed to chronic hypoxia and miR-145 knockout mice has a pro-
tective role on the development of chronic hypoxia induced pulmonary hypertension. 
Pharmacological inhibition of miR-145-5p in vivo also protected the development of 
chronic hypoxia induced PH mice model (Caruso et al., 2012). As pulmonary hypertension 
is a disease affecting the small pulmonary vessels, the localised topical therapy in the lungs 
of pulmonary hypertension can be developed as potential drug delivery route. This route 
makes it possible to deposit drugs more site-specifically at high concentrations with the 
diseased lung thereby reducing the drug amount given to patients, as well as increasing lo-
cal drug activity while reducing systemic side effects and first-pass metabolism. This is a 
key area for miRNA therapeutics. Intranasal drug delivery has been recognised to be a 
useful and reliable alternative to oral and parenteral routes. Here, we addressed if blocking 
miR-145-5p following local delivery in vivo is able to attenuate chronic hypoxia induced 
PH. To answer this question, we use nucleic acid modified anti-miR-145-5p knockdown 
probes. The in vivo experiments were performed as described in (Figure 3.19). In this study, 
administration of antimiR-145 intranasal was performed at day 1, 7, 14 and day 21 during 
the period of 28 days in the normoxic condition. To confirm knockdown of miR-145-5p in 
the lung, pulmonary artery (PA) and right ventricle (RV), expression of miR-145-5p was 
evaluated by Taqman qRT-PCR. As shown in, repeated intranasal delivery of anti-
miR-145-5p significantly down-regulated the expression levels of miR-145-5p in lung tis-
sue, pulmonary artery and right ventricle when assessed by Taqman qRT-PCR at day 28 in 
normoxic animals (Figure 3.20) (P < 0.001). Furthermore, fibromodulin (fmod) and angio-
tensin-converting enzyme (ace), which are predicted targets of miR-145, were significantly 
upregulated in the antimiR-145 treated group compared with control groups (Figure 3.21) 
(P < 0.05). Meanwhile, other target gene such as SMAD family member 4 (smad4), 
Kruppel-like factor 5 (klf5), integrin, beta 1(itgb1) and wen inhibitory factor-1 (wif1) were 
also upregulated, but not at significant levels (Figure 3.21).  
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Figure 3.19 Schematic of experimental normoxic mice model with antimiR-145-5p administration 
Female mice were administrated with antimiR-145 and control antimiRNA (Scramble) intranasal at 5mg/kg 
on day 1, 7, 14, and 21 following 28 days normoxic. On day 28, were taken and tissues harvested.  
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Figure 3.20 Analysis of miR-145-5p lung, PA and RV from antimiR-145 treated mice 
Expression of miR-145-5p in female mice lung tissue, pulmonary artery (PA) and right ventricle (RV) from 
antimiR-145-5p intranasal delivery were detected by qRT-PCR. MiR-145-5p expression in lung (A), PA (B) 
and RV (C) significantly reduced in the antimiR-145-5p treated group compared with scramble control. Data 
are expression as mean ± SEM and analysed by Student t-test. n = 6 mice per group. ***P < 0.001 
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Figure 3.21 Analysis of target genes expression of the antimiR-145-5p treated mice 
The expression level of fomd, ace, smad4, klf5, itgb1 and wif1was assessed by Taqman qRT-PCR in the total 
lung of scramble and antimiR-145-5p treated mice. The predicated target gene fibromodulin (fmod) and an-
gitotensin-converting enzyme (ace) were significantly upregulated. The other target genes did not show any 
significant differences. Data are expression as mean ± SEM and analysed by Student t-test. n = 6 mice per 
group. 
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3.3.8 Intranasal Delivery of antimiR-145-5p does not Attenuate Chronic 
Hypoxia Induced Pulmonary Arterial Hypertension 
Multiple doses of antimiR-145-5p via intranasal delivery inhibited miR-145-5p expression 
and upregulated one target gene in total lung in the normoxic condition. In order to deter-
mine the effect of antimiR-145-5p treatment in the chronic hypoxia induced PH mouse 
model, C57BL/6J wild-type female mice were intranasal delivered with antimiR-145-5p at 
day 1, 7, 14 and day 21 during the period of 28 days in the normoxia and chronic hypoxia 
(Figure 3.22).  
 
The miR-145-5p knocking down in the total lung was assessed by Taqman qRT-PCR. Ex-
pressions of miR-145-5p were significantly down-regulated in the antimiR-145-5p treated 
group compared to control antimiRNA (Scramble) and vehicle treated group (P < 0.001) 
(Figure 3.23 A). Also, we selected some miR-145 target genes that were affected by in-
tranasal delivery anti-miR-145-5p under normoxic condition. In chronic hypoxia induced 
lung tissue, only the ace gene was significantly upregulated in anti-miR-145-5p treated 
group compared with scramble and PBS control. There were no changes for other genes. 
(Figure 3.23 B) (P < 0.01). 
 
The effect of knocking down miR-145-5p by intranasal delivery was quantified by meas-
uring the key indictors of disease, RVSP and RVH. We found that anti-miR-145-5p treat-
ment did not attenuate chronic hypoxia induced PAH compared with scramble and PBS 
groups. As shown in (Figure 3.24), hemodynamic data of heart rate, right ventricular sys-
tolic pressure (RVSP) and systolic arterial pressures (SAP) in three groups did not have 
significant difference. There was no change in RVH (RV/LV + S) as well (Figure 3.24).  
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Figure 3.22 Schematic of experimental mice PH model with antimiR-145-5p administration 
Female mice were administrated with antimiR-145-5p, control antimiRNA (Scramble) and PBS intranasal at 
5mg/kg on day 1, 7, 14, and 21 following 28 days normoxic and chronic hypoxia. On day 28, hemodynamic 
measurements were taken and tissues harvested.  
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Figure 3.23 Analysis of target genes expression of miR-145 in lung from the antimiR-145 intranasal 
study 
RNA from lungs was isolated and miR-145 and its targets were determined by Taqman qRT-PCR. (A) 
MiR-145 expression was normalised to U6 and was significantly down-regulated upon treatment with anti-
miR-145 in lung tissue of chronic hypoxia induced pulmonary arterial hypertension. (B) The expression level 
of fomd, ace, smad4 and klf5 was analysed. Data are expression as mean ± SEM and analysed by Student 
t-test and by a one-way ANOVA followed by Tukey’s post hoc tests. n = 8 mice pre group. *P < 0.05, **P < 
0.01. 
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Figure 3.24 Effect of miR-145-5p inhibition on the development of PAH  
Mice were administered antimiR-145-5p, scramble or PBS by intranasal. Two weeks after chronic hypoxia 
exposure hemodynamic measurements were performed. (A) RVSP, (B) RVH, (C) SAP were assessed, (D) 
Heart rate, were measured. There were no significance changes among different groups. All data analysed by 
a one-way ANOVA followed by Tukey’s post hoc tests. n = 6-10 mice per group. 		
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3.4	Discussion	 	
In the chapter, we have assessed the expression of miR-143 in several animal models of 
pulmonary hypertension, as well as in cells and tissues from patients with PAH, revealing 
that miR-143-3p expression levels significantly elevated in PASMCs from patients with 
PAH. In the miR-143 knockout (KO) study, genetic ablation of miR-143 in female mice 
showed significantly reduction of right ventricular systolic pressure (RVSP), right ventric-
ular hypertrophy (RVH) and distal pulmonary vascular remodelling, which is beneficial in 
the hypoxic mouse model of PH. In the prevention study with antimiR-143-3p treatment, 
pharmacological repression of miR-143-3p in animals exposed to chronic hypoxia signifi-
cantly reduced RVSP but had no effect on RVH and pulmonary vascular remodelling 
compared with control group, whereas similar results to the miR-143-/- study were ob-
served in the antimiR-143-3p rescue study, with significantly decreased RVSP, RVH and 
pulmonary vascular remodelling. In addition, in the intranasal delivery study, knocking 
down miR-145-5p using antimiR-145-5p had no effect on RVSP, RVH and pulmonary 
vascular remodelling. Although, antimiR-145-5p treatment by intranasal delivery signifi-
cantly reduced the miR-145-5p level in the lung, little effect on target genes and no effect 
on indices of PH were observed. 
 
MiR-143 and miR-145 are transcribed as a cluster and are cardiac-specific and 
smooth-muscle-specific miRNAs (Cordes et al., 2009). Consistent with these findings, 
Taqman qRT-PCR and in situ hybridization analyses of miR-143-3p expression in mouse 
cardiomyocytes and right ventricle, and also in human PASMCs and pulmonary arteries, 
showed high expression of miR-143-3p. Moreover, we found miR-143-3p expression sig-
nificantly increased in the total lung and right ventricles of mice in which experimental PH 
was induced by exposure to chronic hypoxia. Distal PASMCs isolated from patients with 
PAH showed significantly increased expression of miR-143-3p compared with healthy 
controls. In addition, in situ analyses of constrictive and complex lesions in diseased distal 
pulmonary arteries showed miR-143-3p is localised to the SMC layer of the lesions and 
appears to be highly expressed. This dysregulation of miR-143-3p in mouse PH model and 
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human patients were similar with our previous study in miR-145 (Caruso et al., 2012). A 
previous study revealed that miR-143-3p expression was much higher in concentric lesions 
(CLs) compared with plexiform lesions (PLs). However, this study also showed that 
miR-143 expression in plexiform lesions (PLs) was significantly lower than controls, 
which is not consistent with our finding (Bockmeyer et al., 2012). The possible reasons for 
the difference expression of miR-143-3p in PLs and CLs are the cell-specific expression of 
miR-143 and the structural differences between these lesions. MiR-143 is highly expressed 
in vascular SMC, whereas much lower expresses in endothelial cells (Zhang, 2009). In ad-
dition, plexiform lesions are composed of similar components of vascular SMCs and en-
dothelial cells, and SMCs were predominant in the concentric lesions (Jonigk et al., 2011). 
This may partially explain the higher expression of miR-143-3p in CLs than PLs. There are 
no available perfect pre-clinical models that mimic human PAH disease. That is, no animal 
model can reproduce all the clinical pathological features of any groups of human PH. 
However, each animal model has its features, which are described in the chapter 1. The use 
of animal models of pulmonary hypertension has contributed to the understanding of PH 
pathophysiology and the development of experimental treatments. The animal models in-
clude single-pathological-insult models (SPI) (such as chronic hypoxia or MCT induced 
PH models) and multiple-pathological insult models (such as SU5416 and hypoxia induced 
PH models) (Maarman et al., 2013). Human PAH disease is triggered by genetic, environ-
mental and other factors (Machado et al., 2009). Use different models with different 
pathological-insults will allow us to investigate the pathogenesis of PAH at various disease 
stages and also evaluate the therapeutic role of agents (Stenmark et al., 2009). Thus, in this 
study, we further analysed the miR-143-3p expression in rat SU5416/hypoxia model, hy-
poxia neonatal calves and high-altitude pulmonary hypertension in cattle (brisket disease). 
Consistent with the mouse chronic hypoxia model and human patients, miR-143-3p ex-
pression was significantly upregulated in the total lung of rat SU5416/hypoxia model and 
highly expressed in the distal pulmonary arteries of hypoxia neonatal calves and brisket 
disease. The brisket disease samples in particular share some common features of the hu-
man PAH disease, including right heart failure and the development of complex vascular 
lung lesions. Since expression of miR-143-3p appears high in both mouse chronic hypoxia 
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induced samples, rat SU5416/hypoxia samples, post-mortem human lung and brisket dis-
ease lung samples, which suggests that miR-143-3p expression is elevated and sustained 
during the pathogenesis of PAH, particularly evident in distal small pulmonary vessels.  
 
Although we found miR-143-3p expression increased in PAH, there are studies in different 
vascular disease models demonstrated miR-143-3p decreased in the carotid artery balloon 
injury rat model and carotid artery ligation model. In addition, used adenovirus 
(Ad-miR-143) to overexpress miR-143-3p in WT mice stimulated with balloon injury in 
rat carotids found that miR-143-3p overexpression significantly reduced the balloon injury 
induced neointimal formation. These observations are consistent with miR-143-3p shown 
to be down-regulated during neointimal formation in the carotid artery of the rat (Cordes et 
al., 2009, Elia et al., 2009, Ji et al., 2007). The expression profile of miRNAs is disease 
status-dependent, dependent on the type and nature of the stimuli and the surrounding en-
vironment. Particular pathological processes and stimulations are associated with the ex-
pression of specific group of miRNAs in different diseases.  
 
Genetic ablation of the miR-143 stem loop markedly prevented the development of PH as-
sessed by RVSP, RVH and pulmonary vascular remodelling. This phenotype we also found 
in the miR-145-/- mice (Caruso et al., 2012). Both miR-143-3p and miR-143-5p were de-
leted in the miR-143 knockout mice. The in vitro studies demonstrated that only 
miR-143-3p (guide strand) is functional affected the cell behaviours. Specific pharmaco-
logical inhibition of miR-143-3p rather than miR-143-5p with in vivo exerts protective 
therapeutic role in the disease development and treatment. Thus, this data suggest that the 
guide strand of miR-143 acts as mature functional miRNA in the pathogenesis of PAH.  
 
There is still no definite cure treatment for pulmonary arterial hypertension (PAH). As we 
noticed that miR-143-/- could inhibit the development of chronic hypoxia induced PH, we 
used a pharmacological inhibition strategy to knock down miR-143 in vivo to test whether 
knocking down miR-143 can alleviate PH pathogenesis in the chronic hypoxia model of 
PH. Both prevention and reverse models revealed a protective role of antimiR-143-3p 
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treatment in the development of chronic hypoxia induced PH mice model. Concerning the 
indexes of evaluation of PAH disease features, the reverse therapeutic study showed great-
er efficacy than the prevention study, which only showed a significant decrease in right 
ventricular systolic pressure. And miR-143-3p knocking down significantly reduced the 
pulmonary vascular remodelling and RVH in the reverse therapeutic model. Here we ob-
served a discrepancy results between prevention model and reversal model with anti-
miR-143-3p treatment, both use the same delivery route and same concentration of anti-
miR-143-3p. Chronic Hypoxia exposure activated several signalling pathways in pulmo-
nary hypertension (Stenmark et al., 2006b). The reason to explain the difference in results 
between prevention and reversal study may be due to the activation of different signalling 
pathways, which some pathways will change with miR-143-3p silence by antimiR-143-3p 
administration at different stages. In addition, the reversal therapeutic strategy is much 
more clinically relevant than prevention route.  
 
In our previous study, we found that the expression of miR-145-5p was enhanced in the 
lungs of mice with chronic hypoxia induced PH mouse model and PAH patients. Genetic 
deletion and pharmacological inhibition of miR-145-5p in mice protected against the de-
velopment of PH. This study used subcutaneous injection route, a strategy for systemic de-
livery, for antimiR-145-5p and clearly shown an important role for miR-145-5p in PH 
(Junion et al., 2012). Here, we want to evaluate the efficacy of established mediator of PH 
(miR-145) by using local delivery strategy in the development of chronic hypoxia induced 
PH. As the lungs are capable of absorbing pharmaceuticals either for local and systemic 
delivery, one of the widely use local delivery routes is intranasal route for therapeutic pur-
poses (Patil and Sarasija, 2012). The administration of substances to mice by the intranasal 
route is an effect, non-invasive technique that can be employed for the delivery of drugs or 
gene therapy to the lung (Ciuclan et al., 2013). Previous studies using intranasal admin-
istration of mature let-7 mimic showed efficiently delivery to the lung, with repression of 
the let-7 target IL-13 (Savai et al., 2012) while intranasal delivery of let-7 antimiRNA re-
duced tumour growth in mouse models of lung cancer (Dorfmuller and Humbert, 2012). 
Until now, there has been only one study to use the intranasal route to study PH. In this 
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study, lentivirus encoding miR-424 and miR-503 was administered via intranasal delivery 
to the lung, which exhibited a protective role in the development of PH. Analysis of in-
tranasal delivery efficiency showed that endothelial cells were infected with lentivirus de-
livery (Kim et al., 2013). So, we first use intranasal delivery strategy to deliver anti-
miR-145-5p in mouse chronic hypoxia induced PH model. In order to confirm the intrana-
sal anti-miR-145-5p delivery efficiency, we used the mouse normoxic model to assess the 
efficiency. First, RNA extracted from lung tissue, pulmonary artery, and right ventricle and 
we used Taqman qRT-PCR to analyse the miR-145-5p expression level. The levels were 
approximately 170 fold, 50 fold and 20-fold downregulated in lung tissue, pulmonary ar-
tery and right ventricle separately. Second, the targets of miR-145-5p are upregulated in 
lung, especially fmod and ace that have statistically significant derepression.  
 
However, we employed an established mouse chronic hypoxia induced pulmonary hyper-
tension. Antagonization of miR-145-5p by intranasal delivery of anti-miR-145-5p did not 
protect against the development of PH assessed by hemodynamic data. The target genes 
expression levels of antimiR-145-5p treated mice were not altered except just the ace gene. 
The possible reason of these results maybe including: 1) the miR-145-5p was being signif-
icantly knockdown by antimiR-145-5p treatment in the total lung, however only one target 
gene was modulated. Although we did not analyse many potential target genes of miR-145, 
this suggesting that the local deliver of antimiR-145-5p is potentially not optimal. More 
work need to assess other tissues such as heart, liver and kidney for the targeting effect of 
antimiR-145-5p, as well as specific cell types in the lung and the effects on direct mRNA 
targets. 2) As miR-145-5p is predominantly expressed vascular SMCs layer, we observed 
that miR-145-5p expression was significantly downregulated in the large pulmonary arter-
ies that contain different cell compartments. However, whether the antimiR-145-5p can 
reach to SMCs layer of the distal pulmonary vessels to knock down miR-145 was not in-
vestigated, as PAH is characterised by progressive remodelling of the distal pulmonary ar-
teries. 3) Several circulating miRNAs such as miR-23a/b, miR-451, miR-130a, miR-191 et 
al have been demonstrated as potential maker for PAH. Although lung tissue is the most 
downregulated tissue in mice, there still may have circulating miR-145 in blood that may-
	 155	
be influences disease development, although this is less likely. Also miR-143/145 can be 
secreted from endothelial cells and crosstalk with SMCs in the vasculature, this study also 
highlights the cell-to-cell communication between cell types by miR-143/145 (see Chapter 
4). In addition to this local communications, the secreted miRNAs in the bloodstream also 
can mediate distant cell-to-cell communication, although this remains an area with little 
scientific research to date. One possible explain is the secreted miR-145 (e.g. exosomal 
miR-145) from other parts can circulate to pulmonary vessels to affect the vascular func-
tions. 4) Different antimiRNA (or drug) delivery routes may have different therapeutic ef-
fect on established disease model. The aim of local delivery is to target specific tissues in 
order to minimise the “off-target” effect or targeting unintended tissues. However, the sys-
temic delivery will target nearly all the tissues and have more side effects, limiting transla-
tional appeal.  
 
In summary, miR-143-3p expression is induced in multiple models of PAH and in human 
patients. Silencing of miR-143-3p using genetic ablation or antimiRNA treatment provides 
a beneficial effect in female mice exposed to chronic hypoxia induced PH model. This data 
suggest miR-143-3p is potential therapeutic target in the treatment of PAH. Further studies 
are required to explore the smooth muscle cell and endothelial cell functions and the 
mechanisms including target genes and pathways underlie the beneficial effects.  
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4 The role of miR-143 regulation of smooth 
muscle and endothelial cell crosstalk in 
pulmonary arterial hypertension  
																																
	 157	
4.1	Introduction	
Pulmonary arterial hypertension (PAH) is a deadly disease characterised by vasocon-
striction and abnormal remodelling of pulmonary vessels. The endothelial cells (ECs), 
smooth muscle cells (SMCs), and fibroblasts of the pulmonary vessel walls, as well as in-
flammatory cells and platelets have been demonstrated have a role during the pathogenesis 
of PAH (Yildiz, 2009). The interplay among these cell population is regulated by several 
mediators contributing to the pathophysiologic features of PAH (Nogueira-Ferreira et al., 
2014). In the pulmonary vasculature, both SMCs and ECs are the key cell types involved 
and play a key role in pulmonary vascular remodelling associated with PAH, as both 
smooth muscle cell-dependent medial thickening and endothelial cell-dependent an-
gio-obliteration occur during the development of PAH. (Yuan and Rubin, 2005). The plex-
iform lesion, a histological hallmark of the pulmonary vessels of patients with PAH, has 
been demonstrated to result from disordered endothelial cell proliferation, migration along 
with concurrent neoangiogenesis, and recruitment of other cell types (e.g. macrophages, 
endothelial progenitor cells) (Sakao et al., 2009). Pulmonary artery smooth muscle cell 
(PASMC) hypertrophy, proliferation, migration and anti-apoptosis also contribute to plex-
iform lesion formation (Tajsic and Morrell, 2011). 
 
More recently, miRNAs have been demonstrated as key regulators of a wide range of cel-
lular processes such as proliferation, migration and apoptosis and play a pivotal role in 
vascular remodelling of PAH diseases. MiRNAs are expressed in a cell-and tissue-specific 
manner involved in various biological processes including vascular remodelling in pulmo-
nary vasculature. A number of miRNAs have been shown to regulate PASMCs and PAECs 
behaviours during the pathogenesis of PAH disease such as miR-145, miR-21, miR-204, 
miR-17/92, miR-34a, miR-424/503, miR-210 et al (Bienertova-Vasku et al., 2015).  	
MiR-143 together with miR-145 has been identified as regulators of VSMC contractile 
phenotype. In vitro studies have shown that the promoter region of the miR-143/145 clus-
ter there is a region contained a conserved serum response factor SRF-binding site [CC 
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(A/T)6GG], known as a CArG box. Luciferase reporter assays have shown that the tran-
scription of miR-143/145 can be activated by SRF and its co-factors myocardin-related 
transcription factors (MRTF) and myocardin through binding to this CArG box (Xin et al., 
2009, Davis-Dusenbery et al., 2011, Rangrez et al., 2011, Cordes et al., 2009). TGF-β and 
BMP4 are known to induced SMC contractile phenotype. One of the mechanisms involved 
in this phenotype is TGF-β and BMP4 induce myocardin and MRTF separately that further 
activate the miR-143/145 (Davis-Dusenbery et al., 2011). MiR-143/145 expression levels 
are decreased in VSMCs treated with PDGF, which has been proven to induce migration 
through podosome formation. And the PDGF induce podosome formation in VSMCs 
through regulation of miR-143/145 via Scr and p53 pathway (Quintavalle et al., 2010, 
Wang et al., 2010b). VSMCs isolated from miR-143/145 KO mice showed the KO cells 
were more migratory than WT cells. In addition, Rat VSMC line A7r5 cells showed de-
creased proliferation with Ad-miR-143/145 transduction (Elia et al., 2009). Overexpression 
of miR-143 in VSMCs significantly enhanced H2O2 induced VSMC senescence, and 
recued proliferation and migration with interaction between MEF2A (Zhao et al., 2015b). 
These studies revealed that miR-143 play a vital role in regulation of SMC behaviours. 
MiR-143 particularly enriched in SMCs and expressed low levels in other cell types such 
as endothelial cells. The dysregulation of miR-143 in endothelial cells also found in vari-
ous disease conditions (Climent et al., 2015, Hergenreider et al., 2012, Zhao et al., 2015a). 
However, the miR-143 mediated effects in the pulmonary vasculature are unknown.   
 
The precise and dynamic interactions between smooth muscle cells (SMCs) and endotheli-
al cells are important for maintaining vascular homeostasis through careful regulation of 
cell proliferation, apoptosis, differentiation, migration and survival. Aberrant interactions 
between these cell types have been shown to lead to pathological changes in the vascular 
compartment, including pulmonary vascular remodelling and pulmonary arterial hyperten-
sion (Heydarkhan-Hagvall et al., 2003, Eddahibi et al., 2006). Generally, in the vessel wall, 
there are three broad areas of cellular communications: paracrine signalling (e.g. through 
secretion and exchange of soluble bioactive factors); physical connections (e.g. gap junc-
tions and potassium channels); and exocytosis (Wheelhouse et al., 2003, Lilly, 2014, Dia-
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mant et al., 2004, Freyssinet, 2003, Billaud et al., 2014). In the pulmonary vasculature, it is 
well recognised that endothelial cells can regulate the functions of SMCs by releasing var-
ious factors such as nitric oxide (NO), prostaglandin, prostacyclin, endothelin-1, and (To-
porsian et al., 2005, Dora, 2001). However, the interactions between ECs and SMCs is not 
a simple one-way interaction from the endothelium to the smooth muscle cells but are 
more complicated interactions between each cell types (Gao et al., 2016). In addition to 
such paracrine regulation, there are more complicated communication patterns. Myoendo-
thelial junction (MEJ) is described as the structural location at which an EC or VSMC ex-
tension protrudes through the internal elastic lamina, resulting in plasma membrane juxta-
position with the opposite cell type (Heberlein et al., 2009). There are gap junctions at the 
tip of the MEJ composed of two hemi-channels termed connexions, some of which are as-
sociated with MEJ including connexion 37, 40, and 43. And the smaller arteries are con-
taining more numerous MEJ than the larger diameter arteries (Gao et al., 2016). In the 
pulmonary vasculature, PAECs co-cultured with PASMCs by direct contact each other ac-
tive the TGF-β signalling in PASMCs, which exert a more contractile-like phenotype and 
maintaining the TGF-β-dependent PASMC differentiation. These communications are me-
diated through myoendothelial gap junctions (connexion 43) from PAECs to PASMCs, 
which suggest that dysregulation of this direct interaction is involved in the pathogenesis 
of pulmonary vascular remodelling (Gairhe et al., 2011). Another connected cell to cell 
communication is tunnelling nanotubes (TNTs), which represent a subset of F-actin-rich 
structures containing membranous nanotubes between cells and facilitate the intercellular 
transport of various cellular components (Gurke et al., 2008). Recently, the miR-143/145 
cluster has been demonstrated to act as communication molecules between SMCs and ECs 
via TNTs (Climent et al., 2015).   	
Extracellular vesicles include apoptotic bodies, microparticles/microvesicles, and exo-
somes. Several studies showed cell-to-cell communication can be mediated by exosomes, 
which contain miRNAs (McCoy-Simandle et al., 2016, Ciardiello et al., 2016). Exosomes 
are 40 to 100nm in size and represent a specific subtype of secreted membrane vesicles 
formed through the fusion of multivesicular endosomes with the plasma membrane (Inter-
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national et al., 2000). Exosomes are released by many types of cell, and have been identi-
fied in most body fluids, including as plasma, urine, saliva, cerebrospinal, amniotic and 
synovial fluids. Exosomes are now known to carry a wide array of molecules including: 
proteins, DNAs, mRNAs, miRNAs and lncRNAs, depending on a variety of factors in-
cluding the cell type from which the exosome originates, the state of health of the host, and 
extracellular stimuli (Newman et al., 2004). Exosomes can be taken up by neighbouring or 
distant cells and can be functional in the recipient cells by fusion with the plasma mem-
brane, via receptor-mediated uptake or by internalization via endocytosis or macropinocy-
tosis (Valadi et al., 2007). Since the discovery of miRNA in exosomes, a number of studies 
have focused on the identification and function of exosomal miRNAs in cancer (Kosaka, 
2016) and cardiovascular diseases (Waldenstrom and Ronquist, 2014, Yellon and Davidson, 
2014, Sahoo and Losordo, 2014, Loyer et al., 2014, Kishore and Khan, 2016). Interestingly, 
cancer cell derived exosomes contain key components of microRNA biogenesis including 
RISC, AGO2, Dicer, and TRBP, which displayed cell-independent capacity to process 
precursor miRNAs into mature miRNAs (Melo et al., 2014).  	
DNA damage in cells is cause by intrinsic and extrinsic genotoxic stresses, including ultra-
violet (UV) radiation, ionizing radiation (IR), chemo- and radiotherapeutic agents, reactive 
oxygen species, as well as the strong inflammation environment which is known to be tox-
ic for the cells (Suzuki et al., 2009). Inflammatory cytokines (e.g. TNF-α and IL-6) and 
growth factors (e.g. PDGF) also induce DNA damages (Fehsel et al., 1991, Yun et al., 2012, 
Squatrito and Holland, 2011, Soon et al., 2010). One of the features of PAH is inflamma-
tion, which characterised by sustained elevation of circulating pro-inflammatory molecules 
such as tumour necrosis factor α (TNF-α) and interleukin 6 (IL-6) in patients with PAH 
(Caruso et al., 2012). In the human distal pulmonary arteries (PAs), DNA damage is sig-
nificantly increased in PAH patients compared with normal tissue controls. Consistent with 
the findings in PAs, PASMCs isolated from patients with PAH also showed increased DNA 
damage in comparison with healthy control cells (Shiloh, 2001). Several studies have 
demonstrated that DNA damage can regulate miRNAs expression at the transcriptional 
level and regulate miRNAs by modulating the miRNA processing and maturation steps 
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(Bottai et al., 2014, Bienertova-Vasku et al., 2015). Several miRNAs including 
miR-143/145 have been found to be upregulated by DNA damage induced by irradiation 
(Hu and Gatti, 2011). However, the role of miR-143 response to DNA damage in PAH still 
unknown.   	
In the chapter 3, we showed a consistent up-regulation of miR-143-3p expression in dif-
ferent animal PH models and PAH patients. In addition, miR-143-3p knockdown signifi-
cantly alleviated the development of chronic hypoxia induced PH mice model. Thus, this 
chapter was designed to study the mechanisms underlie the protective role of miR-143 ab-
lation in the development of PAH, and assess the effects of modulating miR-143-3p ex-
pression in PASMCs and PAECs with respect to cell functions and target gene expression. 
In addition, we also aimed to use an in vitro cell-to-cell communication co-culture model 
to investigate the crosstalk between PASMCs and PAECs via miR-143-3p in the pulmo-
nary vasculature.  								
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4.2	Aims	 	
l To analyse the effect of miR-143 on PASMC and PAEC proliferation, migration, 
apoptosis and angiogenesis and identify the potential pathways of miR-143-3p in vitro 
l To purify the exosomes secreted by PASMCs and identify the enrichment of miR-143 
in PASMC-derived exosomes  
l To assess whether PAECs can ingest miR-143-3p enriched exosomes secreted by 
PASMCs, and the effect this may have on PAEC behaviour.  				
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4.3	Results	 	
4.3.1 MiR-143 Expression is Significantly Upregulated During Scratch 
Closure in PASMCs 
In the previous chapter, we demonstrated that miR-143 was enriched in SMC, and that 
knockdown could inhibit the development of PAH. PASMC proliferation, migration and 
apoptosis contribute to the development of vascular remodelling, which is central to the 
pathobiology of PAH (Tajsic and Morrell, 2011). We therefore sought to understand 
whether manipulation of miR-143 in PASMC could affect these cellular processes in vitro 
(These PASMCs were derived from proximal pulmonary arteries). In order to understand 
whether manipulation of miR-143 could affect cell migration, we first created multiple 
scratch wounds in cultured PASMCs to analyse expression levels of the miR-143/145 
cluster at different time points after scratch. We showed rapid transcriptional activation of 
the pri-miR-143/145 precursors at 3 h post-scratch, which was maintained over time for 
pri-miR-143 but was later repressed for pri-miR-145 (Figure 4.1) (P < 0.05, P < 0.01, and 
P < 0.001). We further analysed the expression of mature lead and passenger strands of 
miR-143 and -145 during PASMC migration. Although the mature form of miR-143-3p 
lead strand was significantly upregulated in a time-dependent manner after scratch 
wounding, the expression of the miR-145-5p lead strand did not significantly change (Fig-
ure 4.2 A) (P < 0.05, P < 0.01, and P < 0.001). In addition, the expression of miR-143-5p 
and miR-145-3p passenger strands did not change significantly during the PASMC migra-
tion (Figure 4.2 B). Taken together, these results show that miR-143-3p expression is se-
lectively induced in migrating PASMCs.  
 					
	 164	
		
				
Figure 4.1 Analysis of the expression of pri-miR-143 and pri-miR-145 during PASMC migration in 
vitro 
Multiple scratches were performed on PASMCs to induce cell migration. TaqMan qRT-PCR analyses were 
performed to evaluate the expression of pri-miR-143 and pri-miR-145 during PASMC scratch closure at dif-
ferent time points. Pri-miR-143 was significantly increased at all time points after scratch compared with 
control. Pri-miR-145 was significantly upregulated 3 h after injury and then significantly downregulated 
from 16 to 24 h. Data represented as fold change ± SEM and analysed by a one-way ANOVA followed by 
Tukey’s post hoc tests. n = 3 per group in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001. This work was 
done by Dr. Francisco J. Blanco.  				
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Figure 4.2 Analysis of the expression of miR-143/145 lead and passenger strands during PASMC mi-
gration in vitro. 
Multiple scratches were performed on PASMCs to induce cell migration. Taqman qRT-PCR analyses were 
performed to evaluate the expression of the mature forms of miR-143 and miR-145 during PASMC scratch 
closure at different time points. (A) The expression of the miR-143 lead strand (miR-143-3p) was signifi-
cantly increased after scratch while the expression of the miR-145 lead strand (miR-145-5p) remained un-
changed. (B) The expression of both passenger strands of miR-143 (miR-143-5p) and miR-145 (miR-145-3p) 
did not change during scratch closure of PASMC. Data represented as fold change ± SEM and analysed by a 
one-way ANOVA followed by Tukey’s post hoc test. n = 3 per group in triplicate. *P < 0.05, **P < 0.01, 
***P < 0.001. This work was done by Dr. Francisco J. Blanco. 
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4.3.2 MiR-143-3p Expression is Dysregulated During Scratch Closure in 
Distal PASMCs from HPAH/IPAH Patients and Controls 
We observed that both primary and mature forms of miR-143-3p expressions were signifi-
cantly upregulated in wound healing assays performed in healthy human PASMCs. In or-
der to assess miR-143-3p expression during wound healing in the context of disease, we 
analysed miR-143-3p expression in distal PASMCs isolated from patients with HPAH and 
healthy controls with multiple scratch. In PASMCs from healthy controls, pri-miR-143 ex-
pression was significantly induced 3 h after scratch. This increase in expression was sus-
tained to the 8 h time point (Figure 4.3A) (P < 0.01 and P < 0.001). Pri-miR-145 expres-
sion was significantly increased at 1 and 3 h then decreased at 8 h post-scratch (Figure 4.3 
A) (P < 0.001). Only the mature form of miR-143-3p expression was significantly in-
creased at different time point (Figure 4.3 B) (P < 0.05 and P < 0.001). There was no dif-
ference in the expression of miR-145-5p mature form (Figure 4.3 B). This data is con-
sistent with the data we obtained from PASMCs isolated from the larger pulmonary arteries 
(section 4.3.1). In PASMCs from HPAH patients, pri-miR-143 expression was significantly 
upregulated during scratch closure (Figure 4.4 A) (P < 0.01 and P < 0.001), while the ex-
pression of pri-miR-145 was significantly decreased at 1 and 3 h (Fig. 4.4 A) (P < 0.05 and 
P < 0.01). We also observed that the expression of both mature form of 
miR-143-3p/miR-145-5p significantly induced (Figure 4.4 B) (P < 0.05 and P < 0.001). In 
PASMCs from patients with IPAH, a similar pattern of miR-143/145 expression was ob-
served, with pri-miR-143 expression significantly upregulated and pri-miR-145 expression 
significantly downregulated during scratch closure (Figure 4.5 A) (P < 0.05, P < 0.01, and 
P < 0.001). Mature form of miR-143-3p not miR-145-5p significantly increased during the 
wound healing (Figure 4.5 B) (P < 0.001). Taken together, we observed the same patterns 
of miR-143/145 expression in distal PASMCs from HPAH/IPAH patients and healthy con-
trols during scratch closure, compared to culture PASMCs from the larger pulmonary ar-
teries.  		
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Figure 4.3 Comparative analysis of migration in distal PASMC from healthy donors 
Cells were grown in monolayer and the expression levels of miR-143 and miR-145 precursors and mature 
forms were detected by Taqman qRT-PCR at the indicated time after multiple scratches in control distal 
PASMC (84MP). (A) The pri-miR-143 expression significantly increased time dependently and pri-miR-145 
expression increased at first and then decreased. (B) The mature form of miR-143-3p expression significantly 
increased but no change in miR-145-5p mature form. Data represented as fold change ± SEM and analysed 
by a one-way ANOVA followed by Tukey’s post hoc test. Experiments were performed in one control pa-
tient cells. n = 3 per group in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001. This work was done by Dr. 
Francisco J. Blanco. 
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Figure 4.4 Comparative analysis of migration in distal PASMC from HPAH patients 
Cells were grown in monolayer and the expression levels of miR-143 and miR-145 precursors and mature 
forms were detected by Taqman qRT-PCR at the indicated time after multiple scratches in hereditable PAH 
patients distal PASMCs (73MP (HPAH)). (A) The pri-miR-143 significantly increased at all the time points 
and pri-miR-145 significantly decreased. (B) The mature forms of both miR-143-3p and miR-145-5p were 
significantly increased. Data represented as fold change ± SEM and analysed by a one-way ANOVA fol-
lowed by Tukey’s post hoc test. Experiments were performed in one HPAH patient cells. n = 3 per group in 
triplicate. *P < 0.05, **P < 0.01, ***P < 0.001. This work was done by Dr. Francisco J. Blanco.	
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Figure 4.5 Comparative analysis of migration in distal PASMC from IPAH patients 
Cells were grown in monolayer and the expression levels of miR-143 and miR-145 precursors and mature 
forms were detected by Taqman qRT-PCR at the indicated time after multiple scratches in idiopathic PAH 
patients distal PASMCs (37MP (IPAH)). (A) The pri-miR-143 was significantly increased at all the time 
points and pri-miR-145 was significantly decreased. (B) The mature form miR-143-3p was significantly in-
creased but no difference for miR-145-5p mature form. Data represented as fold change ± SEM and analysed 
by a one-way ANOVA followed by Tukey’s post hoc test. Experiments were performed in one IPAH patient 
cells. n = 3 per group in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001. This work was done by Dr. Fran-
cisco J. Blanco. 
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4.3.3 Overexpression and Knockdown of miR-143-3p in PASMCs Affects 
Cell Migration 
As we observed that miR-143-3p expression was increased during scratch wound healing 
both in the PASMCs from larger healthy human pulmonary arteries and distal pulmonary 
arteries from PAH patients and healthy donors, we next aimed to manipulate miR-143-3p 
levels in vitro to identify whether miR-143-3p plays an important role in PASMC migra-
tion phenotype. First, we overexpressed miR-143-3p in PASMC by transfecting cells with 
a synthetic pre-miR-143-3p. Overexpression of miR-143-3p was confirmed by Taqman 
qRT-PCR (Figure 4.6 B) (P < 0.001). Transfection with pre-miR-143-3p significantly in-
duced PASMC migration in a scratch wound healing assay (Figure 4.6 A) (P < 0.05). 
Meanwhile, knockdown of miR-143-3p using the antimiR-143-3p significantly inhibited 
PASMC migration (Figure 4.7 A) (P < 0.01). Knockdown of miR-143-3p was confirmed 
by Taqman qRT-PCR (Figure 4.7 B) (P < 0.01). Taken together, these results demonstrate 
that miR-143-3p can induce the migration of PASMCs in vitro.  																
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Figure 4.6 Assessment of miR-143-3p overexpression on cell migration in wound healing assay 
Single scratch was applied on monolayer PASMCs, and capture of images at time point 0 h and 10 h. Migra-
tion distance between these two time-points was analysed by Image J. (A) Representative micrographs and 
quantification of a wound-healing assay after miR-143-3p overexpression by pre-miR-143-3p transfection, in 
comparison with vehicle and negative control (NC). MiR-143-3p overexpression significantly induced cell 
migration. (B) MiR-143-3p significantly increased with pre-miR-143-3p transfection confirm by Taqman 
qRT-PCR. Data represented as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s 
post hoc test. n = 3 per group in triplicate. *P < 0.05, ***P < 0.001. Scale bar = 200 µm.	 	
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Figure 4.7 Assessment of miR-143-3p knockdown on cell migration in wound healing assay 
Single scratch was applied on monolayer PASMCs, and capture of images at time point 0 h and 10 h. Migra-
tion distance between these two time-points was analysed by Image J. (A) Representative micrographs and 
quantification of a wound-healing assay after miR-143-3p knockdown by antimiR-143-3p transfection, in 
comparison with vehicle and negative control (NC). MiR-143-3p knockdown significantly inhibited cell mi-
gration. (B) MiR-143-3p was significantly knockdown with antimiR-143-3p transfection confirm by Taqman 
qRT-PCR. Data represented as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s 
post hoc test. n = 3 per group in triplicate. **P < 0.01. Scale bar = 200 µm.	
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4.3.4 Manipulation of miR-143-3p Affects PASMC Apoptosis but not 
Proliferation 
Having identified a role for miR-143-3p in the regulation of PASMC migration, we next 
aimed to assess the effect of miR-143-3p manipulation on PASMC proliferation and apop-
tosis. To be consistent with our migration assays, we utilised pre-miR-143-3p transfection 
and antimiR-143-3p treatment to increase or decrease the expression of miR-143-3p, re-
spectively. BrdU incorporation assay and western blotting for PCNA analysed cell prolif-
eration of PASMCs, while apoptosis was evaluated by measuring Caspase3/7 activity. First, 
we observed that PDGF treatment significantly induced PASMC proliferation compared 
with controls (Figure 4.8 A) (P < 0.001). However, pre-miR-143-3p treatment of 
PDGF-stimulated PASMC had no effect on proliferation (Figure 4.8 A). Consistent with 
the Absorbance450 results, a PCNA western blot showed no difference in PCNA expression 
between pre-miR-143-3p treated cells compared with controls (Figure 4.8 B). In addition, 
antimiR-143-3p treatment significantly induced apoptosis in H2O2-treated PASMCs com-
pared to controls (Figure 4.9) (P < 0.001), and treatment with pre-miR-143-3p significantly 
inhibited the apoptosis compared with scramble control (Figure 4.9) (P < 0.001).  																			
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Figure 4.8 Evaluation of the proliferation of PASMCs after transfection with pre-miR-143-3p 
PASMCs were transfected with pre-miR-143-3p and negative controls. BrdU incorporation assay and west-
ern blot assay were performed. (A) There was no difference in BrdU incorporation assay analysis in PASMC 
with miR-143-3p overexpression (n = 5). (B) Western blot assessed the PCNA protein level in PASMC with 
miR-143-3p over expression did not show any difference. β-Tubulin was used as internal control (n = 3). 
Data represented as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc 
test. *** P < 0.001. 		
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Figure 4.9 Analysis of apoptosis in PASMCs with miR-143-3p overexpression and knockdown  
Caspase 3/7 assay for PASMC apoptosis induced by H2O2 treatment with miR-143-3p overexpression and 
knockdown by transfected with pre-miR-143-3p and anti-miR-143-3p. AntimiR-143-3p treatment signifi-
cantly induced cell apoptosis, and pre-miR-143-3p treatment inhibited but not significantly to the cell apop-
tosis. Data represented as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post 
hoc test. n = 8 wells per group. ***P < 0.001. 
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4.3.5 DNA Damage in PASMCs Induces miR-143-3p Expression 
DNA damage is known be caused by highly inflammatory cellular environments, which 
are toxic for cells (Wheelhouse et al., 2003, Fehsel et al., 1991, Gorenne et al., 2013). The 
development of PAH involves a chronic inflammatory response, characterised by sustained 
elevation of circulating pro-inflammatory molecules such as tumour necrosis factor α 
(TNF-α) and interleukin-6 (IL-6) (Soon et al., 2010), and recent studies indicate that the 
Poly (ADP-ribose) polymerase-1 (PARP-1) DNA damage pathway is activated in human 
distal pulmonary arteries and cultured PASMCs from PAH patients (Meloche et al., 2014b). 
Given the potential importance of the DNA damage pathway in PAH pathogenesis, we as-
sessed the influence of DNA damage on miR-143-3p expression in PASMC. PASMC were 
treated with TNF-α (100 ng/mL), IL-6 (100 µM) or PDGF (30 ng/mL) for 48 h to induce 
DNA damage. γH2AX nuclear staining confirmed DNA damage in PASMC (Figure 4.10 B) 
and Taqman qRT-PCR analyses revealed a significant upregulation of miR-143-3p follow-
ing different inductions of DNA damage (Figure 4.10 A) (P < 0.05, P < 0.01).  		
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Figure 4.10 Analysis of miR-143-3p expression following induction of DNA damage in PASMC 
Taqman qRT-PCR analysed miR-143-3p in PASMC treated with TNF-α (100 ng/mL), IL-6 (100 µm) or 
PDGF (30 ng/mL) for 48 h. (A) MiR-143-3p expression significantly induced with DNA damage stimulation. 
(B) Immunofluorescence for γH2AX nuclear staining for DNA damage in PASMC. Data are expression as 
mean ± SEM and analysed by Student t-test. n = 3 per group in triplicate. *P < 0.05, **P < 0.01. Scale bar = 
20 µm. 						
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4.3.6 Extracellular Vesicles from PASMC-derived Culture Medium can 
Transfer miR-143-3p to PAECs 
As shown above, we observed that manipulation of miR-143-3p expression could affect 
PASMC migration and apoptosis. Previous studies have shown that miR-143/145 mediates 
cell-to-cell communication between smooth muscle cells and endothelial cells (Hergenrei-
der et al., 2012). In order to explore whether miR-143-3p was involved in cell-to-cell 
communication between PASMCs and PAECs, we performed a co-culture assay of PAEC 
with PASMC in Boyden chambers, in which cells were physically separated by 0.4 µm 
membrane to prevent direct cell-cell contact and transfer of larger vesicles (Figure 4.11 A). 
MiR-143-3p is more highly expressed in smooth muscle cells in contrast to endothelial 
cells, which show very low levels of expression of miR-143-3p. In the co-culture experi-
ments, the basal level of miR-143-3p in PAECs was significantly upregulated by co-culture 
with PASMCs showing the transfer of endogenous miR-143-3p from PASMCs to PAECs 
(Figure 4.11 B) (P < 0.05). In order to visualise whether miRNAs released from PASMCs 
in extracellular vesicles are transported to PAECs, we transfected PASMC with a 
Cy3-labeled precursor miRNA prior to co-culturing with PAECs for 24 h. Fluorescence 
imaging of PAECs showed that Cy3-labeled miRNAs derived from PASMCs could be de-
tected in PAECs in the co-culture system (Figure 4.11 C). In addition, pre-miR-143-3p 
transfected PASMCs co-cultured with PAECs significantly induced miR-143-3p level in 
PAECs at 24 h (Figure 4.12 A) (P < 0.001) and 48 h (Figure 4.12 B) (P < 0.001) after 
co-culture.  								
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Figure 4.11 Analysis of cell-to-cell communication between PASMCs and PAECs 
(A) Diagram of the transwell used for the in vitro co-culture system. (B) Co-culture system applied with 
PASMCs (insert) and PAECs (bottom) for 48 h to assess the transfer of endogenous miR-143-3p from 
PASMCs to PAECs. Taqman qRT-PCR showed that the expression of miR-143-3p was significantly in-
creased in PAECs compared with control after co-culture with PASMCs (n = 6 wells per group). (C) 
PASMCs in the upper chamber were transfected with Cy3-pre-miRNA. Cy3-labeled miRNA were released 
and transferred to PAEC in the lower chamber after 24 h. Data are expression as mean ± SEM and analysed 
by Student t-test. n = 3 per group in triplicate. *P < 0.05. Scale bar = 50 µm.  	
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Figure 4.12 Analysis the cell-to-cell communications between PASMCs and PAECs via miR-143-3p 
PASMCs were transfected with pre-miR-143-3p or negative control (NC), then co-cultured with PAECs for 
24 (A) or 48 h (B) and expression of miR-143-3p was measured in PASMCs and PAECs by Taqman 
qRT-PCR. MiR-143-3p expression levels in both PASMCs and PAEC were significantly upregulated at 24 h 
and 48 h after co-culture. Data represented as fold change ± SEM and analysed by a one-way ANOVA fol-
lowed by Tukey’s post hoc test. n = 3 per group in triplicate. ***P < 0.001. 
 
A 
B 
Ve
hic
le NC
Pr
e-m
iR1
43
0
2
4
6
8
10
100
120
140
160
180
200
***
PASMC 24 h
R
el
at
iv
e 
ex
pr
es
si
on
Data 5
Ve
hic
le NC
pr
e-m
iR
-14
3-3
p
0
1
2
3
4
Data 5
Ve
hic
le NC
pr
e-m
iR
-14
3-3
p
0
1
2
3
4
Ve
hic
le NC
Pr
e-m
iR1
43
0
2
4
6
8
10
100
120
140
160
180
200
***
PAEC 24 h
R
el
at
iv
e 
ex
pr
es
si
on
Ve
hic
le NC
Pr
e-m
iR1
43
0
2
4
6
8
10
100
150
200
250
300
PASMC 48 h
***
Re
la
tiv
e 
ex
pr
es
si
on
Data 5
Ve
hic
l
pr
e-m
iR
-14
3-3
p
0
1
2
3
4
Data 5
Ve
hic
le NC
pr
e-m
iR
-14
3-3
p
0
1
2
3
4
Ve
hi
l
Pr
e-m
iR
14
3
0
2
4
6
8
10
20
25
30
35
40 ***
PAEC 48 h
R
el
at
iv
e 
ex
pr
es
si
on
	 181	
4.3.7 MiR-143-3p Secreted by PASMC Induces PAEC Cell Migration   
We had observed that miR-143-3p secreted from PASMCs could be taken up by PAEC 
during in vitro co-culture. Here, we further investigated whether miR-143-3p secreted form 
PASMC can affect PAEC migration. PASMCs were transfected with pre-miR-143-3p prior 
to co-culture. Wound healing assay showed that miR-143-3p overexpression significantly 
induce PAEC migration in the co-culture model (Figure 4.13 A) (P < 0.05). The overex-
pression of miR-143-3p confirm by Taqman qRT-PCR (Figure 4.13 B) (P < 0.001). In ad-
dition, conditioned medium taken from the transfected PASMCs with pre-miR-143-3p also 
significantly increased miR-143-3p expression (Figure 4.14 B) (P < 0.01) and induced cell 
migration in PAECs (Figure 4.14 A) (P < 0.05). Taken together, miR-143-3p secreted from 
PASMCs affected endothelial cell migration, which demonstrated the cell-to-cell commu-
nication between PASMCs and PAECs through miR-143-3p.  																									
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Figure 4.13 Analysis cell migration of PAECs in co-culture with PASMCs with pre-miR-143-3p trans-
fection  
PASMCs were transfected with pre-miR-143-3p, co-culture was set up with PAECs after 24 h transfection. A 
single scratch was applied to the PAEC monolayer, with images of scratch captured at the 0h and 12h time 
points. Image J was used to analyse the migration distance between these two time-points. (A) Representa-
tive micrographs and relative migration distance of PAEC migration during scratch closure in co-culture with 
pre-miR-143-3p-transfected PASMC showed miR-143-3p significantly induced cell migration. (B) Taqman 
qRT-PCR confirmed the overexpression of miR-143-3p in PAEC compared with controls. Data represented 
as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. n = 3 per 
group in triplicate. *P < 0.05, ***P < 0.001. Scale bar = 200 µm. 		
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Figure 4.14 Analysis cell migration of PAECs treated with conditioned medium from PASMCs with 
pre-miR-143-3p transfection  
Conditioned medium was harvest from PASMCs transfected with pre-miR-143-3p after 48 h and then cul-
tured with PAECs for 24 h. A single scratch was applied to the PAEC monolayer, with images of scratch 
captured at the 0h and 12h time points. Image J was used to analyse the migration distance between these two 
time-points. (A) Representative micrographs and relative migration distance of PAECs during scratch closure 
in the presence of conditioned medium from pre-miR-143-3p transfected PASMCs showed miR-143-3p sig-
nificantly induced cell migration. (B) Taqman qRT-PCR confirmed the overexpression of miR-143-3p in 
PAEC compared with controls. Data represented as fold change ± SEM and analysed by a one-way ANOVA 
followed by Tukey’s post hoc test. n = 3 per group in triplicate. *P < 0.05, **P < 0.01. Scale bar = 200 µm.	
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4.3.8 Isolation and Characterisation of Exosomes Derived from PASMCs 
Previous studies have reported that exosomes can carry functional miRNAs between cells 
(Valadi et al., 2007, Shimbo et al., 2014). To investigate the function of the extracellular 
vesicles containing miR-143-3p in the co-culture system and in conditioned medium, we 
first isolated exosomes from conditioned PASMC medium and assessed the exosomes by 
NanoSight and western blot. Exosomes were of the expected diameter and size (between 
30-130 nm) and showed expression of the exosome specific markers CD9 and CD63 (Fig-
ure 4.15 A and B). In order to analyse whether both strands of miR-143 were present with-
in PASMC-derived exosomes, Taqman qRT-PCR analysis was performed, showing that 
miR-143-3p/5p was present at high levels in the RNA isolated from PASMC-derived exo-
somes. MiR-143-3p showed higher expression levels than miR-143-5p. As a positive con-
trol, the Ct value of miR-143-3p expression in PASMCs is shown, which showed higher 
levels of miR-143-3p expression compared to PASMC exosomes (Figure 4.15 C). In addi-
tion, we isolated exosomes from the medium of PASMCs transfected with different con-
centrations of pre-miR-143-3p and quantified the levels of miR-143-3p in the exosomes 
and transfected cells. The incorporation of miR-143-3p into exosomes was confirmed by 
Taqman qRT-PCR assessing both the cell-associated and extracellular levels of 
miR-143-3p 24 h post-transfection. As expected, we found a dose-dependent increase in 
miR-143-3p in PASMCs (Figure 4.16 A) (P < 0.001) and accumulation of miR-143-3p in 
exosomes derived from PASMCs (Figure 4.16 B) (P < 0.001). Taken together, this data 
clearly demonstrates that miR-143-3p is present in exosomes derived from PASMCs. In 
addition, the quantity of miR-143-3p incorporated into PASMC exosomes is positively 
correlated with the expression level of miR-143-3p in PASMCs. 									
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Figure 4.15 Identification of PASMC-derived exosomes and analysis of miR-143 expression in exo-
somes 
Exosomes were isolated from PASMC culture medium by ultracentrifugation. (A) The exosome pellet was 
re-suspended in PBS and visualised on the NanoSight instrument. The analysis shows the size of isolated 
exosomes is between 30-130nm. (B) Western Blot for the exosomes markers CD9 and CD63 in PASMC de-
rived exosome protein, n = 2 per group in duplicate. (C) Taqman qRT-PCR shows Ct value analysis of 
miR-143-3p/5p in PASMCs and exosomes derived from PASMCs. n = 3 in per group in triplicate.  								
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Figure 4.16 Analysis of miR-143-3p exosomes derived from PASMCs with pre-miR-143-3p transfection 
at different concentration  
PASMCs were transfected with different concentration with pre-miR-143-3p, and exosomes were purified 
from the culture medium 48 h after transfection. (A and B) Taqman qRT-PCR analysis of miR-143-3p ex-
pression in PASMCs and PASMC-derived exosomes after the cells were transfected with negative control or 
pre-miR143-3p (10nM, 50nM and 100nM). MiR-143-3p expression increased with dose dependent manner 
in exosomes. RNU48 and cel-miR-39 were used as internal loading controls for cells and exosomes respec-
tively. Data represented as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s 
post hoc test. n =3 per group in triplicate. ***P < 0.001 
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4.3.9 MiR-143-3p Enriched Exosomes Treatment and Direct Transfection 
of pre-miR-143-3p Induced Cell migration and Angiogenesis in PAECs  
We have demonstrated that miR-143-3p secreted by PASMCs induces cell migration in 
PAECs, and that miR-143-3p is enriched in PASMC-derived exosomes. In order to inves-
tigate the functions of miR-143-3p in PASMC exosomes, we performed a wound-healing 
assay to examine whether exosome-derived miR-143-3p has similar functional effects on 
PAECs to that observed in the co-culture and conditioned medium experiments. 
PASMC-derived exosomes induced PAEC migration in a similar manner to that observed 
in co-culture and conditioned medium experiments (Figure 4.17 A) (P < 0.05, and P < 
0.01), with a corresponding increase in the intracellular levels of miR-143-3p (Figure 4.17 
B) (P < 0.01). We further performed wound-healing assay in PAECs with pre-miR-143-3p 
direct transfection. Consistent with our experiments using miR-143-3p enriched exosomes, 
direct transfection of PAECs with pre-miR-143-3p significantly induced cell migration 
(Figure 4.18 A) (P < 0.05) and increased the miR-143-3p expression level (Figure 4.8 B) 
(P < 0.001) (Figure 4.18 B). In addition, disordered angiogenesis contributed to the plexi-
form lesions formation (Pietra et al., 2004). Here, we observed that miR-143-3p overex-
pression via the uptake of miR-143-3p enriched exosomes derived from PASMCs and 
pre-miR-143-3p transfection significantly induced angiogenesis in matrigel assays in 
PAEC (Figure 4.19) (P < 0.01, P < 0.001).   															
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Figure 4.17 Analysis cell migration of PAECs treated miR-143-3p enriched exosomes derived from 
PASMCs with pre-miR-143-3p transfection  
A single scratch was applied to the PAEC monolayer, with images of scratch captured at the 0 h and 12 h 
time points. Image J was used to analyse the migration distance between these two time-points. (A) Repre-
sentative micrographs and relative migration distance of PAECs during scratch closure, after treatment with 
isolated exosomes derived from PASMCs transfected with pre-miR-143-3p, vehicle or negative control (NC). 
The results showed that miR-143-3p significantly induced cell migration. (B) Taqman qRT-PCR confirmed 
the overexpression of miR-143-3p in PAEC compared with controls. Data represented as fold change ± SEM 
and analysed by a one-way ANOVA followed by Tukey’s post hoc test. n = 3 per group in triplicate. Scale 
bar = 200 µm. *P < 0.05, **P < 0.01.  
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Figure 4.18 Analysis cell migration of PAECs with pre-miR-143-3p transfection  
A single scratch was applied to the PAEC monolayer, with images of scratch captured at the 0h and 12h time 
points. Image J was used to analyse the migration distance between these two time-points. (A) Representa-
tive micrographs and relative migration distance of PAECs during scratch closure after direct transfection 
with pre-miR-143-3p. The results showed that miR-143-3p significantly induced cell migration. (B) Taqman 
qRT-PCR confirmed the overexpression of miR-143-3p in PAEC compared with controls. Data represented 
as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. n = 3 per 
group in triplicate. Scale bar = 200 µm. *P < 0.05, *** P < 0.001. 	
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Figure 4.19 Angiogenesis analysis of PAECs with miR-143-3p overexpression via treated with 
miR-143-3p enriched exosomes and transfected with pre-miR-143-3p 
(A) Matrigel angiogenesis assay analysis in PAECs transfected with pre-miR-143-3p or loaded with 
miR-143-3p enriched exosomes derived from PASMCs with pre-miR-143-3p transfection. (B) Quantification 
of total tube lengths in PAECS treated with exosomes from pre-miR-143-3p transfection and (C) Quantifica-
tion of total tube lengths in PAECS transfected with premiR-143-3p. Data represented as fold change ± SEM 
and analysed by a one-way ANOVA followed by Tukey’s post hoc test. n = 6 wells per group. Scale bar = 
250 µm. *P < 0.05, **P < 0.01, *** P < 0.001.  
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4.3.10 Overexpression of miR-143-3p in PAECs Has No Effect on Cell 
Proliferation and Apoptosis 
In addition to analysing the role of miR-143-3p during PAEC migration and tube formation, 
we also assessed the effect of miR-143-3p on PAEC proliferation and apoptosis. Overex-
pression of miR-143-3p was achieved via pre-miR-143-3p transfection, while cell prolifer-
ation was analysed by BrdU incorporation assay and evaluation of PCNA protein levels by 
western. We observed that VEGF significantly induced PAEC proliferation compared to 
unstimulated control cells (Figure 4.20 A) (P < 0.001). However, there was no difference 
between pre-miR-143-3p treated groups compared with control groups. Consistent with 
our BrdU results, PCNA western blots showed that there was no difference in 
pre-miR-143-3p treated cells compared with controls (Figure 4.20 B). Cell apoptosis was 
analysed using a Caspase3/7 activity assay. Neither pre-miR-143-3p transfection nor ex-
posure to miR-143-3p enriched exosomes affected PAEC apoptosis when assayed in this 
way (Figure 4.21 A and B). However, we observed the Scramble transfected group signifi-
cantly induced the apoptosis (Figure 4.21 B) (P < 0.001) compared control and 
pre-miR-143-3p. This may due to the target effect of scramble control.   	
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Figure 4.20 Proliferation analysis of PAECs with miR-143-3p transfection 
PAECs were transfected with pre-miR-143-3p. BrdU incorporation assays and PCNA western blot assays 
were performed to evaluate PAEC proliferation (A) There was no difference in BrdU incorporation by PAEC 
following miR-143-3p overexpression (n = 5). (B) Western blots analysis did not reveal any effect on PCNA 
protein expression in PAEC following miR-143-3p overexpression. β-Tubulin was used as internal loading 
control (n = 3). Data represented as fold change ± SEM and analysed by a one-way ANOVA followed by 
Tukey’s post hoc test. *** P < 0.001.  						
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Figure 4.21 Apoptosis analysis of PAECs with miR-143-3p overexpression via pre-miR-143-3p trans-
fection and treated with miR-143-3p enriched exosomes  
PAEC apoptosis was assessed by performing Caspase 3/7 activity assays on cells following TNF-α and Cy-
cloheximide (CHX) treatment in the presence or absence of miR-143-3p overexpression (pre-miR-143-3p 
transfection) or miR-143-3p enriched PASMC exosomes. Neither condition affected PAEC apoptosis com-
pared with controls. Data represented as fold change ± SEM and analysed by a one-way ANOVA followed 
by Tukey’s post hoc test. n = 8 well per group. ***P < 0.001. 					
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4.3.11 Cy3-labelled pre-miR-143-3p is Transferred from PASMC to 
PAEC in Exosomes  
We have demonstrated that exosomes mediate the cell-to-cell communication between 
PASMCs and PAECs, with transfer of miR-143-3p between the two cell types. In order to 
track the secretion and uptake of miR-143-3p during cell-to-cell communication, we la-
belled pre-miR-143-3p with Cy3 and then transfected PASMCs with Cy3-labelled 
pre-miR-143-3p. Cy3-labelling pre-miRNA, which can be transfer from PASCMs to 
PAECs in the co-culture model, used as positive control. Confocal microscopy analysis 
showed red fluorescence in transfected PASMC, which demonstrated the transfection suc-
cess (Figure 4.22 A). To show direct transfer of Cy3-labelled pre-miR-143-3p between 
PASMCs and PAECs, exosomes purified from the culture medium 48 h after PASMC 
transfection were incubated with PAECs for a period of 24 h. Confocal microscopy analy-
sis of fluorescence showed high levels of Cy3 fluorescence in PAEC transfected with la-
belled pre-miR-143-3p and positive control pre-miR, compared to control (Figure 4.22 B).  																		
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Figure 4.22 Tracking analysis of cell-to-cell communication between PASMCs and PAECs via 
Cy3-labled pre-miR-143-3p 
(A) PASMC transfected with Cy3-labled pre-miRNA and Cy3-labled pre-miR-143-3p. Confocal images were 
taken after 48 h showed red fluorescence (Cy3). (B) Exosomes were purified from the supernatants of 
PASMC transfected with Cy3-labelled pre-miRNA or Cy3-labled pre-miR-143-3p. Confocal microscopy 
analysis was performed following 24 h of PAEC exposure to exosomes, showed red fluorescence compared 
with control exosomes. n = 3 per group in triplicate.  		
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4.3.12 AntimiR-143-3p Treatment Reversed the Pro-migratory Effect of 
miR-143-3p Enriched Exosomes Derived from PASMCs 
In order to further confirm that PASMC-derived miR-143-3p enriched exosomes are in-
volved in the cell-to-cell communication between PASMCs and PAECs and regulate the 
migration behaviour, we performed reverse experiments to investigate whether inhibiting 
the exosome-induced overexpression of miR-143-3p in PAEC could inhibit migration. The 
experimental design is showed in (Figure 4.23). We first verified the miR-143-3p expres-
sion levels in PAECs exposed to various treatments. In the exosome-free groups, anti-
miR-143-3p transfection significantly reduced the expression of miR-143-3p level (unde-
tectable by Taqman qRT-PCR) compared with vehicle and scramble groups. As shown 
previously, the PASMC-derived exosome treated groups had a much higher level of 
miR-143-3p than the exosome-free groups. In particular, miR-143-3p expression in PAECs 
exposed to exosomes from PASMCs transfected with pre-miR-143-3p was dramatically 
increased compared with all other groups. AntimiR-143-3p transfection significantly re-
duced miR-143-3p expression in these cells, although levels were still higher than vehicle 
and scramble exosomes treated cells (Figure 4.24 A) (P < 0.01). Importantly, the wound 
healing assay showed that treatment of PAECs with exosomes derived from 
pre-miR-143-3p transfected PASMCs significantly induced cell migration compared with 
all other groups, while transfection of antimiR-143-3p reversed this increase in cell migra-
tion (Figure 4.24 B) (P < 0.05). Taken together, these data show that the induction of 
PAEC migration in the presence of PASMC derived exosomes are mediated by transfer of 
exosomal miR-143-3p between these two cell types.    										
	 197	
			
			
Figure 4.23 Schematic diagrams to shown the experiments work model 
(A) Cartoon showing the wound-healing assay in PAECs with a single scratch. (B) Design of reversal ex-
periments evaluating the effect of miR-143-3p enriched PASMC exosomes on PAEC migration. There are 
seven groups, which are vehicle, scramble transfection, antimiR-143-3p transfection, vehicle (exosomes de-
rived from untransfected PASMCs), scramble (exosomes derived from PASMCs transfected with a scramble 
control), miR-143-3p-enriched exosomes (derived from PASMCs transfected with pre-miR-143-3p), and 
antimiR-143-3p transfection together with treatment of miR-143-3p-enriched exosomes derived from 
PASMCs transfected with pre-miR-143-3p. 									
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Figure 4.24 Migration analysis of PAECs with modulation of miR-143-3p expression with transfection 
and/or miR-143-3p enriched exosome treatment 
(A) Analysis of miR-143-3p expression in PAEC with different treatments. PAECs were transfected with 
antimiR-143-3p, or pre-miR-143-3p, or combination of pre-miR-143-3p transfection and treatment with 
miR-143-3p enriched exosomes derived from PASMCs transfected with pre-miR-143-3p. (B) Analysis of 
relative migration distance in PAEC showed that antimiR-143-3p transfection could inhibit the increase in 
migration caused by exposure to miR-143-3p enriched exosomes from PASMCs. Data represented as fold 
change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. n = 3 per group in 
triplicate. **P < 0.01 compared with Vehicle-T and Scramble-T, && P < 0.01 compared with any other groups. 
*P < 0.05 compared with all other groups.  
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4.3.13 Pathway Analysis of PASMCs and PAECs 
In order to identify potential pathways that may be involved in the miR-143-3p-mediated 
regulation of PASMC and PAEC migration, we carried out expression microarray on 
PASMCs and PAECs. PASMCs were transfected with pre-miR-143-3p and PAECs were 
treated with miR-143-3p enriched exosomes derived from PASMCs transfected with 
pre-miR-143-3p. Taqman qRT-PCR confirmed up-regulation of miR-143-3p in PASMC 
and PAEC following transfection and exosome treatment respectively (Figure 4.25) (P < 
0.01). In PASMCs transfected with pre-miR-143-3p, 68 regulated targets known to be in-
volved in cell migration were identified (Table 4-1). Further, “migration of cancer cells” 
was identified as a significantly enriched pathway (P = 0.0001) identified by ingenuity 
pathway analysis (Table 4-2 and Figure 4.26). These findings are consistent with the hy-
pothesis that miR-143-3p can increase migration in PASMCs. In PAECs exposed to 
miR-143-3p-loaded PASMC exosomes, we observed the regulation of multiple targets in-
volved in cell death and survival (Table 4-3 and 4-4). Further these targets might suggest 
that miR-143-3p reduces cell death in PAEC (Figure 4.27).  																					
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Figure 4.25 Validation of miR-143-3p expression in PASMCs and PAECs array samples 
PASMCs were transfected with pre-miR-143-3p or a negative control for 48 h. PAECs were treated with 
miR-143-3p-enriched exosomes derived from PASMC transfected with pre-miR-143-3p. Taqman qRT-PCR 
analysis of theses samples showed a significant increase in miR-143-3p compared to controls. Data repre-
sented as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. n = 4 
wells in per group. **P < 0.01 
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Figure 4.26 Pathway analysis in PASMC by microarray 
Selected significant functional annotation relating to increased ‘migration of cancer cells’ (P < 1.43 x 10-4) 
using Ingenuity Pathway Analysis. Orange represents an increase in migration of cancer cells, green fill rep-
resents decrease and red an increase in gene expression levels in miR-143-3p transfected cells compared to 
controls. 
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Figure 4.27 Pathway analysis in PAEC by microarray 
Selected significant functional annotation relating to decrease in ‘cell death and survival’ (P < 1.56 x 10-3) 
using Ingenuity Pathway Analysis. Blue represents a decrease in ‘cell death of B lymphocytes’, green fill 
represents decrease and red an increase in gene expression levels in miR-143-3p-enriched exosome treated 
cells compared to controls. 
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Table 4-1 Disease and function annotation relating to migration in the smooth muscle 
cell gene expression dataset.  
 
Categories 
Diseases or 
Functions An-
notation p-Value 
Gene 
Count Molecules 
Cellular 
Movement 
 
migration of 
brain cells 5.53E-05 9 APP,BTG2,CDK5,FN1,FUT10,GNA13,LAMA1,PTEN,RERE 
 
migration of 
breast cancer 
cell lines 2.96E-03 12 
ANKS1A,CCL5,CTGF,CTNNB1,CTSL,DDR2,FLNA,FN1,GIT1,M
LLT4,SNAI2,TGM2 
 
migration of 
cancer cells 1.43E-04 13 
AD-
AM10,AHCY,CCL5,CSF2RA,CTBP2,CTGF,CTNNB1,F3,FN1,IL1
1,LAMA5,PTEN,SNAI2 
 
 
 
 
 
 
 
migration of 
cells 3.64E-04 68 
AD-
AM10,ADORA1,AHCY,ANGPTL4,ANKS1A,APP,ARHGDIA,AS
AP2,BBS1,BTG2,CCL5,CCR5,CD58,CD63,CDK5,CSF2RA,CTBP
1,CTBP2,CTGF,CTNNA1,CTNNB1,CTSL,DDR2,DIAPH1,DOCK
3,F3,FCAR,FLNA,FN1,FUT10,FUT8,GIT1,GNA13,GNG12,HDAC
3,HDC,HLA-G,HRH1,IL11,JAK1,LAMA1,LAMA5,LDLR,LPA,M
ATN2,MLLT4,MYOCD,PKD1,PKM,PLEC,PRRX1,PTEN,PTPRU,
RERE,RHOG,SCARB1,SEMA3E,SLC3A2,SLC9A1,SNAI2,SPRY
4,TGM2,TP53INP1,TPT1,TRPV1,WHSC1,YWHAE,YY1AP1 
 
migration of 
central nervous 
system cells 2.37E-05 10 
APP,BTG2,CDK5,CTGF,FN1,FUT10,GNA13,LAMA1,PTEN,RER
E 
 
migration of 
chondrosar-
coma cells 1.03E-02 2 CCL5,IL11 
 
migration of 
embryonic cells 3.08E-03 7 CCL5,CDK5,FN1,IL11,LAMA1,LAMA5,SLC3A2 
 
migration of 
endothelial 
cells 9.72E-03 14 
AD-
AM10,ANGPTL4,CCL5,CD63,CTGF,F3,FLNA,FN1,HRH1,PKM,P
TEN,SCARB1,SEMA3E,SPRY4 
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migration of 
extravillous 
trophoblast 
cells 3.00E-03 2 CCL5,IL11 
 
migration of 
fibroblast cells 3.48E-03 8 CTNNB1,FN1,GNG12,PKD1,PTEN,RHOG,TGM2,TP53INP1 
 
migration of 
glioma cells 9.43E-03 3 CSF2RA,CTGF,F3 
 
migration of 
hepatic stellate 
cells 6.56E-03 3 CCL5,CCR5,CTGF 
 
migration of 
kidney cell 
lines 1.57E-03 7 ANKS1A,APP,CCL5,CCR5,FN1,PKD1,RHOG 
 
migration of 
leukemia cells 5.33E-04 7 APP,CCL5,CCR5,FLNA,FN1,GNA13,TGM2 
 
migration of 
melanoma cells 8.41E-03 3 ADAM10,FN1,SNAI2 
 
migration of 
monocytes 6.45E-03 6 APP,CCL5,CTGF,FN1,JAK1,LDLR 
 
migration of 
mononuclear 
leukocytes 6.50E-03 16 
AD-
AM10,APP,CCL5,CCR5,CD58,CTGF,DIAPH1,FN1,GNA13,HDC,
HLA-G,JAK1,LDLR,PLEC,PTEN,TGM2 
 
migration of 
neural precur-
sor cells 2.12E-03 3 APP,BTG2,FUT10 
 
migration of 
neuroglia 
 
9.97E-03 
 
5 
 
APP,CTGF,FN1,MATN2,PTEN 
 
migration of 
neurons 2.06E-03 13 
AD-
AM10,BBS1,CDK5,CTNNB1,DIAPH1,FLNA,FN1,GNA13,LAMA
1,MATN2,PTEN,RERE,YWHAE 
 
migration of 2.92E-03 4 CDK5,FN1,PRRX1,TP53INP1 
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pancreatic can-
cer cell lines 
 
migration of 
pericytes 7.70E-04 4 CCL5,CCR5,CTGF,FN1 
 
migration of 
phagocytes 1.16E-02 12 
APP,CCL5,CCR5,CD58,CTGF,DDR2,FLNA,FN1,JAK1,LDLR,PT
EN,TRPV1 
 
migration of 
prostate cells 4.45E-03 2 FN1,WHSC1 
 
migration of 
Purkinje cells 4.24E-05 4 CDK5,GNA13,PTEN,RERE 			
Table 4-2 Gene expression data from the ‘migration of cancer cell’ functional annota-
tion relating to migration in the smooth muscle cell gene expression dataset. 	
Symbol Illumina p-value Log Ratio 
Entrez Gene ID for 
Human 
ADAM10 ILMN_2148360 0.00749 0.32705 102 
AHCY ILMN_1657862 0.00741 -0.33416 191 
CCL5 ILMN_2098126 0.00023 0.45211 6352 
CSF2RA ILMN_1661196 0.00239 0.44034 1438 
CTBP2 ILMN_3250209 0.00809 0.39629 1488 
CTGF ILMN_2115125 0.00012 -0.61260 1490 
CTNNB1 ILMN_1746396 0.00256 -0.36541 1499 
F3 ILMN_2129572 0.00201 0.37686 2152 
FN1 ILMN_1778237 0.00041 -0.45445 2335 
IL11 ILMN_1788107 0.00526 0.33755 3589 
LAMA5 ILMN_1773567 0.04814 -0.34166 3911 
PTEN ILMN_1880406 0.00718 -0.32989 5728 
SNAI2 ILMN_1655740 0.03198 -0.34327 6591 									
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Table 4-3 Gene expression data from the ‘cell death and survival’ functional annota-
tion relating to survival in the endothelial cell gene expression dataset. 	
Categories 
Diseases or Func-
tions Annotation p-Value Gene Count Molecules 
 
Cell Death and 
Survival 
 
apoptosis of follic-
ular B lymphocytes 1.25E-03 2 BCL2A1,CD80 
 
 
cell death of B 
lymphocytes 1.56E-03 5 BCL11A,BCL2A1,CD80,MS4A1,VAV3 
 
 
apoptosis of pro-B 
lymphocytes 4.58E-03 2 BCL11A,VAV3 
 
 
apoptosis of B-2 
lymphocytes 6.00E-03 1 BCL2A1 
 
 
apoptosis of B 
lymphocytes 7.40E-03 4 BCL11A,BCL2A1,CD80,VAV3 
 
 
apoptosis of ger-
minal center B 
lymphocytes 1.79E-02 1 CD80 
 
 
loss of long-lived 
plasma cell 1.79E-02 1 CD80 
 
 
cell death of lym-
phoblastoid cell 
lines 2.12E-02 3 RAP1GDS1,TGIF2LX,VAV3 
 
 
apoptosis of leu-
kocyte cell lines 2.71E-02 4 BCL2A1,IKZF3,MS4A1,PMAIP1 
 
 
apoptosis of pros-
tate cancer cell 
lines 2.85E-02 4 HOXC6,IGFBP1,ILK,PMAIP1 
 
 
apoptosis of 4.02E-02 3 BCL2A1,MS4A1,PMAIP1 
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B-lymphocyte 
derived cell lines 
 
 
cell viability of 
germ cell tumor 
cell lines 4.13E-02 1 PMAIP1 
 
 
apoptosis of fibro-
sarcoma cell lines 4.31E-02 2 BCL2A1,PMAIP1 
 
 
anoikis of breast 
cell lines 4.70E-02 1 ILK 		
Table 4-4 Gene expression data from the ‘cell death and survival’ functional annota-
tion relating to survival in the endothelial cell gene expression dataset. 	
Symbol Illumina p-value Log Ratio 
Entrez Gene ID for 
Human 
BCL11A ILMN_1752899 0.00215 0.36538 53335 
BCL2A1 ILMN_1769229 0.00205 0.35285 597 
CD80 ILMN_1716736 0.00333 -0.32993 941 
MS4A1 ILMN_1776939 0.00339 -0.39392 931 
VAV3 ILMN_2290068 0.00137 0.35903 10451 	
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4.4	Discussion	
In this chapter, in vitro techniques have been used to assess the role of miR-143-3p in vas-
cular cell function and in cell-to-cell communication between PASMCs and PAECs. The 
potential gene targets of miR-143-3p and dysregulated signalling pathways in vascular 
cells were also investigated. In summary, using cultured PASMCs, over-expression or 
knockdown of miR-143-3p promoted or reduced migration, and inhibited or induced 
apoptosis respectively. However, modulation of miR-143-3p had no effect on cellular pro-
liferation. Using an in vitro co-culture model, we showed that PASMCs secrete 
miR-143-3p-enriched exosomes that can be taken up by PAECs, further inducing endothe-
lial cell migration and tube formation but with no effect on proliferation and apoptosis. 
Concerted efforts were made to identify the potential target genes of miR-143-3p in 
PASMCs and PAECs, however we were unable to validate any of the putative targets pre-
viously identified in the literature. Furthermore, we performed gene expression microarray 
experiments on PASMCs transfected with pre-miR-143-3p and PAECs treated with 
miR-143-3p-enriched exosomes derived from PASMCs and identified 68 regulated targets 
that are involved in cell migration in PASMCs and multiple targets involved in cell death 
and survival in PAECs. We further performed the same experiments in distal PASMCs 
from PAH patients (IPAH and HPAH) and healthy donor controls. The similar responses 
were also observed but even enhanced in distal PASMCs form PAH patients. This may 
partially contribute to the up-regulation of miR-143-3p observed in PAH patient cells.  	
Increased muscularisation of the small pulmonary vessels, driven partly by increased pro-
liferation and migration of pulmonary arterial smooth muscle cells (PASMCs), is a key 
component of the vascular remodelling process that drives the development of PAH.  
Dysregulation of PASMC normal cells function is associated with the development of PAH 
pathophysiology, as many in vivo and in vitro studies have previously shown (Humbert et 
al., 2004b, Archer et al., 2010, Cordes et al., 2009, Leggett et al., 2012). Many different 
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growth factors and transcriptions factor such as PDGF, VEGF, Oct-4, and Notch-3 are play 
a key role in influencing PASMC dysfunction. In addition, several recent studies have re-
ported that miRNAs associated with vascular remodelling can regulate PASMC prolifera-
tion and migration, albeit not always in parallel (Grant et al., 2013). For example, previous 
in vitro study on miR-145 demonstrated that delivery of miR-145 mimic inhibits PASMC 
proliferation, but has no effect on cell migration (Caruso et al., 2012). In addition, other 
studies have shown that miR-143 and miR-145 are not redundant and hence do not always 
act in parallel in vitro and in vivo (Xin et al., 2009, Cordes et al., 2009). Here, we used a 
wound healing assay to evaluate the role of miR-143 in PASMC or PAEC migration.  
This assay is based on the principle that after creating multiple wounds to intact cell mon-
olayers, a high proportion of cells will migrate to fill the scratch (or wound). In this study 
we first applied multiple scratches to PASMC monolayer, then harvested the cells at dif-
ferent time-points to analyse the expression of the miR-143/145 cluster during cell migra-
tion. We found that both pri-miR-143 and the lead strand of miR-143 (miR-143-3p) were 
significantly increased during cell migration, with a sustained up-regulation from 3 h to 24 
h after scratch. The expression of the miR-143 passenger strand (miR-143-5p) remained 
unchanged. This sustained upregulation of miR-143 suggested that miR-143-3p may spe-
cifically be involved in the biological processes underlying PASMC migration. Conversely, 
although pri-miR-145 expression was upregulated at 3 h post-scratch, it was then signifi-
cantly reduced at the ensuing time points (16-24 h). We did not observe any changes in ex-
pression of mature miR-145-5p. These data are consistent with the previous study from our 
group that showed miR-145-5p did not affect PASMC migration (Caruso et al., 2012).  
 
During miRNA biogenesis, it has been generally thought that the “passenger” strand of the 
miRNA duplex is rapidly degraded and only the lead stand (guide stand) remains bound to 
Ago as mature miRNA to become the functional strand (Wahid et al., 2010). Recently, 
several studies have demonstrated that passenger strands are loaded into RISC and can also 
target mRNAs, thereby playing a biological role in pathologies such as cancer and cardio-
vascular disease (Yang et al., 2013, Shan et al., 2013, Bang et al., 2014). In chapter 3, in 
vivo animal models and PAH patients showed that only miR-143-3p expression was sig-
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nificantly elevated in the disease conditions and pharmacological inhibition of miR-143-3p 
prevented the development of chronic hypoxia induced PH. Here, we also showed that 
miR-143-3p expression was increased in migrated PASMCs and manipulation of 
miR-143-3p affected the cell behaviour of PASMCs and PAECs. In addition, pervious 
study also demonstrated that only miR-145-5p knockdown exert a protective role in the 
development of chronic hypoxia induced PH (Caruso et al., 2012). All of which indicate 
that the lead strands of miR-143/145 are functional in the setting of PAH. However, genetic 
ablation of both miR-143 and miR-145 in vivo showed the same protective effect in the 
development of hypoxic-induced PH (Caruso et al., 2012). As the genetic ablation inhibit-
ed both strands of miR-143 and miR-145, whether the inhibition of miR-143-5p or 
miR-145-3p will exert protective role in the development of PAH need to be further inves-
tigated. The in vitro data showed that miR-145-5p inhibited the PASMCs proliferation but 
no effect on cell migration (Caruso et al., 2012), and we showed that miR-143-3p induced 
the cell migration and prevented cell apoptosis in PASMCs. In addition, we also observed 
the different expression profiles of pri-miR-143/145 and mature form of miR-143/145 in 
the migrated PASMCs. This suggests that there may be differential post-transcriptional 
regulation of each individual miRNA within the cluster. This alternative processing has 
been already reported for other miRNA clusters, for example the up-regulation of all 
members of the polycistronic miR-17-92 cluster during endothelial differentiation of 
mouse embryonic stem cells apart from miR-92a, which is repressed (Treguer et al., 2012). 
Another explanation is that the miR-143-5p is believed to be degraded and inactivated but 
need further experimental validation. As accumulating evidence has suggested that pas-
senger miRNA strands can be loaded into Ago2 protein and contributed to the regulating 
mRNA translation (Mah et al., 2010). In summary, we demonstrate that miR-143-3p sig-
nificantly increases during cell migration in PASMCs. However, miR-145 expression is not 
significantly changed during the cell migration, which indicates that miR-143-3p is in-
volved in the cell migration process in PASMCs.  
 
In order to further confirm that miR-143-3p is an important regulator of PASMC migration, 
we use gain-of-function and loss-of-function approaches to evaluate the effect of modulat-
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ing miR-143-3p expression on wound healing. Our results indicate that miR-143-3p over-
expression induces PASMC migration, whereas miR-143-3p knockdown inhibits this effect. 
This reduction in cell migration with miR-143-3p knockdown in vitro is consistent with in 
vivo data showing that miR-143 knockout (KO) mice (and mice treated with anti-
miR-143-3p) exhibit protection from chronic hypoxia induced PH (chapter 3). By contrast, 
we did not observe any effect of miR-143-3p on the proliferation of PASMCs both in vivo 
and in vitro, as measured by PCNA expression and BrdU analysis. miR-143-3p has been 
previously reported as a tumor suppressor by inhibiting proliferation and migration in sev-
eral cancer cells (Ma et al., 2013, Xu et al., 2011, Zhang et al., 2012) which suggests that 
miR-143-3p function strongly depends on the specific cellular context.  
 
In addition to increases in vascular cell proliferation and migration, PAH also characterised 
by the development of an anti-apoptotic phenotype (Courboulin et al., 2012). In PAH, 
PASMC apoptosis is suppressed (Courboulin et al., 2012). There are several miRNAs have 
been demonstrated regulate PASMCs apoptosis; for example, inhibition of miR-204 in 
PASMC resulted in an increased resistance to apoptosis (Vaidya and Gupta, 2015), over-
expression of miR-138 suppressed PASMC apoptosis (Li et al., 2013) and overexpression 
of miR-328 induced PASMC apoptosis (Guo et al., 2012). In this study, we found that 
overexpression or knockdown of miR-143-3p in PASMCs resulted in resistance to apopto-
sis or augmentation of apoptosis respectively. This is the first time that an anti-apoptotic 
role for miR-143-3p has been demonstrated, as previous studies in cancer cell lines indi-
cate that miR-143-3p promotes apoptosis (Liu et al., 2012, Zhang et al., 2013b). Although 
PAH shares some similarities of mechanism with cancer (Courboulin et al., 2016), these 
results indicate that the functions of miRNAs in different diseases and settings may not be 
consistent. This might be expected considering the target mRNA transcriptome in these 
different settings will be substantially different.  
 
Mechanistically, we used an unbiased approach to assess the effect of miR-143-3p overex-
pression on the transcriptional profile of PASMCs by microarray. Informatic analysis of 
the data highlighted a migratory phenotype. There are a number of genes related to migra-
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tion significantly changed, which including adam10, ahcy, ccl5, csf2ra, ctbp2, ctgf, ctnnb1, 
f3, fn1, il11, lama5, pten, and snai2. In addition, an expression microarray also carried out 
on PAECs treated with miR-143-3p enriched exosome derived from PASMCs transfection 
with scramble and pre-miR-143-3p. We observed the regulation of multiple targets, which 
involved in cell death and survival. The significantly changed genes include bcl11a, bcl2a1, 
cd80, ms4a1, and vav3. However, we did not do any validation of these significantly 
change genes in this study. Further work need to address on the validation of these genes, 
which might be a target of miR-143-3p and involved in the protective role of miR-143-3p 
knockdown in the development of PAH.  
 
DNA damage is a normal and frequent phenomenon in the human body, as we are con-
stantly exposed to genotoxic agents at the molecular level (De Bont and van Larebeke, 
2004, Kawanishi et al., 2006). To respond to the threat of DNA damage, cells have evolved 
mechanisms to detect DNA lesions, signal their presence and promote their repair, which is 
termed the DNA damage response (DDR) (Harper and Elledge, 2007, Rouse and Jackson, 
2002, Harrison and Haber, 2006). Previous studies have shown that DNA damage and 
DNA damage repair pathways are etiologically implicated in PAH patients (Caruso et al., 
2012). In the clinical scenario, DNA damage has been suspected to be responsible for the 
occurrence of PH after etoposide treatment, an anticancer drug promoting DNA damage 
(Yeh et al., 2004). PAH is characterised by sustained sterile inflammation and elevated 
circulating cytokines such as TNF-α and IL-6, which are known to promote DNA damage 
(Wheelhouse et al., 2003, Fehsel et al., 1991). Moreover, the cytokine driven inflammatory 
process is a major contributor to the development of PAH (Soon et al., 2010, Groth et al., 
2014). In addition, the right ventricle of rats (SU5416/hypoxia rat PH model) exhibits ex-
tensive DNA damage (Gomez-Arroyo et al., 2013). We therefore aimed to assess the role 
of miR-143-3p in DNA damage. Firstly, we demonstrated that PASMCs exposed to known 
inducers of PAH (TNF-α, IL-6 and PDGF) showed increased DNA damage, measured by 
immunocytochemistry for γ-H2AX. MiR-143-3p expression was significantly increased in 
PASMCs following induction of DNA damage, indicating that miR-143-3p may be in-
volved in the DNA damage process during PAH pathogenesis. Another study showed that 
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miR-143/145-dependent MDM2 turnover contributes to the control of p53 dynamics in re-
sponse to DNA damage in cancer cells (Zhang et al., 2013a) further indicating that 
miR-143-3p is responsible for DNA damage.  
 
Several studies revealed the emerging role of exosomes in the development of PH. Lee 
et.al carried out intravenous delivery of mesenchymal stromal cell (MSC)-derived exo-
somes inhibited vascular remodelling and exert a pleiotropic protective effect on the lung 
and chronic hypoxia induced PH in mice. The mechanism of this protective effect is 
through suppression of hyperproliferative pathways including STAT3-mediated signalling 
induced by chronic hypoxia  (Lee et al., 2012a). Extracellular vesicles isolated from the 
circulation or lungs of mice with monocrotaline-induced pulmonary hypertension 
(MCT-PH) induced right ventricular hypertrophy (RVH) and pulmonary vascular remodel-
ling when injected in to healthy mice (Aliotta et al., 2013). In order to determine which 
extracellular vesicles contributed to the disease induction, the same group found that the 
exosomes isolated from mice with MCT-PH are responsible for inducing pulmonary hy-
pertensive changes in healthy mice, and that exosomes isolated from MSC can prevent or 
reverses MCT-PH. The mechanism underlying this phenotype was shown to be loading of 
miRNAs known to be involved in the pathogenesis of PAH into MCT-PH-derived exo-
somes, whereas MSC-derived exosomes contained increased levels of miRNAs that blunt 
angiogenesis, inhibit proliferation of neoplastic cells, and induced senescence of vascular 
SMCs and endothelial progenitor cells (EPCs) (Aliotta et al., 2016).  
 
The studies described above demonstrate that exosomes can participate in the development 
of PAH. However, there is no report about exosomal miRNA in the PAH disease. Therefore, 
it is reasonable to investigate the role exosomal miRNAs in this disease setting. Previous 
studies demonstrated that exosomes derived from endothelial cells transfer both 
miR-143-3p and miR-145-5p to smooth muscle cells, affecting the SMC functions and 
regulate target genes (Hergenreider et al., 2012). In addition, miR-143-3p-enriched exo-
somes are known to be secreted from mesenchymal stem cells, and were able to suppress 
the migration of osteosarcoma cells following exposure (Shimbo et al., 2014). These stud-
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ies revealed that exosomal miR-143-3p can functionally mediated cell to cell communica-
tions between vascular SMC/EC cells and other cell types. In order to investigate whether 
exosomal miR-143-3p can mediate the cell to cell communications between PASMCs and 
PAECs, in this study, we first demonstrated that PASMCs could communicate with PAECs 
by miRNA via the co-culture experiment between PASMCs with Cy-3 labelled pre-miRNA 
transfected and PAECs, which found Cy3-labelling miRNA in the PAECs. MiR-143-3p is 
highly expressed in smooth muscle cells and very low expressed in endothelial cell. We 
applied the co-culture experiment between PASMCs and PAECs without any stimulation. 
Taqman qRT-PCR analysis showed that the miR-143-3p is significantly increased in 
PAECs compared with cell without co-culture application. This suggest that endogenous 
miR-143-3p in PASMCs can be transferred and uptake by PAECs. Function assessment of 
PAECs co-cultured with PASMC transfected pre-miR-143-3p or treated with conditioned 
medium taken from PASMCs transfected with pre-miR-143-3p found that miR-143-3p se-
creted from PASMCs significantly induced PAEC migration. It was recently reported that 
exosomes are effective carriers of miRNAs, and the identification of exosomal miRNAs 
has been performed by a number of researchers (Loyer et al., 2014). We purified exosomes 
from PASMCs and found that isolated exosomes from PASMC culture medium are en-
riched in miR-143-3p, and to a lesser extent, the miR-143-5p passenger strand. Functional 
study revealed that exosomal miR-143-3p derived from PASMCs induced PAECs migra-
tion and angiogenesis. We further performed a reverse experiment, which PAECs first 
treated with miR-143-3p enriched exosomes derived from PASMCs and then transfected 
with antimiR-143-3p to decrease the miR-143-3p level in PAECs. Migration assay analysis 
showed that antimiR-143-3p transfection in PAECs prevented the pro-migratory effect of 
PAECs mediated by miR-143-3p enriched exosome derived from PASMCs. These data 
suggested that exosomal miR-143-3p secreted by PASMCs specifically regulate the migra-
tion behaviour of PAECs. Thus, we provide the first evidence that miR-143-3p acts as a 
paracrine signalling mediator and is involved in the induction of PAEC migration and an-
giogenesis but not proliferation and apoptosis. This cell-cell communication by exosomal 
miR-143-3p in the pulmonary vascular system is relevant to the functional changes in cell 
behaviour that help drive the pathogenesis of PAH, which indicate that exosomes contain-
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ing miR-143-3p and secreted by PAH-PASMCs might enhance the development of lesions 
associated with pulmonary hypertension and could be of clinical importance. Furthermore, 
we observed a reduction in microvessel density in the miR-143-/- hypoxic lungs compared 
to WT, suggesting that miR-143-3p transport in exosomes might contribute to the enhanc-
ing microvessel density and lung perfusion. Further experiments will be needed to address 
this effect in vivo.  
 
Moreover, miR-143-3p may act via multiple mechanisms in PASMCs and indeed PAECs 
following exosome-mediated transport and uptake, including cell migration and apoptosis 
(PASMC), cell death/survival and angiogenesis (PAEC). A recent study highlighted anoth-
er important cell to cell communication route tunnelling nanotubes (TNTs), which mediat-
ed the cell to cell communications between SMCs and ECs via miR-143/145 cluster. The 
mechanisms underlying these functional miR-143/145 meditated angiogenesis and prolif-
eration in PAECs are through targeting hexokinaseⅡ(hkⅡ) and integrin beta 8 (itgb8) 
(Climent et al., 2015). Another study showed the endothelial cells can secert and transfer 
functional exosomal miR-143/145 to SMCs to mediate an atheroprotective SMC pheno-
type via leading to an enhanced repression of miR-143/145 target genes and 
de-differentiation-associated gene expression (Hergenreider et al., 2012). Clearly, 
cell-to-cell communication of miR-143-3p is of fundamental importance in related patho-
logical settings including PAH diseases. The mechanisms involve this exosomal 
miR-143-3p mediated PASMCs and PAECs communications still unknown. This will re-
quire detailed further analysis but suggest a complex environment where miR-143-3p up-
regulation in hypoxia or inhibition (therapeutically) can modulate phenotypes in both 
PASMC and PAEC compartments. As we observed both cardiac and lung phenotypes with 
miR-143 loss, the generation of conditional knockouts will help define cell-specific con-
tributions to the underpinning role of miR-143 in this setting. 
 
In conclusion, we have demonstrated that miR-143-3p induced migration and inhibited 
apoptosis in PASMCs. This is also the first time that miRNAs have been shown to be in-
volved in cell-to-cell communication between PASMCs and PAECs in PAH. Mechanisti-
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cally, miR-143-3p -enriched exosomes derived from PASMCs induced PAEC migration 
and angiogenesis, which indicates that exosomal miR-143-3p may act as a crucial para-
crine signalling mediator during the remodelling of the pulmonary vasculature. The pro-
posed mechanism of miR-143/145 cluster in PAH (Figure 4.28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28 Proposed mechanism of miR-143/145 cluster in PAH 
Several signalling pathways related to the pathogenesis of PAH regulate miR-143/145 expression by activat-
ing the promoter region of the miR-143/145 cluster in PASMCs. MiR-143-3p can affect cellular migration 
and apoptosis and acts as a paracrine signalling mediator during vascular remodelling. During the develop-
ment of PAH, PASMCs secrete exosomes enriched with miR-143-3p, which are transported to PAEC, in-
ducing migration and angiogenesis. Adapted from (Deng et al., 2015). 
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5 The role of long non-coding RNA in PAH 
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5.1	Introduction	 	
Mutations in the bmpr2 gene have been found in more 70% of HPAH. In addition, up to 25% 
of patients with apparently sporadic IPAH have been demonstrated to harbour similar mu-
tations. BMPR2 is a member of the transforming growth factor-beta (TGF-β) receptor su-
perfamily (Atkinson et al., 2002, Aldred et al., 2006, Cogan et al., 2006, Thomson et al., 
2000). Consistent with the mutations of bmpr2, PAH patients without mutation of bmpr2 
and the experimental models of PAH showed decreased expression levels of BMPR2 (At-
kinson et al., 2002). BMPR2 is highly expressed in the endothelium of the pulmonary ar-
teries and expressed at lower levels in PASMCs and fibroblasts (Morrell, 2006). Further, 
BMPR2 signalling showed a critical role in preventing vascular remodelling through pro-
moting survival of pulmonary arterial endothelial cells (Atkinson et al., 2002). BMPR2 
signalling can inhibit proliferation, induce apoptosis (Hansmann et al., 2008, Zhang et al., 
2003, Morrell et al., 2001), promote motility (Spiekerkoetter et al., 2009), repress growth 
(Perez et al., 2011), and differentiation in PASMCs (Yu et al., 2008). In addition, BMPR2 
signalling exerts anti-inflammatory effects, with loss of BMPR2 activity that results in 
unopposed IL-6 production (Hagen et al., 2007). These observations suggest that the aber-
rant expression of BMPR2 is critical mediator to the pathogenesis of PAH. 
 
The penetrance of the bmpr2 mutation is low with an estimated lifetime risk of 20% and 
this develops into PAH disease (Loyd et al., 1995, Rich et al., 1987, Sztrymf et al., 2007, 
West et al., 2008a). Thus, indicating that the mutation of the bmpr2 receptor alone is insuf-
ficient to cause the disease onset and also suggesting that there could be other secondary 
genetic and /or environmental factors that may be required for the clinical manifestation of 
PAH (Liu and Morrell, 2013). In the context of multifactorial events, several factors can 
trigger inappropriate cellular responses in the background of genetic susceptibility. Trig-
gers for disease may include inflammation, hypoxia, shear stress and vascular injury 
(Humbert et al., 2004b).  
 
Previous studies demonstrated that BMP/TGF-β signalling pathways play an important 
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role in the pathobiology of PAH. Bone morphogenetic proteins (BMPs) activate the ca-
nonical Smad 1/5/9 pathway via BMPR2. TGF-β activates the Smad2/3 pathway via the 
ALK5 in a complex with the TGF-β typeⅡreceptor (TGF-βR-Ⅱ) (Upton and Morrell, 
2013). In the monocrotaline (MCT-PAH) rat model, the BMP signalling was reduced and 
the transforming growth factor-β1 signalling was enhanced (Steinle et al., 2002, Morty et 
al., 2007). BMP4 inhibited proliferation of PASMCs isolated from proximal pulmonary 
arteries via a SMAD-dependent pathway. However, BMP4 stimulated proliferation of 
PASMCs from peripheral arteries, conferred protection from apoptosis, which was de-
pendent on p38 and ERK signalling pathways (Yang et al., 2005). In vivo data demon-
strated that Smad3 signalling was significantly increased in the lungs of MCT-PAH and on 
the contrary it was decreased in chronic hypoxia induced pulmonary hypertension (Steinle 
et al., 2002). In addition, several studies have shown that the TGF-β signalling pathway 
inhibitor (such as IN-1233, SB525334, and SD208) attenuated the disease progression in 
MCT-PAH (Steinle et al., 2002, Zaiman et al., 2008, Thomas et al., 2009). In vitro, TGF-β 
inhibits the serum-induced proliferation of proximal PASMCs from healthy individuals, 
whereas PASMCs from idiopathic PAH patients showed enhanced proliferation to TGF-β 
stimulation (Morrell et al., 2001). The loss of repressive effects of TGF-β on PASMCs pro-
liferation was directly associated with reduced bmpr2 (Davies et al., 2012). In addition, 
TGF-β inhibited BMP4-mediated target genes transcription in both control and HPAH 
PASMCs with bmpr2 mutations (Upton et al., 2013). 
 
Growth factors, including platelet-derived growth factor (PDGF), vascular endothelial 
growth factor (VEGF), serotonin, and fibroblast growth factor 2 (FGF2) are important in-
hibitors of apoptosis in vascular cells and are also involved in the remodelling of vascula-
ture during PAH (Perros et al., 2008, Hassoun et al., 2009). PDGF and PDGF receptor 
mRNA (PDGFR) expression levels were increased in the small pulmonary arteries from 
patients with PAH. In addition, the protein levels of both PDGF/PDGFR were shown to be 
expressed in PASMCs and endothelial cell in pulmonary arteries of PAH patients. In vitro, 
PDGF induces the proliferation and migration of PASMCs, which can be specifically in-
hibited by imatinib (Perros et al., 2008). Several studies have demonstrated the therapeutic 
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role of PDGF inhibition by imatinib in PAH disease (Schermuly et al., 2005, Souza et al., 
2006, Patterson et al., 2006, Ghofrani et al., 2005). VEGF is an endothelial cell-specific 
mitogen and survival factor in the lung and affects functional properties including NO and 
prostacyclin synthesis (Voelkel et al., 2006). The platelet VEGF levels were elevated in 
patients with PAH (Eddahibi et al., 2000) as well as systemic sclerosis patients with sPAP 
≥35 mmHg (Papaioannou et al., 2009). As blockade of VEGF function will induce endo-
thelial cell dysfunction and death promote apoptosis-resistant endothelial cell proliferation. 
Overexpression of VEGF exerted a protective role against the hypoxic pulmonary hyper-
tension (Partovian et al., 2000) and ameliorated the pulmonary hypertension indexes in the 
rat model of idiopathic pulmonary fibrosis (IPF) (Farkas et al., 2009). On the contrary, 
blockade of VEGF results in severe pulmonary hypertension by inducing endothelial cell 
dysfunction (Sakao et al., 2009). VEGF receptor (VEGFR) inhibitor SU5416 impaired 
pulmonary vascular growth and postnatal alveolarisation and caused severe pulmonary 
hypertension in new-born rats (Phan, 2002). The protein levels of FGF2 in pulmonary ar-
tery endothelial cells (PAECs) were markedly increased in patients with IPAH compared 
with healthy controls and in situ hybridization further confirmed the FGF2 predominantly 
expressed in the remodelled vascular endothelium of lungs from patients with IPAH. In 
addition, FGF2-siRNA and FGFR1 inhibitor SU5402 treatment reversed the rat MCT-PAH 
model (Izikki et al., 2009). The conditioned medium of PAECs from IPAH significantly 
increased PASMCs proliferation compared with control PAEC conditioned medium. 
 
Several studies demonstrated that inflammatory cytokines and chemokines are key factors 
contributing to the pathogenesis of pulmonary hypertension (Stenmark et al., 2011, Sten-
mark et al., 2006a, Durmowicz et al., 1994). Both pulmonary vascular cells and inflamma-
tory cells are important local sources of cytokines and chemokines that can affect pulmo-
nary vascular remodelling in PAH (Touyz and Schiffrin, 2004, Prockop, 1997). Inflamma-
tory cytokines including TNF-α, interferon-γ, IL-1, 2, 4, 6, 8, and 10 were significantly el-
evated in the serum levels of patients with idiopathic and heritable PAH compared with 
control subjects. In addition, the elevated levels of IL-6 correlated with decreased survival 
in PAH patients (Stenmark et al., 2002, Gao et al., 2003, Touyz and Briones, 2011). Fur-
	 221	
thermore, several chemokine ligands including CXCL2 (Stenmark et al., 2002), CXCL5 
(Li et al., 2008), CXCL10 (Shi-Wen et al., 2004), CXCL13 (Gallucci et al., 2006), 
CXCL12, and CXCL16 (Meier et al., 1989) expression levels have also showed signifi-
cantly increased in plasma of PAH patients compared with healthy controls.   
 
Apart from inflammatory cytokines and chemokines, ncRNAs also have shown important 
roles in PAH. The role of miRNAs in PAH has been widely demonstrated in recent years 
(Boucherat et al., 2015, Bienertova-Vasku et al., 2015, Zhou et al., 2015, Meloche et al., 
2014a). Dysregulation of lncRNAs is associated with several human diseases, including 
cancers (Bartonicek et al., 2016, Lavorgna et al., 2016, Schmitt and Chang, 2016), cardio-
vascular diseases (Archer et al., 2015, Lorenzen and Thum, 2016), and respiratory diseases 
(Liu et al., 2015, Booton and Lindsay, 2014). In addition, accumulating early evidence 
suggests that lncRNAs may play an important role in vascular cell pathophysiology. Early 
studies identified ANRIL, a lncRNA to be expressed in VSMC, and shown to regulate 
CDKN2A/B expression in aortic VSMC and attenuate proliferation in atherosclerosis 
(Congrains et al., 2012b, Motterle et al., 2012, Congrains et al., 2012a) as well as modulate 
inflammatory responses in coronary artery disease (Zhou et al., 2016). Lnc-Ang362, har-
bouring the miR-221 and miR-222 genes, first identified to be regulated by angiotensin II 
in VSMC, and was in turn able to modulate VSMC proliferation, vascular remodelling and 
neointimal hyperplasia in concert with miR-221 and miR-222 (Moledina et al., 2011, 
Chistiakov et al., 2015, Liu et al., 2009). These studies showed that lncRNA were involved 
in the control of cell proliferation, and could be regulated alongside proximal miRNAs in 
VSMCs. RNA-seq analysis of human coronary artery SMC revealed a novel lncRNA, 
LncRNA SENCR is expressed in both VSMCs and ECs. In VSMC, knockdown of SENCR 
decreased the expression of myocardin and numerous smooth muscle contractile genes and 
increased a number of pro-migratory genes (namely MDK and PTN). Inhibition of these 
two genes reversed the increased VSMC migration mediated by SENCR silencing, which 
suggested that the expression of these genes was partially regulated by SENCR in these 
cells. However, the functions of SENCR in ECs were not reported in this study (Bell et al., 
2014). Our group further revealed that SENCR induced the proliferation, migration and 
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angiogenesis of HUVECs. In patient samples, SENCR expression was altered in vascular 
tissues and cells derived from patients with critical limb ischemia and premature coronary 
artery disease compared with healthy controls (Boulberdaa et al., 2016). These two studies 
revealed than SENCR could modulate the behaviour of both smooth muscle and ECs, and 
exhibited altered expression patterns in vascular tissues and cells from human vascular 
disease patients. However, the exact molecular targets and mechanisms of SENCR in 
pathological vascular remodelling remain to be determined.  
 
Similar to SENCR, LincRNA-p21 is expressed in both VSMC and vascular ECs. In human 
VSMC, lincRNA-p21 repressed cell proliferation and induce apoptosis in vitro. Lin-
cRNA-p21 also inhibited neointima formation in carotid arteries and repressed prolifera-
tion and induced apoptosis in carotid artery injury model in vivo. The authors further con-
firmed that lincRNA-p21 was decreased in patients with coronary heart disease (Wu et al., 
2014). In mouse vascular ECs, lincRNA-p21 induced cell apoptosis and cell cycle progres-
sion. In addition, lincRNA-p21 inhibited cell proliferation through binding miR-130b (He 
et al., 2015). Unlike many lncRNAs, LincRNA-p21 is a conserved lncRNA, which pro-
vided the possibility of using an in vivo animal model to study the role of this lncRNA 
(Tang et al., 2015). These data identified lincRNA-p21 is a key regulator of cell prolifera-
tion and apoptosis in vascular cells, which are primary contributors to vascular remodelling. 
Consistent with the human in vitro data, knockdown of lincRNA-p21 resulted in dramatic 
neointimal hyperplasia in a mouse model of carotid artery injury, which indicated that lin-
cRNA-p21 could serve as therapeutic target to treat vascular remodelling diseases (Wu et 
al., 2014).  
 
Using RNA-seq, we recently defined a novel smooth muscle specific lncRNA SMILR, 
which could be induced by IL-1α and PDGF in human saphenous vein smooth muscle cells 
(HSVSMCs). Knockdown of SMILR markedly reduced HSVSMC proliferation, likely 
through regulation of the HAS2 gene, located proximal to the genetic locus for SMILR. In 
human samples, SMILR expression increased in unstable atherosclerotic plaques and plas-
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ma from patients with high plasma C-reactive protein (Ballantyne et al., 2016b). These da-
ta suggested that inhibiting SMILR expression could be a potential target for treating vas-
cular diseases characterised by VSMC proliferation.  
 
In the context to ECs, studies have shown that the lncRNA MALAT1 could regulate retinal 
vessel remodelling by affecting retinal EC proliferation, migration and tube formation, as 
genetic ablation of MALAT1 inhibited the proliferation of ECs and reduced neonatal retina 
vascularization in vivo (Liu et al., 2014, Michalik et al., 2014). In human aortic ECs, 
knockdown of the lncRNA H19 reduced cell proliferation and activated p21/CDKN1A, 
increasing apoptosis, decreasing angiogenesis, and diminishing the number of cells in 
G0/G1 and S phases in cell cycle (Voellenkle et al., 2016). These two lncRNAs are highly 
expressed in ECs and were shown to be multifunctional both in vivo and in vitro. In this 
context, although numerous lncRNAs have been investigated in vascular cells, the role for 
lncRNAs in pulmonary vascular cells and PAH disease still unknown.  
 
In this study, we collaborated with Joseph Miano (University of Rochester) and Xiaochun 
Long (Albany Medical Center) to study novel vascular smooth muscle cell 
(VSMC)-specific lncRNAs in PAH. They used RNA-seq in Myocardin (MYOCD) over-
expressing human coronary artery SMCs (HCSMCs) to identify new lncRNAs. Here, we 
investigate two new lncRNAs they found based on the RNA-seq data, MYOcardin-induced 
Smooth Muscle Long noncoding RNA, Inducer of Differentiation (MYOSLID) and MYO-
cardin-lncRNA16 (Myolnc16).  											
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5.2	Aims	 	
l To functionally characterise two novel lncRNAs MYOSLID and Myolnc16 in the 
pulmonary vasculature  
l To understand the cellular functions of MYOSLID and Myolnc16  
l To find the potential signalling pathways of MYOSLID and Myolnc16 	
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5.3	Results	
5.3.1 LncRNA MYOSLID 
5.3.1.1	Identification	and	Genomic	Location	of	MYOSLID	 	
This work was done by Joseph Miano (University of Rochester) and Xiaochun Long. Hu-
man coronary artery SMCs (HCASMs) transduced with adenovirus carrying Myocardin 
(MYOCD), a potent SRF cofactor for the vascular SMC differentiation program. RNA-seq 
performed in these conditions to identify lncRNAs associated with vascular SMC differen-
tiation. A total of 265 lncRNAs were found to be expressed in HCASMs, among which, 54 
were annotated lncRNAs in the UCSC Genome Browser and the remaining were novel 
lncRNAs. In addition, 137 lncRNA were significantly regulated by MYOCD with 79 up-
regulated and 46 downregulated. QRT-PCR validated 13 selected lncRNAs and finally 
chooses MYOSLID and Myolnc16 for further study.  
 
MYOSLID is located in a lncRNA-rich genomic region of chromosome 2 where the closet 
protein coding genes are 70 kb (KLF7) and 200 kb (CREB1) away from its 5’ end and 3’ 
end, respectively (Figure 5.1). 
 
 
Figure 5.1 Genomic location of MYOSLID 
 
 
Location: chr2:207,239,811-207,245,887
MYOSLID
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5.3.1.2 MYOSLID is Upregulated by Multiple Triggers of PH in PASMC 
and PAH Patients 
To validate MYOSLID expression in the pulmonary system, we aimed to determine wheth-
er MYOSLID was regulate by any known triggers of PH and hence analysed its expression 
in hypoxic conditions. Previous studies demonstrated that chronic hypoxia alone can in-
duce pulmonary hypertension by promoting significant structural remodelling of pulmo-
nary arteries in humans (Arias-Stella and Saldana, 1963). We found that MYOSLID is sig-
nificantly unregulated upon exposure to hypoxia (1% O2) in PASMCs (P < 0.05) and 
PAECs (P < 0.01) (Figure 5.2). As bone morphogenetic protein (BMP) and transforming 
growth factor-β (TGF-β) signalling pathways are dysregulated in pulmonary arterial hy-
pertension (Morty et al., 2007, Ogo et al., 2013), we assessed MYOSLID expression in re-
sponse to BMP4 and TGF-β. PASMCs were treated with TGF-β (10 ng/ml) and BMP4 (10 
ng/ml) and their corresponding inhibitors for 24 h and found that MYOSLID expression is 
significantly induced both BMP4 (P < 0.01) and TGF-β (P < 0.05) (Figure 5.3 A and B). 
Conversely, treatment of TGF-β stimulated PASMC with the TGF-β type I receptor inhib-
itor, SB525334 (1 nM) reversed the effect of TGF-β stimulation (Figure 5.3 A) (P < 0.01), 
while treatment of BMP4-stimulated cells with an inhibitor of BMP signalling (K02288) 
abolished the BMP4-mediated increase in MYOSLID expression (P < 0.01) (Fig 5.2 B). 
Interestingly, we found that the TGF-β type I receptor inhibitor (SB525334) treatment also 
significantly inhibited the MYOSLID expression. This finding suggest that MYOSLID 
maybe the direct target of TGF-β signalling pathway. Apart from BMP and TGF-β treat-
ment, we further investigated the effect of PDGF, VEGF, and FGF2 treatment in pulmo-
nary vascular cells. In our results, we found that MYOSLID was significantly upregulated 
in PASMCs with PDGF treatment (P < 0.01) and in PAECs with FGF2 and VEGF stimu-
lation (Figure 5.4) (P < 0.01). In addition, we found that MYOSLID expression was in-
creased in distal PASMCs from PAH patients (IPAH and FPAH) compared to healthy 
controls (Figure 5.5 A). There were no significant changes of the MYOSLID expression 
level in bmpr2-mutant endothelial progenitor cells (EPCs) from patient with PAH com-
pared with controls (Figure 5.5 B) (P = 0.28). Taken together, these data demonstrated that 
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MYOSLID might be involved in several pathways related to the pathogenesis of PAH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Analysis of MYOSLID in the cells with hypoxia exposure 
PASMCs and PAECs seeded in 6-well plates were exposed to hypoxia with 1%O2 for 24 h. TaqMan 
qRT-PCR assessed the MYOSLID expression in these cell types. The results showed that MYOSLID expres-
sion significantly upregulated in the hypoxia condition in both PASMCs and PAECs. Data are expression as 
mean ± SEM and analysed by Student t-test. All experiments were repeated at least 3 independent times. n = 
3 per group in triplicate. *** P < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
rm
ox
ia
Hy
po
xia
0
1
2
3
R
el
at
iv
er
 e
xp
re
ss
io
n
***
PASMC
No
rm
ox
ic
Hy
po
xic
0.0
0.5
1.0
1.5
2.0
2.5
R
el
at
iv
er
 e
xp
re
ss
io
n
***
PAEC
	 228	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Analysis of MYOSLID expression in PASMCs with TGF-β and BMP4 stimulation  
PASMCs were seeded in 6-well plates and stimulated with TGF-β and BMP4. The inhibitors of TGF-β and 
BMP4 signalling were added to the cells 1 h before the stimulation. TaqMan qRT-PCR assessed the MYO-
SLID expression in these treated cells and controls. (A) TGF-β and (B) BMP4 stimulation significantly in-
duced MYOSLID expression and the expression was reversed by TGF-β type I receptor inhibitor (SB525334 
(1 nM)) and type I bone morphogenic protein (BMP) receptors (K02288 (10 nM). Data represented as fold 
change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. All experiments were 
repeated at least 3 independent times. n = 3 per group in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001.  
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Figure 5.4 Analysis of MYOSLID in PASMCs and PAECs with various stimulations 
PASMCs and PAECs were seeded into 6-well plates and then stimulated with PDGF (20 ng/ml), VEGF (50 
ng/ml) and FGF2 (25 ng/ml) for 24 h. Taqman qRT-PCR assessed the MYOSLID expression in these stimu-
lated cell types. (A) PDGF stimulation significantly induced the expression of MYOSLID in PASMCs. (B) 
and (C) MYOSLID expression significantly increased in PAECs with VEGF and FGF2 stimulations. Data are 
represented as mean ± SEM and analysed by Student t-test. All experiments were repeated at least 3 inde-
pendent times. n = 3 per group in triplicate. ** P < 0.01.  
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Figure 5.5 Analysis of MYOSLID in PAH patients 
Distal PASMCs and EPC cells were obtained from patients with PAH and healthy controls. (A) Taqman 
qRT-PCR analysed the MYOSLID expression in the distal PASMCs from patients with PAH (IPAH and 
FPAH), which showed significantly upregulated compared with healthy controls (n = 4 healthy control and n 
= 6 PAH patients). (B) Taqman qRT-PCR analysed the MYOSLID expression in EPC cells from bmpr2 mu-
tant patients and controls, which showed no significant changes (P = 0.28) (n = 2 control patients and n = 3 
bmpr2 mutant patients). Data is represented as mean ± SEM and analysed by Student t-test. *P < 0.05.  
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5.3.1.3	 Downregulation	MYOSLID	 Induces	 Apoptosis	 and	 Inhibits	 Cellular	
Migration	in	PASMCs	
Previous data showed that MYOSLID expressions were altered with various stimulations 
(Hypoxia, PDGF, BMP4 and TGF-β) and in distal PASMC obtained from PAH patients. 
We further sought to assess the impact of knockdown of MYOSLID on PASMCs functions 
including migration, proliferation and apoptosis to assess functional consequences. We 
first sought to evaluate the expression profile of MYOSLID during cell migration processes 
(by making a multiple scratches) in PASMCs. The MYOSLID expression was induced at 8 
h and was significantly upregulated at 24 h (Figure 5.6). Since we observed that MYOSLID 
expression was increased in the PASMC migrating cells, we performed wound-healing as-
say by knocking down MYOSLID (using siRNAs) and found that MYOSLID significantly 
reduced the cell migration in PASMCs (P < 0.01) (Figure 5.7 A). MYOSLID knockdown 
was confirmed by Taqman qRT-PCR, and the expression was significantly reduced com-
pared with control groups (Figure 5.7 B) (P < 0.001). In addition, Caspase3/7 assay 
showed that knockdown of MYOSLID significantly induced PASMC apoptosis with hy-
drogen peroxide (H2O2) treatment (Figure 5.8 A) (P < 0.01). However, assessment of 
PASMC proliferation using the EdU incorporation assay showed no significant change 
with MYOSLID knockdown (Figure 5.8 B). Taken together, knocking down MYOSLID af-
fected the cell migration and apoptosis but not proliferation in PASMCs.  	
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Figure 5.6 Analysis of MYOSLID in PASMCs during the cell migrations 
Multiple scratches were applied in PASMC monolayer and cells harvested at different time points after 
scratches. Taqman qRT-PCR analysed the MYOSLID expressions at different time points showed that MYO-
SLID was significantly induced during migration at 8 h and sustained the upregulation till 24 h. Data repre-
sented as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. n = 3 
per group in triplicate. **P < 0.01, and ***P < 0.01.  
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Figure 5.7 Analysis of the migration of PASMCs with MYOSLID knock down 
PASMCs were transfected with siMYOSLID and a single scratch was applied on monolayer PASMCs, and 
the pictures were captured and analysed the migrated distances at time point 0 h and 12 h. (A) Representative 
micrographs and quantification of a wound healing assay after MYOSLID knockdown in comparison with 
vehicle and siRNA control. MYOSLID knockdown significantly inhibited cell migration. (B) Taqman 
qRT-PCR confirmed the knocking down of MYOSLID in PASMCs by siMYOSLID transfection. Data repre-
sented as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. All 
experiments were repeated at least 3 independent times. n = 3 per group in triplicate. **P <0.01, and ***P < 
0.001. 
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Figure 5.8 Analysis of proliferation and apoptosis of PASMCs with MYOSLID knock down 
PASMCs were transfected with siMYOSLID. (A) Caspase 3/7 activity assay was assessed in PASMCs in-
duced by H2O2. Knocking down MYOSLID significantly induced cell apoptosis compared with controls. (B) 
Edu incorporation assay was performed in transfected cells and controls. There was no change in cell prolif-
eration with MYOSLID knocking down. Data represented as fold change ± SEM and analysed by one-way 
ANOVA followed by Tukey’s post hoc test. Experiments were done by once. n = 8 wells per group. **P < 
0.01. 
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5.3.1.4	MYOSLID	Knockdown	Decreased	the	Proliferation	of	PAEC	 	
We have demonstrated that MYOSLID knockdown affected the cell function of PASMCs. 
Here we further assessed the functions of PAECs with MYOSLID knockdown. Wound 
healing assay showed that knocking down MYOSLID had no effect on cell migration (Fig-
ure 5.9). The cell proliferation of PAECs was induced by VEGF stimulation and analysed 
by BrdU incorporation and PCNA protein level. These results showed that MYOSLID 
knockdown significantly decreased the cell proliferation in PAECs (P < 0.05, and P < 
0.001) (Figure 5.10). Taken together, this data revealed that MYOSLID affected the prolif-
eration and had no affect on the migration of PAECs.  																												
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Figure 5.9 Analysis of cell migration of PAECs upon MYOSLID knockdown  
PAECs were transfected with siMYOSLID. Then single scratch was made on monolayer PAECs, and the pic-
tures were captured and the migratory distances were analysed at time point 0 h and 12 h. (A) Representative 
micrographs and quantification of a wound healing assay after MYOSLID knockdown in comparison with 
vehicle and siRNA control. MYOSLID knockdown had no effect on cell migration. (B) MYOSLID expression 
was analysed by Taqman qRT-PCR, which showed that MYOSLID significantly decreased in siMYOSLID 
transfected group compared with control groups. Data represented as fold change ± SEM and analysed by a 
one-way ANOVA followed by Tukey’s post hoc test. All experiments were repeated at least 3 independent 
times. n = 3 per group in triplicate. **P < 0.01 
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Figure 5.10 Analysis of proliferation in PAECs with MYOSLID knocking down  
PAECs were transfected with siMYOSLID. (A) transfected and control cells were stimulated with VEGF and 
0.2% FBS for 48 h. Proliferation assay by BrdU incorporation showed that MYOSLID knocking down sig-
nificantly reduced cell proliferation in both 0.2% FBS and VEGF stimulation conditions (n = 5). (B) Western 
blot of PCNA showed that knocking down of MYOSLID decreased the PCNA expression in PAECs. 
β-Tubulin was used as internal control (n = 3). Data represented as fold change ± SEM and analysed by a 
one-way ANOVA followed by Tukey’s post hoc test.  ***P < 0.001 and §§§P < 0.001. 		
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5.3.1.5	MYOSLID	 Knockdown	Modulates	 the	 Expression	 of	 BMP	 Pathway	
Components	in	PASMC	 	
In our previous results, we had showed that MYOSLID expression is significantly induced 
by BMP4 stimulation (Figure 5.3 B). As BMP signalling plays a prominent role in PAH 
pathogenesis, we went on to assess the effect of MYOSLID modulation on the expression 
of BMP signalling pathway components and target genes. SiRNA-mediated knockdown of 
MYOSLID significantly induced the expression of BMP signalling pathway receptor 
BMPR1α and BMPR2, as well as the BMP4 target genes ID1 and ID3 (Figure 5.11) (P < 
0.05). The MYOSLID expression was significantly decreased with SiRNA transfection (P 
< 0.001) (Figure 5.11). In addition, we performed MYOSLID overexpression in PASMCs 
by lentivirus transduction and analysed the receptors and target genes expression. We 
found that overexpression of MYOSLID did not affect the bmpr1α, bmpr2, id1, and id3 ex-
pression, although the MYOSLID expression was significantly elevated with lentivi-
rus-MYOSLID transduction (Figure 5.12) (P < 0.001). It has been demonstrated that muta-
tions in the bmpr2 gene have been found in approximately 70% of familial PAH (FPAH) 
(Machado et al., 2006), and up to 25% of sporadic IPAH patients also have been found to 
harbour similar mutations (Thomson et al., 2000). We further analysed the protein level of 
BMPR2 with MYOSLID knockdown and overexpression in PASMCs and PAECs.  In the 
PASMCs, we found knocking down MYOSLID increased the BMPR2 protein level (Figure 
5.13 A), and overexpression of MYOSLID reduced the BMPR2 protein level (Figure 5.13 
B). However, we did not find any change in PAECs with MYOSLID knocking down (Fig-
ure 5.12 C). Furthermore, in the non-canonical BMP pathway, we found that ERK1/2 pro-
tein levels were decreased in both control and BMP4 stimulated cell (30 min and 1 h) with 
MYOSLID knockdown (Figure 5.14 A). In the canonical BMP pathway, the p-SMAD1/5/9 
protein level was decreased at 30 min with BMP4 stimulation in PASMCs but slightly in-
creased at 1 h in the MYOSLID knockdown condition (Figure 5.14 B).  				
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Figure 5.11 Analysis of BMP pathway components with MYOSLID knockdown 
PASMCs were transfected with siMYOSLID and control siRNAs for 48 h. Taqman qRT-PCR analysed the 
gene expressions of receptors and target of BMP signalling. MYOSLID expression was significantly reduced 
with siMYOSLID transfection. bmpr1α, bmpr2, id1, and id3 expression were significantly increased with 
MYOSLID knockdown. Data represented as fold change ± SEM and analysed by a one-way ANOVA fol-
lowed by Tukey’s post hoc test. All experiments were repeated with at least n = 3 independent replicates. n = 
3 per group in triplicate. *P < 0.05, and ***P < 0.001. 
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Figure 5.12 Analysis of BMP pathway components with MYOSLID overexpression 
PASMCs were infected with lentivirus of MYOSLID and control lentivirus for 48 h. Taqman qRT-PCR ana-
lysed the gene expressions of receptors and target of BMP signalling. MYOSLID expression was significantly 
increased with lentivirus infection at different multiplicity of infection (MOI). bmpr1α, bmpr2, id1, and id3 
expression have no change with MYOSLID overexpression. Data represented as fold change ± SEM and ana-
lysed by a one-way ANOVA followed by Tukey’s post hoc test. All experiments were repeated at least n = 3 
independent times. n = 3 per group in triplicate. ***P < 0.001. 
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Figure 5.13 Analysis of BMPR2 protein level with MYOSLID knockdown and overexpression 
PASMCs were transfected with siMYOSLID and infected with lentivirus of MYOSLID and controls for 48 h. 
Western blot was performed and BMPR2 protein levels were analysed. (A) BMPR2 protein level was in-
creased in PASMCs with MYOSLID knockdown compared with controls. (B) BMPR2 protein level was de-
creased in PASMCs with MYOSLID overexpression compared with controls. (C) Change in BMPR2 protein 
level in PAEC with MYOSLID knockdown. All experiments were repeated at least n = 3 independent times. n 
= 2/3 wells per group.						
VehiclesiControlsiMYOSLID
BMPR2 (130kDa)
β-Tubulin (55kDa)
VehicleLenti-vectorLenti-MYOSLID
BMPR2 (130kDa)
GAPDH (37kDa)
BMPR2 (130kDa)
GAPDH (37kDa)
Vehicle siControl siMYOSLID
A
B
C
	 242	
		
						
Figure 5.14 Effect of MYOSLID knockdown on the canonical and non-canonical BMP pathway  
PASMCs were transfected with siMYOSLID and then stimulated with BMP4 (10 ng/ml) for 30 min and 1 h 
time points and western blots were performed (A) p-ERK1/2 protein levels were analysed for non-canonical 
BMP pathway, which showed significant decrease in p-ERK1/2 levels upon MYOSLID knockdown. (B) 
p-SMAD1/5/9 protein levels were accessed to check the activation of the canonical BMP pathway, which 
was blocked upon MYOSLID knockdown at 30 min and was slightly enhanced at 1 h with BMP4 stimulation. 
All experiments were performed in twice. n = 1 well per condition.  
 					
A 
B 
Erk1/2
(42, 44 kDa)
pERK1/2 (42,
44 kDa)
Co
nt
ro
l 
- BMP4 (1 h)
Si
RN
A
 C
trl
M
yo
sli
d 
Si
RN
A
 
Co
nt
ro
l 
+ BMP4 (1 h)
Si
RN
A
 C
trl
M
yo
sli
d 
Si
RN
A
 
Co
nt
ro
l 
- BMP4 (30 min)
Si
RN
A
 C
trl
M
yo
sli
d 
Si
RN
A
 
Co
nt
ro
l 
+ BMP4 (30 min)
Si
RN
A
 C
trl
M
yo
sli
d 
Si
RN
A
 
Co
nt
ro
l 
- BMP4 (1 h)
Si
RN
A
 C
trl
M
yo
sli
d 
Si
RN
A
 
Co
nt
ro
l 
+ BMP4 (1 h)
Si
RN
A
 C
trl
M
yo
sli
d 
Si
RN
A
 
Co
nt
ro
l 
- BMP4 (30 min)
Si
RN
A
 C
trl
M
yo
sli
d 
Si
RN
A
 
Co
nt
ro
l 
+ BMP4 (30 min)
Si
RN
A
 C
trl
M
yo
sli
d 
Si
RN
A
 
pSMAD 159
(60 kDa)
SMAD 1
(60 kDa)
	 243	
5.3.2 LncRNA Myolnc16   
5.3.2.1	Genomic	Location	of	Myolnc16	
Myolnc16 is identified through RNA-seq same as MYOSLID discussed above. Myolnc16 is 
located in the chromosome 4 where several chemokine protein-coding genes are locating 
from its 3’ end. These chemokine genes include CXCL1, CXCL2, CXCL3, CXCL4, 
CXCL5, CXCL6, CXCL7, and CXCL8 (Figure 5.15).  							
	
Figure 5.15 Genomic location of Myolnc16 										
Location: chr4:74,566,683-74,590,931
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5.3.2.2	Inflammatory	Cytokines	Induced	Myolnc16	Expression	in	PASMC	
Based on the information from the genomic location of Myolnc16. We found several cyto-
kines located downstream of this lncRNA. Previous studies demonstrated that inflamma-
tory cytokines are triggers of PH, including IL-1, IL-6 and TNF-α (Humbert et al., 1995, 
Soon et al., 2010). In order to assess the Myolnc16 expression in response to inflammatory 
cytokines, we treated PASMCs with IL-1, IL-6 and TNF-α at two different concentrations 
(10 ng/ml and 20 ng/ml). The results showed that IL-1 and TNF-α significantly induced 
Myolnc16 dose-dependently in PASMCs (Figure 5.16 A) (P < 0.001). However, there was 
no change with IL-6 stimulation (Figure 5.16 A). In addition, we analysed the expression 
of Myolnc16 during early time points and found that Myolnc16 to be induced at 1 h and 
was significantly upregulated at 6 h with IL-1 and TNF-α stimulation in PASMCs (Figure 
5.16 B) (P < 0.05, and P < 0.01).  
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Figure 5.16 Analysis of Myolnc16 expression with inflammatory cytokines stimulation 
PASMCs were stimulated with IL-1, IL-6 and TNF-α. (A) Taqman qTR-PCR analysed the Myolnc16 expres-
sion with IL-1 (10 ng/ml, and 20 ng/ml), IL-6 (10 ng/ml, and 20 ng/ml) and TNF-α (10 ng/ml, and 20 ng/ml) 
for 24 h. IL-1 and TNF-α stimulation significantly increased the Myolnc16 expression in PASMCs. (B) and 
(C) Taqman qTR-PCR analysed the Myolnc16 expression with IL-1 (10 ng/ml) and TNF-α (10 ng/ml) at 1 h 
and 6 h. Myo1nc16 was significantly upregulated at 6 h with IL-1 and TNF-α stimulation. Data are expres-
sion as mean ± SEM and analysed by Student t-test. All experiments were repeated twice. n = 3 per group in 
triplicate. * P < 0.05, ** P < 0.01, and *** P < 0.001.  
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5.3.2.3	Myolnc16	Knockdown	Induced	IL-1	and	TNF-α	Expression	and	Inhib-
ited	IL-6	Expression	
As we observed that Myolnc16 was upregulated to IL-1 and TNF-α stimulation. We further 
aimed to functionally characterise the role of Myolnc16 and its effect on inflammatory cy-
tokines in PASMCs. Hence, we performed Myolnc16 knockdowns in PASMCs with siR-
NAs and then stimulated with or without TNF-α (10 ng/ml) for 24 h. Taqman qRT-PCR 
showed Myolnc16 expression was significantly decreased with siRNA transfection in with 
or without TNF-α stimulation (P < 0.001) (Figure 5.17 A). Consistent with previous data, 
TNF-α significantly induced Myolnc16 expression (Figure 5.17 A). In addition, TNF-α 
significantly induced IL-6 expression in PASMCs and Myolnc16 knockdown significantly 
decreased the elevation of IL-6 mRNA expression level (Figure 5.17 B) (P < 0.05). But in 
the unstimulated condition, there was no change of IL-6 expression with Myolnc16 
knockdown (Figure 5.17 B). Furthermore, knockdown of Myolnc16 significantly induced 
IL-1 and TNF-α expression in both unstimulated and with TNF-α stimulation condition 
(Figure 5. 18) (P < 0.01, and P < 0.001). 																				
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Figure 5.17 Analysis of IL-6 expression with Myolnc16 knockdown with or without TNF-α stimulation 
PASMCs were transfected with siMyolnc16 and then stimulated with or without TNF-α for 24 h. (A) Taqman 
qRT-PCR was performed to analyse the knockdown of Myolnc16 in PASMCs with or without TNF-α stimu-
lation. Myolnc16 expression was significantly reduced with siMyolnc16 transfection. (B) Taqman qRT-PCR 
analysed the expression of IL-6 in PASMCs with Myolnc16 knockdown with or without TNF-α stimulation. 
IL-6 expression was significantly decreased in the TNF-α stimulated condition. Data are represented as fold 
change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. All experiments were 
done by once. n = 3 per group in triplicate. *P < 0.05, ***P < 0.001, and §§§P < 0.001. 		
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Figure 5.18 Analysis of IL-1 and TNF-α expression in PASMCs with Myolnc16 knockdown 
PASMCs were transfected with siMyolnc16 and then stimulated with or without TNF-α for 24 h. Taqman 
qRT-PCR analysed the expression of (A) IL-1 and (B) TNF-α in PASMCs with Myolnc16 knockdown with or 
without TNF-α stimulation. IL-1 and TNF-α expressions were significantly increased with Myolnc16 knock-
down in both with and without TNF-α stimulation condition compared with controls. Data are represented as 
fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. All experiments 
were done by once. n = 3 per group in triplicate. **P < 0.01, ***P < 0.001, and §§§P < 0.001. 	
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5.3.2.4	Myolnc16	Knockdown	Decreased	the	Chemokine	1,6	8	Expression	
Based on the genomic location of Myolnc16, there are several chemokine genes located 
near to the Myolnc16. In order to investigate the effect of Myolnc16 knockdown on the ex-
pression of chemokine genes, we stimulated PASMCs with or without TNF-α for 24 h. In 
the unstimulated condition, Myolnc16 knockdown had no effect on CXCL1, CXCL6, and 
CXCL8 expression. However, we found Myolnc16 knockdown significantly reduced 
CXCL1, CXCL6, and CXCL8 expression with TNF-α stimulation (Figure 5.19) (P < 0.05, 
P < 0.01, and P < 0.001).  																															
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Figure 5.19 Analysis of chemokine gene expression in PASMCs with Myolnc16 knockdown 
PASMCs were transfected with siMyolnc16 and then stimulated with or without TNF-α for 24 h. Taqman 
qRT-PCR analysed the expression of CXCL1, CXCL6, and CXCL8 in PASMCs with Myolnc16 knockdown 
with or without TNF-α stimulation. CXCL1, CXCL6, and CXCL8 expressions were significantly decreased 
with siMyolnc16 with TNF-α stimulation condition compared with controls. Data are represented as fold 
change ± SEM and analysed by a one-way ANOVA followed by Tukey’s post hoc test. All experiments were 
done by once. n = 3 per group in triplicate. *P < 0.05, **P < 0.01, and ***P < 0.001.  		
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5.3.2.5	Myolnc16	Knockdown	Decreased	the	MAPK/ERK	Pathway	
Previous study demonstrated that inhibition of mitogen-activated protein kinase attenuates 
monocrotaline-induced pulmonary hypertension in rats (Lu et al., 2004). Activation of mi-
togen-activated protein kinase pathways including p38, ERK1/2, and JNK can be induced 
by TNF-α (Bian et al., 2001). Here we investigated the effect of Myolnc16 knockdown on 
ERK1/2 and p38 activation. Our results showed that the pERK1/2, and pp38 protein levels 
were decreased upon Myolnc16 inhibition in both control and TNF-α stimulated condition 
(Figure 5.20). However, this experiments need to repeat to confirm the knockdown of My-
olnc16 affecting the protein levels of p-ERK1/2, and p-p38.  
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Figure 5.20 Effect of Myolnc16 knockdown on ERK1/2 and p38 activation in PASMCs 
PASMCs were transfected with siMyolnc16 and then stimulated with TNF-α for 5 min and 15 min. Western 
blot analysed the protein level of ERK1/2 and p38. Myolnc16 knockdown decreased the protein levels of 
ERK1/2 and p38 in control and TNF-α stimulation condition compared with vehicle and siRNA control 
groups. All experiments were performed once. n = 1 well per condition.  
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5.3.2.6	Myolnc16	Knockdown	Decreased	the	Migration	and	Proliferation	in	
PASMCs	
In order to investigate the effect of Myolnc16 knockdown on the cellular function of 
PASMCs, we analysed the migration and proliferation of PASMCs with Myolnc16 knock-
down. Wound healing assay demonstrated that Myolnc16 knockdown significantly inhibit-
ed the cell migration (Figure 5.21 A) (P < 0.01). Taqman qRT-PCR confirmed the knock-
down of Myolnc16 (Figure 5.21 B) (P < 0.001). In addition, employing EdU incorporation 
assay clearly showed that Myolnc16 knockdown significantly decreased the cell prolifera-
tion (Figure 5.21 C).  
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Figure 5.21 Effect of Myolnc16 knockdown on PASMC cell functions 
PASMCs were transfected with siMyolnc16. A single scratch was applied on monolayer PAECs, and the mi-
croscopic pictures were captured and the migrated distances at time point 0 and 12 h were analysed. (A) 
Representative micrographs and quantification of a wound healing assay after Myolnc16 knockdown in 
comparison with vehicle and siRNA control. Myolnc16 knockdown significantly inhibited cell migration. (B) 
Taqman qRT-PCR analysed the expression of Myolnc16, which showed that Myolnc16 significantly de-
creased in siMyolnc16-transfected group compared to control groups. (C) EdU incorporation assay assessed 
the proliferation of PASMCs with Myolnc16 knockdown, which revealed that Myolnc16 knockdown signifi-
cantly inhibited the cell proliferation. Data are represented as fold change ± SEM and analysed by a one-way 
ANOVA followed by Tukey’s post hoc test. n = 3 per group in triplicate. **P < 0.01, and ***P < 0.001. 
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5.4	Discussion	 	
Mammalian genomes encode numerous long non-coding RNAs (LncRNAs), which are 
defined as non-protein-coding transcripts over 200nt in length. LncRNAs have been shown 
to perform important functions within the cell, including chromatin modification, RNA 
processing and structural scaffolding, which affects cell behaviours on cell and tissue pro-
cesses such as proliferation, migration, apoptosis, invasion, etc. Despite the biological im-
portance of lncRNAs, it is not yet clear whether lncRNAs are involved in the regulation of 
PAH. In this study, we report that several growth factors that trigger PAH/PH induce MY-
OSLID expression. These are hypoxia, PDGF, VEGF, FGF2, BMP4, and TGF-β treatment 
in pulmonary vascular cells (PASMCs and PAECs) in vitro. In addition, MYOSLID ex-
pression is significantly increased in distal PASMCs from patients with PAH disease 
(IPAH, FPAH and bmpr2 mutant PAH patients) and compared to healthy controls. To-
wards functional studies, MYOSLID knockdown in PASMCs induced cell apoptosis and 
inhibited cell migration but had no effect on cell proliferation. In PAECs, MYOSLID 
knockdown prevented the cell proliferation without any effect on cell migration. Further-
more, MYOSLID knockdown modulated the expression of BMP pathway components and 
affected the BMP-Smad and BMP-non-Smad signalling pathways in PASMCs. Myolnc16, 
which is an inflammatory lncRNA, was induced by inflammatory cytokines (IL-1 and 
TNF-α) treatment in PASMCs. Knockdown Myolnc16 in PASMCs affected the expression 
levels of inflammatory cytokines (IL-1, IL-6 and TNF-α) and decreased the expression of 
chemokines (cxcl1, cxcl6 and cxcl8). In addition, Myolnc16 knockdown decreased the 
MAP kinase signalling pathway and inhibited cell migration and proliferation in PASMCs.  
 
Hypoxia is an important factor in the pathogenesis of pulmonary hypertension and pulmo-
nary vascular remodelling (Aaronson et al., 2006). Chronic hypoxia is a well-known stim-
ulus for abnormal proliferation and migration of vascular smooth muscle cells and remod-
elling in patients with PAH (Zhou et al., 2009, Eul et al., 2006, Sarkar et al., 2010). How-
ever, few studies have been done on hypoxia of PAECs. In the bovine PAECs, hypoxia 
exposure showed a decrease in PAEC proliferation after 5 days of exposure to 0% oxygen 
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and a decrease in DNA synthesis after exposure to 0% for 24 and 48 h. Another study us-
ing human pulmonary microvascular endothelial cells revealed that 1% oxygen exposure 
significantly induced cell proliferation during 5 days incubation. In our study, MYOSLID 
significantly increased in both PASMCs and PAECs with 1% oxygen exposure for 24 h. 
This data indicated that MYOSLID might be hypoxia-sensitive lncRNA in vascular cells 
and could be involved in the hypoxia induced cellular changes in the pulmonary vascula-
ture and thus might affect the vascular remodelling and development of PAH. Although 
there are no reports on hypoxia induced lncRNAs (hypoxic-lncRNAs) in the pulmonary 
vascular cells, there are several novel hypoxia-sensitive lncRNAs found in endothelial 
cells and play a significant role in the hypoxic response of endothelial cells. The first 
lncRNA to be described in endothelial cell was an overlapping antisense transcript (sONE, 
known as eNOS antisense) to eNOS/NOS3 that was implicated in the post-transcriptional 
regulation of eNOS. In hypoxic ECs, sONE expression negatively correlated with eNOS 
expression and RNA interference-mediated degradation of the sONE transcript blunted the 
fall in eNOS RNA and protein during prolonged hypoxia (Fish et al., 2007). RNA-seq 
analysis of HUVECs revealed high expression levels and conserved lincRNA MALAT1 
induced by hypoxia. Knockdown of MALAT1 in ECs results in a pro-migratory phenotype 
in vitro and reduced capillary density and blood flow in a hindlimb ischemia model in vivo 
(Michalik et al., 2014). Another study used both microarray and RNA-seq approaches to 
analyse the hypoxia-sensitive lncRNAs in HUVEC exposure to hypoxia. Two novel hy-
poxia-sensitive lncRNAs (LINC00323-003 and MIR503HG) were identified and further 
characterised by applying loss-and gain of function assessments revealing an important 
role for both these lncRNAs in endothelial biology (Fiedler et al., 2015). Recently, 
paired-end sequencing of polyadenylated RNA derived from HUVECs exposed to 1% O2 
or normoxia was performed and identified 122 lncRNAs that differentially expressed. 
They further validated several lncRNAs including H19, MIR210HG, MEG0, MALAT1 
and MIR22HG and found them to be induced in a mouse model of hindlimb ischemia and 
they further investigated the effect H19 knockdown on endothelial cell growth and angio-
genesis (Voellenkle et al., 2016). In contrast to ECs, there are no reports suggesting hy-
poxia regulated lncRNAs in the VSMCs. However, there are a number studies on hypoxia 
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regulated lncRNAs identified in cancer diseases (Chang et al., 2016). Taken together, our 
findings show that MYOSLID is hypoxia responsive lncRNA in pulmonary vascular cells. 
These findings suggest that lncRNAs are important regulators of hypoxia signalling path-
way in various disease conditions. Our work on MYOSLID is ongoing and we are currently 
investigating the cellular functions of this lncRNA during hypoxia conditions to explore its 
functional relevance and mechanisms that underlie the hypoxic processes.  
 
It is well accepted that in PASMCs during vascular remodelling, there is excessive prolif-
eration, migration and resistance to apoptosis. Besides, PASMCs, PAECs in the intima are 
also involved in the vascular remodelling and in the development of PAH. There is an in-
crease in PAECs proliferation in plexiform lesion, a complex pathological vascular struc-
ture seen in the late stage of PAH (Jeffery and Wanstall, 2001). In addition, several studies 
have demonstrated the PAECs dysfunctions involved in the pathogenesis of PAH (Hum-
bert et al., 2004b, Archer et al., 2010, Cordes et al., 2009). Our data shows that knockdown 
of MYOSLID can inhibit PASMC migration and induce PASMC apoptosis but have no ef-
fect on PASMC proliferation. In addition, MYOSLID knockdown inhibited PAEC prolifer-
ation but had no effect on cell migration. Regarding to another lncRNA Myolnc16, we 
found knockdown of Myolnc16 significantly reduced cell migration and proliferation in 
PASMCs. Taken together, these data demonstrated that manipulation of MYOSLID and 
Myolnc16 affected the cell behaviours of pulmonary vascular cells including proliferation, 
migration, and apoptosis, which are key contributors to the vascular remodelling in the 
development. This suggests that MYOSLID and Myolnc16 may play a vital role in the vas-
cular remodelling processes in PAH. 
 
The BMP signalling involves binding to its BMP Type 1 and Type 2 serine/threonine ki-
nase receptors and the subsequent activation of Smad-dependent (Smad1/5/9) and 
Smad-independent (ERK1/2 and p38 MAPK) pathways, resulting in the regulation of 
plethora of genes to cell functions (Derynck and Zhang, 2003, Yang et al., 2005, Yang et 
al., 2007). The Smad pathway is the canonical pathway that mediates the anti-proliferative 
or pro-apoptotic effects of various BMP ligands. In the PAH setting, BMP4 was demon-
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strated as an important factor mediating the process of pulmonary arterial remodelling in-
cluding the regulation of cell proliferation, migration, intracellular calcium homeostasis 
(Eickelberg and Morty, 2007, Frank et al., 2005, Long et al., 2006). Germline mutations in 
the bone morphogenetic protein type II receptor (bmpr2) gene, a transforming growth fac-
tor-β (TGF-β) receptor superfamily member, cause in majority of cases heritable pulmo-
nary arterial hypertension (HPAH) (Beppu et al., 2004, International et al., 2000, Machado 
et al., 2006). bmpr2 mutations in PASMCs reduce downstream Smad1/5 phosphorylation. 
And loss of bmpr2 function or knockdown of id1, a key target gene in response to BMP 
signalling, both lead to loss of the growth suppressive effects of BMPs (Yang et al., 2008, 
Miyazono et al., 2005, Yang et al., 2005). Hence bmpr2 mutation leads to a proprolifera-
tive, apoptosis-resistant cell phenotype in PASMCs that may contribute to the process of 
vascular remodelling observed in the lung of patients with PAH (Morrell et al., 2001). In 
our study, we found that both BMP4 and TGF-β stimulation can significantly induce MY-
OSLID expression in PASMCs, and these effects could be rescued with respective specific 
inhibitors. This data indicates that MYOSLID is involved in the TGF-β and BMP4 signal-
ling. We further found MYOSLID knockdown significantly increased both the mRNA and 
protein levels of BMPR2 in PASMCs. In addition, BMPR1α and target genes of BMP sig-
nalling id1 and id3 were significantly increased with MYOSLID knockdown in PASMCs. 
However, when we overexpress MYOSLID using lentivirus transduction in PASMCs, we 
found the overexpression of MYOSLID did not affect the mRNA expression levels of 
bmpr2, bmpr1α and BMP pathway target genes id1 and id3. However, the BMPR2 protein 
level was decreased. This data indicate that MYOSLID knockdown restored the BMPR2 
levels and increased the BMP signalling in PASMCs, which is beneficial to the treatment 
of PAH disease. Here, we did not found any difference of gene expression in the MYO-
SLID overexpression conditions. The possible reasons may include: the endogenous level 
of MYOSLID is already high, and the additional overexpression cannot affect the MYO-
SLID mediated pathways; we performed this experiment on the non-stimulation condition, 
and the effect of knockdown MYOSLID may not affect the BMP signalling without BMP4 
stimulation; we found the BMPR2 protein level was decreased with MYOSLID overexpres-
sion but not mRNA level, and may due to the post-transcriptional regulation of MYOSLID. 
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Furthermore, we found that MYOSLID knockdown at 30 min decreased Smad1/5/9 phos-
phorylation upon BMP4 stimulation but increased phosphorylation of Smad1/5/9 at 1 h 
stimulation with BMP4 in PASMCs. To understand the BMP signalling dynamics upon 
knockdown and overexpression (via lentiviral transductions) of MYOSLID, our ongoing 
studies are focusing towards optimizing the time-course experiments and possibly this will 
shed light on the MYOSLID mediated regulation of BMP signalling.  
 
Apart from activation of canonical Smad-dependent signalling pathway, there is accumu-
lating evidence that MAPKs, mainly ERK1/2 and p38 MAPK, are also activated by BMP4 
in several cell types (including human PASMCs) through Smad-independent pathways 
(Nohe et al., 2004, Zhou et al., 2007, Moon et al., 2009, Jeffery et al., 2005, Yang et al., 
2005, Morty et al., 2007, Yu et al., 2008). The BMP signalling can stimulate MAPK path-
ways has been demonstrated and is functionally linked to the proliferative responses and to 
the regulation of numerous gene expressions involved in cell growth and differentiation. In 
PASMCs, the p38 MAPK and ERK1/2 is pro-proliferative and anti-apoptotic whereas 
Smad signalling is anti-proliferative. (Jeffery et al., 2005, Dewachter et al., 2009, Lee et al., 
2012b, Yang et al., 2005, Frank et al., 2005). Previous studies demonstrated that phos-
phorylation of p38 MAPK and ERK1/2 is increased in PASMCs from PAH patients and 
experimental models of pulmonary hypertension (Welsh et al., 2001, Zeng et al., 2010, 
Long et al., 2006, West et al., 2008b). Inhibition of MAPK signalling decreases the exces-
sive proliferation of PAH-PASMCs and prevents the development of the disease in model 
systems, suggesting that Smad-independent pathways play a key role in disease pathogen-
esis (Weerackody et al., 2009, Dewachter et al., 2009). Our study showed that MYOSLID 
knockdown decreased the phosphorylation of ERK1/2 in PASMCs upon BMP4 treatment 
at both 30 min and 60 min time-point, which suggest that knockdown of MYOSLID affects 
the Smad-independent pathway in PASMCs. The decreased phosphorylation of ERK1/2 
with MYOSLID knockdown can be explained by induced apoptosis with MYOSLID 
knockdown in PASMCs, as p38 MAPK and ERK1/2 exert anti-apoptotic effect in 
PASMCs. Apart from BMP mediated Smad-independent pathways, our current ongoing 
studies are also focusing towards understanding the role of MYOSLID during 
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TGF-β-Smad-independent pathways as we found that MYOSLID expression was signifi-
cantly induced with TGF-β treatment in PASMCs.  
 
We found that MYOSLID expression was significantly elevated in the PASMCs from pa-
tients with PAH (IPAH and FPAH) compared with controls. In addition, several studies 
have showed that endothelial progenitor cells were beneficial to treatment of pulmonary 
hypertension (Fadini et al., 2010, Takahashi et al., 2004, Zhao et al., 2005, Zeng et al., 
2007, Wang et al., 2007, Ward et al., 2007, Yip et al., 2008, Sun et al., 2009). And we 
found that MYOSLID expression increased in the circulating endothelial progenitor cells 
(ECPs) from PAH patients with bmpr2 mutant compared to controls. The upregulation of 
MYOSLID in these two cell types from patients with PAH suggested that MYOSLID 
dysregulation might contribute to the pathogenesis of PAH. 
 
Cytokines and chemokines emerged as important contributing factors that can lead to pul-
monary vascular remodelling and participate into the pathogenesis of PAH (Huertas et al., 
2014, Ricard et al., 2014, Groth et al., 2014). In this study, we found the novel lncRNA 
Myolnc16 was significantly induced by IL-1 and TNF-α stimulation in PASMCs, which 
suggests that Myolnc16 is an inflammatory lncRNA. Knockdown of Myolnc16 signifi-
cantly decreased the TNF-α induced IL-6 mRNA expression in PASMCs. Previous studies 
demonstrated that IL-6 is one of the most important cytokines involved in the pathogenesis 
of PAH and chronic hypoxia induced pulmonary hypertension. Experimental evidences 
from animal model studies showed that IL-6 mRNA levels in total lung were increased in 
MCT-rats, and treatment with immunosuppressive steroids decreased the levels of IL-6 
and further reduced pulmonary pressures and RVH (Bhargava et al., 1999). Similar study 
in mice injecting supraphysiological high doses of IL-6 resulted in pulmonary hypertension 
and showed a severe disease phenotype under chronic hypoxia conditions (Golembeski et 
al., 2005). Furthermore, other studies also used lung-specific IL-6 overexpression trans-
genic mice to investigate the role of IL-6 in pulmonary hypertension. These mice exhibited 
elevated right ventricular systolic pressures and right ventricular hypertrophy with corre-
sponding pulmonary vasculopathic changes. In addition, IL-6 overexpression enhanced 
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muscularisation of both the proximal arterial tree and the distal arteriolar vessels that were 
characterised with the formation of occlusive neointimal angioproliferative lesions com-
posed of endothelial cells and T-lymphocytes, and all of these diseases features were exac-
erbated in the chronic hypoxia conditions (Steiner et al., 2009). Furthermore, IL-6 genetic 
ablation mice showed decreased in RVSP, RVH, and the number and media thickness of 
muscular pulmonary vessels compared to wild-type mice in the chronic hypoxia condition. 
On the contrary, chronic hypoxia IL-6-/- mice showed less inflammatory cell recruitment in 
the lungs compared with wild-type mice. In vitro studies showed that IL-6 was prominent-
ly synthesised by PASMCs compared to microvascular endothelial cells and IL-6 also 
stimulated PASMC migration (Savale et al., 2009). All these studies demonstrated that low 
levels of IL-6 in vivo and in vitro are beneficial to the development of PAH.  
 
However, we found Myolnc16 knockdown in PASMCs significantly induced IL-1 and 
TNF-α expression with both with or without TNF-α stimulation. And these two inflamma-
tory cytokines levels have been founded elevated in the patients with PAH (Soon et al., 
2010). In the rat pulmonary hypertension model, high levels of IL-1 were founded in the 
MCT rat model and treatment with recombinant human interleukin-1 receptor antagonist 
reduced pulmonary hypertension and right ventricular hypertrophy, while no protective 
effect was observed in the chronic hypoxia rat model (Voelkel et al., 1994). Rats fed with 
recombinant human TNF-α resulted in increased vascular reactivity to hypoxia and ANG II, 
which could cause the development of pulmonary hypertension (Stevens et al., 1992). 
Similarly, TNF-α overexpressed in alveolar type II cells resulted in chronic pulmonary in-
flammation, severe alveolar air space enlargement, septal destruction, bronchiolitis, and 
pulmonary hypertension (Fujita et al., 2001). Injection of TNF-α antagonist Etanercept 
prevented and reversed MCT-induced pulmonary hypertension in rat in vivo. In PASMCs 
treated with TNF-α, pyruvate dehydrogenase (PDH) activity was significantly decreased, 
which plays an important role towards providing resistance to apoptosis (Sutendra et al., 
2011). In the endotoxemic-shock-induced pig pulmonary hypertension models, etanercept 
treatment reduced both pulmonary arterial pressure and pulmonary vascular resistance 
compared with pigs without etanercept therapy (Mutschler et al., 2006). In another study, 
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rats treated with TNF-α antagonist, recombinant TNF-α receptor II: IgG Fc fusion protein 
(rhTNFRFc), attenuated the process of MCT-induced PH through the anti-inflammatory 
responses (Wang et al., 2013). On the contrary, other studies showed that TNF-α antago-
nists (infliximab, and etanercept) have no improvement of pulmonary hypertension (Chung 
et al., 2003, Henriques-Coelho et al., 2008a). In addition, we also found that the lncRNA 
Myolnc16 knockdown reduced the phosphorylation of both ERK1/2 and p38 MAPK in 
PASMCs with TNF-α stimulation. As studies have demonstrated that inhibition of p38 
MAPK pathway prevented the development of PH (Weerackody et al., 2009, Church et al., 
2015), knockdown Myolnc16 may exert a protective role in the development of PH. Taken 
together, IL-1, IL-6, TNF-α and p38 MAPK pathway play an important role in the devel-
opment of pulmonary hypertension, and studies showed that inhibition these cytokines 
production and p38 MAPK pathway is beneficial to PAH disease. In this study we showed 
Myolnc16 knockdown increased the il-1 and tnf-α mRNA levels in PASMCs while de-
creasing the IL-6 levels in PASMCs. In addition, Myolnc16 knockdown inhibited the p38 
MAPK pathway. Currently, in our ongoing studies, we further analyse the protein level of 
these cytokines secreted in PASMCs. Also, the follow up study will focus on the mecha-
nistic regulation of Myolnc16 in the inflammatory cytokine signalling and p38 MAPK 
pathway and its effects on the IL-1, IL6 and TNF-α.  
 
In addition to the inflammatory cytokines, we found that Myolnc16 knockdown signifi-
cantly reduced the mRNA levels of chemokines including cxcl1, cxcl6 and cxcl8. Previous 
studies showed that CXCL8 (IL-8) was elevated in the serum of PAH patients and CXCL8 
have pro-angiogenic and anti-apoptotic activities and acts as a growth factor to endothelial 
cells (Li et al., 2005). These effects are in consistent with higher CXCL8 serum levels 
were detected in PAH patients in association with connective tissue diseases compared 
with patients without PAH (Riccieri et al., 2011). There is no report about CXCL1 and 
CXCL6 in pulmonary hypertension disease. However, CXCL6 antibody blockade attenu-
ated acute inflammation and reduced lung toxicity associated with bleomycin treatment in 
mice (Besnard et al., 2013) and enhanced CXCL1 production induced pulmonary angio-
genesis (Mohsenin et al., 2007). There are several chemokines levels have been demon-
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strated elevated in PAH patients including CXCL2, CXCL5, CXCL10, CXCL12, CXCL13, 
and CXCL16 (see introduction). Taken together, we found that Myolnc16 knockdown can 
inhibit chemokine production in PASMCs, which suggest that inhibition of chemokines 
production by Myolnc16 can be serve as a potential therapeutic target.  
 
In summary, our study identified two novel lncRNAs MYOLSID and Myolnc16 that are 
regulated by discrete signalling pathways in PASMCs and down-regulation of these 
lncRNAs can modulate vascular cell behaviours, which suggest that inhibition of these 
lncRNAs can serve as a novel therapeutic strategy for PAH treatment.   
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6 General Discussion 
PAH is a rare, severe and progressive disease characterised by vasoconstriction and 
remodelling that mainly affects the small pulmonary arteries with an estimated prevalence 
of ~ 15-50 cases per million population (Thenappan et al., 2012). The consequences of this 
is increased pulmonary arterial pressure, right heart failure and eventual death if left un-
treated. The etiology of PAH is still not entirely clear, but a genetic component is contrib-
uted. From the pathophysiology of this disease, the PAH disease is based on genetic pre-
disposition (e.g. bmpr2), vessel injury, vascular tone imbalance, increased proliferation and 
resistance to apoptosis of PASMCs and PAECs, increased proliferation of fibroblasts in the 
adventitial layer of the vascular wall, inflammation, and in situ thrombosis (Biener-
tova-Vasku et al., 2015). Despite the modern therapeutic advances, the survival rates of 
PAH patients remain unacceptably low. Therefore, new treatments and therapeutic strate-
gies (such as ncRNAs) that target disease progression and focus at alleviating vascular re-
modelling are desperately needed to improve the outcome of patients with PAH.  
 
The first study to demonstrate that miRNA expression profiles are dysregulated during the 
development of PAH was carried out by our lab, using chronic hypoxia or monocrotaline 
(MCT) induced PH models (Caruso et al., 2010). This study indicated that miRNA dysreg-
ulation might participate in the pathogenesis of PAH and highlighted the potential im-
portance of miRNAs in disease progression, and also their possible role as therapeutic tar-
gets. While numerous studies have since elucidated the roles of specific miRNA in PAH, 
miRNA therapies remain to be applied in the clinical setting. However, the lncRNA field 
has only recently been developed and the lncRNA studies are considerably less advanced 
in the PAH field in comparison to studies on miRNAs. Recently, another similar study an-
alysed the expression profile of long noncoding RNA in the chronic hypoxia induced rat 
model. Hundreds of lncRNAs were identified to be significantly differentially expressed, 
indicating that lncRNAs might also be involved in the pathogenesis of PAH and may po-
tentially provide novel therapeutic targets (Wang et al., 2016). However, to date no indi-
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vidual lncRNA has been investigated in this disease setting. Thus, it is important to further 
explore the role of miRNAs and lncRNAs in PAH.  
 
This thesis has focused on identifying the role of noncoding RNAs (miRNAs and lncRNAs) 
during the development of PAH. We were particularly focused on four individual noncod-
ing RNAs: miR-143, miR-145, MYOSLID, and Myolnc16, aiming to establish the roles of 
these ncRNAs during PAH pathogenesis and explore the potential mechanisms involved 
using both in vivo and in vitro models.  
 
MiR-143 expression is often downregulated in cancer cells and has been associated with 
reduced migration, proliferation and metastasis (Lee et al., 2013, Xu et al., 2011). MiR-143 
expression is also reduced following vascular injury. Overexpression of miR-143 de-
creased neointimal formation in a rat model of balloon injury (Elia et al., 2009). These 
studies demonstrated that miR-143 exerted a protective role in the cancer disease and cer-
tain vascular disease. In the PAH setting,  previous study performed in our lab showed 
that miR-143 expression was significantly upregulated in lung and right ventricle samples 
from mice with chronic hypoxia induced PH, potentially due to a release from 
BMPR2-mediated transcriptional suppression (Caruso et al., 2012). However, this study 
did not further investigate the expression profile in different PH models and patients with 
PAH. The lack of evidence of manipulation of miR-143 in vivo also founded in this study. 
Thus, the studies described in chapter 3 aimed at investigating the expression profiles of 
miR-143 using four different small and large animal models of PH and PAH patient sam-
ples. We showed that MiR-143-3p expression is consistently upregulated across all animal 
models of PH that were assessed (chronic hypoxia induced PH mice model, hypox-
ia/SU5416 rat model, hypoxia neonatal calves model, brisket disease) as well as in 
PASMCs and lung samples from PAH patients. In addition, miR-143 genetic knockout and 
miR-143-3p knockdown via antimiR-143-3p treatment (both prevention and reversal stud-
ies) in the chronic hypoxia induced mice PH model demonstrated a protective effect on the 
development of PH. Therefore, inhibition of miR-143-3p might be a novel therapeutic tar-
get in PAH.  
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One of the limitations of this study is only using the chronic hypoxia induced PH mice 
model to investigate the therapeutic role of miR-143-3p knockdown. This model is charac-
terised by hypoxic pulmonary vasoconstriction and subsequently leads to increased pul-
monary arterial pressure. As a number of various animal models of PH can simulate the 
different disease stages or features of human PAH, and also can reflect various pathophysi-
ological pathways involved in PAH development. The chronic hypoxia induced PH model 
cannot fully recapitulate certain stages/clinical features of PAH. (Stenmark et al., 2009). 
Thus, more animal PH models such as monocrotaline (MCT) and hypoxia/SU5416 
mice/rat PH models should be used to further investigate the important role of miR-143-3p 
knockdown in PH development. These animals can help to understand the pulmonary vas-
cular remodelling and plexiform lesions progress characteristic of human PAH. Another 
limitation of this study is lacking of in vivo signalling pathways mediated by miR-143-3p 
in the development of chronic hypoxia induced PH. Previous studies have demonstrated 
the dysregulation of BMP and TGF-β signalling in both the chronic hypoxia and mono-
crotaline models of PAH. Reduced BMPR2 expression in lung and reduced signalling via 
the downstream Smad1/5 pathway are observed. However, TGF-β signalling is increased, 
with increased Smad3 phosphorylation and increased expression of TGF-β target genes 
(Long et al., 2009). These observations are greater in the monocrotaline model compared 
with chronic hypoxia model. Interestingly, miR-143 and miR-145 are co-transcribed from 
a common bicistronic precursor and the expression of miR-143/145 is transcriptionally ac-
tivated by signalling molecules including TGF-β and BMP4. The activation of 
miR-143/145 by TGF-β and BMP4 leads to down-regulation of their target genes KLF4 
and KLF5 resulting in increased expression of smooth muscle specific genes (Da-
vis-Dusenbery et al., 2011, Long and Miano, 2011, Cordes et al., 2009, Xin et al., 2009). 
Thus, it is valuable to investigate whether the protective role of miR-143-3p knock-
out/knockdown is via affecting the TGF-β/BMP4 signalling in vivo in both chronic hypox-
ia and monocrotaline PH models.  
 
At the clinical level, the incidence of nearly all classifications of PH and PAH show an en-
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hanced female susceptibility with about 4:1 in ratio between females and males (Rich et al., 
1987, Humbert et al., 2006, Badesch et al., 2010, Ling et al., 2012). This sex-ratio imbal-
ance suggests that gender is involved in the development of PAH. However, female PAH 
patients appear to have longer survival time than males and females develop lesser degree 
of disease than males (Humbert et al., 2010a, Humbert et al., 2010b). The sex hormone 
oestrogen is thought to exert a protective role in PAH, based on studies showing that bilat-
eral ovariectomization of female rats results in an exacerbation of PH and cardiac remodel-
ling in response to monocrotaline, an effect that could be reversed with estradiol admin-
istration (Ahn et al., 2003). Interestingly, several miRNAs exhibit gender-specific differ-
ences in regulation, such as miR-96, which plays a role in the development of PH in a 
sex-dependent manner by regulating 5-hydroxytryptamine 1B receptor (5-HT1BR) expres-
sion and hence serotonin-induced proliferation (Wallace et al., 2015) and miR-223, which 
expression levels are significantly decreased in female patients rather than male patients 
(Zeng et al., 2016). Understanding the different roles of miRNAs between the genders and 
the effect of sex hormones on miRNA expression in the pulmonary system is essential if 
these miRNAs are to be developed as therapeutic targets for PAH treatment. Our lab has 
recently showed that miR-143 expression levels were significantly elevated with estradiol 
treatment in PASMCs (Deng et al., 2015). However, we still do not know whether 
miR-143 acts in a gender-specific manner, which should be validated in future studies.  
 
Pre-miRNAs and anti-miRNAs were used successfully to induce and knockdown 
miR-143-3p expression in pulmonary vascular cells (PASMCs and PAECs). In chapter 4, 
in vitro modulation of miR-143-3p showed that miR-143-3p overexpression promoted mi-
gration and inhibited apoptosis while miR-143-3p knockdown prevented migration and 
induced apoptosis in PASMCs No effect of miR-143-3p modulation on PASMC prolifera-
tion was observed. We focus on PASMC behaviours due to their documented highly pro-
liferative, migratory, and apoptotic response to PH stimuli (Rabinovitch, 2012, Gerthoffer, 
2007, Tajsic and Morrell, 2011). There is also a significant increase in the muscularisation 
of distal small pulmonary arteries leading to the vascular remodelling of these vessels, 
which highlights the importance of PASMCs in the pulmonary vascular remodelling pro-
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cess. In addition to this, we evaluated the functional effect of miR-143-3p modulation in 
PAECs, which also play a vital role in the cellular response to PH; notably, ECs are the 
principal cell type involved in the formation of plexiform lesions in PAH patients (Wide-
man et al., 2011). In chapter 4, we showed that miR-143-3p overexpression significantly 
induced cell migration and angiogenesis of PAECs but had no effect on proliferation and 
apoptosis. Thus, manipulation of miR-143-3p affects PASMC and PAEC function in vitro, 
which contributes to the vascular aberrant remodelling observed in PAH pathogenesis.  
 
PASMCs and PAECs are two key cell components of the pulmonary vasculature that paly a 
major role in the pathobiology of PH. Under physiological conditions, interactions between 
PASMCs and PAECs are required to maintain pulmonary vascular homeostasis; aberrant 
interactions between these two cell types may lead to disease onset or contribute to PAH 
disease progression (Gao et al., 2016). Several previous studies have investigated the role 
of miRNAs in PAH disease (Zhou et al., 2015), and one important study have showed the 
role of miRNA mediated crosstalk between PASMCs and PAECs (Kim et al., 2013). 
MiR-424 and miR-503 are expressed at higher levels in PAECs compared with PASMCs, 
and the expression levels of these two miRNAs are significantly downregulated in PAH 
PAECs but no significant changes in PAH PASMCs compared to control cells. Conditioned 
media from control PAECs resulted in a significant increased in PASMCs proliferation, 
and conditioned media from PAH PAECs induced a greater degree of PASMC proliferation. 
In addition, conditioned media from either control or PAH PAECs transfected with 
miR-424 and miR-503 significantly reduced the proliferation of PASMCs. Mechanistically, 
the miR-424/503 effect was abrogated by concurrently transfecting PAECs with an FGF2 
overexpression construct, demonstrating FGF2 reversed the PAEC derived paracrine effect 
of miR-424/503. Conditioned media from normal PAECs with APLN knockdown signifi-
cantly induced PASMC proliferation, which was reversed by overexpression of 
miR-424/503 in PAECs. PAECs with FGF2 knockdown also led to decreased proliferation 
PASMCs exposure to PAEC conditioned media. Moreover, the proliferative response of 
PASMCs to conditioned media from PAEC with APLN knockdown was rescued by con-
current FGF2 knockdown. This study showed APLN-miR-424/503-FGF2 signalling path-
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way in PAECs could regulate PASMC proliferation in a paracrine manner (Kim et al., 
2013), which is the first study showing miRNA mediated cell-to-cell communication be-
tween PAECs and PASMCs. These findings are also consistent with the emerging role of 
PAEC-PASMC crosstalk in the pathogenesis of PAH (Izikki et al., 2009, Eddahibi et al., 
2006, Dewachter et al., 2006).  
 
In chapter 4, we evaluated exosomal cell-to-cell communication between PASMCs and 
PAECs, focusing on the role of miR-143-3p in this process. MiR-143-3p is expressed at 
much higher levels in PASMCs compared to PAECs. Co-culture experiments showed that 
miR-143-3p expression was significantly increased in PAECs co-cultured with PASMCs 
with or without pre-miR-143-3p transfection. PAEC migration was increased following 
co-culture with PASMC transfected with pre-miR-143-3p, as well as in the presence of 
conditioned media from transfected PASMCs. In further validating the crosstalk between 
PASMCs and PAECs, we found that PASMC-derived exosomes were enriched in 
miR-143-3p and exosomal miR-143-3p derived from PASMC transfected with 
pre-miR-143-3p significantly induced PAEC migration and tube formation in angiogenesis 
assays. To complement this data, we have recently published studies identifying several 
PAH-related signalling pathway elements that regulate miR-143/145 expression by binding 
the promoter region of the miR-143/145 cluster. Firstly, estradiol (E2) treatment activated 
the estrogen receptor and significantly triggered the expression of miR-143/145 cluster, 
which in consistent with the fact that gender per se is a risk factor in the pathogenesis of 
PAH (Mair et al., 2014). In the same way, PASMCs treated with 9-cis-retinoic acid (9cRA) 
and/or 22R-hydroxycholesterol (22R) upregulated miR-143/145 expression. In addition, 
hypoxia exposure and TGF-β but not BMP4 induced the expression of miR-143/145 clus-
ter (Deng et al., 2015). Taken together, these results are the first demonstration of the pro-
moter sequence controlling transcription of the miR-143/145 cluster, unravelling the most 
significant signalling pathways involved. Many of these signalling pathways have previ-
ously been implicated in the development of PAH, in which the expression of miR-143 is 
increased. Moreover, this is also the first report about exosomal miRNA-mediated cross-
talk in pulmonary vasculature homeostasis, in which exosomal miR-143-3p from PASMC 
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can regulate PAEC behaviour in a paracrine manner. 
 
However, in chapter 4, we did not investigate signalling pathways and target genes in-
volved in miR-143-3p modulation effect on pulmonary vascular function and the exosomal 
miR-143-3p mediated crosstalk between PASMCs and PAECs. As described in the previ-
ous paragraph, there are several signalling pathways known to regulate miR-143-3p ex-
pression in PASMCs and these pathways are involved in PAH disease. The further study 
will be required to investigate whether miR-143 modulation will affect these signalling 
pathways in PASMCs. In addition, activation all these signalling pathways induce the ex-
pression of miR-143-3p expression in PASMCs. Theoretically, the miR-143-3p expression 
levels in the PASMCs are positively corrected with the miR-143-3p expression levels in 
PASMC-derived exosomes. As we have demonstrated that miR-143-3p levels in PASMC 
are positively corrected with expression levels in exosomes with different concentration of 
pre-miR-143-3p transfection. But, whether exosomes derived from PASMCs with these 
signalling pathways activation will functionally affect the PAEC behaviours need to be 
further investigated. Conversely, if the activation of these signalling pathways induce 
PASMC dysfunction and also regulate the PAEC behaviours via cell-to-cell communica-
tion by exosomes, we are still not knowing whether this effect is specifically mediated by 
exosomal miR-143-3p derived from PASMCs. Therefore, a reversal study (by decreasing 
the expression level of miR-143-3p to baseline) should be carried out to address this ques-
tion, as activation of pathogenic signalling pathways in PASMCs definitely will affect the 
expression of a number of miRNAs or other biological substances. To identify potential 
target genes of miR-143-3p, we performed two gene expression microarrays in PASMCs 
and PAECs overexpressing miR-143-3p and identified a number of dysregulated genes, 
including 68 genes involved in cell migration (in PASMC arrays; Chapter 4) and multiple 
targets involved in cell death and survival (in PAEC arrays; Chapter 4). However, due to 
time constraints we did not validate any of these potential targets. Individual miRNA can 
target several hundreds of mRNAs on the basis of sequence complementarity, and a sub-
stantial fraction of these predicted interactions may depend on cell type and context (Ja-
cobsen et al., 2013). It is possible that the predicted but not validated targets of 
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miR-143-3p may also contribute to the cellular and in vivo consequences of manipulation 
of miR-143-3p. Thus, further studies should be performed to validate predicted targets of 
miR-143-3p in the context of PAH.  
 
In summary, in chapters 3 and 4, we have demonstrated that miR-143-3p expression is el-
evated in several animal PH models and in PASMCs and lung tissue from human patients 
of PAH. Studies performed in the chronic hypoxia induced mouse model of PH showed 
that genetic ablation of miR-143 and pharmacological inhibition of miR-143-3p exerted a 
protective role in the development of PH. In addition, this is the first study to show that 
exosomal miRNAs are involved in the cell-to-cell communications between PASMCs and 
PAECs in the pulmonary vasculature, suggesting that miR-143-3p may act as a crucial 
paracrine signalling mediator during pulmonary vascular remodelling. Thus, this study il-
lustrates a novel role for miR-143-3p as a potential therapeutic target in the treatment of 
PAH.  
 
In addition to miRNA, there is another group of noncoding RNAs that have emerged as 
important players in the regulation of cell function and behaviour in vascular homeostasis 
and dysfunction. As described in the introduction to chapter 5, ncRNAs work through mul-
tiple mechanisms. Of particular relevance to this project, LncRNA can act as endogenous 
sponges to regulate miRNA functions and miRNA have been shown to bind and regulate 
lncRNA stability (Ballantyne et al., 2016a). There is very little known about the expression 
and function of lncRNA in vascular diseases such as pulmonary hypertension. In order to 
identify whether lncRNAs can regulate the miR-143/145 cluster in the setting of PAH, our 
group recently cloned a novel promoter region that is rich in lncRNAs 
(miR-143-3p/145HG lncRNA). Preliminary evidence (unpublished data, Anderson and 
Baker) suggests that manipulation of miR-143HG modulates miR-143 expression in 
PASMCs, suggesting that miR-143HG lncRNA may play a role in the pathogenesis of PH. 
Further studies will focus on several aspects of miR-143HG biology, including the expres-
sion profile of miR-143HG in animal models of PH and in PAH patients; the regulation of 
the miR-143HG axis in response to pathogenic stimuli; the impact and function of the 
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miR-143HG axis on the expression and function of the miR-143/145 cluster, and the effect 
of miR-143HG modulation on the development of PH. This study may further strengthen 
the important role of lncRNA-miRNA-143 axis in PAH development.  
 
In chapter 5, we show preliminary evidence of the function and mechanisms of two novel 
lncRNAs (MYOSLID and Myolnc16) in pulmonary vascular cells. MYOSLID expression is 
elevated in PASMCs following exposure to numerous PAH stimuli such as hypoxia, BMP4, 
TGF-β, and PDGF. Knockdown of MYOSLID induced the mRNA expression of BMP sig-
nalling pathway components include bmpr1α, bmpr2, id1, and id3. However, lentivirus 
overexpression of MYOSLID did not have the opposite effect. The possible reason is that 
the MYOSLID knockdown by siRNA is in a sequence-specific manner, which can directly 
affect the expression level of MYOSLID in the genomic location. MYOSLID overexpres-
sion was achieved using a lentiviral approach. As lentiviral vectors favour integration in 
active transcription units, the local chromosomal environment into which integration has 
occurred can affect transgene expression. The functional consequence can be varied de-
pend on where the lncRNA is overexpressed. Similar findings in our lab showed that 
RNA-interference-mediated knockdown of smooth muscle-induced lncRNA enhances rep-
lication (SMILR) significantly decreased the proximal gene hyaluronan synthase 2 (HAS2) 
expression. However, lentiviral-mediated overexpression of SMILR did not affect HAS2 
expression (Ballantyne et al., 2016c). Thus, further work need to localise the cellular local-
isation of MYOSLID in basic condition and with lentivirus overexpression. Because the 
cellular localization of lncRNA will affect the silencing efficiency of lncRNA (Lennox and 
Behlke, 2016).  
 
In addition to modulating mRNA expression of BMP signalling pathway components, 
MYOSLID was able to regulate BMPR2 protein expression. Functional study revealed that 
MYOSLID knockdown inhibited the cell migration and induced cell apoptosis of PASMCs. 
Mechanistically, MYOSLID knockdown reduced the protein levels of pERK1/2 and affect-
ed the protein levels of Smad1/5/9. Previous study showed in normal PASMCs, BMP4 ac-
tivated Smad15/9 as well as p38 MAPK and ERK1/2. Smad signalling was an-
	 273	
ti-proliferative, whereas p38 MAPK and ERK1/2 signalling were pro-proliferative and an-
ti-apoptotic (Yang et al., 2005). In PASMCs from PAH patients with BMPR2 mutations, 
Smad signalling was defective and the cells were unresponsive to the anti-proliferative ef-
fect of BMP4. The BMPR2 mutations also can lead to unopposed the activation of 
pro-proliferative p38 MAPK and ERK1/2 signalling (Yang et al., 2008). In consistent with 
these finding, PASMCs from heritable PAH patients show no BMP4-induced Smad1/5/9 
phosphorylation but BMP4-induced activation of p38 MAPK pathway. PASMCs from 
PAH patients with an in vitro proliferative and anti-apoptotic pattern that can be inhibited 
by BMP4 in idiopathic PAH but no in heritable PAH (Dewachter et al., 2009). Our data 
may indicate that MYOSLID knockdown increased the BMP4-Smad signalling pathway 
and reduced the p38 MAPK and ERK1/2 signalling leading to inhibition of cell migration 
and induced cell apoptosis. However, to confirm this regulation of MYOSLID, more ex-
periments need to be addressed including analysing the protein levels of p38 MAPK, and 
the Smad1/5/9 at various time point. Whether lentiviral overexpression of MYOSLID also 
affected these two signalling pathways need to be analysed. Furthermore, the expression 
levels of MYOSLID is elevated in PASMCs from PAH patients. In order to analyse the ef-
fect of MYOSLID in regulating the signalling pathways in PAH disease, PASMCs with 
and/or without BMPR2 mutations cells need to be used for analysis. The MYOSLID 
knockdown may compensate the defective BMP4-Smad signalling pathway to exert a pro-
tective phenotype. We found not all the patient cells express high levels of MYOSLID, ex-
ploring the underlying mechanisms of this difference will be done.  
 
Apart from PASMCs, MYOSLID is also expressed in PAECs. MYOSLID knockdown sig-
nificantly decreased PAEC proliferation. In chapter 4, we showed cell-to-cell communica-
tion between PASMCs and PAECs by exosomal miRNA may contribute to the vascular 
remodelling process during PAH pathogenesis. Similar to miRNAs, recent studies have 
reported that lncRNA are present in exosomes and account for 20.19% of exosomal RNA 
extracted from the plasma of castration-resistant prostate cancer patients (Huang et al., 
2015). Other exosomal lncRNAs include HOTAIR (Botti et al., 2015), H19 (Conigliaro et 
al., 2015), ROR (Takahashi et al., 2014a), Linc-VLDLR (Takahashi et al., 2014b), TUC339 
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(Kogure et al., 2013), lncRNA-p21 (Isin et al., 2015). For example, sunitinib resistance is a 
major challenge for advanced renal cell carcinoma, and developing effective strategies 
against sunitinib resistance are highly desired in the clinical treatment. In this study, 
lncARSR was shown to be secreted by resistant cells via exosomes, and could be taken up 
by sunitinib-senstitive cells to transform sunitinib-senstitive cells into resistant cells (Qu et 
al., 2016). This study revealed that exosomal lncRNAs could functionally mediate 
cell-to-cell communication in disease content. Thus, it would be interesting to investigate 
whether PASMCs and/or PAEC-derived exosomes contain MYOSLID, and whether exo-
somal MYOSLID can mediate the functional crosstalk between PASMCs and PAECs.  
 
Myolnc16 is another novel lncRNA investigated in this chapter. In PASMCs, the expres-
sion of Myolnc16 is significantly induced by inflammatory cytokines (TNF-α and IL-1) at 
very early time points. Myolnc16 knockdown significantly reduced the expression levels of 
il-6, cxcl1, cxcl6, and cxcl8, which were activated by TNF-α treatment in PASMCs. 
Mechanistically, knockdown of Myolnc16 reduced p38 MAPK and ERK1/2 signalling 
pathway activation in PASMCs, which are known to drive proliferation and inhibit apopto-
sis of PASMCs (Yang et al., 2005). Consistent with this observation, in vitro functional 
experiments showed that Myolnc16 knockdown inhibited the proliferation and migration of 
PASMCs, potentially via inhibition of p38 MAPK and ERK1/2 signalling. Further experi-
ments are required to analyse the cell apoptosis of PASMCs with Myolnc16 knockdown. 
Given that inflammatory pathways appear to the key targets of Myolnc16, it would be im-
portant to evaluate the role of Myolnc16 in NF-κB pathway. Nuclear factor κ-B (NF-κB) is 
activated in the pulmonary vessels of PAH patients (Price et al., 2013) and NF-κB inhibi-
tion exerts an anti-remodelling effect in PASMCs (Hosokawa et al., 2013, Ogbozor et al., 
2015). In vivo inhibition of NF-κB prevents monocrotaline-induced PH in mice (Li et al., 
2014). As Myolnc16 is induced by inflammatory cytokines and NF-κB pathway plays a 
vital role in inflammatory signalling pathways, it is important for further studies focusing 
on the role of modulation of Myolnc16 in the NF-κB pathway in PAH setting. In addition, 
overexpression of Myolnc16 should be considered in all these experiments to assess 
whether Myolnc16 could reverse the cell functions and signalling pathways.  
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The translation of ncRNAs from bench to bedside has received considerable attention in 
the context of PAH. In general, therapeutic approaches involve the inhibition or overex-
pression of ncRNAs. Several approaches to manipulate ncRNAs are currently in use 
pre-clinically, including miRNA antagonists, miRNA mimics, antisense oligonucleotide 
(ASO), small interfering RNA (siRNA), and GapmeRs. The first anti-miRNA (Miravirsen) 
to enter clinical trials is a locked nucleic acid-modified DNA phosphorothioate antisense 
oligonucleotide targeting miR-122, which sequesters mature miR-122 to treat patients with 
hepatitis C. Miravirsen is currently in phase 2 clinical trials (Sanchez-Nino and Ortiz, 2013, 
Janssen et al., 2013). MRX34, a double-stranded miR-34 RNA mimic encapsulated in a 
liposomal nanoparticle formulation, is the first miRNA mimic to enter phase I clinical tri-
als (Adams et al., 2015). Several antimiRNA/mimic therapeutics targeting miRNAs are 
currently under development, including Let-7, miR-21, miR-208, miR-195, miR-221, 
miR-29, miR-155, miR-10b, and miR-103/107. Four of these miRNA-based therapeutic 
drugs have entered into phase 1 clinical trials (Trajkovski et al., 2011, Li and Rana, 2014, 
Xiao et al., 2012, Butovsky et al., 2015, van Rooij and Kauppinen, 2014). Therefore, 
pharmacological targeting disease related miRNAs is showing promising therapeutic po-
tential and miRNA-based therapeutics can be expected to apply in the human disease 
treatment.  
 
Despite intensive studies of miRNAs in vascular disease, there are currently no miR-
NA-based therapeutics entering clinical trials for PAH treatment. The obstacles impeding 
development of miRNA-based therapeutics are low delivery efficacy to the vasculature and 
the likely need for repeated delivery, which means that high concentrations with substantial 
risks of off-target effects are required for vascular delivery. The administration route for 
miRNA therapies is also an important consideration in the PAH setting. PAH mainly tar-
gets the small pulmonary arteries, so ideally, local administration (such as intranasal and 
intratracheal delivery) direct to the pulmonary circulation should be used to minimise 
off-target effects and maximise therapeutic effects. Some existing PAH treatments (e.g. 
aerosolised iloprost and trepostinil) are delivered directly to the lungs via the inhalational 
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route, enhancing the pulmonary specificity and reducing systemic adverse effects. Howev-
er this route requires frequent administration and has a tendency to cause airway symptoms 
(Hill et al., 2015). Formulation of inhalable miRNA drugs and stability of these drugs dur-
ing the inhalation process are key challenges to solve.  
 
Off-target effects of therapies are a particular concern with miRNAs, as individual miR-
NAs can target hundreds of mRNAs and direct modulation of miRNAs may lead to off 
target effects in vivo due to the pleiotropic effect of these small RNA molecules. The key 
function of miRNAs is to regulate their targets to participating the pathophysiological pro-
cess and the expression levels of miRNAs in different cells and tissues are various. More-
over, directly targeting miRNA target genes in the pre-clinical and clinical setting may 
prove to be beneficial, while also reducing concerns regarding the diversity of genes tar-
geted by individual miRNAs. Thus, the identification of genuine target genes is key not 
only to understanding the mechanisms of miRNA action, but also for the development of 
new PAH treatments. However, despite the challenges of therapeutic modulation of miR-
NA, pharmacological manipulation of disease-associated miRNAs shows promising ther-
apeutic potential in pre-clinical models of PAH. With more and intensive studies of miR-
NAs in vitro and in vivo pre-clinical models and in tissues from human patients, we hope 
that the application of miRNA-based therapeutics in the clinic can become a reality.  
 
As stated previously, to date there is no specific lncRNA has been intensively investigated 
in PAH disease. As the important role of lncRNAs in human disease, it is no doubt that the 
understanding of lncRNAs in the development of PAH will contribute to the disease treat-
ment in the future. In general, there are several obstacles facing the development of 
lncRNA-based therapeutics. First, the functions of, and mechanisms used by lncRNAs are 
much more complex and diversified than miRNAs (Ballantyne et al., 2016a). Despite re-
cent advances in our understanding of lncRNA biology, lncRNAs are still largely an “un-
known” with regards to their cellular functions and molecular mechanisms. Second, the 
majority of lncRNAs that localise to the nucleus are thought to act as epigenetic regulators 
(Djebali et al., 2012). This feature makes it hard to target lncRNAs using siRNA, which is 
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a potential therapeutic strategy. Recently, in vivo animal work using GapmeR-mediated 
silencing of lncRNA Chast (cardiac hypertrophy-associated transcript) prevented and at-
tenuated transverse aortic constriction (TAC)-induced pathological cardiac remodelling 
with no obvious side-effects (Viereck et al., 2016). This study revealed that inhibition of 
specific lncRNA by GapmeRs in vivo provided a potential therapeutic strategy for the pre-
clinical and clinical development of drugs. Third, most lncRNAs lack conservation be-
tween species, which restricts the utility of pre-clinical disease models. One possible strat-
egy to overcome these issues is to identify the direct targets of disease-associated lncRNAs 
and use pre-clinical disease models to assess the therapeutic role of these targets in disease 
pathogenesis and/or use innovative human-based model systems ex vivo and in vitro.  
 
In summary, the evidence presented in this thesis extends our understanding of ncRNA bi-
ology in the setting of PAH. MiR-143-3p is consistently dysregulated across several small 
and large animal models of PH, as well as in lung samples from patients with PAH. Genet-
ic ablation and pharmacological inhibition of miR-143-3p protected animals against the 
development of chronic hypoxia induced PH. Modulation of miR-143-3p had significant 
effects on pulmonary vascular cell migration, apoptosis and angiogenesis, while 
miR143-3p in exosomes was shown to mediate crosstalk between PASMCs and PAECs. 
However, the exact mechanisms involved in the protective role of miR-143 in PAH require 
further investigation. In addition, we have shown that local delivery of antimiR-145-5p had 
no protective effect on PH development compared to systemic delivery, indicating that lo-
cal antimiRNA delivery approaches require further refinement before they can be utilised 
in the pre-clinical setting. Further, our preliminary data have showed modulation of 
lncRNA MYOSLID and Myolnc16 regulated several signalling pathways related to the 
pathogenesis of PAH and regulated cell functions in pulmonary vascular cells. Future work 
will continue focus on the functions and mechanisms of these lncRNAs in the PAH setting. 
 
This thesis has demonstrated the involvement of specific ncRNAs in the development of 
PAH. In the future perspective, the therapeutic target of these ncRNAs may provide poten-
tial treatment strategy in patients with PAH.  
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